<tstset trglang="any" setid="test" srclang="any">
<doc sysid="Edinburgh" docid="doc">
<seg id="1">This document is a summary of the European Public Health Report (EPAR) in which explains how the Committee for Medicinal Products (CHMP) evaluated the conducted studies to make recommendations concerning the application of the medicine.</seg>
<seg id="2">"" "" "" "if you need more information about your illness or treatment, please read the packaging supplement (also included in the EPAR) or contact your doctor or pharmacist." "" "" ""</seg>
<seg id="3">"" "" "" "for more information on the basis of the CHMP recommendations, please read the scientific discussion (also part of EPAR)." "" "" ""</seg>
<seg id="4">"" "" "" "it is available as a 5 mg, 10 mg, 15 mg and 30 mg tablets, as a solution for intake (1 mg / ml) and as an injection solution (7.5 mg / ml)." "" "" ""</seg>
<seg id="5">"" "" "" "B. cervical thinking and speaking, hallucinations (hearing or seeing of things that are not present), mistrust and delusions; • Bipolar-I disorder, a mental disorder where patients may have manic episodes (periods of abnormal mood) alternating with periods of normal mood." "" "" ""</seg>
<seg id="6">Abilify is used to treat moderate to severe manic episodes and to prevent manic episodes in patients who have addressed the drug in the past.</seg>
<seg id="7">"" "" "" "the injection solution is used to monitor increased unrest or behavioural disorders, if the oral intake of the medicine is not possible." "" "" ""</seg>
<seg id="8">"" "" "" "for both diseases, the solution can be used for taking or applying the tablets in patients who have difficulty swallowing tablets." "" "" ""</seg>
<seg id="9">"" "" "" "for patients who use other medicines same as Abilify, the dose should be adapted to Abilify." "" "" ""</seg>
<seg id="10">"" "" "" "this impairs the signal transmission between brain cells through" neurotransmitters, "i.e. chemical substances that enable communication of nerve cells to each other." "" "" ""</seg>
<seg id="11">Aripiprazol probably works mainly as a "partial agonist" for the receptors for neurotransmitters dopamine and 5-hydroxytryptamin (also called serotonin).</seg>
<seg id="12">"" "" "" "this means that Aripiprazol like 5-hydroxytryptamin and dopamine, but to a lesser degree, acts as neurotransmitters to activate the receptors." "" "" ""</seg>
<seg id="13">"" "" "" "since dopamine and 5-hydroxytryptamin play a role in schizophrenia and bipolar disorder, Aripiprazol helps to normalize the activity of the brain, thereby reducing psychotic or manic symptoms and preventing its recurrence." "" "" ""</seg>
<seg id="14">"" "" "" "the efficacy of Abilify, the recurrence of symptoms, was studied in three studies of up to one year." "" "" ""</seg>
<seg id="15">"" "" "" "the effectiveness of the injection solution was compared in two studies in 805 patients with schizophrenia or similar diseases, which led to increased unrest, over a period of two hours with a placebo." "" "" ""</seg>
<seg id="16">"" "" "" "in another study, Abilify was compared to 347 patients with haloperidol versus Abilify and placebo to prevent recurrence of 160 patients with Abilify." "" "" ""</seg>
<seg id="17">The efficacy of Abilify Injection Solution was compared in a study of 301 patients with bipolar disorder that led to increased unrest with the treatment of Lorazepam (another antipsychotic) and placebo over a period of two hours.</seg>
<seg id="18">"" "" "" "in all studies, the change in the patient's symptoms was examined using a standard scale for bipolar disorder or the number of patients addressed to the treatment." "" "" ""</seg>
<seg id="19">"" "" "" "the company also conducted studies to investigate how the body absorbs the enamel tablets, and the solution to absorb (absorbs)." "" "" ""</seg>
<seg id="20">"" "" "" "in the two trials with the injection solution, patients showed Abilify in doses of 5.25 mg, 9.75 mg or 15 mg, significantly greater disruption in the symptoms than the patients receiving a placebo." "" "" ""</seg>
<seg id="21">"" "" "" "in the treatment of bipolar disorder, Abilify decreased in four of the five short-term studies of manic symptoms more effectively than placebo." "" "" ""</seg>
<seg id="22">"" "" "" "Abilify, for up to 74 weeks, prevented the recurrence of manic episodes in previously treated patients and when administered in addition to an existing treatment." "" "" ""</seg>
<seg id="23">Bilify injections in 10 or 15 mg doses also reduced more effective than placebo the symptoms of increased unrest and were similarly effective as Lorazepam.</seg>
<seg id="24">The most common side effects of Abilify for intake (observed in 1 to 10 of 100 patients) are extrapyramidal disorders (swelling), headache, blurred vision (sleepiness) and drowsiness (increased saliva production); fatigue and exhaustion; tranquillity; insomnia (sleeping disorders) and anxiety.</seg>
<seg id="25">The Committee for Medicinal Products (CHMP) concluded that the benefits of abilify in the treatment of schizophrenia and of moderate to severe manic episodes in bipolar-I-disorder and the prevention of a new manic episode in patients with mainly manic episodes and in which the manic episodes discussed the treatment with Aripiprazol.</seg>
<seg id="26">"" "" "" "in addition, the Committee came to the conclusion that the benefits of the injection solution in patients with schizophrenia or in patients with manic episodes in bipolar-I disorder if oral therapy is not suitable to outweigh the risks." "" "" ""</seg>
<seg id="27">"" "" "" "June 2004, the European Commission granted approval to the company Otsuka Pharmaceutical Europe Ltd. approval for the placing of Abilify in the European Union." "" "" ""</seg>
<seg id="28">ABILIFY is indicated for the treatment of moderate to severe manic episodes of bipolar disorder and for preventing a new manic episode in patients who had mostly manic episodes and their manic episodes on the treatment with Aripiprazol (see section 5.1).</seg>
<seg id="29">"" "" "" "the recommended starting dose for ABILIFY is 10 or 15 mg / day at a maintenance dose of 15 mg / day, independent of meals." "" "" ""</seg>
<seg id="30">"" "" "" "increased efficacy in doses over a daily dose of 15 mg was not proven, although individual patients could benefit from a higher dose." "" "" ""</seg>
<seg id="31">"" "" "" "the recommended starting dose for ABILIFY is 15 mg once a day, independent of meals as monotherapy or combination therapy (see Section 5.1)." "" "" ""</seg>
<seg id="32">The efficacy of ABILIFY in the treatment of schizophrenia and bipolar disorder in patients ≥ 65 years has not been proven.</seg>
<seg id="33">"" "" "" "considering the greater sensitivity of these patients, a lower initial dose should be considered when clinical factors justify this (see Section 4.4)." "" "" ""</seg>
<seg id="34">"" "" "" "if the CYP3A4 inductor is removed from combination therapy, the Aripiprazol dose should be reduced to the recommended dose (see section 4.5)." "" "" ""</seg>
<seg id="35">"" "" "" "the occurrence of suicidal behavior belongs to psychotic diseases and affective disorders, and was reported in some cases after the beginning or after changes of an antipsychotic therapy, also in treatment with Aripiprazol (see Section 4.8)." "" "" ""</seg>
<seg id="36">Results of an epidemiological study showed that in patients with bipolar disorder there was no increased suicidal risk associated with Aripiprazol compared to other antipsychotics.</seg>
<seg id="37">"" "" "" "Aripiprazol should be used with caution in patients with known cardiovascular diseases (myocardial infarction or ischemic heart disease, cardiac insufficiency, hypovolemia, treatment with blood pressure lowering drugs) or hypertension (including active and malignant forms)." "" "" ""</seg>
<seg id="38">"" "" "" "3 late dyspesia: in clinical trials lasting one year or less, there were occasional reports of dyskinesia occurring during the treatment with Aripiprazol." "" "" ""</seg>
<seg id="39">"" "" "" "if there are signs and symptoms of a late dyskinesia treated with ABILIFY, consideration should be taken to reduce the dose or cancel the treatment." "" "" ""</seg>
<seg id="40">"" "" "" "when a patient develops signs and symptoms that indicate a mn, or unclear high fever without an additional clinical manifestation of mns, all antipsychotics, including ABILIFY, must be removed." "" "" ""</seg>
<seg id="41">"" "" "" "therefore, Aripiprazol should be used with caution in patients with seizures in the anamnesis or in conditions associated with seizures." "" "" ""</seg>
<seg id="42">"" "" "" "56 - 99 years) with Aripiprazol in patients with psychosis associated with Alzheimer's disease, patients diagnosed with Aripiprazol had an increased risk of death compared to placebo." "" "" ""</seg>
<seg id="43">"" "" "" "however, in one of these studies, there was a study with fixed dosage, a significant relationship between the dosage and the response for unwanted cerebrovascular events in patients treated with Aripiprazol." "" "" ""</seg>
<seg id="44">"" "" "" "hyperglycemia, in some cases extremely and associated with ketoacidosis or hyperosmolarem coma or death, was reported in patients who were treated with atypical antipsychotic agents, including ABILIFY." "" "" ""</seg>
<seg id="45">There is no precise risk assessment for hyperglycemia-related adverse events in patients treated with ABILIFY and other atypical antipsychotic drugs that allow direct comparisons.</seg>
<seg id="46">"" "" "" "polydipsy, polyuria, polyphagia and weakness are observed and patients with diabetes mellitus or with risk factors for diabetes mellitus should be regularly monitored with regard to worsening of glucose levels." "" "" ""</seg>
<seg id="47">"" "" "" "a weight gain is generally observed in schizophrenia patients and in patients with bipolar deficiency, the use of anti-psychotics, in which weight gain is known as side effects, and could lead to serious complications." "" "" ""</seg>
<seg id="48">Due to the primary effect of Aripiprazol on the central nervous system caution is advisable when Aripiprazol is used in combination with alcohol or other centrally effective medicines with overlapping side effects such as sedation (see Section 4.8).</seg>
<seg id="49">"" "" "" "the H2 antagonist Famotidin, a gastric acid blocker, decreases the absorption rate of Aripiprazol, but this effect is considered clinically irrelevant." "" "" ""</seg>
<seg id="50">"" "" "" "in a clinical study with healthy volunteers, a highly effective CYP2D6 inhibitor (chinidin) increased the AUC of Aripiprazol by 107% while the CMAx remained unchanged." "" "" ""</seg>
<seg id="51">"" "" "" "it is expected that other highly effective inhibitors of CYP2D6, such as Fluoxetine and Paroxetine, have similar effects." "" "" ""</seg>
<seg id="52">CYP2D6 'bad' (= 'poor') may result in common application with effective inhibitors of CYP3A4 in higher plasma concentrations of Aripiprazol versus CYP2D6 extensives.</seg>
<seg id="53">"" "" "" "if you consider the joint gift of ketoconazole or other highly effective CYP3A4 inhibitors with ABILIFY, the potential benefits should outweigh the potential risks for the patient." "" "" ""</seg>
<seg id="54">"" "" "" "other highly effective inhibitors of CYP3A4, such as Itraconazole and HIV protease inhibitors, should have similar effects." "" "" ""</seg>
<seg id="55">"" "" "" "after the CYP2D6- or 3A4 inhibitors, the dose of ABILIFY should be lifted to the dose level before the beginning of the accompanying therapy." "" "" ""</seg>
<seg id="56">Diltiazem or escitalopram) or CYP2D6 together with ABILIFY can be administered together with a moderate increase in Aripiprazol- concentrations.</seg>
<seg id="57">In clinical trials doses of 10-30 mg Aripiprazol showed no significant effect on the metabolism of the substrates of CYP2D6 (Dextromethororphan / 3-Methoxymorphinan ratio) and 2C9 (warfarin) and 3A4 (Dextromethomorphan).</seg>
<seg id="58">"" "" "" "patients should be advised to inform their doctor, if they are pregnant or plan a pregnancy during the treatment with Aripiprazol." "" "" ""</seg>
<seg id="59">"" "" "" "this drug may not be used in pregnancy due to insufficient data storage for human safety and for the concerns arising in animal reproduction studies, unless the potential benefits justifies the potential risk for the fetus." "" "" ""</seg>
<seg id="60">"" "" "" "however, as with other antipsychotics patients should be warned against operating dangerous machines, including vehicles, until they are sure that Aripiprazol has no negative influence on them." "" "" ""</seg>
<seg id="61">"" "" "" "the following side effects were more common (≥ 1 / 100) than placebo, or were classified as possible medically relevant side effects (*):" "" "" ""</seg>
<seg id="62">"" "" "" "the frequency of the side effects listed below is defined according to the following criteria: frequently (&gt; 1 / 100, &lt; 1 / 10); occasionally (&gt; 1 / 1000, &lt; 1 / 100)." "" "" ""</seg>
<seg id="63">"" "" "" "schizophrenia - in a controlled long-term study over 52 weeks, in patients treated with Aripiprazol, a total less incidence (25.8%) of EPS including Parkinsonism, Dystcolony and Dyskinesia, compared to patients treated with haloperidol (57.3%)." "" "" ""</seg>
<seg id="64">"" "" "" "in a placebo-controlled long-term study over 26 weeks, the incidence of EPS was 19% in patients with Aripiprazol treatment and 13.1% in patients under placebo." "" "" ""</seg>
<seg id="65">"" "" "" "in another controlled long-term study over 26 weeks, the incidence of EPS 14.8% in patients treated with Aripiprazol was 15.1% in patients suffering from Olanzapine therapy." "" "" ""</seg>
<seg id="66">Manic episodes in bipolar-I disorder - In a controlled trial over 12 weeks the incidence of EPS 23.5% in patients with Aripiprazol- treatment and 53.3% in patients with haloperidol treatment.</seg>
<seg id="67">"" "" "" "in another study over 12 weeks, the incidence of EPS 26.6% in patients with Aripiprazol treatment was 17.6% for those under lithium-treatment." "" "" ""</seg>
<seg id="68">In the long-term maintenance phase over 26 weeks in a placebo-controlled trial the incidence of EPS 18.2% for patients under Aripiprazol- treatment and 15.7% for patients treated with placebo.</seg>
<seg id="69">A comparison between the patient groups under Aripiprazol and placebo in which potentially clinically significant changes in routine controlled laboratory parameters showed no medically significant differences.</seg>
<seg id="70">Increases in CPK (creatine phosphokinase) - generally temporary and asymptomatic - were observed at 3.5% of patients treated with Aripiprazol compared to 2.0% of patients treated with placebo.</seg>
<seg id="71">"" "" "" "the malignant neuroleptic syndrome, chronic cerebrovascular events and increased mortality in elderly dementia patients, hyperglycemia and diabetes mellitus (see section 4.4)." "" "" ""</seg>
<seg id="72">"" "" "" "in clinical trials and since the market launch, unintentional or intentional overdosage with Aripiprazol was observed alone in adult patients with estimated doses of up to 1260 mg and without death." "" "" ""</seg>
<seg id="73">"" "" "" "although there is no information about the efficacy of a hemodialysis in the treatment of overdosage with Aripiprazol, it is unlikely that haemodialysis is useful in the treatment of overdosage since Aripiprazol has a high plasma protein binding." "" "" ""</seg>
<seg id="74">It is presumed that the effectiveness of Aripiprazl in schizophrenia and bipolar-I disorder on the combination of a partially agonistic effect on dopamine D2- and serotonin 5HT1 receptors and an antagonistic effect on serotonin 5HT2a receptors is mediated.</seg>
<seg id="75">Aripiprazol showed in vitro a high affinity with dopamine D2- and D3 receptor and a serotonin 5HT2a receptor and a moderate affinity with dopamine D4- and 5HT7- to alpha-1-adrenergic and the histamine H1receptor.</seg>
<seg id="76">In the dosage of Aripiprazol in dosages of 0.5 to 30 mg once a day more than 2 weeks of healthy volunteers showed a dose-dependent reduction in the binding of 11C-Racloprid and a D2 / D3 receptor ligand at the Nucleus caudatus and the putamen.</seg>
<seg id="77">In three placebo-controlled short-term studies (4 to 6 weeks) with positive or negative symptoms Aripiprazol showed a statistically significant improvement of the psychotic symptoms compared to placebo.</seg>
<seg id="78">"" "" "" "in a half-surgery controlled trial, 52% of respondents participating in the study were similar in both groups (Aripiprazol 77% and haloperidol 73%)." "" "" ""</seg>
<seg id="79">"" "" "" "current values from measurement scales defined as secondary study targets, including PANSS and the Montgomery-Asberg- Depressions Rates, showed significantly greater improvement than in haloperidol." "" "" ""</seg>
<seg id="80">In a placebo-controlled trial over 26 weeks of stabilised patients with chronic schizophrenia demonstrated for Aripiprazol a significantly higher reduction of the return rate that was found at 34% in the Aripiprazol group and 57% below placebo.</seg>
<seg id="81">In an Olanzapine-controlled multi-blind study at schizophrenia more than 26 weeks ago which included 314 patients and in which the primary study target 'weight gain' was included in significantly less patients a weight gain of at least 7% compared to the initial value (i.e. an increase of at least 5.6 kg) at an average weight of ca.</seg>
<seg id="82">In two placebo-controlled monotherapy studies with flexible dosage over 3 weeks with patients with a manic or mixed episode of bipolar I disorder presented Aripiprazol a versus placebo superior efficacy in reducing manic symptoms over 3 weeks.</seg>
<seg id="83">In a placebo-controlled monotherapy trial over 3 weeks with fixed dose with patients with a manic or mixed episode of bipolar-I disorder Aripiprazol showed no superior efficacy compared to placebo.</seg>
<seg id="84">"" "" "" "in two placebo and active controlled monotherapy studies over 12 weeks in patients with a manic or mixed episode of bipolar-I disorder, with or without psychotic traits, Aripiprazol showed a placebo superior versus placebo in week 12." "" "" ""</seg>
<seg id="85">"" "" "" "in week 12, Aripiprazol showed a comparable proportion of patients with symptomatic remission of the mania, such as lithium or haloperidol." "" "" ""</seg>
<seg id="86">In a placebo-controlled trial over 6 weeks with patients with a manic or mixed episode of bipolar-I-disturbance with or without psychotic characteristics which partially over 2 weeks did not respond to lithium or valproat monotherapy with therapeutic serum levels resulted in a superior efficacy in reducing manic symptoms compared to monotherapy with lithium or valproate.</seg>
<seg id="87">"" "" "" "10 In a placebo-controlled trial over 26 weeks followed by a long-term enlargement period over 74 weeks in manic patients who had reached remission with Aripiprazol, mainly in preventing a bipolar relapse, mainly in preventing a relapse into mania." "" "" ""</seg>
<seg id="88">"" "" "" "based on in vitro studies, the enzymes CYP3A4 and CYP2D6 are responsible for hydroxymethylation and hydroxymethylation of Aripiprazol." "" "" ""</seg>
<seg id="89">The mean elimination period is approximately 75 hours for Aripiprazol with Extensive Metabolic Metabolic Metabolic Metabolic Metabolic Rate of CYP2D6 and approximately 146 hours with 'bad' (= 'poor') metabolites over CYP2D6.</seg>
<seg id="90">"" "" "" "in Aripiprazol, there are no differences in pharmacokinetics between male and female healthy subjects, as well as a pharmacokinetic examination of schizophrenic patients." "" "" ""</seg>
<seg id="91">A simulation-specific evaluation of pharmacokinetics did not reveal any clinically significant differences in terms of ethnicity or effect of smoking on the pharmacokinetics of Aripiprazol.</seg>
<seg id="92">The pharmacokinetic properties of Aripiprazol and Dehydro-Aripiprazol were similar to patients with severe kidney failure in comparison to young healthy volunteers.</seg>
<seg id="93">A single dose study in subjects with various liver cirrhosis (Child-Pugh class A, B and C) showed no significant effect regarding the impairment of liver function on the pharmacokinetics of Aripiprazol and Dehydro-Aripiprazol but the study included only 3 patients with cirrhosis of the class C which is not sufficient to draw conclusions on their metabolic capacity.</seg>
<seg id="94">"" "" "" "based on the conventional research on safety spharmacology, toxicity in repeated application, reproductive toxicity, genotoxicity and the carcinogenic potential the preclinical data could not detect any particular danger to humans." "" "" ""</seg>
<seg id="95">"" "" "" "toxicological significant effects were only observed in doses or exposures, which significantly exceeded the maximum dosage or exposure in humans, so they have limited or no importance for clinical use." "" "" ""</seg>
<seg id="96">The effects included a dose-dependent adrenal-loss-toxicity (Lipofuscin-Pigment accumulation and / or parenchymal loss) in rats after 104 weeks at 20 to 60 mg / kg / day (equivalent to 3 to 10 times the middle steady state exposure (AUC) at the recommended maximum dose in humans.</seg>
<seg id="97">Cholelithiasis was also detected as a result of the precipitation of sulfate conjugates of yopprazol in the gall of monkeys after repeated oral administration of 25 to 125 mg / kg / day (1 to 3 times the recommended maximum dose in humans based on mg / m2).</seg>
<seg id="98">The concentrations of hydroxy- Aripiprazol sulfate conjugates of hydroxy- Aripiprazol found no more than 6% of the concentrations found in the study of 39 weeks in the Galle of apes and lie far below the limit values (6%) of the in vitro solubility.</seg>
<seg id="99">"" "" "" "in rabbits, these effects were observed after dosages which led to exposures of the 3 and 11 times the middle Steady state AUC at the recommended clinical maximum dose." "" "" ""</seg>
<seg id="100">"" "" "" "perforated blister packs for submission of single boxes made of aluminium in folding cartons with 14 x 1, 28 x 1, 49 x 1, 56 x 1, 98 x 1 tablets." "" "" ""</seg>
<seg id="101">"" "" "" "15 late dyspesia: in clinical studies, which lasted one year or less, there were occasional reports of dyskinesia occurring during the treatment with Aripiprazol." "" "" ""</seg>
<seg id="102">It is presumed that the effectiveness of Aripiprazl in schizophrenia and bipolar-I disorder on the combination of a partially agonistic effect on dopamine D2- and serotonin 5HT1 receptors and an antagonistic effect on serotonin 5HT2a receptors is mediated.</seg>
<seg id="103">22 In a placebo-controlled trial over 26 weeks followed by a long-term enlargement period over 74 weeks in manic patients who had reached remission over a period before randomisation Aripiprazol showed itself above the placebo with regard to the prevention of a bipolar relapse.</seg>
<seg id="104">"" "" "" "27 late dyspesia: in clinical trials lasting one year or less, there were occasional reports of dyskinesia occurring during the treatment with Aripiprazol." "" "" ""</seg>
<seg id="105">It is presumed that the effectiveness of Aripiprazl in schizophrenia and bipolar-I disorder on the combination of a partially agonistic effect on dopamine D2- and serotonin 5HT1 receptors and an antagonistic effect on serotonin 5HT2a receptors is mediated.</seg>
<seg id="106">"" "" "" "34 weeks in a placebo-controlled trial over 26 weeks followed by a long-term enlargement period over 74 weeks in manic patients who had reached remission with Aripiprazol, mainly in preventing a bipolar relapse." "" "" ""</seg>
<seg id="107">"" "" "" "39 Spätdyskinesia: in clinical trials lasting one year or less, there were occasional reports of dyskinesia occurring during the treatment with Aripiprazol." "" "" ""</seg>
<seg id="108">It is presumed that the effectiveness of Aripiprazl in schizophrenia and bipolar-I disorder on the combination of a partially agonistic effect on dopamine D2- and serotonin 5HT1 receptors and an antagonistic effect on serotonin 5HT2a receptors is mediated.</seg>
<seg id="109">46 In a placebo-controlled trial over 26 weeks followed by a long-term enlargement period over 74 weeks in manic patients who had reached remission over a period before randomisation Aripiprazol showed itself above the placebo with regard to the prevention of a bipolar relapse.</seg>
<seg id="110">"" "" "" "the recommended starting dose for Aripiprazol is 10 or 15 mg / day at a maintenance dose of 15 mg / day, independent of meals." "" "" ""</seg>
<seg id="111">Patients who have difficulty swallowing ABILIFY tablets may alternatively take tablets to ABILIFY tablets (see Section 5.2).</seg>
<seg id="112">The occurrence of suicidal behavior belongs to psychotic diseases and affective disorders was reported in some cases after the beginning or after changes of an antipsychotic therapy. also in treatment with Aripiprazol (see Section 4.8).</seg>
<seg id="113">"" "" "" "late dyskinesia: in clinical trials lasting one year or less, there were occasional reports of dyskinesia occurring during the treatment with Aripiprazol." "" "" ""</seg>
<seg id="114">"" "" "" "clinical manifestations of a mn are high fever, rigidity, changing levels of consciousness and signs of autonomous instability (irregular pulse or blood pressure, tachycardia, sweating and arrhythmia)." "" "" ""</seg>
<seg id="115">A weight gain is generally observed in schizophrenia patients and in patients with bipolar mania because of comorbidities in which weight gain is known as side effects or an unhealthy lifestyle and could lead to serious complications.</seg>
<seg id="116">"" "" "" "patients should be advised to inform their doctor if they are pregnant, or during the treatment with Aripiprazol" "" "" ""</seg>
<seg id="117">The following side effects were more common (≥ 1 / 100) than placebo or were classified as possible medically relevant side effects of the medicine (*):</seg>
<seg id="118">In two placebo-controlled monotherapy studies with flexible dosage over 3 weeks with patients with a manic or mixed episode of bipolar I disorder presented Aripiprazol a versus placebo superior efficacy in reducing manic symptoms over 3 weeks.</seg>
<seg id="119">58 In a placebo-controlled trial over 6 weeks with patients with a manic or mixed episode of bipolar-I disorder with or without psychotic characteristics which partially over 2 weeks did not respond to lithium or valproat monotherapy with therapeutic serum levels resulted in a superior efficacy in reducing manic symptoms compared to monotherapy with lithium or valproate.</seg>
<seg id="120">"" "" "" "in a placebo-controlled trial over 26 weeks followed by a long-term enlargement period over 74 weeks in manic patients who had reached remission with Aripiprazol during a stabilisation phase, mainly in preventing a bipolar relapse." "" "" ""</seg>
<seg id="121">"" "" "" "in rabbits, these effects were based on dosages leading to prepositions of the 3 and 11 times the middle Steady state AUC at the recommended clinical phase." "" "" ""</seg>
<seg id="122">Patients who have difficulty swallowing ABILIFY tablets may alternatively take tablets to ABILIFY tablets (see Section 5.2).</seg>
<seg id="123">"" "" "" "late dyskinesia: in clinical trials lasting one year or less, there were occasional reports of dyskinesia occurring during the treatment with Aripiprazol." "" "" ""</seg>
<seg id="124">71 In a placebo-controlled trial over 6 weeks with patients with a manic or mixed episode of bipolar-I-disturbance with or without psychotic characteristics which partially over 2 weeks did not respond to lithium or valproat monotherapy with therapeutic serum levels resulted in a superior efficacy in reducing manic symptoms compared to monotherapy with lithium or valproate.</seg>
<seg id="125">Patients who have difficulty swallowing ABILIFY tablets may alternatively take tablets to ABILIFY tablets (see Section 5.2).</seg>
<seg id="126">"" "" "" "late dyskinesia: in clinical trials lasting one year or less, there were occasional reports of dyskinesia occurring during the treatment with Aripiprazol." "" "" ""</seg>
<seg id="127">84 In a placebo-controlled trial over 6 weeks with patients with a manic or mixed episode of bipolar-I-disturbance with or without psychotic characteristics which partially over 2 weeks did not respond to lithium or valproat monotherapy with therapeutic serum levels resulted in a superior efficacy in reducing manic symptoms compared to monotherapy with lithium or valproate.</seg>
<seg id="128">200 mg of fructose per ml 400 mg of Sucrose per ml 1.8 mg of methyl-4-hydroxybenzoate (E218) each ml 0.2 mg of proyl-4 hydroxybenzoate (E216) per ml.</seg>
<seg id="129">"" "" "" "the recommended starting dose for ABILIFY is 15 mg once a day, independent of meals as monotherapy or combination therapy (see Section 5.1)." "" "" ""</seg>
<seg id="130">"" "" "" "to prevent recurrence of manic episodes in patients who have already received Aripiprazol, the therapy should be continued with the same dose." "" "" ""</seg>
<seg id="131">"" "" "" "late dyskinesia: in clinical trials lasting one year or less, there were occasional reports of dyskinesia occurring during the treatment with Aripiprazol." "" "" ""</seg>
<seg id="132">"" "" "" "hyperglycemia, in some cases extremely and associated with ketoacidosis or hyperosmolarem coma or death, was reported in patients who were treated with atypical antipsychotic agents, including ABILIFY." "" "" ""</seg>
<seg id="133">There is no precise risk assessment for hyperglycemia-related adverse events in patients treated with ABILIFY and other atypical antipsychotic drugs that allow direct comparisons.</seg>
<seg id="134">92 in a clinical study with healthy volunteers a highly effective CYP2D6 inhibitor (chinidin) increased the AUC of Aripiprazol by 107% while the CMAx remained unchanged.</seg>
<seg id="135">Diltiazem or escitalopram) or CYP2D6 together with ABILIFY can be administered together with a moderate increase in Aripiprazol- concentrations.</seg>
<seg id="136">"" "" "" "in a controlled trial over 12 weeks, the incidence of EPS 23.5% in patients under Aripiprazol-" "" "" ""</seg>
<seg id="137">It is presumed that the effectiveness of Aripiprazl in schizophrenia and bipolar-I disorder on the combination of a partially agonistic effect on dopamine D2- and serotonin 5HT1 receptors and an antagonistic effect on serotonin 5HT2a receptors is mediated.</seg>
<seg id="138">In an Olanzapine-controlled multi-blind study at schizophrenia more than 26 weeks ago which included 314 patients and in which the primary study target 'weight gain' was included in significantly less patients a weight gain of at least 7% compared to the initial value (i.e. an increase of at least 5.6 kg) at an average weight of ca.</seg>
<seg id="139">97 In a placebo-controlled monotherapy trial over 3 weeks with fixed dosage with patients with a manic or mixed episode of bipolar I disorder showed Aripiprazol versus placebo no superior efficacy.</seg>
<seg id="140">In a relative bioavailability study comparing the pharmacokinetics of 30 mg Aripiprazol as a solution for taking with 30 mg Aripiprazol in tablet form in healthy subjects lay the relationship between the geometrical CMAx mean value of the solution and the value of the tablets at 122% (N = 30).</seg>
<seg id="141">99 Furthertheless a cholelithiasis was detected as a result of the precipitation of sulfate conjugates of yopprazol in the gall of monkeys after repeated oral administration of 25 to 125 mg / kg / day (1 to 3 times the recommended maximum dose in humans based on mg / m2).</seg>
<seg id="142">"" "" "" "in rabbits, these effects were observed after dosages which led to exposures of the 3 and 11 times the middle Steady state AUC at the recommended clinical maximum dose." "" "" ""</seg>
<seg id="143">ABILIFY injection solution is used to quickly control agility and behavior in patients with schizophrenia or in patients with manic episodes of bipolar I disorder if oral therapy is not appropriate.</seg>
<seg id="144">"" "" "" "once it is clinically appropriate, the treatment with Aripiprazol injection solution should be terminated and started with oral application of Aripiprazol." "" "" ""</seg>
<seg id="145">"" "" "" "in order to increase the resorption and minimize the variability, an injection in the M. Deltoideus or deep into the gluteus maximus muscle is recommended with circumvention of adipous regions." "" "" ""</seg>
<seg id="146">A lower dose of 5.25 mg (0.7 ml) may be given depending on the individual clinical status taking into account the medicines used for maintenance or acute therapy (see section 4.5).</seg>
<seg id="147">"" "" "" "if a further oral treatment with Aripiprazol is indicated, see the summary of the characteristics of the medicine on ABILIFY tablets, ABILIFY melt tablets or ABILIFY solution." "" "" ""</seg>
<seg id="148">There are no investigations about the effectiveness of Aripiprazol induction solution in patients with agility and behavioural disorders that were otherwise caused by schizophrenia and manic episodes of bipolar-I disorder.</seg>
<seg id="149">"" "" "" "if parenteral therapy with benzodiazepins is considered necessary in addition to the Aripiprazol induction solution, patients should be observed in terms of extreme sedation or blood pressure drop (see section 4.5)." "" "" ""</seg>
<seg id="150">Investigations on the safety and efficacy of Aripiprazol Injection Solution are not available for patients with alcohol or drug poisoning (prescribed or illegal drugs).</seg>
<seg id="151">"" "" "" "Aripiprazol should be used with caution in patients with known cardiovascular diseases (myocardial infarction or ischemic heart disease, cardiac insufficiency, hypovolemia, treatment with blood pressure lowering drugs) or hypertension (including active and malignant forms)." "" "" ""</seg>
<seg id="152">"" "" "" "late dyskinesia: in clinical trials lasting one year or less, there were occasional reports of dyskinesia occurring during the treatment with Aripiprazol." "" "" ""</seg>
<seg id="153">"" "" "" "clinical manifestations of a mn are high fever, stiffness, changing levels of consciousness and signs of autonomous instability (irregular pulse or blood pressure, tachycardia, sweating and arrhythmia)." "" "" ""</seg>
<seg id="154">"" "" "" "polydipsy, polyuria, polyphagia and weakness) are observed and patients with diabetes mellitus or with risk factors for diabetes mellitus should be regularly monitored with regard to worsening of glucose levels." "" "" ""</seg>
<seg id="155">A weight gain is generally observed in schizophrenia patients and patients with bipolar mania because of comorbidities in which weight gain is known as side effects or an unhealthy lifestyle and could lead to serious complications.</seg>
<seg id="156">"" "" "" "nevertheless, the intensity of Sedation was greater compared with the after sole administration of Aripiprazol, in a study where healthy volunteers were administered intramuscular (15 mg dose) and the simultaneous Lorazepam (2 mg dose) intramuscular." "" "" ""</seg>
<seg id="157">"" "" "" "105 The H2 antagonist Famotidin, a gastric acid blocker, decreases the absorption rate of Aripiprazol, but this effect is considered clinically irrelevant." "" "" ""</seg>
<seg id="158">In CYP2D6 'bad' (= 'poor') Metabolic regulators can result in higher plasma concentrations of CYP3A4 in higher plasma concentrations of Aripiprazol.</seg>
<seg id="159">Other highly effective inhibitors of CYP3A4 such as Itraconazole and HIV- proteaseinhibitors should have similar effects and therefore similar can-reductions should be made.</seg>
<seg id="160">"" "" "" "after the CYP2D6- or 3A4 inhibitors, the dose of ABILIFY should be lifted to the dose level before the beginning of the accompanying therapy." "" "" ""</seg>
<seg id="161">"" "" "" "106 Lorazepam (2 mg dose) were administered intramuscular, the intensity of the Sedation was greater compared to the after sole administration of Aripiprazol." "" "" ""</seg>
<seg id="162">The following side effects occurred more frequently in clinical trials involving Aripiprazol injection solution than placebo or were classified as possible medically relevant side effects (*) (see Section 5.1):</seg>
<seg id="163">"" "" "" "the frequency of the side effects listed below is defined according to the following criteria: often (≥ 1 / 100, &lt; 1 / 10); occasionally (≥ 1 / 1000, &lt; 1 / 100)." "" "" ""</seg>
<seg id="164">107 The following side effects were more frequent (≥ 1 / 100) than placebo or were classified as possible medically relevant side effects (*) in clinical studies with oral Aripiprazol (see Section 5.1):</seg>
<seg id="165">"" "" "" "in a placebo-controlled long-term study over 26 weeks, the incidence of EPS was 19% in patients with Aripiprazol- treatment and 13.1% in patients under placebo." "" "" ""</seg>
<seg id="166">"" "" "" "in another study over 12 weeks, the incidence of EPS 26.6% in patients with Aripiprazol- treatment and 17,6% for those under lithium-treatment." "" "" ""</seg>
<seg id="167">In the long-term maintenance phase over 26 weeks in a placebo-controlled trial the incidence of EPS 18.2% for patients with Aripiprazol treatment and 15.7% for patients treated with placebo.</seg>
<seg id="168">A comparison between the patient groups under Aripiprazol and placebo in which potentially clinically significant changes in routine controlled laboratory parameters showed no medically significant differences.</seg>
<seg id="169">Increases in CPK (creatinphosphokinase) - generally temporary and asymptomatic - were observed at 3.5% of patients treated with Aripiprazol compared to 2.0% of patients treated with placebo.</seg>
<seg id="170">"" "" "" "the malignant neuroleptic syndrome, late dyskinesia, and increased mortality in elderly dementia patients, hyperglycemia and diabetes mellitus (see section 4.4)." "" "" ""</seg>
<seg id="171">110 and behavioural disturbances was the Aripiprazol induction solution associated with statistically significant improvements of agility / behavioural disorders compared to placebo and was similar to Haloperidol.</seg>
<seg id="172">In a placebo-controlled short-term trial (24 h) with 291 patients with bipolar disorder as well as agility and behavioural disorders the Aripiprazol induction solution was associated with a statistically significant increase in symptoms with regard to placebo and similar to the Lorazepam reference arm.</seg>
<seg id="173">The observed mean improvement from baseline value on the PANSS Excitement Component score at the primary 2-hour end point was 5.8 for placebo and 9.6 for Lorazepam and 8.7 for Aripiprazol.</seg>
<seg id="174">"" "" "" "in analyses of sub-groups in patients with mixed episodes or patients with severe agility, a similar efficacy was observed in terms of the overall population, but a statistical significance could be determined because of a reduced number of patients." "" "" ""</seg>
<seg id="175">In three placebo-controlled short-term studies (4 to 6 weeks) with positive or negative symptoms Aripiprazol (oral) compared to placebo showed a statistically significant improvement of the psychotic symptoms.</seg>
<seg id="176">"" "" "" "in a half-surgery controlled trial, 52% of responder patients enrolled in the study were similar in both groups (Aripiprazol 77% (oral) and haloperidol 73%)." "" "" ""</seg>
<seg id="177">"" "" "" "current values from measurement scales defined as secondary study targets, including PANSS and Montgomery-Asberg depression rates, showed significantly greater improvement than in haloperidol." "" "" ""</seg>
<seg id="178">In a placebo-controlled trial over 26 weeks of stabilised patients with chronic schizophrenia demonstrated for Aripiprazol (oral) a significantly higher reduction of the return rate that was found at 34% in the Aripiprazol- (oral) group and 57% below placebo.</seg>
<seg id="179">In an Olanzapine-controlled multi-blind study in schizophrenia over 26 weeks that included 314 patients and in which the primary study target 'weight gain' was included in significantly less patients a weight gain of at least 7% compared to the initial value (i.e. an increase of at least 5.6 kg) at an average weight of ca.</seg>
<seg id="180">111 In a placebo-controlled trial over 6 weeks with patients with a manic or mixed episode of bipolar-I disorder with or without psychotic characteristics which partially over 2 weeks did not respond to lithium or valproat monotherapy with therapeutic serum levels resulted in a superior efficacy in reducing manic symptoms compared to monotherapy with lithium or valproate.</seg>
<seg id="181">"" "" "" "in a placebo-controlled trial over 26 weeks followed by a 74-week study expansion in manic patients who had reached remission with Aripiprazol during a stabilisation phase, mainly in preventing a bipolar relapse." "" "" ""</seg>
<seg id="182">The Aripiprazol AUC is 90% larger in the first 2 hours after intramuscular injection of the same dose as tablet; systemic exposure was similar between the two formulations.</seg>
<seg id="183">"" "" "" "in 2 studies involving healthy volunteers, the average time to reach the maximum plasma level was 1 to 3 hours after application." "" "" ""</seg>
<seg id="184">The gift of Aripiprazol induction solution was well tolerated by rats and monkeys and resulted in no direct toxicity of a target organ after repeated use in a systemic exposure (AUC) which was 15 or 5 times over the maximum human-therapeutic exposure of 30 mg intramuscular.</seg>
<seg id="185">Studies on the reproductive toxicity following IV application showed no safety-relevant concerns following maternal exposure that lay in 15- (rats) and 29 times (rabbits) above the maximum human-therapeutic exposure of 30 mg.</seg>
<seg id="186">"" "" "" "based on conventional research with Aripiprazol (oral) for safety spatology, toxicity in repeated application, reproductive toxicity, genotoxicity and the kanogenic potential, pre-clinical data could not detect any particular danger to humans." "" "" ""</seg>
<seg id="187">"" "" "" "toxicological significant effects were only observed in doses or exposures, which significantly exceeded the maximum dosage or exposure in humans; therefore, they have limited or no importance for clinical use." "" "" ""</seg>
<seg id="188">The effects included a dose-dependent adrenal-loss-toxicity (Lipofuscin-Pigment accumulation and / or parenchymal loss) in rats after 104 weeks at 20 to 60 mg / kg / day (equivalent to 3 to 10 times the mean cell-state exposition (AUC) at the recommended maximum dose in humans.</seg>
<seg id="189">Cholelithiasis was also detected as a result of the precipitation of sulfate conjugates from 25 to 125 mg / kg / day (1 to 3 times of the recommended clinical dose or from 16- to 81-times the recommended maximum dose in humans based on mg / m2).</seg>
<seg id="190">"" "" "" "in rabbits, these effects were observed after dosages which led to exposures of the 3 and 11-times the mean cell state AUC at the recommended clinical maximum dose." "" "" ""</seg>
<seg id="191">"" "" "" "pharmaceutical vigilance system The authorisation holder must ensure that before and while the product is marketed, the pharmacovigilance system, as described in version 1.0 of module 1.8.1. of the authorisation application, is furnished and functional." "" "" ""</seg>
<seg id="192">"" "" "" "according to the" CHMP Guideline on Risk Management Systems for "products for human use," the updated risk management plan must be submitted simultaneously with the next Periodic Safety Update Report (PSUR). "" "" "" "</seg>
<seg id="193">"" "" "" "in addition, an updated risk management plan must be submitted when new information is being disclosed that may affect the current security data, the pharmacovigilance plan or risk management measures within 60 days." "" "" ""</seg>
<seg id="194">14 x 1 tablets 28 x 1 tablets 56 x 1 tablets 98 x 1 tablets</seg>
<seg id="195">EU / 1 / 04 / 276 / 276 / 276 / 002 28 x 1 tablets EU / 1 / 04 / 276 / 004 56 x 1 tablets EU / 1 / 04 / 276 / 276 / 276 / 276 / 276 / 005 98 x 1 tablets</seg>
<seg id="196">EU / 1 / 04 / 276 / 006 14 x 1 tablets EU / 1 / 04 / 276 / 008 49 x 1 tablets EU / 1 / 04 / 276 / 276 / 276 / 276 / 276 / 276 / 276 / 276 / 276 / 276 / 010 98 x 1 tablets</seg>
<seg id="197">EU / 1 / 04 / 276 / 011 28 x 1 tablets EU / 1 / 04 / 276 / 013 56 x 1 tablets EU / 1 / 04 / 276 / 014 56 x 1 tablets EU / 1 / 04 / 276 / 276 / 276 / 015 98 x 1 tablets</seg>
<seg id="198">EU / 1 / 04 / 276 / 017 28 x 1 tablets EU / 1 / 04 / 276 / 018 56 x 1 tablets EU / 1 / 04 / 276 / 018 56 x 1 tablets EU / 1 / 04 / 276 / 276 / 020 98 x 1 tablets</seg>
<seg id="199">"" "" "" "if any of the side effects listed you have significantly impaired or you notice side effects that are not stated in this information, please inform your doctor or pharmacist." "" "" ""</seg>
<seg id="200">"" "" "" "it is used for the treatment of adults suffering from a disease characterized by symptoms such as hearing, seeing or feeling of things that are not present, distrust, delusions, unrelated language, incoherent behavior and bad mood." "" "" ""</seg>
<seg id="201">"" "" "" "ABILIFY is used in adults to treat a condition with excessive feeling of feeling excessive energy, much less sleep than usual, very fast talk with fast-changing ideas and sometimes strong irritability." "" "" ""</seg>
<seg id="202">"" "" "" "high blood sugar or cases of diabetes (diabetes) in the family Anzures involuntary, irregular muscle movements, especially in the face heart or vascular disease in the family, stroke or temporary cerebral thrombosis (ischemic ischemic attack / TIA), abnormal blood pressure." "" "" ""</seg>
<seg id="203">"" "" "" "if you are suffering from dementia (loss of memory or other mental abilities), you or a relative should tell your doctor if you have ever had a stroke or a temporary cerebral thrombosis." "" "" ""</seg>
<seg id="204">"" "" "" "inform your doctor promptly if you suffer from stiffness or stiffness combined with high fever, sweating, altered mental condition or very fast or irregular heartbeat." "" "" ""</seg>
<seg id="205">"" "" "" "children and adolescents ABILIFY are not to be used in children and adolescents, as it has not been studied in patients under the age of 18." "" "" ""</seg>
<seg id="206">"" "" "" "if you are taking ABILIFY with other medicines, tell your doctor or pharmacist if you are taking other medicines or applying it recently, even if it is not prescription medicine." "" "" ""</seg>
<seg id="207">Medicines used to treat heart rhythms antidepressants or herbal medicines used to treat depression and anxiety states are used for treating HIV infection to anticonvulsants used to treat epilepsy.</seg>
<seg id="208">"" "" "" "pregnancy and lactation should not take ABILIFY if you are pregnant, unless you have discussed this with your doctor." "" "" ""</seg>
<seg id="209">Traffic tightness and operation of machinery you should not drive car and operate no tools or machines until you know how ABILIFY works with you.</seg>
<seg id="210">"" "" "" "after consultation with your doctor, please consult your doctor if you are aware that you suffer from a intolerance to certain sugars." "" "" ""</seg>
<seg id="211">Please talk to your doctor or pharmacist if you have the impression that the effect of ABILIFY is too strong or too weak.</seg>
<seg id="212">"" "" "" "even if you feel better, change or replace the daily dose of ABILIFY without asking your doctor beforehand." "" "" ""</seg>
<seg id="213">If you have taken a larger amount of ABILIFY tablets when you should notice that you have taken more ABILIFY tablets than recommended by your doctor (or if someone has taken some of your ABILIFY tablets) contact your doctor promptly.</seg>
<seg id="214">"" "" "" "if you forgot to take ABILIFY when you miss a dose, take the missed dose once you think about it, but do not take twice a day." "" "" ""</seg>
<seg id="215">"" "" "" "frequent side effects (in more than 1 out of 100, less than 1 out of 10 treatment) uncontrollable sugar movements, headache, fatigue, nausea, vomiting, increased saliva production, drowsiness, anxiety, drowsiness, trembling and blurred vision." "" "" ""</seg>
<seg id="216">"" "" "" "occasional side effects (with more than 1 of 1,000 or less than 1 out of 100 patients) can feel dizzy, especially when standing out of a lying or sitting position or they can determine an accelerated pulse." "" "" ""</seg>
<seg id="217">Inform your doctor or pharmacist if any of the side effects listed you have considerably impaired or you notice side effects that are not stated in this use information.</seg>
<seg id="218">Like ABILIFY looks and contents of the package ABILIFY 5 mg tablets are rectangular and blue with embossing of A-007 and 5 on one side.</seg>
<seg id="219">"" "" "" "inform your doctor promptly if you suffer from stiffness or stiffness combined with high fever, sweating, altered mental condition or very fast or irregular heartbeat." "" "" ""</seg>
<seg id="220">"" "" "" "even if you feel better, change or replace the daily dose of ABILIFY without asking your doctor beforehand." "" "" ""</seg>
<seg id="221">Like ABILIFY looks and contents of the package ABILIFY 10 mg tablets are rectangular and pink with embossing of A-008 and 10 on one side.</seg>
<seg id="222">"" "" "" "inform your doctor promptly if you suffer from stiffness or stiffness combined with high fever, sweating, altered mental condition or very fast or irregular heartbeat." "" "" ""</seg>
<seg id="223">"" "" "" "even if you feel better, change or replace the daily dose of ABILIFY without asking your doctor beforehand." "" "" ""</seg>
<seg id="224">Like ABILIFY looks and contents of the package ABILIFY 15 mg tablets are round and yellow with embossing of A-009 and 15 on one side.</seg>
<seg id="225">"" "" "" "inform your doctor promptly if you suffer from stiffness or stiffness combined with high fever, sweating, altered mental condition or very fast or irregular heartbeat." "" "" ""</seg>
<seg id="226">"" "" "" "even if you feel better, change or replace the daily dose of ABILIFY without asking your doctor beforehand." "" "" ""</seg>
<seg id="227">"" "" "" "as ABILIFY looks and contents of the pack ABILIFY 30 mg tablets are round and pink, with embossing of A-011 and 30 on one side." "" "" ""</seg>
<seg id="228">"" "" "" "171 If you suffer from dementia (loss of memory or other mental abilities), you or a relative should tell your doctor if you have ever had a stroke or a temporary cerebral thrombosis." "" "" ""</seg>
<seg id="229">"" "" "" "inform your doctor promptly if you suffer from stiffness or stiffness combined with high fever, sweating, altered mental condition or very fast or irregular heartbeat." "" "" ""</seg>
<seg id="230">Important information on certain other components of ABILIFY patients who are not allowed to take phenylalanine should be observed that ABILIFY are contained melting tablets aspartame as a source for phenylalanine.</seg>
<seg id="231">"" "" "" "immediately after opening the blister pack, take the tablet with dry hands and put the tablet in the whole on the tongue." "" "" ""</seg>
<seg id="232">"" "" "" "even if you feel better, change or replace the daily dose of ABILIFY without asking your doctor beforehand." "" "" ""</seg>
<seg id="233">If you have taken a larger amount of ABILIFY when you should determine that you have taken more ABILIFY melt tablets than recommended by your doctor (or if someone else has taken some of your ABILIFY melting tablets) contact your doctor promptly.</seg>
<seg id="234">"" "" "" "calcium trimetasilicate, Croscarecless sodium, Cropovidon, siliciumdioxide, xylitol, microcrystalline cellulose, aspartame, acid stearate, iron (III) - oxide (E172)." "" "" ""</seg>
<seg id="235">"" "" "" "like ABILIFY, the ABILIFY 10 mg fusion tablets are round and pink, with the" A "over" 640 "on one side and" 10 "on the other." "" "" ""</seg>
<seg id="236">"" "" "" "177 If you suffer from dementia (loss of memory or other mental abilities), you or a relative should tell your doctor if you have ever had a stroke or a temporary cerebral thrombosis." "" "" ""</seg>
<seg id="237">"" "" "" "inform your doctor promptly if you suffer from stiffness or stiffness combined with high fever, sweating, altered mental condition or very fast or irregular heartbeat." "" "" ""</seg>
<seg id="238">"" "" "" "calcium trimetAsian licate, Cropovidon, Si, xylitol, microcrystalline cellulose, aspartame, acid stearate, iron (III) - hydroxide oxide x H2O (E172)." "" "" ""</seg>
<seg id="239">Like ABILIFY looks and contents of the pack The ABILIFY 15 mg Melting tablets are round and yellow with embossing of "A" over "641" on one side and "15" on the other.</seg>
<seg id="240">"" "" "" "183 If you suffer from dementia (loss of memory or other mental abilities), you or a relative should tell your doctor if you have ever had a stroke or a temporary cerebral thrombosis." "" "" ""</seg>
<seg id="241">"" "" "" "inform your doctor promptly if you suffer from stiffness or stiffness combined with high fever, sweating, altered mental condition or very fast or irregular heartbeat." "" "" ""</seg>
<seg id="242">"" "" "" "like ABILIFY, the ABILIFY 30 mg fusion tablets are round and pink, with the" A "over" 643 "on one side and" 30 "on the other." "" "" ""</seg>
<seg id="243">"" "" "" "inform your doctor promptly if you suffer from stiffness or stiffness combined with high fever, sweating, altered mental condition or very fast or irregular heartbeat." "" "" ""</seg>
<seg id="244">Traffic tightness and operation of machinery you should not drive car and operate no tools or machines until you know how ABILIFY works with you.</seg>
<seg id="245">190 Important information about certain other components of ABILIFY Anyone ml ABILIFY solution for intake contains 200 mg of fructose and 400 mg of Sucrose.</seg>
<seg id="246">"" "" "" "if your doctor tells you that you are suffering from a intolerance to certain sugars, contact your doctor before taking this medicine." "" "" ""</seg>
<seg id="247">The dose of ABILIFY solution for taking must be measured using the calibrated measuring cup or the calibrated 2 ml dropper pette included in the package.</seg>
<seg id="248">Please talk to your doctor or pharmacist if you have the impression that the effect of ABILIFY is too strong or too weak.</seg>
<seg id="249">If you have taken a larger amount of ABILIFY when you should determine that you have taken more ABILIFY solution as recommended by your doctor (or if someone has taken ABILIFY solution for intake) contact your doctor promptly.</seg>
<seg id="250">"" "" "" "dinatrium edetate, fructose, glycerol, lactic acid, propyl-4 hydroxybenzoate (E216), propyl hydroxide, sucrose, purified water and natural orange-cream flavour with other natural flavours." "" "" ""</seg>
<seg id="251">"" "" "" "as ABILIFY looks and contents of the package ABILIFY 1 mg / ml solution for taking is a clear, colorless to light yellow liquid in bottles with a child-safe polypropylene seal and 50 ml, 150 ml or 480 ml." "" "" ""</seg>
<seg id="252">"" "" "" "ABILIFY injection solution is used for the rapid treatment of increased unrest and desperate behavior that can occur as symptoms of a disease characterized as symptoms such as: hearing, seeing or feeling of things that are not present, distrust, delusions, disconnected speech, incoherent speech." "" "" ""</seg>
<seg id="253">"" "" "" "people with this disease can also feel depressed, feel guilty, anxious or tense. excessive feeling of feeling excessive energy to have much less sleep than usual, very quick talk with changing ideas and sometimes strong irritability." "" "" ""</seg>
<seg id="254">"" "" "" "inform your doctor promptly if you suffer from stiffness or stiffness combined with high fever, sweating, altered mental condition or very fast or irregular heartbeat." "" "" ""</seg>
<seg id="255">"" "" "" "if you use ABILIFY with other medicines, tell your doctor or pharmacist if you are taking other medicines or applying it recently, even if it is not prescription medicine." "" "" ""</seg>
<seg id="256">Medicines used to treat heart rhythms antidepressants or herbal medicines used to treat depression and anxiety states are used for treating HIV infection to anticonvulsants used to treat epilepsy.</seg>
<seg id="257">"" "" "" "196 pregnancy and lactation you should not apply ABILIFY if you are pregnant, unless you have discussed this with your doctor." "" "" ""</seg>
<seg id="258">Traffic tightness and operation of machinery you should not drive car and operate no tools or machines if you feel behaved after the application of ABILIFY injections solution.</seg>
<seg id="259">"" "" "" "if you have doubts that you receive more ABILIFY injection solution than you need to believe, please talk to your doctor or nurse about it." "" "" ""</seg>
<seg id="260">"" "" "" "frequent side effects (in more than 1 out of 100, less than 1 out of 10 treatment) of ABILIFY injection solution are tiredness, dizziness, headaches, restlessness, nausea and vomiting." "" "" ""</seg>
<seg id="261">"" "" "" "occasional side effects (in more than 1 out of 100 patients) Some people can feel dizzy, feel dizzy or have a fast pulse, have a dry feeling in the mouth or feel depressed." "" "" ""</seg>
<seg id="262">"" "" "" "frequent side effects (in more than 1 out of 100, less than 1 out of 10 treatment) uncontrollable sugar movements, headache, fatigue, nausea, vomiting, increased saliva production, drowsiness, anxiety, drowsiness, trembling and blurred vision." "" "" ""</seg>
<seg id="263">"" "" "" "if you need more information about your illness or treatment, please read the packing supplement (also included in the EPAR) or contact your doctor or pharmacist." "" "" ""</seg>
<seg id="264">"" "" "" "only under the supervision of a qualified oncologist, Abraxane should be applied to the application of Cytostatica (killing of cells) specialized departments." "" "" ""</seg>
<seg id="265">"" "" "" "in patients with certain side effects on the blood or nervous system, the dose may be reduced or the treatment may be interrupted." "" "" ""</seg>
<seg id="266">(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail @ emea.europa.eu http: / / www.emea.europa.eu © EMEA 2007 Reproduction and / or distribution of this document is bound to a protein called "nanoparticles."</seg>
<seg id="267">"" "" "" "the efficacy of Abraxane was studied in a major study involving 460 women with metastatic breast cancer, some of whom had received an anthracycline about three quarters earlier." "" "" ""</seg>
<seg id="268">The effect of Abraxane (in the sole application or as a monotherapy) was compared to the medicine containing a conventional paclitaxel (given in combination with other medicines to reduce side effects).</seg>
<seg id="269">"" "" "" "in total, 72 (31%) of 229 patients treated with Abraxane received treatment compared to 37 (16%) of the 225 patients with conventional paclitaxel." "" "" ""</seg>
<seg id="270">"" "" "" "only patients who were treated for the first time for metastatic breast cancer were not seen in terms of efficacy indicators, such as time to deterioration of disease and survival." "" "" ""</seg>
<seg id="271">"" "" "" "in contrast, patients who previously had other treatments of their metastatic breast cancer showed that Abraxane was more effective than conventional paclitaxel." "" "" ""</seg>
<seg id="272">"" "" "" "it may also not be used in patients who are breastfeeding, or at the beginning of treatment, have low neutrospinal cords in the blood." "" "" ""</seg>
<seg id="273">"" "" "" "the Medicines Committee for Medicinal Products (CHMP) states that, in contrast to other paclitaxel drugs, it was not more effective than conventional paclitaxel, and that it does not have to be given with other medicines to decrease side effects." "" "" ""</seg>
<seg id="274">"" "" "" "January 2008, the European Commission issued an authorisation for the placing of Abraxane in the European Union." "" "" ""</seg>
<seg id="275">Abraxane-monotherapy is indicated for the treatment of metastatic breast cancer in patients in which the first-line treatment for metastatic disease is missing and is not indicated for the standard anthracycline-containing therapy (see section 4.4).</seg>
<seg id="276">In patients with severe neutropenia (Neutrophilanthropology &lt; 0.50 x 109 / l over a period of one week or longer) or severe sensory neuropathy during the Abraxane therapy the dose should be reduced to 220 mg / m2.</seg>
<seg id="277">"" "" "" "in sensory neuropathy Level 3, the treatment is to be interrupted until an improvement is reached on level 1 or 2, and at all subsequent cycles the dose must be reduced." "" "" ""</seg>
<seg id="278">There is currently no adequate data for the recommendation of dose adjustments in patients with mild to moderate impairment of the liver function (see section 4.4. and 5.2).</seg>
<seg id="279">No studies with patients with impaired renal function have been carried out and there is currently no adequate data for the recommendation of dose adjustments in patients with impairment of kidney function (see Section 5.2).</seg>
<seg id="280">"" "" "" "abrasion is not recommended for use in children under 18 years of age, due to not sufficient data for safety and efficacy." "" "" ""</seg>
<seg id="281">Abraxane is a albumin-bound nanoparticle formulation of paclitaxel that could have essentially other pharmacological characteristics than other formulations of paclitaxel (see Section 5.1 and 5.2).</seg>
<seg id="282">"" "" "" "if an allergic reaction occurs, the medicine should be stopped immediately and a symptomatic treatment should be initiated, and the patient must not be treated with paclitaxel again." "" "" ""</seg>
<seg id="283">"" "" "" "in patients, no new abrasion treatment cycles should be resumed until the neutrons rise again &gt; 1.5 x 109 / l and the thrombocyte number rose to &gt; 100 x 109 / l again." "" "" ""</seg>
<seg id="284">Patients with severe liver dysfunction (Bilirubin &gt; 5 x ULN or ASL / ALT &gt; 10 x ULN) should not be treated with Abraxane.</seg>
<seg id="285">"" "" "" "while a clearly marked Kardiotoxicity was not detected, cardiac outages in the indicated patient collective are not unusual, especially in patients with previous anthracycline treatment or underlying heart or lung disease." "" "" ""</seg>
<seg id="286">"" "" "" "if the patients receive nausea, vomiting and diarrhoea after the gift of Abraxane, they can be treated with the usual antiemetic agents and constitious remedies." "" "" ""</seg>
<seg id="287">"" "" "" "Abraxane should not be used in pregnant women or for women in childbearing age, who do not exercise effective eption contraception, except for the treatment of the mother with paclitaxel is essential." "" "" ""</seg>
<seg id="288">"" "" "" "during and up to 1 month after the treatment with Abraxane, women in childbearing age should apply a reliable contraception method." "" "" ""</seg>
<seg id="289">"" "" "" "male patients treated with Abraxane will be advised, while and up to six months after the treatment no child will be able to testify." "" "" ""</seg>
<seg id="290">"" "" "" "male patients should be advised prior to the treatment of a sperm conservation, as the treatment with Abraxane is the possibility of irreversible infertility." "" "" ""</seg>
<seg id="291">"" "" "" "Abraxane can cause side effects like tiredness (very frequent) and dizziness (frequent), which can affect the transport tightness and the ability to operate machinery." "" "" ""</seg>
<seg id="292">"" "" "" "listed below are the most common and most important incidents of side effects reported in 229 patients with metastatic breast cancer, which were treated once every three weeks with 260 mg / m2 of Abraxane." "" "" ""</seg>
<seg id="293">Neutropenia was the most eye-catching important hematological toxicity (reported in 79% of patients) and was fast reversible and dose-dependent; leukopenia was reported in 71% of patients.</seg>
<seg id="294">Anemia (Hb &lt; 10 g / dl) was observed in 46% of patients treated with Abraxane and was severe in three cases (Hb &lt; 8 g / dl).</seg>
<seg id="295">"" "" "" "in Table 1, the side effects are reported which occurred in combination with the gift of Abraxane as monotherapy for each dose and indication in trials (N = 789)." "" "" ""</seg>
<seg id="296">"" "" "" "very common (≥ 1 / 100, &lt; 1 / 100); occasionally (≥ 1 / 1000, &lt; 1 / 100); very rare (≥ 1 / 10)." "" "" ""</seg>
<seg id="297">"" "" "" "occasionally: increased blood pressure, weight gain, increased lactate hydrogenase in the blood, increased glucose in the blood, increased glucose in the blood, reduced potassium in the blood heart disease:" "" "" ""</seg>
<seg id="298">"" "" "" "dysphagy, flatulence, tongue burning, dry mouth, pain in the lower abdomen, soreness in the mouth, oral pains, rectal bleeding disorders of the kidneys and urinary tract:" "" "" ""</seg>
<seg id="299">"" "" "" "pain in the chest wall, weakness of muscles, toothache, chest pain, muscle spasms, pain in skeletal musculature, chest pain, discomfort in the limbs, muscle weakness Very common:" "" "" ""</seg>
<seg id="300">Restlessness 1 The frequency of hypersensitivity reactions is calculated based on a definite in related case in a population of 789 patients</seg>
<seg id="301">"" "" "" "as these events were reported on a voluntary basis during clinical practice, no estimates of the actual frequency were possible and no causal connection with these events was established." "" "" ""</seg>
<seg id="302">Paclitaxel is an optimization microtubules agent that promotes the interaction of microtubules from tubulae and stabilizes microtubules by inhibiting their deolymerisation.</seg>
<seg id="303">"" "" "" "this stabilization leads to a escapement of the normal dynamic reorganization of the microtubular network, which is essential for the vital interphase and the mitotic cell functions." "" "" ""</seg>
<seg id="304">It is known that albumin mediates the transcytosis of plasma components into endothelial cells and in vitro studies have been proven that the presence of albumin promotes the transport of paclitaxel through endothelial cells.</seg>
<seg id="305">It is assumed that this improved transendothelial transport is mediated by the gp-60-albumreceptor and due to the albumbinds protein SPARC (secondary protein acidic rich in cysteine) a paclitaxel accumulation occurs in the tumor area.</seg>
<seg id="306">The use of Abraxane for metastatic breast cancer is supported by data of 106 patients in two argues untreated studies and 454 patients treated in a randomised Phase III trial study.</seg>
<seg id="307">"" "" "" "in a study 43 patients with metastatic breast carcinoma were treated with Abraxane, which was given in the form of an infusion over 30 minutes with a dose of 175 mg / m2." "" "" ""</seg>
<seg id="308">"" "" "" "in the second study, a dose of 300 mg / m2 was used as an infusion over 30 minutes to 63 patients with metastatic breast cancer." "" "" ""</seg>
<seg id="309">This multicenter study was performed in patients with metastatic breast cancer either in the form of solvent containing paclitaxel 175 mg / m2 as a 3-hour infusion with premedication for preventing an allergic reaction (N = 225) or in the form of an allergic reaction (N = 225) or in the form of an allergic reaction (N = 229).</seg>
<seg id="310">"" "" "" "in the study, 64% of patients had a impaired general condition (ECOG 1 or 2), 79% had visceral metastases and 76% had more than 3 metastasels." "" "" ""</seg>
<seg id="311">"" "" "" "14% of patients had previously not received chemotherapy, 27% had only adjuvant chemotherapy, 40% only for metastasis and 19% due to metastasis and adjuvant treatment." "" "" ""</seg>
<seg id="312">"" "" "" "9 Results of the overall response rate and time to progression of the disease, and progression-free survival and survival for patients receiving &gt; First-Line therapy are explained below." "" "" ""</seg>
<seg id="313">Neurotoxicity versus paclitaxel was evaluated by the improvement of a degree for patients who experienced peripheral neuropathy grade 3 at a time during therapy.</seg>
<seg id="314">The natural course of peripheral neuropathy for abrasion on baseline due to the cumulative toxicity of Abraxane after &gt; 6 treatment courses has not been evaluated and remains unknown.</seg>
<seg id="315">The pharmacokinetics of the total paclitaxel after 30- and 180-minute infusions of Abraxane with a dose of 80 to 375 mg / m2 was determined in clinical studies.</seg>
<seg id="316">The exposure to active ingredient (AUC) increased linear from 2653 to 16736 ng.h / ml analogously to a dose of 80 to 300 mg / m2.</seg>
<seg id="317">10 After an intravenous application of Abraxane in patients with metastatic breast cancer in the recommended clinical dose of 260 mg / m2 the Paclitaxel plasma concentration took place in multiphase mode.</seg>
<seg id="318">The average distribution volume was 632 l / m2; the high distribution volume indicates a far-reaching extravascular distribution and / or consecration of paclitaxel.</seg>
<seg id="319">In a study with patients with advanced solid tumours the pharmacokinetic properties of paclitaxel with intravenous 30 minutes infusion of 260 mg / m2 of Abraxane were compared with the values after a 3-hour injection of 175 mg / m2 of solvent containing paclitaxel.</seg>
<seg id="320">The clearance of Paclitaxel was higher (43%) than after a solvent containing paclitaxel and also the distribution volume was higher with Abraxane (53%).</seg>
<seg id="321">In the published literature on in-vitro studies of human liver microsome and tissue layers it reports that paclitaxel is primarily metabolized to 6α-hydroxypaclitaxel and to two smaller metabolites (3 "-p-hydroxypaclitaxel and 6α-hyxypaclitaxel).</seg>
<seg id="322">After a 30-minute infusion of 260 mg / m2 of Abraxane in patients with metastatic breast cancer the mean value for cumulative urination of the unchanged active ingredient was 4% of the total dose of 6α-Hydroxypaclitaxel and 3 "-p-hydroxypaclitaxel.</seg>
<seg id="323">"" "" "" "however, there are only a few data available about patients at the age of over 75, because only 3 patients of this age group participated in pharmacokinetic analysis." "" "" ""</seg>
<seg id="324">"" "" "" "chemical and physical stability was detected at 2 ° C - 8 ° C in original box, and above light light for over 8 hours." "" "" ""</seg>
<seg id="325">Paclitaxel is a cytotoxic anticarcinogenic drug and similar to other potentially toxic substances should be treated with the use of Abraxane caution.</seg>
<seg id="326">Using a sterile syringe slowly injected over a period of at least 1 minute 20 ml of a 9 mg / ml (0.9%) sodium chloride infusion solution into a Abraxane penetration bottle.</seg>
<seg id="327">"" "" "" "after full addition of the solution, the penetration bottle should be at least 5 minutes to ensure a good wetting of the solid material." "" "" ""</seg>
<seg id="328">"" "" "" "then, the deflector should be slowly and gently turned and / or inverted for at least 2 minutes until complete resusability of the powder is performed." "" "" ""</seg>
<seg id="329">"" "" "" "if cavities or sinks are visible, the penetration bottle must be gently inverted in order to achieve a complete resusboard before applying." "" "" ""</seg>
<seg id="330">The exact total dose volume of the 5 mg / ml suspensions necessary for the patient is calculated and the corresponding amount of the reconstituted Abraxane is injected into an empty sterile PVC- or non-PVC infusion bag.</seg>
<seg id="331">Pharmaceutical vigilance system The owner of approval for placing on the market must make sure that the pharmacovigilance system as described in Version 2.0 and presented in module 1.8.1. the authorisation application is and works before and while the medicine is brought into circulation.</seg>
<seg id="332">Risk management plan The owner of approval for the placing on the market is obliged to carry out the studies described in the pharmacovigilance plan and further pharmacovigilance activities described in version 4 of the risk management plan (RMP) and all subsequent updates of the RMP that are agreed with the CHMP.</seg>
<seg id="333">"" "" "" "according to the CHMP directive on risk management systems for use on people, the updated RMP should be submitted simultaneously with the next Periodic Safety Update Report (PSUR)." "" "" ""</seg>
<seg id="334">"" "" "" "in addition, an updated RMP must be submitted • When new information may impact the current security specification, the pharmacovigilance plan or risk management activities • Inquiry of EMEA" "" "" ""</seg>
<seg id="335">"" "" "" "8 hours in the refrigerator in a glass bottle, when it is stored in a box to protect the contents from light." "" "" ""</seg>
<seg id="336">"" "" "" "Abraxane is used to treat breast carcinoma when other therapies have been tried, but not successful, and if you do not get into question for anthracycline-containing therapies." "" "" ""</seg>
<seg id="337">Abraxane may not be used: if you are hypersensitive to Paclitaxel or any of the other components of Abraxane are • if you are breastfeeding • if your white blood cells are humiliated (baseline values for neutrons of &lt; 1.5 x 109 / l - your doctor will inform you about it)</seg>
<seg id="338">"" "" "" "special caution when using Abraxane is required: • If you have a impaired kidney function, if you suffer from numbness, tingling, tingling sensation, touch sensitivity or muscle weakness, if you have heart problems" "" "" ""</seg>
<seg id="339">"" "" "" "if you use Abraxane with other medicines, please inform the doctor if you have other medicines or recently used, even if it is not prescription medicine, as these might cause an interaction with Abraxane." "" "" ""</seg>
<seg id="340">"" "" "" "during and up to 1 month after the treatment with Abraxane, women in childbearing age should apply a reliable contraception method." "" "" ""</seg>
<seg id="341">"" "" "" "in addition, they should be advised prior to the treatment of a sperm conservation, as the possibility of persistent infertility is due to the Abraxane treatment." "" "" ""</seg>
<seg id="342">Transport tightness and the operation of machines Abraxane can cause side effects like tiredness (very frequent) and dizziness (frequent) which can affect the transport tightness and the ability to operate machinery.</seg>
<seg id="343">"" "" "" "if you receive other medicines during your treatment, you should consult your doctor regarding driving or serving machines." "" "" ""</seg>
<seg id="344">"" "" "" "22 • Effect on peripheral nerves (pain and numbness) • pain in one or more joints • pain in the muscles • nausea, diarrhea • vomiting • weakness and tiredness" "" "" ""</seg>
<seg id="345">"" "" "" "frequent Side Effects (reported at least 1 of 100 patients) are: • rash, itching, dry skin, respiratory disorders, abdominal pain • swelling of the mucous membranes or soft tissue, painful mouth or sore tongue, mouthsoor • sleeping disorders" "" "" ""</seg>
<seg id="346">"" "" "" "the rare side effects (at least 1 of 10,000 patients reported) are: • lung infection • skin reaction to another substance after radiotherapy • Blood clots" "" "" ""</seg>
<seg id="347">Inform your doctor or pharmacist if any of the side effects listed you have considerably impaired or you notice side effects that are not stated in this use information.</seg>
<seg id="348">"" "" "" "if it is not used immediately, it can be stored in the glass bottle up to 8 hours in the refrigerator (2 ° C - 8 ° C) in order to protect the contents from light." "" "" ""</seg>
<seg id="349">Each glass bottle contains 100 mg Paclitaxel. • After the reconstitution contains each ml of the Suspension 5 mg Paclitaxel. • The other component is albumin solution from man (contains sodium) sodium caprylate and N acetyltryptophan (Ph.Eur.)).</seg>
<seg id="350">Precautions for the preparation and application of Paclitaxel is a cytotoxic antimicrocarcinogenic drug and as also in other potentially toxic substances should be observed when handling Abraxane.</seg>
<seg id="351">Using a sterile syringe should be injected slowly over a period of 1 minute 20 ml of a 9 mg / ml (0.9%) sodium chloride infusion solution into a Abraxane penetration bottle.</seg>
<seg id="352">"" "" "" "after this, pierce the cup for at least 2 minutes slowly and carefully and / or invert until a complete resusboard is done." "" "" ""</seg>
<seg id="353">"" "" "" "the exact total dose volume of the 5 mg / ml suspensions necessary for the patient, and the corresponding amount of the reconstituted Abraxane in an empty, sterile PVC infusion bag type IV injected." "" "" ""</seg>
<seg id="354">"" "" "" "parenteral drugs should be subjected to any particle and discolouration prior to the application of a visual inspection, whenever the solution or the container permit this." "" "" ""</seg>
<seg id="355">"" "" "" "stability unopened penetration bottles with Abraxane are stable until the date specified on the packaging, when the glass bottle is stored in the box to protect the contents from light." "" "" ""</seg>
<seg id="356">"" "" "" "after the first reconstitution, the suspension should be filled immediately into an infusion bag." "" "" ""</seg>
<seg id="357">"" "" "" "" "" "" "" "member states must ensure that the holder of approval for the placing of goods before the market launch of medical professionals in dialysis centres and retail pharmacies provided with the following information and materials:" "" "" ""</seg>
<seg id="358">"" "" "" "• Educational brochure • summary of the characteristics of the medicine (expert information), labelling and packaging supplement. • With a clear picture of the correct application of the product, refrigerators are provided for transport by patients." "" "" ""</seg>
<seg id="359">"" "" "" "this means that it is similar to a biological medicine approved in the European Union (EU) and contains the same substance (called" "" "" "" "reference drug" "" "" "" ")." "" "" ""</seg>
<seg id="360">"" "" "" "it is used in patients with normal blood pressure levels in which blood transfusion complications may occur, and blood loss can be expected from 900 to 1 800 ml." "" "" ""</seg>
<seg id="361">"" "" "" "treatment with grayamed treatment must be initiated under the supervision of a physician, which has experience in the treatment of patients with diseases indicated for the medicine." "" "" ""</seg>
<seg id="362">"" "" "" "in patients with kidney problems and in patients who want to make an own blood donation, Abyamed is injected into a vein." "" "" ""</seg>
<seg id="363">"" "" "" "the injection can also be made by the patient or his caregiver, provided that they have received an appropriate guidance." "" "" ""</seg>
<seg id="364">"" "" "" "in patients with chronic kidney failure or in patients receiving chemotherapy, haemoglobin values should always be in the recommended range (between 10 and 12 grams per deciliter in adults and between 9.5 and 11 g / dl in children)." "" "" ""</seg>
<seg id="365">"" "" "" "the iron values of all patients must be checked before the treatment to ensure that there is no iron deficiency, and iron supplements should be administered throughout the treatment." "" "" ""</seg>
<seg id="366">"" "" "" "in patients who receive chemotherapy, or in patients with kidney problems, anaemia can be caused by an erythropoietine deficiency or that the body does not respond adequately to the body's own erythropoietin." "" "" ""</seg>
<seg id="367">Erythropoietin is also used before surgery to increase the number of red blood cells and thus reduce the consequences of blood loss.</seg>
<seg id="368">"" "" "" "it is produced by a cell in which a gene (DNA) was placed, which enables them to form epoetin alfa." "" "" ""</seg>
<seg id="369">"" "" "" "when administered as an injection into a vein in a study with 479 patients, the anaemia was compared to the anaemia caused by kidney problems." "" "" ""</seg>
<seg id="370">All patients participating in this study had been injected with Eprex / Erypo for at least eight weeks before they were either switched to seamed or continued to receive Eprex / Erypo.</seg>
<seg id="371">The main indicator of efficacy was the change of haemoglobin values between the beginning of the study and the assessment period in weeks 25 to 29.</seg>
<seg id="372">"" "" "" "in addition, the company presented the results of a study where the effects of injected in the skin were analysed with those of Eprex / Erypo in 114 cancer patients receiving chemotherapy." "" "" ""</seg>
<seg id="373">"" "" "" "in the study with patients suffering from a renaemia caused by kidney problems, the haemoglobin values were maintained in the same measure as in those patients who continue to receive Eprex / Erypo." "" "" ""</seg>
<seg id="374">"" "" "" "in comparison, patients who continued to receive Eprex / Erypo showed an increase of 0.063 g / dl of the starting value of 12.0 g / dl." "" "" ""</seg>
<seg id="375">"" "" "" "the most common side effect of abseamed is an increase in blood pressure, which occasionally leads to symptoms of encephalopathy (brain problems) such as sudden, bursting migraine headaches and confusion." "" "" ""</seg>
<seg id="376">"" "" "" "thamed should not be used in patients who are possibly hypersensitive to epoetin alfa, or any of the other ingredients." "" "" ""</seg>
<seg id="377">"" "" "" "Abyamed as an injection under the skin is not recommended for treating kidney problems, as further studies are required to ensure that there is no allergic reaction." "" "" ""</seg>
<seg id="378">"" "" "" "the Commission for Human Use (CHMP) concluded that in accordance with the provisions of the European Union, it has been proven that the medicine has a comparable quality, safety and efficacy profile as Eprex / Erypo." "" "" ""</seg>
<seg id="379">"" "" "" "the company that produces Abseamed will provide information packages for medical professionals in all Member States, including information about the safety of the medicine." "" "" ""</seg>
<seg id="380">"" "" "" "August 2007, the European Commission granted Medice Medicines Pütter GmbH & Co KG to obtain approval for the placing of streamed in the whole European Union." "" "" ""</seg>
<seg id="381">"" "" "" "treatment of anaemia and reduction of transfusion needs in adults with solid tumours, malignant lymphomas or multi-plem myeloma, which is a risk of transfusion because of the general condition (e.g. cardiovascular status, pre-existing anemia at the beginning of chemotherapy)." "" "" ""</seg>
<seg id="382">The treatment should only be performed in patients with moderate anemia (hemoglobin [Hb] 10 - 13 g / dl [6.2 - 8.1 mmol / l] (no iron deficiency) if blood-saving measures are not available or insufficient in case of planned major operating procedures (4 or more units of blood in women; 5 or more units of blood in men).</seg>
<seg id="383">"" "" "" "for reduction of foreign blood, a large elective orthopedic surgery can be used without iron deficiency in which a high risk of transfusion complications can be expected." "" "" ""</seg>
<seg id="384">HB 10-13 g / dl) and an expected blood loss of 900-1800 ml can be applied not to participate in an autologous blood donation program.</seg>
<seg id="385">Hemoglobin concentration is between 10 and 12 g / dl (6.2 - 7.5 mmol / l) except for pediatric patients with hemoglobin concentration between 9.5 and 11 g / dl (5.9 - 6.8 mmol / l).</seg>
<seg id="386">"" "" "" "symptoms and symptoms may vary depending on age, sex and total disease burden; therefore, the assessment of the individual clinical course and disease status is required by the doctor." "" "" ""</seg>
<seg id="387">An increase in hemoglobin by more than 2 g / dl (1.25 mmol / l) over a period of four weeks should be avoided.</seg>
<seg id="388">"" "" "" "due to the variability between patients, individual hemoglobin values can occasionally be observed over or below the hemoglobin- target concentration." "" "" ""</seg>
<seg id="389">In view of this hemoglobin variability a corresponding dose management should be tried to achieve haemoglobin target concentration of 10 g / dl (6.2 mmol / l) to 12 g / dl (7.5 mmol / l).</seg>
<seg id="390">If the haemoglobin value increases by more than 2 g / dl (1.25 mmol / l) per month or if the permanent hemoglobin value exceeds 12 g / dl (7.5 mmol / l) the epoetin-alfa dose is reduced by 25%.</seg>
<seg id="391">"" "" "" "patients should be closely monitored to ensure that epoetin alfa is applied in the lowest permitted dose, which is required for the control of anemia and anemia." "" "" ""</seg>
<seg id="392">The clinical results suggest that patients with initially very low pH value (&lt; 6 g / dl or &lt; 3.75 mmol / l) may need higher maintenance doses than patients in which initial anaemia is less pronounced (Hb &gt; 8 g / dl or &gt; 5 mmol / l).</seg>
<seg id="393">The clinical results suggest that patients with initially very low pH value (&lt; 6.8 g / dl or &lt; 4.25 mmol / l) may need higher maintenance doses than patients in which initial anaemia is less pronounced (Hb &gt; 6.8 g / dl or &gt; 4.25 mmol / l).</seg>
<seg id="394">Initial dose 50 I.E. / kg three times a week using intravenous application if necessary with a dose increase of 25I.E. / kg (three times a week) until the desired target value is reached (this should take place in increments of at least 4 weeks).</seg>
<seg id="395">"" "" "" "symptoms of symptoms and symptoms may vary depending on age, sex and total disease burden; therefore, the assessment of the individual clinical course and disease status is required by the doctor." "" "" ""</seg>
<seg id="396">In view of this hemoglobin variability a corresponding dose management should be tried to achieve haemoglobin target concentration of 10 g / dl (6.2 mmol / l) to 12 g / dl (7.5 mmol / l).</seg>
<seg id="397">"" "" "" "patients should be closely monitored to ensure that epoetin alfa is applied in the lowest permitted dose, which is required for controlling anemia symptoms." "" "" ""</seg>
<seg id="398">If after 4 treatment weeks the hemoglobin value has increased by at least 1 g / dl (0.62 mmol / l) or the reticulocyte quantity to ≥ 40.000 cells / µl compared to the starting value should the dose of 150 I.U. / kg be maintained three times a week or 450 I.U. / kg once a week.</seg>
<seg id="399">If the hemoglobin-rise &lt; 1 g / dl (&lt; 0.62 mmol / l) and the reticulocyte number &lt; 40.000 cells / µl has increased compared to the starting value the dose should be increased to 300 I.U. / kg three times a week.</seg>
<seg id="400">If after further 4 treatment weeks with 300 I.E. / kg three times a week the hemoglobin value by ≥ 0.1 ml / dl (≥ 0.62 mmol / l) or the reticulocyte number increased by ≥ 40.000 cells / µl the dose should be kept at 300 I.U. / kg three times a week.</seg>
<seg id="401">"" "" "" "on the other hand, the haemoglobin value increased by &lt; 1 g / dl (&lt; 0,62 mmol / l) and the reticulocyte size by &lt; 40,000 cells / µl compared to the output value." "" "" ""</seg>
<seg id="402">Patients with mild anemia (haematocrit 33 - 39%) in which the precautionary deposit of ≥ 4 blood constants is required should be obtained in a dose of 600 I.E. / kg bodyweight twice a week for 3 weeks before the surgical procedure.</seg>
<seg id="403">"" "" "" "the iron substitution should be started as early as possible, e.g. several weeks before the start of the autologous blood donation program." "" "" ""</seg>
<seg id="404">"" "" "" "6 The recommended dosage is 600 I.U. / kg epoetin alfa, which should be given once a week over three weeks (day 21, 14 and 7) prior to surgery and on the day of surgery (day 0)." "" "" ""</seg>
<seg id="405">"" "" "" "epoetin alfa should present 300 I.U. / kg preoperatively 10 consecutive days, on the day of surgery and 4 days immediately thereafter." "" "" ""</seg>
<seg id="406">"" "" "" "alternatively, the injection can be given at the end of dialysis via the tube of a fistula, followed by 10 ml of isotonic salt solution to insure the hose and ensure adequate injection of the drug in the circulation." "" "" ""</seg>
<seg id="407">Patients suffering from the treatment with any erythropoopopenie (Pure Red Cell Aplasia (PRCA) should not get amed or other erythropopoetin (see section 4.4 - erythroblastoenie).</seg>
<seg id="408">"" "" "" "heart attack or stroke within a month before treatment, unstable angina, increased risk of deep vein thrombosis (e.g. anamnesia-known venous thromboembolia)." "" "" ""</seg>
<seg id="409">"" "" "" "the application of epoetin alfa is contraindicated in patients suffering from a greater elective orthopedic disease: severe coronary heart disease, peripheral arterial occlusion, vascular disease of carotides or cerebrovascular disease; in patients with a recent heart attack or cerebrovascular event." "" "" ""</seg>
<seg id="410">Erythroblastoopenie (PRCA) Very rare was reported about the appearance of an antiendogenous PRCA after monate- to years of treatment with subcutaneous erythropopoetin.</seg>
<seg id="411">"" "" "" "in patients with sudden loss of time, defined as reduction of haemoglobin values (1 - 2 g / dl per month) with increased need for transfusions." "" "" ""</seg>
<seg id="412">"" "" "" "if the reticulocyte value is low (&lt; 20,000 / mm3 or &lt; 20,000 / microlitre or &lt; 0.5%), the thrombocyte and leukocyte figures are determined and an examination of the bone marrow should be induced to diagnose a PRCA." "" "" ""</seg>
<seg id="413">The data on immunogenicity in subcutaneous use of patients with a risk of an antibody-induced PRCA (patients with renal anemia) are not sufficient.</seg>
<seg id="414">"" "" "" "8 In patients with chronic kidney failure, the upper limit of hemoglobin target concentration should not be exceeded in maintenance therapy." "" "" ""</seg>
<seg id="415">In clinical trials an increased risk of mortality and risk of severe cardiovascular events was observed when erythropoesis-stimulating agents (ESA) were given with haemoglobin concentration of more than 12 g / dl (7.5 mmol / l).</seg>
<seg id="416">Controlled clinical studies have shown no significant benefit to the gift of epoetins when the haemoglobin concentration is increased by the concentration required for the control of the seizures and the avoidance of blood transfusions.</seg>
<seg id="417">The hemoglobin increase should be approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of an increase in high blood pressure.</seg>
<seg id="418">In patients with chronic kidney failure and clinically evidence coronary heart disease or insufficiency in maintenance therapy the upper limit of hemoglobin target concentration should not be exceeded.</seg>
<seg id="419">"" "" "" "the treatment of anaemia associated with epoetin alfa in adults with renal insufficiency, which is not dialysis, does not accelerate the progression of renal insufficiency." "" "" ""</seg>
<seg id="420">Tumour patients receiving chemotherapy should be considered for the assessment of epoetin alfa a 2-3-week delay between epoetin-alfa and erythropopoetin response (patients who may have to be transacted).</seg>
<seg id="421">If the Hb increase is exceeded 2 g / dl (1.25 mmol / l) per month or a Hb value of 13 g / dl (8.1 mmol / l) the dose must be adjusted in accordance with section 4.2 to minimize the risk of possible thrombotic events (see section 4.2 treatment of patients with chemotherapy-related anemia - dose adjustment with the aim of keeping the hemoglobin value between 10 g / dl and 12 g / dl).</seg>
<seg id="422">The combination of recombinant erythropoetine should be based on the benefit-risk assessment of the patient's participation and should also consider the specific clinical context.</seg>
<seg id="423">"" "" "" "if possible before beginning of epoetin-alfa therapy, the cause of anaemia should be examined and treated accordingly." "" "" ""</seg>
<seg id="424">Patients undergoing a larger elective orthopedic procedure should have adequate thromboseprophylaxis since they have an increased risk of thrombotic and vascular diseases especially in the underlying cardiovascular disease.</seg>
<seg id="425">"" "" "" "in addition, it cannot be excluded that during treatment with epoetin alfa for patients with an output oglobin value of &gt; 13 g / dl an increased risk of postoperative thrombotic / vascular events can exist." "" "" ""</seg>
<seg id="426">"" "" "" "in several controlled trials, epoetine was not proven to improve overall survival or reduce the risk of tumour progression in tumour patients with symptomatic anaemia." "" "" ""</seg>
<seg id="427">"" "" "" "4 months in patients with metastatic breast cancer receiving chemotherapy, a hemoglobin target concentration of 12 - 14 g / dl (7.5 - 8.7 mmol / l) was aspired" "" "" ""</seg>
<seg id="428">"" "" "" "if epoetin alfa is used together with iclosporin, blood levels should be controlled by Ciclosporin and the ciclosporin dose should be adapted to increasing haematocrit." "" "" ""</seg>
<seg id="429">In vitro studies on tumor tissues there is no indication of interaction between epoetin alfa and G-CSF or GM-CSF regarding haematological differentiation or proliferation.</seg>
<seg id="430">"" "" "" "over thrombotic, vascular events such as myocardial infarction, cerebral thrombosis, pulmonary thrombosis, pulmonary thrombosis, pulmonary thrombosis and 11 blood clots in artificial kidneys was reported in patients under epoetin alfa." "" "" ""</seg>
<seg id="431">The most common side effect during treatment with epoetin alfa is a dose-dependent increase in blood pressure or the worsening of existing hypertension.</seg>
<seg id="432">Increased incidence of thrombolic events (see section 4.4 and section 4.8 - General) was observed in patients with erythropoetry.</seg>
<seg id="433">"" "" "" "regardless of erythropopoetin treatment, surgical patients with cardiovascular disease can occur after repeated blood donations to thrombotic and vascular complications." "" "" ""</seg>
<seg id="434">The genetic-derived epoetin alfa is glycosized and identical to the amino acids and the carbohydrate part is identical to the endogenous human erythropoetin that was isolated from the urine of anemic patients.</seg>
<seg id="435">"" "" "" "with the help of cultures of human bone marrow cells, epoetin alfa specifically stimulated the erythropoesis and did not affect leukoplaesis." "" "" ""</seg>
<seg id="436">"" "" "" "389 patients with hemoblastants (221 multiple myeloma, 144 non-Hodgkin lymphoma and 24 other hemoblastomomas, 23 bronchial carcinomas, 22 prostate carcinomas, 21 gastrointestinal carcinomas and 30 others)." "" "" ""</seg>
<seg id="437">"" "" "" "1895 patients with solid tumours (683 mammal carcinoma, 260 bronchial carcinomas, 300 gastrointestinal tumors and 478 others) and 802 patients with hemoblastants." "" "" ""</seg>
<seg id="438">Survival and tumour progression were studied in five large controlled trials involving 2833 patients; four of these studies were double-blind placebo-controlled studies and</seg>
<seg id="439">"" "" "" "in the open study, there was no difference in overall survival between the patients treated with recombinant human erythropopoetin and the control patients." "" "" ""</seg>
<seg id="440">"" "" "" "in these studies, patients treated with recombinant human erythropopoetin demonstrated an unexplained, statistically significant higher mortality rate than the controls." "" "" ""</seg>
<seg id="441">Overall survival in the studies could not be explained by differences in the incidence of thrombosis and related complications in patients treated with recombinant human erythropopoetin.</seg>
<seg id="442">"" "" "" "there is an increased risk of thromboembolic events in tumour patients treated with recombinant human erythropopoetin, and a negative effect on overall survival cannot be excluded." "" "" ""</seg>
<seg id="443">It is not clear how far these results are transferred to the application of recombinant human erythropopoetin in tumour patients who are treated with chemotherapy with the aim of obtaining a hemoglobin value below 13 g / dl as too few patients with these characteristics were included in the checked data.</seg>
<seg id="444">Epoetin-alfa provisions after repeated intravenous application showed a half-life of approximately 4 hours in healthy volunteers and a slightly extended half-life of about 5 hours in patients with kidney failure.</seg>
<seg id="445">"" "" "" "after subcutaneous injection, the serum levels of epoetin alfa are much lower than the serum levels that are achieved after intravenous injection." "" "" ""</seg>
<seg id="446">"" "" "" "there is no accumulation: the serum levels remain the same regardless of whether they are determined 24 hours after the first gift, or 24 hours after the last gift." "" "" ""</seg>
<seg id="447">"" "" "" "(bone marfibrosis is a known complication of chronic kidney failure in humans, and could be due to secondary hyperparathyreoidism or unknown factors." "" "" ""</seg>
<seg id="448">"" "" "" "in a study of haemodialysis patients, which were treated three years with epoetin alfa, the incidence of bone marfibrosis was not increased compared to the control group with epoetin alfa." "" "" ""</seg>
<seg id="449">"" "" "" "14 In veterinary studies with approximately the 20ples recommended for use at humans, epoetin alfa led to reduced levels of body weight, to a delay of the Ossification and to a rise in fetal mortality." "" "" ""</seg>
<seg id="450">"" "" "" "these reports are based on vitro findings with cells of human tumor tissue samples, which are of insecure significance for the clinical situation." "" "" ""</seg>
<seg id="451">"" "" "" "within the framework of outpatient treatment, the patient can temporarily store Abseamed for a maximum period of 3 days outside of the fridge and not above 25 ° C." "" "" ""</seg>
<seg id="452">"" "" "" "syringes are provided with graduation rings and the filling volume is indicated by a pasted label, making it possible to measure partial quantities." "" "" ""</seg>
<seg id="453">"" "" "" "treatment with grayamed treatment must be initiated under the supervision of doctors, which have experience in treating patients with the above indications." "" "" ""</seg>
<seg id="454">"" "" "" "21 The recommended dosage is 600 I.U. / kg epoetin alfa, which should be given once a week over three weeks (day 21, 14 and 7) prior to surgery and on the day of surgery (day 0)." "" "" ""</seg>
<seg id="455">"" "" "" "23 In patients with chronic kidney failure, the upper limit of hemoglobin target concentration should not be exceeded in maintenance therapy." "" "" ""</seg>
<seg id="456">The hemoglobin increase should be approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of an increase in high blood pressure.</seg>
<seg id="457">"" "" "" "over thrombotic, vascular events such as myocardial infarction, cerebral thrombosis, pulmonary thrombosis, pulmonary thrombosis, pulmonary thrombosis and 26 blood clots in artificial kidneys was reported in patients under epoetin alfa." "" "" ""</seg>
<seg id="458">Increased incidence of thrombolic events (see section 4.4 and section 4.8 - General) was observed in patients with erythropoetry.</seg>
<seg id="459">"" "" "" "389 patients with hemoblastants (221 multiple myeloma, 144 non-Hodgkin lymphoma and 24 other hemoblastomomas, 23 bronchial carcinomas, 22 prostate carcinomas, 21 gastrointestinal carcinomas and 30 others)." "" "" ""</seg>
<seg id="460">"" "" "" "29 In veterinary studies with approximately 20 times the weekly dose recommended for use at humans, epoetin alfa led to reduced cervical weight, to a delay of the Ossification and to a rise in fetal mortality." "" "" ""</seg>
<seg id="461">"" "" "" "within the framework of outpatient treatment, the patient can temporarily store Abseamed for a maximum period of 3 days outside of the fridge and not above 25 ° C." "" "" ""</seg>
<seg id="462">"" "" "" "36 The recommended dosage is 600 I.U. / kg epoetin alfa, which should be given once a week over three weeks (day 21, 14 and 7) prior to surgery and on the day of surgery (day 0)." "" "" ""</seg>
<seg id="463">"" "" "" "38 For patients with chronic kidney failure, the upper limit of hemoglobin target concentration should not be exceeded in maintenance therapy." "" "" ""</seg>
<seg id="464">The hemoglobin increase should be approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of an increase in high blood pressure.</seg>
<seg id="465">"" "" "" "over thrombotic, vascular events such as myocardial infarction, cerebral thrombosis, pulmonary thrombosis, pulmonary thrombosis, pulmonary thrombosis and 41 blood clots in artificial kidneys was reported in patients under epoetin alfa." "" "" ""</seg>
<seg id="466">Increased incidence of thrombolic events (see section 4.4 and section 4.8 - General) was observed in patients with erythropoetry.</seg>
<seg id="467">"" "" "" "389 patients with hemoblastants (221 multiple myeloma, 144 non-Hodgkin lymphoma and 24 other hemoblastomomas, 23 bronchial carcinomas, 22 prostate carcinomas, 21 gastrointestinal carcinomas and 30 others)." "" "" ""</seg>
<seg id="468">"" "" "" "44 In veterinary studies with approximately the 20ples recommended for use at humans, epoetin alfa led to reduced levels of body weight, to a delay of the Ossification and to a rise in fetal mortality." "" "" ""</seg>
<seg id="469">"" "" "" "within the framework of outpatient treatment, the patient can temporarily store Abseamed for a maximum period of 3 days outside of the fridge and not above 25 ° C." "" "" ""</seg>
<seg id="470">"" "" "" "51 The recommended dosage is 600 I.U. / kg epoetin alfa, which should be given once a week over three weeks (day 21, 14 and 7) prior to surgery and on the day of surgery (day 0)." "" "" ""</seg>
<seg id="471">"" "" "" "53 In patients with chronic kidney failure, the upper limit of hemoglobin target concentration should not be exceeded in maintenance therapy." "" "" ""</seg>
<seg id="472">The hemoglobin increase should be approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of an increase in high blood pressure.</seg>
<seg id="473">"" "" "" "over thrombotic, vascular events such as myocardial infarction, cerebral thrombosis, pulmonary thrombosis, pulmonary thrombosis, pulmonary thrombosis, pulmonary thrombosis and 56 blood clots." "" "" ""</seg>
<seg id="474">Increased incidence of thrombolic events (see section 4.4 and section 4.8 - General) was observed in patients with erythropoetry.</seg>
<seg id="475">"" "" "" "389 patients with hemoblastants (221 multiple myeloma, 144 non-Hodgkin lymphoma and 24 other hemoblastomomas, 23 bronchial carcinomas, 22 prostate carcinomas, 21 gastrointestinal carcinomas and 30 others)." "" "" ""</seg>
<seg id="476">"" "" "" "59 In veterinary studies with approximate 20 times of recommended weekly dose, epoetin alfa led to reduced cervical weight, to a delay of the Ossification and to a rise in fetal mortality." "" "" ""</seg>
<seg id="477">"" "" "" "within the framework of outpatient treatment, the patient can temporarily store Abseamed for a maximum period of 3 days outside of the fridge and not above 25 ° C." "" "" ""</seg>
<seg id="478">"" "" "" "66 The recommended dosage is 600 I.U. / kg epoetin alfa, which should be given once a week over three weeks (day 21, 14 and 7) prior to surgery and on the day of surgery (day 0)." "" "" ""</seg>
<seg id="479">"" "" "" "68 In patients with chronic kidney failure, the upper limit of hemoglobin target concentration should not be exceeded in maintenance therapy." "" "" ""</seg>
<seg id="480">The hemoglobin increase should be approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of an increase in high blood pressure.</seg>
<seg id="481">"" "" "" "over thrombotic, vascular events such as myocardial infarction, cerebral thrombosis, pulmonary thrombosis, pulmonary thrombosis, pulmonary thrombosis and 71 blood clots in artificial kidneys was reported in patients under epoetin alfa." "" "" ""</seg>
<seg id="482">Increased incidence of thrombolic events (see section 4.4 and section 4.8 - General) was observed in patients with erythropoetry.</seg>
<seg id="483">"" "" "" "389 patients with hemoblastants (221 multiple myeloma, 144 non-Hodgkin lymphoma and 24 other hemoblastomomas, 23 bronchial carcinomas, 22 prostate carcinomas, 21 gastrointestinal carcinomas and 30 others)." "" "" ""</seg>
<seg id="484">"" "" "" "74 In animal experiments with approximately the 20ples recommended for use at people recommended weekly dose, epoetin alfa led to reduced cervical weight, to a delay of the Ossification and to a rise in fetal mortality." "" "" ""</seg>
<seg id="485">"" "" "" "within the framework of outpatient treatment, the patient can temporarily store Abseamed for a maximum period of 3 days outside of the fridge and not above 25 ° C." "" "" ""</seg>
<seg id="486">"" "" "" "81 The recommended dosage is 600 I.U. / kg epoetin alfa, which should be given once a week over three weeks (day 21, 14 and 7) prior to surgery and on the day of surgery (day 0)." "" "" ""</seg>
<seg id="487">"" "" "" "83 In patients with chronic kidney failure, the upper limit of hemoglobin target concentration should not be exceeded in maintenance therapy." "" "" ""</seg>
<seg id="488">The hemoglobin increase should be approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of an increase in high blood pressure.</seg>
<seg id="489">"" "" "" "chronic thrombosis, pulmonary thrombosis, pulmonary thrombosis, pulmonary thrombosis, pulmonary thrombosis, pulmonary thrombosis and 86 blood clots." "" "" ""</seg>
<seg id="490">Increased incidence of thrombolic events (see section 4.4 and section 4.8 - General) was observed in patients with erythropoetry.</seg>
<seg id="491">"" "" "" "389 patients with hemoblastants (221 multiple myeloma, 144 non-Hodgkin lymphoma and 24 other hemoblastomomas, 23 bronchial carcinomas, 22 prostate carcinomas, 21 gastrointestinal carcinomas and 30 others)." "" "" ""</seg>
<seg id="492">"" "" "" "89 In veterinary studies with approximately the 20ples recommended for use at humans, epoetin alfa led to reduced cervical weight, to a delay of the Ossification and to a rise in fetal mortality." "" "" ""</seg>
<seg id="493">"" "" "" "within the framework of outpatient treatment, the patient can temporarily store Abseamed for a maximum period of 3 days outside of the fridge and not above 25 ° C." "" "" ""</seg>
<seg id="494">"" "" "" "96 The recommended dosage is 600 I.U. / kg epoetin alfa, which should be given once a week over three weeks (day 21, 14 and 7) prior to surgery and on the day of surgery (day 0)." "" "" ""</seg>
<seg id="495">"" "" "" "98 In patients with chronic kidney failure, the upper limit of hemoglobin target concentration should not be exceeded in maintenance therapy." "" "" ""</seg>
<seg id="496">The hemoglobin increase should be approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of an increase in high blood pressure.</seg>
<seg id="497">"" "" "" "over thrombotic, vascular events such as myocardial infarction, cerebral thrombosis, pulmonary thrombosis, pulmonary thrombosis, pulmonary thrombosis and 101 blood clots in artificial kidneys was reported in patients under epoetin alfa." "" "" ""</seg>
<seg id="498">Increased incidence of thrombolic events (see section 4.4 and section 4.8 - General) was observed in patients with erythropoetry.</seg>
<seg id="499">"" "" "" "389 patients with hemoblastants (221 multiple myeloma, 144 non-Hodgkin lymphoma and 24 other hemoblastomomas, 23 bronchial carcinomas, 22 prostate carcinomas, 21 gastrointestinal carcinomas and 30 others)." "" "" ""</seg>
<seg id="500">"" "" "" "104 In animal experiments with approximately the 20ples recommended for use at humans, epoetin alfa led to reduced cervical weight, to a delay of the Ossification and to a rise in fetal mortality." "" "" ""</seg>
<seg id="501">"" "" "" "within the framework of outpatient treatment, the patient can temporarily store Abseamed for a maximum period of 3 days outside of the fridge and not above 25 ° C." "" "" ""</seg>
<seg id="502">"" "" "" "111 The recommended dosage is 600 I.U. / kg epoetin alfa, which should be given once a week over three weeks (day 21, 14 and 7) prior to surgery and on the day of surgery (day 0)." "" "" ""</seg>
<seg id="503">"" "" "" "113 In patients with chronic kidney failure, the upper limit of hemoglobin target concentration should not be exceeded in maintenance therapy." "" "" ""</seg>
<seg id="504">The hemoglobin increase should be approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of an increase in high blood pressure.</seg>
<seg id="505">"" "" "" "over thrombotic, vascular events such as myocardial infarction, cerebral thrombosis, pulmonary thrombosis, pulmonary thrombosis, pulmonary thrombosis, pulmonary thrombosis and 116 blood clots in artificial kidneys was reported in patients under epoetin alfa." "" "" ""</seg>
<seg id="506">Increased incidence of thrombolic events (see section 4.4 and section 4.8 - General) was observed in patients with erythropoetry.</seg>
<seg id="507">"" "" "" "389 patients with hemoblastants (221 multiple myeloma, 144 non-Hodgkin lymphoma and 24 other hemoblastomomas, 23 bronchial carcinomas, 22 prostate carcinomas, 21 gastrointestinal carcinomas and 30 others)." "" "" ""</seg>
<seg id="508">"" "" "" "in animal experiments with approximate 20 times of recommended weekly dose, epoetin alfa led to reduced cervical weight, delaying the Ossification and an increase in fetal mortality." "" "" ""</seg>
<seg id="509">"" "" "" "within the framework of outpatient treatment, the patient can temporarily store Abseamed for a maximum period of 3 days outside of the fridge and not above 25 ° C." "" "" ""</seg>
<seg id="510">"" "" "" "126 The recommended dosage is 600 I.U. / kg epoetin alfa, which should be given once a week over three weeks (day 21, 14 and 7) prior to surgery and on the day of surgery (day 0)." "" "" ""</seg>
<seg id="511">"" "" "" "in the case of maintenance therapy, the upper limit of hemoglobin target concentration should not be exceeded in patients with chronic kidney failure." "" "" ""</seg>
<seg id="512">The hemoglobin increase should be approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of an increase in high blood pressure.</seg>
<seg id="513">"" "" "" "over thrombotic, vascular events such as myocardial infarction, cerebral thrombosis, pulmonary thrombosis, pulmonary thrombosis, pulmonary thrombosis and 131 blood clots in artificial kidneys was reported in patients under epoetin alfa." "" "" ""</seg>
<seg id="514">Increased incidence of thrombolic events (see section 4.4 and section 4.8 - General) was observed in patients with erythropoetry.</seg>
<seg id="515">"" "" "" "389 patients with hemoblastants (221 multiple myeloma, 144 non-Hodgkin lymphoma and 24 other hemoblastomomas, 23 bronchial carcinomas, 22 prostate carcinomas, 21 gastrointestinal carcinomas and 30 others)." "" "" ""</seg>
<seg id="516">"" "" "" "134 In veterinary studies with approximately the 20ples recommended for use at people recommended weekly dose, epoetin alfa led to reduced cervical weight, to a delay of the Ossification and to a rise in fetal mortality." "" "" ""</seg>
<seg id="517">"" "" "" "within the framework of outpatient treatment, the patient can temporarily store Abseamed for a maximum period of 3 days outside of the fridge and not above 25 ° C." "" "" ""</seg>
<seg id="518">"" "" "" "141 The recommended dosage is 600 I.U. / kg epoetin alfa, which should be given once a week over three weeks (day 21, 14 and 7) prior to surgery and on the day of surgery (day 0)." "" "" ""</seg>
<seg id="519">"" "" "" "143 In patients with chronic kidney failure, the upper limit of hemoglobin target concentration should not be exceeded in maintenance therapy." "" "" ""</seg>
<seg id="520">The hemoglobin increase should be approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of an increase in high blood pressure.</seg>
<seg id="521">"" "" "" "over thrombotic, vascular events such as myocardial infarction, cerebral thrombosis, pulmonary thrombosis, pulmonary thrombosis, pulmonary thrombosis and 146 blood clots in artificial kidneys was reported in patients under epoetin alfa." "" "" ""</seg>
<seg id="522">Increased incidence of thrombolic events (see section 4.4 and section 4.8 - General) was observed in patients with erythropoetry.</seg>
<seg id="523">"" "" "" "389 patients with hemoblastants (221 multiple myeloma, 144 non-Hodgkin lymphoma and 24 other hemoblastomomas, 23 bronchial carcinomas, 22 prostate carcinomas, 21 gastrointestinal carcinomas and 30 others)." "" "" ""</seg>
<seg id="524">"" "" "" "in animal experiments with approximately the 20ples recommended for use at humans, epoetin alfa led to reduced cervical weight, to a delay of the Ossification and to a rise in fetal mortality." "" "" ""</seg>
<seg id="525">"" "" "" "within the framework of outpatient treatment, the patient can temporarily store Abseamed for a maximum period of 3 days outside of the fridge and not above 25 ° C." "" "" ""</seg>
<seg id="526">"" "" "" "the holder of approval for placing on the market has to supply medical professionals in dialysis centres and retail pharmacies with the following information and materials: • Education brochure • summary of the features of the medicine (expert information), labelling and packaging." "" "" ""</seg>
<seg id="527">The owner of the authorisation for the placing of goods has to ensure that the pharmacovigilance system described in Version 3.0 and approved in module 1.8.1. the pharmaceutical vigilance system has been set up and functional before the medicine is brought into circulation and as long as the medicine is used in the transport.</seg>
<seg id="528">"" "" "" "the owner of the licensing agreement stipulates that the Risk Management Plan (RMP) specified in the pharmacovigilance plan, as specified in Version 5 of the Risk Management Plan (RMP) approved in Module 1.8.2." "" "" ""</seg>
<seg id="529">"" "" "" "an updated RMP should be provided with the next updated report on the safety of the drug (Periodic Safety Update Report, PSUR) according to the" CHMP Guideline on Risk Management Systems for the use. "" "" "" ""</seg>
<seg id="530">"" "" "" "in addition, an updated RMP should be submitted: • to obtain new information, influence on current safety specifications (Safety Specification), the pharmacovigilance plan or risk reduction measures • by request from EMEA" "" "" ""</seg>
<seg id="531">• In a month before your treatment have suffered a heart attack or a stroke • if you suffer from instable angina pectoris (for the first time or increased chest pain) - the danger of a coronary thrombosis in the veins (deep vein thrombosis) is - if you have previously performed such a blood clutropause.</seg>
<seg id="532">"" "" "" "you suffer from severe bleeding disturbances of the heart (coronary artery disease), arteries of the legs or arms (peripheral arterial disease) or brain (cerebrovascular disease) you have recently had a heart attack or stroke." "" "" ""</seg>
<seg id="533">"" "" "" "during the treatment with Abseamed, there can be a slight dose-dependent increase in the number of blood platelets within the normal range, which reforms again during further treatment." "" "" ""</seg>
<seg id="534">"" "" "" "if necessary, your doctor will perform regular blood tests to regularly monitor the number of platelets during the first 8 weeks of treatment." "" "" ""</seg>
<seg id="535">"" "" "" "iron deficiency, dissolving of the red blood cells (haemolysis), blood loss, vitamin B12 or folic acid deficiency should be considered and treated before the beginning of treatment with seamed amed." "" "" ""</seg>
<seg id="536">"" "" "" "after months of treatment with subcutaneous (under the skin), erythropopoetin was reported very rarely." "" "" ""</seg>
<seg id="537">"" "" "" "if you suffer from erythroblastoy, it will break your treatment with thamed treatment and determine how your anaemia is best treated." "" "" ""</seg>
<seg id="538">"" "" "" "therefore, Abyamed can be given by injection into a vein (intravenous) if you are treated for anaemia due to kidney disease." "" "" ""</seg>
<seg id="539">"" "" "" "a high haemoglobin value is the risk of problems with the heart or blood vessels, and the risk of death could be increased." "" "" ""</seg>
<seg id="540">"" "" "" "in case of elevated or rising potassium levels, your doctor may consider an interruption of the treatment with Abseamed, until the potassium values are back in the normal range." "" "" ""</seg>
<seg id="541">"" "" "" "if you suffer from chronic kidney weakness and clinically exposed coronary heart disease or stowage signs due to insufficient cardiac performance, your doctor will make sure that your hemoglobin mirror does not exceed a certain value." "" "" ""</seg>
<seg id="542">"" "" "" "according to the current findings, the treatment of hemorrhage in adults with chronic kidney failure (renal insufficiency), which is not dialysis, does not accelerate the progression of renal insufficiency." "" "" ""</seg>
<seg id="543">A 2 - 3-week delay between epoetin-alfa-gift and the desired effect should be considered for assessing the effectiveness of streamed amed.</seg>
<seg id="544">200 Your doctor will regularly determine your values of the red blood dye (hemoglobin) and adjust your grayamed dose accordingly to minimize the risk of a coronary thrombosis (thrombotic event).</seg>
<seg id="545">"" "" "" "this risk should be weighed very carefully compared to the advantages derived from the treatment with epoetin alfa, especially if you have an increased risk of thrombotic vascular events (e.g. a deep vein thrombosis or pulmonary embolism)." "" "" ""</seg>
<seg id="546">"" "" "" "in case you are a cancer patient, aamed amed like a growth factor for blood cells, and in certain circumstances can have a negative effect on the tumor." "" "" ""</seg>
<seg id="547">"" "" "" "if you have an orthopedic surgery, you should study the cause of your anaemia prior to treatment and be treated accordingly." "" "" ""</seg>
<seg id="548">"" "" "" "if your values of the red blood dye (hemoglobin) are too high, you should not get Abseamed because there is an increased risk of blood clotting after surgery." "" "" ""</seg>
<seg id="549">"" "" "" "please tell your doctor or pharmacist if you are taking other medicines / applying it or applying it recently, even if it is not prescription medicine." "" "" ""</seg>
<seg id="550">"" "" "" "if you are using Ciclosporin (means to suppress the immune system) during your treatment with Abyamed, your doctor may order certain blood tests to measure the blood level of Ciclosporin." "" "" ""</seg>
<seg id="551">Laboratory tests have shown no interaction between epoetin alfa and G-CSF or GM-CSF (G-CSF and GM-CSF are means to build the immune system e.g. for cancer chemotherapy or HIV).</seg>
<seg id="552">"" "" "" "depending on how your anemia (anemia) responds to treatment, the dose can be adjusted for about every four weeks until your condition is under control." "" "" ""</seg>
<seg id="553">"" "" "" "if necessary, your doctor will arrange regular blood tests to verify the success of your treatment and make sure that the drug works properly and does not exceed your haemoglobin value." "" "" ""</seg>
<seg id="554">"" "" "" "once you are well adjusted, you receive regular doses of between 25 and 50 I.U. / kg twice weekly, distributed on two equally large injections." "" "" ""</seg>
<seg id="555">"" "" "" "if necessary, your doctor will arrange regular blood tests to verify the success of the treatment and make sure that your hemoglobin value does not exceed a certain value." "" "" ""</seg>
<seg id="556">"" "" "" "depending on how anaemia refers to treatment, the dose can be adjusted for about every four weeks until the condition is under control." "" "" ""</seg>
<seg id="557">"" "" "" "to ensure this and ensure that the hemoglobin value does not exceed a certain value, the doctor treating physician will carry out regular blood tests." "" "" ""</seg>
<seg id="558">"" "" "" "if necessary to shorten treatment time prior to surgery, a dose of 300 I.U. / kg can be given at 10 consecutive days before surgery, on the day of surgery and another 4 days after surgery." "" "" ""</seg>
<seg id="559">"" "" "" "however, if your doctor thinks this is appropriate, you can also learn how to splash Abseamed himself under the skin." "" "" ""</seg>
<seg id="560">"" "" "" "heart, heart attacks, cerebral bleedings, cerebral thrombosis, pulmonary thrombosis, pulmonary thrombosis, pulmonary thrombosis, pulmonary thrombosis, pulmonary thrombosis." "" "" ""</seg>
<seg id="561">"" "" "" "eyelids and the lips (Quincke edema) and shock-like allergic reactions with symptoms such as tingling, redness, itching, heat sensation and accelerated pulse were reported in rare cases." "" "" ""</seg>
<seg id="562">Erythroblastoopenia means that no more red blood cells can be formed in the bone marrow (see section "Special precautions in applying seamed flamed treatment").</seg>
<seg id="563">"" "" "" "after repeated blood donations, it may occur - regardless of the treatment with seamed amed - to a coronary thrombosis (thrombotic vascular events)." "" "" ""</seg>
<seg id="564">The treatment with Abseamed can be associated with an increased risk of blood prop after surgery (post-operative thrombotic vascular events) if your output level is too high.</seg>
<seg id="565">Inform your doctor or pharmacist if any of the listed side effects you notice significantly or if you notice side effects that are not stated in this use information.</seg>
<seg id="566">"" "" "" "when a syringe has been taken out of the refrigerator and has reached room temperature (up to 25 ° C), it must be used either within 3 days or discarded." "" "" ""</seg>
<seg id="567">"" "" "" "Aclasta is used to treat the following diseases: • osteoporosis (a disease that makes the bones brittle), both in women after menopause and in men." "" "" ""</seg>
<seg id="568">"" "" "" "it is used in patients with a high risk of fractures (bone fractures), including in patients who have recently suffered a minor traumatic hip fracture like the Hinfestation; • Morbus Paget of the bone, a disease that changes the normal course of bone growth." "" "" ""</seg>
<seg id="569">"" "" "" "in addition, patients with Morbus Paget should take at least 500 mg of calcium twice a day for at least 10 days after the treatment; patients with hip fracture should receive a large dose of vitamin D (50 000 to 125 000 IE) before the first infusion or by injection into a muscle." "" "" ""</seg>
<seg id="570">"" "" "" "the administration of paracetamol or ibuprofen (remedy against inflammation) shortly after the application of Aclasta can reduce the symptoms such as fever, muscle pain, flu-like symptoms, joint pain and headache." "" "" ""</seg>
<seg id="571">"" "" "" "to treat the disease, Aclasta may only be prescribed by doctors who have experience in treating this disease." "" "" ""</seg>
<seg id="572">"" "" "" "as the active ingredient in Aclasta is the same as in Zometa, a part of the data material for Zometa was used to evaluate Aclasta." "" "" ""</seg>
<seg id="573">"" "" "" "in the first study, nearly 8 000 elderly women were involved in osteoporosis, and the number of spine and hip fractures was examined over a period of three years." "" "" ""</seg>
<seg id="574">"" "" "" "the second study included 2 127 men and women with osteoporosis over 50 years, who recently suffered a hip fracture; the number of fractures was examined over a period of up to five years." "" "" ""</seg>
<seg id="575">"" "" "" "at Morbus Paget, Aclasta was tested in two trials involving 357 patients and compared with risedronate (another bisphosphonate) for six months." "" "" ""</seg>
<seg id="576">"" "" "" "the main indicator for the efficacy was whether the alkaline phosphatase in serum (an enzyme that deconstructs bone substance) was again normalized in the blood, or decreased by at least 75% compared to the baseline." "" "" ""</seg>
<seg id="577">"" "" "" "in the study with elderly women, the risk of fractures in patients under Aclasta (without other osteoporosis therapies) was reduced by 70% over a period of three years." "" "" ""</seg>
<seg id="578">"" "" "" "in comparison with patients under Aclasta (with or without other osteoporosis therapies), the risk of hip fractures was reduced by 41%." "" "" ""</seg>
<seg id="579">In the study involving men and women with hip fracture 9% of patients under Aclasta had a fracture (92 of 1 065) compared to 13% of patients with placebo (139 of 1 062).</seg>
<seg id="580">"" "" "" "most Aclasta side effects occur within the first three days after infusion, and are less frequent in repeated infusions." "" "" ""</seg>
<seg id="581">"" "" "" "aclasta must not be used in patients who are possibly hypersensitive to cioledronacid or other bisphosphonate, or any other ingredients." "" "" ""</seg>
<seg id="582">"" "" "" "as with all bisphosphonates, patients at Aclasta are liable to the risk of kidney problems, reactions to infusion and osteoarthritis (death of bone tissue) in the jaw." "" "" ""</seg>
<seg id="583">"" "" "" "the Aclasta manufacturer provides information for doctors who prescribe Aclasta to treat osteoporosis, as well as similar material for patients in which the drugs side effects are explained and indicated when they should consult the doctor." "" "" ""</seg>
<seg id="584">"" "" "" "April 2005, the European Commission granted the Novartis Europharm Limited Company a permit for the placing of Aclasta in the European Union." "" "" ""</seg>
<seg id="585">Terms & Conditions OR Restrictions with regard to THE SICHERE AND ENTIANING OF SPECTIONS FOR THE COURE AND PEACTIONS WITH AND POACTIONS OF COMMENDING DES Medicines Which implement THE DURCH THE member states ZU SIND</seg>
<seg id="586">"" "" "" "osteoporosis treatment in postmenopausal women and in men with increased risk for fractures, including patients with a recent low-traumatic hip fracture." "" "" ""</seg>
<seg id="587">"" "" "" "the patient information package should be provided and the following core messages include: • The prevention of pregnancy and breastfeeding, appropriate physical activity, non-smoking and a healthy diet • Important signs and symptoms for serious side effects • When to resort to medical or nursing assistance" "" "" ""</seg>
<seg id="588">"" "" "" "osteoporosis treatment • for postmenopausal women • in men with increased risk for fractures, including in patients with a recent low-traumatic hip fracture." "" "" ""</seg>
<seg id="589">"" "" "" "for the treatment of postmenopausal osteoporosis and osteoporosis in men, an intravenous infusion of 5 mg aclasta is recommended once a year." "" "" ""</seg>
<seg id="590">"" "" "" "in patients with low-traumatic hip fractures, the administration of Aclasta is recommended two or more weeks after operative care of hip fractures (see Section 5.1)." "" "" ""</seg>
<seg id="591">"" "" "" "for the treatment of the Morbus Paget, Aclasta should only be prescribed by doctors who have experience in the treatment of the Morbus Paget." "" "" ""</seg>
<seg id="592">"" "" "" "after a treatment by the Morbus Paget with Aclasta, a long remission period was observed in patients who responded to the therapy (see section 5.1)." "" "" ""</seg>
<seg id="593">"" "" "" "in addition, it is very advisable in patients with Morbus Paget an adequate intake of calcium, accordingly twice daily at least 500 mg of elementary calcium, for at least 10 days following the gift of Aclasta (see section 4.4)." "" "" ""</seg>
<seg id="594">"" "" "" "in patients with a recent low-traumatic hip fracture, an initial dose of 50,000 to 125,000 I.U. oralem or intramuscular vitamin D is recommended prior to the first aclasta infusion." "" "" ""</seg>
<seg id="595">"" "" "" "the frequency of symptoms, which occur within the first three days after the administration of Aclasta, can be reduced by offering paracetamol or ibuprofen shortly after the application of Aclasta." "" "" ""</seg>
<seg id="596">Patients with kidney dysfunctions (see section 4.4) For patients with a Kreatinin-Clearance &lt; 35 ml / min Aclasta is not recommended as limited clinical experiences are available for these patients.</seg>
<seg id="597">"" "" "" "the elderly patient (≥ 65 years) is not necessary because the bioavailability, distribution and elimination of older patients is similar to younger patients." "" "" ""</seg>
<seg id="598">"" "" "" "children and adolescents Aclasta are not recommended for use in children and adolescents under 18 years of age, since data are missing for safety and efficacy." "" "" ""</seg>
<seg id="599">"" "" "" "in patients with severe kidney failure (creatinin-Clearance &lt; 35 ml / min), Aclasta is not recommended as a limited clinical experience exists for this patient population." "" "" ""</seg>
<seg id="600">Preexisting hypocalcemia must be treated with an adequate intake of calcium and vitamin D before the treatment begins with Aclasta (see Section 4.3).</seg>
<seg id="601">"" "" "" "due to the rapid initiation of the effect of cioledronic acid on bone reconstruction, a temporary, sometimes symptomatic hypokalzaemia can develop whose maximum occurs within the first 10 days after the infusion of Aclasta (see Section 4.8)." "" "" ""</seg>
<seg id="602">"" "" "" "in addition, it is very advisable in patients with Morbus Paget an adequate intake of calcium, accordingly twice daily at least 500 mg of elementary calcium, for at least 10 days following the gift of Aclasta (see section 4.2)." "" "" ""</seg>
<seg id="603">"" "" "" "cancer, chemotherapy, treatment with corticosteroids, bad oral hygiene) should be considered a dental examination using appropriate preventive dental treatment before applying bisphosphonates." "" "" ""</seg>
<seg id="604">"" "" "" "for patients who need dental surgery, no data is available whether the interruption of the treatment with bisphosphonates reduces the risk of osteonecrosis in the jaw area." "" "" ""</seg>
<seg id="605">The clinical evaluation by the doctor treating physician should be the basis for the treatment plan of each patient and based on an individual benefit-risk assessment.</seg>
<seg id="606">The frequency of symptoms that occur within the first three days after administration of Aclasta can be reduced by applying paracetamol or ibuprofen shortly after the application of Aclasta (see section 4.2).</seg>
<seg id="607">The frequency of cases reported as serious side effects of atrial fibrillation was increased in patients who received Aclasta (1.3%) (51 of 3.862) compared to patients who received placebo (0.6%) (22 of 3.852).</seg>
<seg id="608">"" "" "" "in the osteoporosis studies (PFT, HORIZON - Recurrent Fracture Trial [RFT]), the overall incidence of atrial fibrillation was comparable to 2.6% and placebo (2.1%)." "" "" ""</seg>
<seg id="609">"" "" "" "very common (≥ 1 / 100, &lt; 1 / 10), occasional (≥ 1 / 1000, &lt; 1 / 100), rare (≥ 1 / 1000, &lt; 1 / 1000) are listed in table 1." "" "" ""</seg>
<seg id="610">Kidney dysfunction Zoledronic acid was associated with kidney function disorders that were associated with a decrease in the renal function (i.e. an increase of serum creatine) and in rare cases referred to as acute renal failure.</seg>
<seg id="611">The changes in the Kreatinin-Clearance (measured annually prior to administration) and the occurrence of kidney failure as well as a restricted kidney function were comparable in a clinical study of osteoporosis over three years between the agclam and the placebo group.</seg>
<seg id="612">A temporary increase of serum creatine within 10 days of gift was observed in 1.8% of patients treated with Aclasta versus 0.8% of patients treated with placebo.</seg>
<seg id="613">"" "" "" "based on the evaluation of laboratory findings, the temporary asymptomatic calcium levels below the normal range of patients (less than 2.10 mmol / l) were compared to 21% of patients treated with Aclasta in the Morbus Paget study." "" "" ""</seg>
<seg id="614">All patients received sufficient amounts of vitamin D and calcium in the study for postmenopausal osteoporosis in the study on preventing clinical fractures after fracture fractures and in the Morbus Paget studies (see section 4.2).</seg>
<seg id="615">"" "" "" "in the study to avoid clinical fractures after a recent hip fracture, the vitamin D levels were not routinely measured, but most of the patients received an initial dose of vitamin D before the administration of Aclasta (see section 4.2)." "" "" ""</seg>
<seg id="616">"" "" "" "local reactions After the administration of Zoledronacid in a large clinical study was reported about local reactions to the infusion point, such as redness, swelling and / or pain (0.7%)." "" "" ""</seg>
<seg id="617">"" "" "" "osteonecrosis in the jaw area was generally treated, especially in cancer patients, about osteonecrosis (primarily in the jaw area), which were treated with bisphosphonates, including cioledronic acid." "" "" ""</seg>
<seg id="618">"" "" "" "many of these patients had signs of local infections including osteoomyelitis, and most of the reports refer to cancer patients after tooth extractions or other dental intervention." "" "" ""</seg>
<seg id="619">"" "" "" "7 study of 7,736 patients showed osteoarthritis in the jaw area, with Aclasta and placebo-treated patients." "" "" ""</seg>
<seg id="620">"" "" "" "in the case of overdosing, which leads to a clinically relevant hypocalcemia, a compensation can be achieved through the application of oral calcium and / or an intravenous infusion of calcium gluconate." "" "" ""</seg>
<seg id="621">Clinical efficacy in the treatment of postmenopausal osteoporosis (PFT) The efficacy and safety of Aclasta 5 mg once a year for 3 consecutive years was identified with either a fracture assessment (BMD) -T-Score for the senkelhas ≤ - 2.5 with or without any signs of an existing vertebral fracture.</seg>
<seg id="622">Effects on morphometric spine fractures Aclasta lowered significantly over a period of three years and already after one year the frequency of one or several new vertebral fractures (see table 2).</seg>
<seg id="623">"" "" "" "Aclasta-treated patients aged 75 years and older, compared to placebo patients, reduced by 60% compared to placebo patients (p &lt; 0,0001)." "" "" ""</seg>
<seg id="624">"" "" "" "effects on hip fractures Aclasta showed a consistent effect over three years, resulting in a reduced risk of hip fractures by 41% (95% CI, 17% to 58%)." "" "" ""</seg>
<seg id="625">"" "" "" "the effect on bone density (BMD) Aclasta increased the bone density of the lumbar spine, hip and distal radius compared to the placebo treatment at all time points (6, 12, 24 and 36 months)." "" "" ""</seg>
<seg id="626">"" "" "" "9 Increasing the bone density of the lumbar spine by 6.7%, the total hip by 6.7%, the skull by 5.1% and the distal radius by 3.2%." "" "" ""</seg>
<seg id="627">Bone histology in 152 postmenopausal osteoporosis patients treated with Aclasta (N = 82) or placebo (N = 70) were removed one year after the third annual dose of bone biopsies from the pelvic ridge.</seg>
<seg id="628">A microcomputer tomography (µCT) analysis showed an increase in the trabecular bone volume and the preservation of the trabecular bone architecture when compared to placebo.</seg>
<seg id="629">Bone replacement markers The bone-specific alkaline phosphatase (BSAP) and the N-terminal propeptide of type I- collagen (P1NP) in serum and the beta-C Telopeptid (b-CTX) in serum were determined in sub-groups of 517 to 1.246 patients in periods during study duration.</seg>
<seg id="630">"" "" "" "after 12 months, the treatment with an annual 5 mg dose of Aclasta reduced 30% compared to baseline and was held at 28% below the initial value up to 36 months." "" "" ""</seg>
<seg id="631">"" "" "" "P1NP was reduced significantly by 61% below the initial value, after 12 months and was kept at 52% below the initial value up to 36 months." "" "" ""</seg>
<seg id="632">"" "" "" "B-CTX was reduced significantly by 61% below the initial value after 12 months, and was held at 55% below the initial value up to 36 months." "" "" ""</seg>
<seg id="633">"" "" "" "the vitamin D levels were not routinely measured, but the majority of patients received a starting dose of vitamin D (50,000 to 125,000 I.U. orally or intramuscular) 2 weeks before infusion." "" "" ""</seg>
<seg id="634">The total mortal spread was 10% (101 patients) in the group treated with Aclasta compared to 13% (141 patients) in the placebo group.</seg>
<seg id="635">Effect on bone mineral density (BMD) In the HORIZON RFT study the Aclasta treatment increased the BMD compared to the placebo treatment at the total stockpile and neck-neck at all time points.</seg>
<seg id="636">"" "" "" "over 24 months, the Aclasta treatment led to an increase in the BMD by 5.4% compared to the placebo treatment and 4.3% on the neck." "" "" ""</seg>
<seg id="637">"" "" "" "clinical efficacy in men in the HORIZON RFT study was randomized to 508 men, and in 185 patients the BMD was assessed after 24 months." "" "" ""</seg>
<seg id="638">The study was not designed to show a reduction in clinical fractures in men; the incidence of clinical fractures was 7.5% in Aclasta-treated men compared to 8.7% in placebo.</seg>
<seg id="639">In another study in men (study CZOL446M2308) the once yearly administration of alendronate was not inferior to the percentage change of the lumbar vertebrae BMD after 24 months compared to baseline.</seg>
<seg id="640">Clinical efficacy of the treatment in patients with Morbus Paget of the Knochens Aclasta was studied in patients and patients aged over 30 years with radiologically confirmed disease (mean serum levels of the alkaline phosphatase according to the 2.6-fold age-specific upper normal value when entering the study).</seg>
<seg id="641">"" "" "" "11 The effectiveness of an infusion of 5 mg of Zoledron acid in comparison to the intake of 30 mg risedronate once a day, during 2 months, was demonstrated in two six months comparative studies." "" "" ""</seg>
<seg id="642">"" "" "" "after 6 months, a similar decrease in pain intensity and pain influence was observed in comparison with the baseline for Aclasta and Risedronat." "" "" ""</seg>
<seg id="643">Patients who were classified as Respondents at the end of the six-month study were included in the follow-up phase.</seg>
<seg id="644">"" "" "" "compared to 71 patients treated with Risedronat, the 143 with Aclasta and the 107 patients treated with Risedronat participated in the follow-up period of 18 months after the application." "" "" ""</seg>
<seg id="645">"" "" "" "simultaneous infusions of 2, 4, 8 and 16 mg of Zoledronic acid in 64 patients showed the following pharmacokinetic data, which proved to be dose-independent." "" "" ""</seg>
<seg id="646">"" "" "" "after that, the plasma level quickly rose to &lt; 10% of the maximum value after 4 h and &lt; 1% after 24 hours, followed by a long period of very low concentration, not more than 0.1% of the maximum value." "" "" ""</seg>
<seg id="647">Rapid biphaseal disappearance from the large cycle with half-life t ½ - 0.24 and t ½ to 1.87 hours followed by a long elimination phase with a terminal elimination time t ½ g 146 hours.</seg>
<seg id="648">"" "" "" "the early phases of decay (α and β, with the above t ½ -values) probably represent the rapid resorption into the bones and excretion over the kidneys." "" "" ""</seg>
<seg id="649">"" "" "" "in the first 24 hours 39 ± 16% of the administered dose is found in the urine, while the rest is mainly bonded to bone tissue." "" "" ""</seg>
<seg id="650">"" "" "" "the total-body-Clearance amounts to 5.04 ± 2.5 l / h independently of the dose and remains unaffected by gender, age, race or body weight." "" "" ""</seg>
<seg id="651">"" "" "" "an extension of the infusion time of 5 to 15 minutes was reduced by 30% at the end of the infusion, but had no effect on the surface under the curve (plasma concentration versus time)." "" "" ""</seg>
<seg id="652">"" "" "" "reduced-dose of cytochrom-P450 enzyme systems is unlikely, because coledronic acid is not metabolized in humans and because it is a weak or no direct and / or irreversible, metabolic inhibitor of the P450-" "" "" ""</seg>
<seg id="653">Specific patient groups (see section 4.2) The renal Clearance of Zoledron Acid correlated with the Kreatinin-Clearance (75 ± 33% of the Kreatinin-Clearance) and was 75 ± 29 ml / min (range 22 to 143 ml / min) in the 64 examined patients.</seg>
<seg id="654">This results in an easy (Clcr = 50- 80 ml / min) and a moderate kidney dysfunction down to a creatinin-Clearance down to 35 ml / min does not require any dose adjustment of the cioledron acid.</seg>
<seg id="655">"" "" "" "because for severe kidney dysfunction (creatin- Clearance &lt; 30 ml / min) only restricted data is available, no statements are possible for this population." "" "" ""</seg>
<seg id="656">Acute toxicity The highest unlethal intravenous single dose in mice was 10 mg / kg of body weight and with rats 0.6 mg / kg bodyweight.</seg>
<seg id="657">"" "" "" "for studies on dogs, single doses of 1.0 mg / kg (based on AUC, six times the recommended human-therapeutic exposure) administered over a period of 15 minutes, good and without a renal influence." "" "" ""</seg>
<seg id="658">Subchronic and chronic toxicity In studies with intravenous application the renal tolerability of zoledron acid in rats was administered in 3-day intervals; in intervals of 2- 3 weeks (a cumulative dose corresponding to the fourfold of the human-therapeutic exposure related to AUC) was administered well.</seg>
<seg id="659">"" "" "" "in long-term studies with repeated use in accumulated exposures that exceeded the maximum of intended human exposure, toxicological effects in other organs, including the Gastrointestinal tract and the liver, as well as the intravenous injection site." "" "" ""</seg>
<seg id="660">"" "" "" "the most common findings in studies with repeated use were an increased primary Spongiosa in the metaphor of long bones in animals in the growth phase with nearly all dosages, an infection that reflects the pharmacological, anti-absorptive effect of the substance." "" "" ""</seg>
<seg id="661">"" "" "" "in rats, one observed a teratogeneity from 0.2 mg / kg as external and internal (visceral) abnormalities and those of the skeleton." "" "" ""</seg>
<seg id="662">"" "" "" "in rabbits, no teratogenic effects or embryo-fetal effects were observed, although the maternal toxicity at 0.1 mg / kg was pronounced as a result of serum-calcium levels." "" "" ""</seg>
<seg id="663">"" "" "" "if the medicine is not used immediately, the user is responsible for the storage time after preparation and the conditions before the application. normally, 24 hours should not be exceeded at 2 ° C to 8 ° C." "" "" ""</seg>
<seg id="664">"" "" "" "Aclasta is delivered as a pack with a bottle as a packing unit or as bundle packing consisting of 5 packages, each containing a bottle." "" "" ""</seg>
<seg id="665">"" "" "" "osteoporosis treatment in postmenopausal women and in men with increased risk for fractures, including patients with a recent low-traumatic hip fracture." "" "" ""</seg>
<seg id="666">"" "" "" "the patient information package should be provided and the following key messages include: • Contra-indications in pregnancy and breastfeeding women • Required a adequate intake of calcium and vitamin D, appropriate physical activity, non-smoking and healthy diet 17 • When on medical or nursing assistance" "" "" ""</seg>
<seg id="667">"" "" "" "July 2007, completed on 29 September 2006, the Pharmacovigilance system described in the module 1.8.1 of the application's application, before and while the product is marketed." "" "" ""</seg>
<seg id="668">Risk Management Plan The owner of approval for placing on the market commits the trials and additional activities to pharmacovigilance carried out in the Pharmacovigilance Plan of the approved version 004 of the Risk Management Plan (RMP) in module 1.8.2 of the authorisation request and all the following versions of the RMP approved by the CHMP.</seg>
<seg id="669">"" "" "" "according to the CHMP directive on risk management systems for human medicines, the revised RMP should be submitted together with the next" Periodic Safety Update Report (PSUR). "" "" "" ""</seg>
<seg id="670">"" "" "" "a revised RMP should be submitted • When new information is known, which could affect the present statements on safety, the pharmacovigilance plan or activities to minimize the risk." "" "" ""</seg>
<seg id="671">"" "" "" "Zoledronacid is a substance called bisphosphonate, and is used for the treatment of osteoporosis in postmenopausal women, osteoporosis in men and the bone of the bone." "" "" ""</seg>
<seg id="672">"" "" "" "decreasing blood levels of sex hormones, especially oestrogens, which are formed from androgens, play a role in the rather gradual loss of bone mass observed in men." "" "" ""</seg>
<seg id="673">"" "" "" "in the Morbus Paget, bone reconstruction is made fast, and new bone material is arranged unordered which makes the bone material weaker than normal." "" "" ""</seg>
<seg id="674">"" "" "" "Aclasta works by normalizing the bone structure, thereby ensuring a normal bone formation and thus gives strength to the bone." "" "" ""</seg>
<seg id="675">"" "" "" "if you are in dental treatment or undergo a dental surgery, tell your doctor that you will be treated with Aclasta." "" "" ""</seg>
<seg id="676">"" "" "" "if you use Aclasta with other medicines, tell your doctor, pharmacist or nursing staff if you are taking other medicines / applied or applied recently, even if it is not prescription medicine." "" "" ""</seg>
<seg id="677">"" "" "" "for your doctor, it is particularly important to know if you are taking medicine that is known to the kidneys." "" "" ""</seg>
<seg id="678">"" "" "" "when using Aclasta together with food and drinks, you are concerned that you have plenty of fluids in accordance with your doctor's instructions before and after treatment with Aclasta." "" "" ""</seg>
<seg id="679">"" "" "" "osteoporosis The usual dose is 5 mg once a year, administered by your doctor or nursing staff as an infusion into a vein." "" "" ""</seg>
<seg id="680">"" "" "" "if you have broken the hips recently, it is recommended to make the administration of Aclasta two or more weeks after the surgical treatment of the hip fracture." "" "" ""</seg>
<seg id="681">"" "" "" "the usual dose is 5 mg, administered by your doctor or nursing staff as an infusion into a vein." "" "" ""</seg>
<seg id="682">"" "" "" "since Aclasta works for a long time, you may need another dose only after one year or longer." "" "" ""</seg>
<seg id="683">"" "" "" "it is important to follow these instructions carefully, so that the calcium level in your blood in time after infusion is not too low." "" "" ""</seg>
<seg id="684">"" "" "" "at Morbus Paget, Aclasta can work for more than one year and your doctor will inform you if you need another treatment." "" "" ""</seg>
<seg id="685">"" "" "" "if you miss Aclasta, contact your doctor or hospital immediately to arrange a new appointment." "" "" ""</seg>
<seg id="686">"" "" "" "before completing the therapy with Aclasta If you are considering the termination of the treatment with Aclasta, please notice your next doctor's date and discuss this with your doctor." "" "" ""</seg>
<seg id="687">"" "" "" "side effects associated with the first infusion occur very frequently (in more than 30% of patients), but are less frequent after the subsequent infusion." "" "" ""</seg>
<seg id="688">"" "" "" "fever and chills, muscle or joint pain and headache occur within the first three days after the administration of Aclasta." "" "" ""</seg>
<seg id="689">"" "" "" "currently it is unclear whether Aclasta causes this irregular heartbeat, but you should report it to your doctor if you notice such symptoms after you have received Aclasta." "" "" ""</seg>
<seg id="690">"" "" "" "physical signs due to low calcium concentration in the blood, such as muscle cramps, or tingling or numb feeling, especially around the mouth." "" "" ""</seg>
<seg id="691">"" "" "" "redness, diarrhea, headache, headache, headache, headache, headache, headache, headache, headache, headache, headache, headache, headache, headache, headache, headache, headache, headache, headache, headache, headache, headache, headache, headache, headache, headache, headache, headache, headache, headache, headache, headache, headache." "" "" ""</seg>
<seg id="692">Persistent pain and / or not curative wounds in the mouth or jaws were reported especially in patients treated with bisphosphonates because of other diseases.</seg>
<seg id="693">"" "" "" "allergic reactions including rare cases of respiratory problems, hives and angioedema (such as swelling in the face, tongue or throat) have been reported." "" "" ""</seg>
<seg id="694">"" "" "" "inform your doctor, pharmacist or nursing staff if any of the side effects listed you have significantly impaired or you notice side effects that are not listed in this information information." "" "" ""</seg>
<seg id="695">"" "" "" "if the medicine is not used immediately, the user is responsible for storage time and conditions up to the application; normally 24 hours should not be exceeded at 2 ° C to 8 ° C." "" "" ""</seg>
<seg id="696">"" "" "" "in patients with low-traumatic hip fractures recently, it is recommended to perform the infusion of Aclasta two or more weeks following the operative care of hip fracture." "" "" ""</seg>
<seg id="697">"" "" "" "before and after the administration of Aclasta, patients have to be sufficiently supplied with liquid; this is particularly important for patients receiving a diuretic therapy." "" "" ""</seg>
<seg id="698">"" "" "" "due to the rapid initiation of the effect of cioledronic acid on bone reconstruction, a temporary, sometimes symptomatic, hypocalcemia can develop whose maximum usually occurs within the first 10 days after the infusion of aclasta." "" "" ""</seg>
<seg id="699">"" "" "" "in addition, it is very advisable in patients with Morbus Paget an adequate intake of calcium, according to at least twice daily 500 mg of elementary calcium, for at least 10 days following the gift of Aclasta." "" "" ""</seg>
<seg id="700">"" "" "" "in patients with low-traumatic hip fractures an initial dose of 50,000 to 125,000 I.U. oralem or intramuscular vitamin D is recommended before the infusion of Aclasta." "" "" ""</seg>
<seg id="701">"" "" "" "if you need more information about your illness or treatment, please read the packaging supplement (also included in the EPAR) or contact your doctor or pharmacist." "" "" ""</seg>
<seg id="702">ACOMPLIA is used in addition to a diet and exercise for the treatment of adult patients with a body mass index (BMI) of 30 kg / m ² or above and / or above (BMI of 27 kg / m ² or above) and one or more of them</seg>
<seg id="703">"" "" "" "in addition, four studies were carried out in more than 7,000 patients in which ACOMPLIA was used as a supporting remedy for setting up smoking." "" "" ""</seg>
<seg id="704">"" "" "" "on the other hand, the studies on the setting of smoking did not show uniform results so that the effect of ACOMPLIA was difficult to assess in this field of application." "" "" ""</seg>
<seg id="705">Which risk is associated with ACOMPLIA? the most common side effects of ACOMPLIA observed during the studies (observed in more than 1 out of 10 patients) were nausea and upper respiratory infections.</seg>
<seg id="706">"" "" "" "it may also not be used in patients who suffer from an existing severe depression or treated with antidepressants, as it can boost the risk of depression and can cause suicidal thoughts among others." "" "" ""</seg>
<seg id="707">"" "" "" "caution is advisable while using ACOMPLIA with medicines such as ketoconazole or Itraconazole (medicines for fungal infections), pelithromycin or clarithromycin (antibiotics)." "" "" ""</seg>
<seg id="708">The Committee on Human Use (CHMP) concluded that the efficacy of ACOMPLIA in terms of weight reduction in patients with obesity or overweight</seg>
<seg id="709">"" "" "" "medicines used in patients that need health and not cosmetic reasons (by providing education packages for patients and doctors), and around the ARZ" "" "" ""</seg>
<seg id="710">"" "" "" "in addition to diet and exercise to treat obesity (BMI, ≥ 30 kg / m ²) or obese patients (BMI &gt; 27 kg / m ²), which has one or more risk factors, such as type 2 diabetes or dyslipidämie (see Section 5.1)." "" "" ""</seg>
<seg id="711">"" "" "" "ACOMPLIA is not recommended for use in children and adolescents under the age of 18, due to lack of data on efficacy and safety." "" "" ""</seg>
<seg id="712">"" "" "" "depressive diseases or mood changes with depressive symptoms were reported in up to 10%, suicidal thoughts in up to 1% of patients receiving Rimonabant (see section 4.8)." "" "" ""</seg>
<seg id="713">"" "" "" "Rimonabant may not be used in case of depressive disorders, unless the benefits of treatment in the individual case outweigh the risk (see Section 4.3 and 4.8)." "" "" ""</seg>
<seg id="714">"" "" "" "even in patients who - besides obesity - have no visible risks, depressive reactions can occur." "" "" ""</seg>
<seg id="715">Relatives or other related persons) must point out that it is necessary to monitor the reoccurrence of such symptoms and immediately pick up medical advice if these symptoms occur. ln</seg>
<seg id="716">• Elder patients The efficacy and safety of Rimonabant in the treatment of patients over 75 years were not shown adequately.</seg>
<seg id="717">Patients with a cardiovascular event (myocardial infarction or stroke etc.) less than 6 months ago were excluded from studies with Rimonabant. ln</seg>
<seg id="718">"" "" "" "Rifampicin, phenytoin, phenobarbital, carbamazepine, carbamazepine, carbamazepine, carbamazepine, carbamazepine, carbamazepine, carbamazepin, carbamazepin, carbamazepin, carbamazepin, carbamazepin, carbamazepin, carbamazepin, carbamazepin, carbamazepin, carbamazepin, carbamazepin, carbamazepin, carbamazepin, carbamazepin, carbamazepin, carbamazepin, carbamazepin, carbamazepin, carbamazepin, carbamazepin, carbamazepin, carb</seg>
<seg id="719">"" "" "" "in addition, 3800 patients are also involved in further indications in patients with obesity." "" "" ""</seg>
<seg id="720">The following table (Table 1) shows the undesirable effects associated with treatment in placebo-controlled trials in patients who were treated to reduce weight and because of accompanying metabolic diseases.</seg>
<seg id="721">"" "" "" "it was statistically significant higher than the corresponding placeborate (for adverse reactions ≥ 1%), or if they were clinically relevant (for unwanted effects &lt; 1%)." "" "" ""</seg>
<seg id="722">"" "" "" "very common (≥ 10%); often (≥ 0.1, &lt; 1%); rarely (≥ 0.01, &lt; 0.1%);" "" "" ""</seg>
<seg id="723">"" "" "" "in a tolerance study, where a limited number of persons were administered up to 300 mg, only slight symptoms were observed." "" "" ""</seg>
<seg id="724">Patients had a BMI ≥ 30 kg / m ² or BMI &gt; 27 kg / m ² and simultaneous hypertension and / or dyslipidemia.</seg>
<seg id="725">N weight reduction after one year was 20 mg 6.5 kg in relation to the starting value compared to 1.6 kg for the placebo group (difference -4.9 kg CI95% -5.3; -4.4, p &lt; 0.001).</seg>
<seg id="726">"" "" "" "patients treated with ACOMPLIA 20 mg, and 1,2 kg in the placebo group (difference -3.8 kg; CI95% -4.4, -3.3; p &lt; 0,001)." "" "" ""</seg>
<seg id="727">"" "" "" "after 2 years, the difference in the total weight reduction between ACOMPLIA and placebo -4.2 kg (CI95% -5.0%; -3.4, p &lt; 0,001)." "" "" ""</seg>
<seg id="728">"" "" "" "9 Weight-reduction and further risk factors In the studies in patients with no diabetes, in which a mixed population of patients with" "" "" ""</seg>
<seg id="729">"" "" "" "under Rimonabant 20 mg, an average triglyceride decrease of 6.9% was seen (baseline value triglyceride 1,62 mmol / l) compared to an increase of 5.8%" "" "" ""</seg>
<seg id="730">In a second study in patients with obesity and previously untreated type 2 diabetes (Serenade) the absolute change in HbA1c value (with an output value of 7.9% for both groups) after 6 months -0.8 for Rimonabant 20 mg and -0.3 under Placebo</seg>
<seg id="731">The percentage of patients who reached HbA1c- value of &lt; 7% was 51% in the Rimonabant Group and 35% in the placebo group.</seg>
<seg id="732">The difference in the middle weight-change between the 20 mg- and the placebo group was 3.8 kg (CI95% -5.0% -2.6 p &lt; 0.001). LN</seg>
<seg id="733">Improvement of the HbA1c value in patients who had taken Rimonabant 20 mg were about 50% due to direct effects of Rimonabant and approximately 50% explained by weight reduction. n eim ARZ</seg>
<seg id="734">2 hours to reach Steady state plasma levels were reached after 13 days (CMAx = 196 ± 28,1 ng / ml; Cin = 91.6 ± 14.1 ng / ml; AUC0-24 = 2960 ± 268 ng.h / ml).</seg>
<seg id="735">"" "" "" "food intake: in the case of food intake, it received a 67% increased CMAx and 48% higher ng AUC in the case of food intake." "" "" ""</seg>
<seg id="736">"" "" "" "patients with black skin color can reduce a CMAx up to 31%, and a 43% lower AUC than patients of other ethnic populations." "" "" ""</seg>
<seg id="737">N populationspharmacokinetic analyses (age range 18- 81 years) is estimated that a 75 year old patient has a 21% higher CMAx and a 27% higher AUC than a 40-year-old.</seg>
<seg id="738">"" "" "" "5.3 Aclinical data on safety of the following adverse effects, which were not observed in clinical trials, which occurred in animals after exposure to the human-therapeutic area were evaluated as potentially relevant for clinical application:" "" "" ""</seg>
<seg id="739">"" "" "" "in some cases, however, not in all cases, the onset of convulsions with procedural stress appears to be connected with the animals." "" "" ""</seg>
<seg id="740">"" "" "" "if Rimonabant was given over a longer period prior to mating (9 weeks), which allowed a recovery from the initial effects of Rimonabant, no unwanted effects were observed on fertility or cycle disorders." "" "" ""</seg>
<seg id="741">"" "" "" "the influence of Rimonabant on pre- and postnatal development was studied at the rat in dosages of up to 10 mg / kg / day." "" "" ""</seg>
<seg id="742">"" "" "" "in a study of rats for pre- and postnatal development, an exposition with Rimonabant in utero and with lactation did not cause any changes in learning behaviour or memory." "" "" ""</seg>
<seg id="743">Detailed information about this medicine is available on the website of the European Medicines Agency (EMEA) http: / / www.emea.europa.eu / available. itte n eim ARZ</seg>
<seg id="744">"" "" "" "La On the packaging supplement of the medicine, the name and address of the manufacturer, responsible for the approval of the concerned batch, must be stated." "" "" ""</seg>
<seg id="745">26 Several psychiatric events such as depression or mood changes were reported in patients who received ACOMPLIA (see paragraph).</seg>
<seg id="746">"" "" "" "if there are symptoms of depression (see below) during the treatment with ACOMPLIA, consult your doctor and break treatment." "" "" ""</seg>
<seg id="747">"" "" "" "dizziness, diarrhea, anxiety, itching, excessive sweating, sore throat and inflammation (tsendinitis), reduced sensitivity (reduced sensation or unusual burning or tingling) at hands and feet, hot flushes, fall, gripping infections, joint destruction." "" "" ""</seg>
<seg id="748">"" "" "" "please inform your doctor or pharmacist, if any of the side effects listed you have considerably impaired or you notice side effects that are not stated in this information." "" "" ""</seg>
<seg id="749">Summary of the EPAR for the public This document is a summary of the European Public Health Report (EPAR) which explains how the Committee for Human Use (CHMP) evaluated the conducted studies to make recommendations concerning the application of the medicine.</seg>
<seg id="750">Actos is used to treat type 2 diabetes (also known as non-insulin dependent diabetes). • It can be used alone (monotherapy) in patients (in particular overweight patients) where metformin (a diabetes drug) is not shown.</seg>
<seg id="751">"" "" "" "in addition to metformin in patients (in particular overweight patients), metformin can not be satisfactory with metformin alone in the highest tolerated dose." "" "" ""</seg>
<seg id="752">"" "" "" "in combination with a sulfonyl harnant or insulin, the current dose of the sulfonyl resin or insulin can be maintained with the beginning of the Actos treatment except for patients with hypoglycemia (low blood sugar); here the dose of the sulphonyl resin or insulin should be reduced." "" "" ""</seg>
<seg id="753">"" "" "" "this means that the body's insulin can be better utilized and the blood sugar level decreases, allowing type 2 diabetes to be better adjusted." "" "" ""</seg>
<seg id="754">"" "" "" "in more than 1,400 patients the efficacy of Actos was studied in tripletherapy; in addition, patients received a combination of metformin with a sulfonyl resin, in addition they received either actos or placebo for up to 3.5 years." "" "" ""</seg>
<seg id="755">"" "" "" "in the studies, the concentration of a substance in the blood (glycosylated hemoglobin, HbA1c) was measured, which indicates how well the blood sugar is set." "" "" ""</seg>
<seg id="756">"" "" "" "Actos led to lowering the HbA1c value, which indicates that the blood sugar levels were reduced from 15 mg, 30 mg and 45 mg." "" "" ""</seg>
<seg id="757">"" "" "" "at the end of the tripletherapy study, the effect of additional treatment with metformin and a sulfonyl resin was reduced by 0.94% while the additional administration of placebo led to a decrease of 0.35%." "" "" ""</seg>
<seg id="758">"" "" "" "in a small study in which the combination of Actos and insulin was studied at 289 patients, patients who took Actos in addition to insulin reported a decrease in HbA1c values of 0.69% after 6 months compared with 0.2% in patients who were in addition to placebo." "" "" ""</seg>
<seg id="759">"" "" "" "the most common side effects associated with Actos were blurred vision, upper respiratory tract infections (colds), weight gain and hypoanesthesia (reduced sensitivity to irritation)." "" "" ""</seg>
<seg id="760">"" "" "" "Actos may not be used in patients who are possibly hypersensitive to pioglitazon or any of the other ingredients, nor in patients with liver problems, heart failure or diabetic ketoacidosis (high ketone levels - in the blood)." "" "" ""</seg>
<seg id="761">It was decided that Actos in the context of monotherapy (for the sole use) should serve as an alternative to standard treatment with metformin in patients with which metformin is not indicated.</seg>
<seg id="762">"" "" "" "October 2000, the European Commission granted the Takeda Europe R & D Centre Limited approval for the placing of Actos throughout the European Union." "" "" ""</seg>
<seg id="763">"" "" "" "the tablets are white to whitish, round, domed and carry on one side the marker" 15 "and on the other hand the inscription" Actos. "" "" "" ""</seg>
<seg id="764">Pioglitazon is also indicated for the combination with insulin in patients with type 2 diabetes mellitus whose blood sugar is inadequate with insulin and where metformin is inadequate due to contraindications or intolerance (see section 4.4).</seg>
<seg id="765">"" "" "" "no data is available for pioglitazon patients under 18 years of age, therefore the application in this age group is not recommended." "" "" ""</seg>
<seg id="766">"" "" "" "in patients receiving at least one risk factor (e.g. previous heart attack or symptomatic coronary heart disease), the physician should start treatment with the lowest available dose and gradually increase the dose." "" "" ""</seg>
<seg id="767">"" "" "" "patients should be observed at signs and symptoms of heart failure, weight gain or edema, especially those with reduced cardiac reserve." "" "" ""</seg>
<seg id="768">"" "" "" "patients should be observed at signs and symptoms of heart failure, weight gain and edema if Pioglitazon is used in combination with insulin." "" "" ""</seg>
<seg id="769">A cardiovascular outcome study with pioglitazon in patients under 75 years with type 2 diabetes mellitus and pre-existing advanced macrovascular disease was performed.</seg>
<seg id="770">"" "" "" "this study showed an increase in heart failure reports, which did not lead to an increase in mortality in the study." "" "" ""</seg>
<seg id="771">"" "" "" "in patients with increased output Liver Enzymes (ALT &gt; 2.5 x upper limit of the normal range), or with other signs of liver disease, pioglitazon may not be used." "" "" ""</seg>
<seg id="772">"" "" "" "if the ALT levels are up to 3 times the upper limit of the normal range, the liver enzymes must be checked again as soon as possible." "" "" ""</seg>
<seg id="773">"" "" "" "if a patient develops symptoms related to hepatic dysfunction, such as unexplained nausea, vomiting, colonizing, fatigue, loss of appetite and / or dark harn, the liver enzymes are to be checked." "" "" ""</seg>
<seg id="774">The decision to continue treatment of patients with pioglitazon should be guided by clinical evaluation until the clinical assessment has been taken.</seg>
<seg id="775">"" "" "" "in clinical trials with Pioglitazon a dose-dependent weight gain was detected, which can be stirred by fat deposits and in some cases linked to fluid retention." "" "" ""</seg>
<seg id="776">"" "" "" "as a result of a hemodilution, a minor reduction of the average hemoglobin values (relative reduction of 4%) and hematokrits (relative reduction of 4.1%) occurred." "" "" ""</seg>
<seg id="777">Similar changes were observed in comparative controlled studies with pioglitazon in patients under Metformin (relative reduction of hemoglobin by 3-4% and hematokrits by 1-2% and hemoglobin reduced by 1-3.2%).</seg>
<seg id="778">"" "" "" "as a result of increased insulin sensitivity, patients receiving pioglitazon as oral two- or triple-combination therapy with insulin receive the risk of dose-dependent hypoglycemia." "" "" ""</seg>
<seg id="779">"" "" "" "after the market launch was reported under the treatment with Thiazole indiones, including Pioglitazon, about an occurrence or worsening of a diabetic macular edema with a reduction in visual acuity." "" "" ""</seg>
<seg id="780">"" "" "" "it is unclear whether there is a direct connection between taking Pioglitazon and the occurrence of macular edema, however, doctors should be aware of the possibility of macular edema if patients are concerned about disturbances of visual acuity; a suitable diagnosis should be taken into account." "" "" ""</seg>
<seg id="781">"" "" "" "in a summary analysis of messages undesirable events regarding bone fractures from randomised, controlled, double-blind clinical studies over a period of up to 3.5 years with over 8,100 patients treated with pioglitazon" "" "" ""</seg>
<seg id="782">"" "" "" "the calculated fracture incidence was 1,9 fractures per 100 patient years in patients treated with pioglitazon and 1.1 fractures per 100 patient years for women who were treated with a comparative medication." "" "" ""</seg>
<seg id="783">"" "" "" "in the ProActive study, a study of 3.5 years for the investigation of cardiovascular events, fractures occurred at 44 / 870 (5.1%; 1.0 fractures per 100 patient years) in patients who were treated with a comparative medication." "" "" ""</seg>
<seg id="784">"" "" "" "patients should be aware of the possibility of pregnancy, and if a patient desires a pregnancy or this occurs the treatment is deprecated (see section 4.6)." "" "" ""</seg>
<seg id="785">Studies on the interactions have shown that Pioglitazon has no relevant effects on pharmacokinetics or drug dynamics of digoxin, warfarin, phenprocoumon and metformin.</seg>
<seg id="786">"" "" "" "drug interactions that are metabolized by these enzymes, e.g. oral contraceptives, cyclosporine, calcium channel blocker and HMGCoA reduction inhibitors are not to be expected." "" "" ""</seg>
<seg id="787">Simultaneous application of Pioglitazon with gemfibrozil (a cyclochrome P450 2C8- Inhibitor) resulted in an increase of the AUC of Pioglitazon by 3-fold.</seg>
<seg id="788">The simultaneous application of Pioglitazon with Rifampicin (a Cytochrom P450 2C8-Intor) resulted in a 54% lowering of the AUC of Pioglitazon.</seg>
<seg id="789">"" "" "" "this is due to the fact that, under treatment with pioglitazon, hyperinsulinemia and increased insulin resistance of the mother animal decreased and thereby reduced the availability of the metabolic substrates for fetal growth." "" "" ""</seg>
<seg id="790">Very common &gt; 1 / 10; frequent &gt; 1 / 100; sometimes &gt; 1 / 1000; rare &gt; 1 / 10000; very rare &lt; 1 / 10000; very rare &lt; 1 / 10000; very rare (not available from this data).</seg>
<seg id="791">"" "" "" "these lead to temporary changes in the lens and refractive index of the lens, as they are observed in other hypoglycaemic agents." "" "" ""</seg>
<seg id="792">"" "" "" "in clinical trials with Pioglitazon, ALT stiege on the three times the upper limit of the normal range often appeared as often as under placebo, but less often than in comparison groups under Metformin or Sulfonyl resin." "" "" ""</seg>
<seg id="793">In an outcome study in patients with pre-existing advanced macrovascular disease the frequency of severe heart failure under Pioglitazon was 1.6% higher than under placebo if Pioglitazon bzw.</seg>
<seg id="794">"" "" "" "since the market launch was rarely reported about heart failure under Pioglitazon, however, if pioglitazon was used in combination with insulin or in patients with heart failure in anamnesis." "" "" ""</seg>
<seg id="795">"" "" "" "a summarizing analysis of messages undesirable from randomised, controlled, double-blind clinical studies over a period of up to 3.5 years with more than 8,100 patients in the groups treated with pioglitazon was carried out in the groups treated with comparison medications." "" "" ""</seg>
<seg id="796">"" "" "" "in the ProActive study of 3.5 years, fractures occurred at 44 / 870 (5.1%) of patients treated with pioglitazon compared to 23 / 905 (2.5%) in patients who were treated with a comparative medication." "" "" ""</seg>
<seg id="797">"" "" "" "when taking the maximum dose of 120 mg / day over four days, 180 mg / day over seven days did not appear any symptoms." "" "" ""</seg>
<seg id="798">Pioglitazon seems to have an activation of specific nuclear receptors (PPAR-γ radiators) which in the animal model lead to increased insulin sensitivity of liver and fat and skeletal muscle cells.</seg>
<seg id="799">It could be shown that Pioglitazon reduces glucose production in the liver and increases the peripheral glucosamine in the event of insulin resistance.</seg>
<seg id="800">A clinical study with Pioglitazon versus Gliclacide as monotherapy was continued for over two years in order to study the period up to the release of the therapeutic effect (defined as HbA1c ≥ 8.0% after the first 6 months of treatment).</seg>
<seg id="801">At the time two years after the beginning of the therapy a blood sugar control (defined as HbA1c &lt; 8.0%) was maintained by pioglitazon in 69% of the treated patients (compared to 50% of patients under Gliclacide).</seg>
<seg id="802">"" "" "" "in a placebo-controlled trial over 12 months, patients whose blood sugar was inadequate despite a three-month optimization phase was randomized to pioglitazon or placebo." "" "" ""</seg>
<seg id="803">Patients under Pioglitazon reduced the mean HbA1c - value by 0.45% compared to the patients who continued to receive insulin; a reduction of insulin dose in the treated group was observed.</seg>
<seg id="804">"" "" "" "in clinical trials over a year, under Pioglitazon a statistically significant decrease in albumin / creatine quotients was statistically significant compared to baseline values." "" "" ""</seg>
<seg id="805">The effect of Pioglitazon (monotherapy with 45 mg versus placebo) was tested in a small 18 weeks study of type 2 diabetics.</seg>
<seg id="806">"" "" "" "in most clinical trials, a reduction of the total plasma triglyceride and free fatty acids and an increase in HDL cholesterol levels and a slight increase in LDL cholesterol levels were observed." "" "" ""</seg>
<seg id="807">"" "" "" "in clinical studies over a period of up to two years, Pioglitazon reduced the total plasma matrix glyceride and the free fatty acids and increased the HDL Cholesterinspiegel." "" "" ""</seg>
<seg id="808">"" "" "" "compared to placebo, no statistically significant increase in LDL cholesterol levels was observed under Pioglitazon while lower values were observed under Metformin and Gliclacide." "" "" ""</seg>
<seg id="809">In a study over 20 weeks Pioglitazon not only reduced the intimidation triglycerides but also improved the post-prandial triglyceride levels as well as the triglyceride absorption and the hepatic triglyceride synthesis.</seg>
<seg id="810">"" "" "" "in the Proactive study, a cardiovascular outcome study, 5238 patients with type 2 diabetes mellitus and pre-existing advanced macrovascular disease were randomized in groups that received either pioglitazon or placebo over a period of up to 3.5 years." "" "" ""</seg>
<seg id="811">"" "" "" "according to oral application, pioglitazon is quickly absorbed, whereby the peak concentrations of unaltered pioglitazon in plasma are usually reached 2 hours after application." "" "" ""</seg>
<seg id="812">"" "" "" "on this basis, the contribution of M-IV contributes to the effectiveness of the effectiveness of Pioglitazon, whereas the relative effectiveness of M-II is minimal." "" "" ""</seg>
<seg id="813">"" "" "" "in interaction studies, pioglitazon has no relevant effect on pharmacokinetics or drug dynamics of digoxin, warfarin, phenprocoumon and metformin." "" "" ""</seg>
<seg id="814">The simultaneous application of pioglitazon with gemfibrozil (a cyclochrome P450 2C8 Inhibitor) or with Rifampicin (a Cytochrom P450 2C8 inductor) increases or lowers plasma concentrations of pioglitazon (see section 4.5).</seg>
<seg id="815">"" "" "" "after oral application of radioactive pioglitazon in humans, the marker was found mainly in the fold (55%) and to a lesser extent in the urine (45%)." "" "" ""</seg>
<seg id="816">"" "" "" "the mean plasma elimination time of immutable Pioglitazon amounts to 5-6 hours in humans, and all active metabolites are 16 - 23 hours." "" "" ""</seg>
<seg id="817">The plasma concentrations of pioglitazon and its metabolites are lower in patients with reduced kidney function than in healthy volunteers.</seg>
<seg id="818">"" "" "" "toxic studies performed in mice, rats, dogs and monkeys after repeated administration of plasma volume enlargement with haemellution, anemia and reversible eccentric heart hypertrophy." "" "" ""</seg>
<seg id="819">"" "" "" "this is due to the fact that, under treatment with pioglitazon, hyperinsulinemia and increased insulin resistance of the mother animal decreased and thereby reduced the availability of the metabolic substrates for fetal growth." "" "" ""</seg>
<seg id="820">"" "" "" "in long-term studies (up to 2 years), increased incidence of hyperplasia (in male and female rats) and tumours (in male rats) was induced by the urinary bladder epithelium." "" "" ""</seg>
<seg id="821">In a animal model of the family adenomatous polyposis (FAP) the treatment with two other Thiazole indions led to increased frequency of colonic tumors.</seg>
<seg id="822">"" "" "" "the tablets are white to whitish, round, flat and carry the inscription" 30 "on one side and the" Actos "inscription on the other hand." "" "" ""</seg>
<seg id="823">"" "" "" "the calculated fracture incidence was 1,9 fractures per 100 patient years in patients treated with pioglitazon and 1.1 fractures per 100 patient years for women who were treated with a comparative medication." "" "" ""</seg>
<seg id="824">"" "" "" "in the ProActive study, a study of 3.5 years for the investigation of cardiovascular events, fractures occurred at 44 / 870 (5.1%; 1.0 fractures per 100 patient years) in patients who were treated with a comparative medication." "" "" ""</seg>
<seg id="825">"" "" "" "in a further two-year study, the effects of metformin combination therapy with pioglitazon or Gliclacide were investigated." "" "" ""</seg>
<seg id="826">"" "" "" "in clinical studies over 1 year, under Pioglitazon a statistically significant decrease in albumin / creatine quotients was statistically significant compared to baseline values." "" "" ""</seg>
<seg id="827">In a study over 20 weeks Pioglitazon not only reduced the intimidation triglycerides but improved the post-prandial triglyceride levels as well as an effect on the triglyceride absorption and the hepatic Tryglizeride synthesis.</seg>
<seg id="828">"" "" "" "although the study missed the target of its primary endpoint, a combination of total mortal, non-fatal myocardial infarction, stroke, acute coronary syndrome and revascularization of the leg arteries suggests that no cardiovascular long-term risks are associated with taking Pioglitazon." "" "" ""</seg>
<seg id="829">"" "" "" "the tablets are white to whitish, round, flat and carry on one side the marker" 45 "and on the other hand the inscription" Actos. "" "" "" ""</seg>
<seg id="830">"" "" "" "in a summary analysis of reports of undesirable events regarding bone fractures from randomised, controlled, double-blind clinical studies over a period of up to 3.5 years with more than 8,100 patients treated with pioglitazon showed an increased incidence of fractures in women." "" "" ""</seg>
<seg id="831">"" "" "" "in the ProActive study, a study of 3.5 years for the investigation of cardiovascular events, fractures occurred at 44 / 870 (5.1%; 1.0 fractures per 100 patient years) in patients who were treated with a comparative medication." "" "" ""</seg>
<seg id="832">In a study over 20 weeks Pioglitazon not only reduced the intimidation triglycerides but improved the post-prandial triglyceride levels as well as an effect on triglyceride absorption and the hepatic triglyceride synthesis.</seg>
<seg id="833">"" "" "" "on the packaging supplement of the medicine, the manufacturer's name and address, which is responsible for the approval of the concerned batch, must be stated." "" "" ""</seg>
<seg id="834">"" "" "" "in September 2005, the pharmaceutical entrepreneur will submit an additional 6 month Periodic Safety Update Report (PSUR) and then annual PSURs, up to a different CHMP decision." "" "" ""</seg>
<seg id="835">It must be presented to an updated risk management plan according to the CHMP Guideline on Risk Management Systems for Medicinal Products for Human Use.</seg>
<seg id="836">"" "" "" "if you are suffering from type 2 diabetes, Actos support 15 mg tablets to control your blood sugar levels by producing a better recovery of your body's insulin." "" "" ""</seg>
<seg id="837">"" "" "" "if you are aware that you are suffering from sugar intolerance, please contact your doctor before taking Actos 15mg tablets." "" "" ""</seg>
<seg id="838">"" "" "" "please tell your doctor or pharmacist if you have other medicines or until recently taken, even if it is not prescription medicine." "" "" ""</seg>
<seg id="839">"" "" "" "if you are taking Actos 15 mg tablets in combination with other medicines for the treatment of diabetes (such as insulin, chloroilamid, Gliclacide, Tolbutamide), your doctor will tell you if you need to reduce the dose of your medicine." "" "" ""</seg>
<seg id="840">"" "" "" "in some patients with longterm type 2 diabetes mellitus and heart disease or early stroke treated with Actos and insulin, heart failure developed." "" "" ""</seg>
<seg id="841">"" "" "" "in clinical trials, in which pioglitazon was compared with other oral antidiabetic or placebo (but not in men), the Pioglitazon showed a higher number of fractures." "" "" ""</seg>
<seg id="842">"" "" "" "if you have accidentally taken too many tablets, or if someone or a child has taken your medicine, you must immediately contact a doctor or pharmacist." "" "" ""</seg>
<seg id="843">"" "" "" "as Actos looks and contents of the package Actos 15 mg tablets are white to whitish, round, domed tablets with marking" 15 "on one side and the inscription" Actos "on the other." "" "" ""</seg>
<seg id="844">"" "" "" "if you are suffering from type 2 diabetes, Actos support 30 mg tablets to control your blood sugar levels by producing a better recovery of your body's insulin." "" "" ""</seg>
<seg id="845">"" "" "" "if you are aware that you are suffering from sugar intolerance, please contact your doctor before taking Actos 30mg tablets." "" "" ""</seg>
<seg id="846">"" "" "" "if you are taking Actos 30 mg tablets in combination with other medicines for the treatment of diabetes (such as insulin, chloroilamid, Gliclacide, Tolbutamide), your doctor will tell you if you need to reduce the dose of your medicine." "" "" ""</seg>
<seg id="847">"" "" "" "61 inform your doctor as soon as possible, if you notice signs of heart failure, such as unusual shortness or rapid weight gain or local swelling (edema)." "" "" ""</seg>
<seg id="848">"" "" "" "in clinical trials, in which pioglitazon was compared with other oral antidiabetic or placebo (but not in men), the Pioglitazon showed a higher number of fractures." "" "" ""</seg>
<seg id="849">"" "" "" "as Actos looks and contents of the Pack Actos 30 mg tablets are white to whitish, round, flat tablets with marking" 30 "on one side and the" Actos "inscription on the other." "" "" ""</seg>
<seg id="850">"" "" "" "if you are suffering from type 2 diabetes, Actos support 45 mg tablets to control your blood sugar levels by producing a better recovery of your body's insulin." "" "" ""</seg>
<seg id="851">"" "" "" "if you are aware that you are suffering from sugar intolerance, please contact your doctor before taking Actos 45mg tablets." "" "" ""</seg>
<seg id="852">"" "" "" "if you are taking Actos 45 mg tablets in combination with other medicines for the treatment of diabetes (such as insulin, chloroilamid, Gliclacide, Tolbutamide), your doctor will tell you if you need to reduce the dose of your medicine." "" "" ""</seg>
<seg id="853">"" "" "" "66 For some patients with longterm type 2 diabetes mellitus, heart disease or early stroke treated with Actos and insulin, heart failure developed." "" "" ""</seg>
<seg id="854">"" "" "" "inform your doctor as soon as possible, if you notice signs of heart failure, such as unusual shortness or rapid weight gain or local swelling (edema)." "" "" ""</seg>
<seg id="855">"" "" "" "in clinical trials, in which pioglitazon was compared with other oral antidiabetic or placebo (but not in men), the Pioglitazon showed a higher number of fractures." "" "" ""</seg>
<seg id="856">"" "" "" "67 If any of the side effects listed you have significantly impaired or you notice side effects that are not stated in this information, please inform your doctor or pharmacist." "" "" ""</seg>
<seg id="857">"" "" "" "as Actos looks and contents of the package Actos 45 mg tablets are white to whitish, round, flat tablets with marking" 45 "on one side and the inscription" Actos "on the other." "" "" ""</seg>
<seg id="858">This document is a summary of the European Public Health Report (EPAR) in which explains how the Committee for Medicinal Products (CHMP) evaluates the conducted studies to make recommendations regarding the application of the medicine.</seg>
<seg id="859">"" "" "" "if you need more information about your medical condition or treatment of your illness, please read the packaging supplement (which is also included in the EPAR) or contact a doctor or pharmacist." "" "" ""</seg>
<seg id="860">"" "" "" "if you would like further information on the basis of the CHMP recommendations, please read the scientific discussion (which is also part of EPAR)." "" "" ""</seg>
<seg id="861">Actraphane 10: soluble insulin 10% and Isophan insulin 80% Actraphane 30: soluble insulin 40% and Isophan insulin: 60% Actraphane 50: soluble insulin 50% and Isophan insulin 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50%</seg>
<seg id="862">"" "" "" "Actraphane is normally used once or twice a day, if a quick initial impact is desired together with a longer lasting effect." "" "" ""</seg>
<seg id="863">(44-20) 74 18 84 00 Fax (44-20) 74 18 86 68 E-mail: mail @ emea.eu.int http: / / www.emea.eu.int © EMEA is / or distribution of this document is Authorised for non business purposes only provided by the EMEA is acknowledged human insulin (rDNA).</seg>
<seg id="864">"" "" "" "Actraphane was examined in 294 patients with type 1 diabetes, in which the pancreas cannot produce insulin, and type 2 diabetes where the body is unable to use insulin effectively." "" "" ""</seg>
<seg id="865">"" "" "" "after 12 weeks, the concentration of a substance (glycosylated hemoglobin is measured, which indicates how well the blood sugar is set." "" "" ""</seg>
<seg id="866">"" "" "" "Actraphane has led to a decrease in HbA1c level, suggesting that blood sugar levels were similar to another human insulin." "" "" ""</seg>
<seg id="867">Actraphane should not be used in patients who are possibly hypersensitive to human insulin (rDNA) or any of the other components.</seg>
<seg id="868">"" "" "" "in addition, the dose of Actraphane may be adjusted if it is administered together with a number of other medicines that can affect blood sugar (see the full list below)." "" "" ""</seg>
<seg id="869">"" "" "" "the Commission for Medicinal Products (CHMP) concluded that the benefits of Actraphane, in the treatment of diabetes, outweigh the risks." "" "" ""</seg>
<seg id="870">"" "" "" "in October 2002, the European Commission issued a permit for the company Novo Nordisk A / S to authorise the placing of Actraphane throughout the European Union." "" "" ""</seg>
<seg id="871">"" "" "" "pre-mixed insulin products are normally used once or twice a day, if a quick initial impact is desired together with a longer lasting effect." "" "" ""</seg>
<seg id="872">"" "" "" "the injection needle must be kept under the skin for at least 6 seconds, ensuring that the entire dose is injected." "" "" ""</seg>
<seg id="873">"" "" "" "patients whose blood sugar levels have improved substantially thanks to an intensive insulin therapy, the hypoglycaemia warning symptoms can be changed and should be advised accordingly." "" "" ""</seg>
<seg id="874">"" "" "" "any change concerning starch, brand (manufacturer), type of insulin (insulin, long-acting insulin, etc.), type of insulin (animal insulin, human insulin or insulin analogue) and / or production method (recombinant DNA versus insulin origin) can cause a change in dosage." "" "" ""</seg>
<seg id="875">"" "" "" "if a dose adjustment is required when changing to Actraphane, it may be necessary during the first dosage or during the first weeks or months after the conversion." "" "" ""</seg>
<seg id="876">"" "" "" "some patients, in which hypoglycaemic reactions occurred after a change from animal to human insulin, reported that the early warning symptoms of hypoglycemia were less pronounced or different from their previous insulin." "" "" ""</seg>
<seg id="877">"" "" "" "when travelling over several time zones, the patient should be advised to collect the advice of his physician, as such trips may lead to insulin and meals to be used or taken at other times." "" "" ""</seg>
<seg id="878">"" "" "" "therefore, the doctor must consider possible interactions with the therapy and ask his patients to always consult with other drugs taken by them." "" "" ""</seg>
<seg id="879">"" "" "" "4 Unless hypoglycemia and hyperglycemia, which can occur in a non-controlled diabetes treatment, increase the risk of abnormalities and fertility in utero." "" "" ""</seg>
<seg id="880">Severe hypoglycemia may lead to unconsciousness and / or seizures and end with temporary or permanent disruption of brain function and even death.</seg>
<seg id="881">Diseases of the nervous system Gelsomely - Peripheral neuropathy A rapid improvement of blood sugar control can be associated with complaints that are referred to as acute painful neuropathy and are normally reversible.</seg>
<seg id="882">"" "" "" "5. intensification of insulin therapy with abrupt improvement in blood sugar levels can, however, be associated with a temporary worsening of diabetic retinopathy." "" "" ""</seg>
<seg id="883">Disorders of the skin and skin tissue tissue jelly - Lipodystrophy At the injection site can arise a lipodystrophy if failed to switch the instituting within the injection area.</seg>
<seg id="884">"" "" "" "local hypersensitivity reactions (redness, swelling, itching, pain and haematoma at the injection site) can occur during insulin therapy." "" "" ""</seg>
<seg id="885">"" "" "" "degenerative disorders, including generalized skin rash, itching, sweating, gastrointestinal disorders, heart palpitations, low blood pressure and impotence / unconsciousness." "" "" ""</seg>
<seg id="886">"" "" "" "hypoglycemia can, however, develop gradually: • Easy hypoglycemia can be treated by oral intake of glucose or sugary foods." "" "" ""</seg>
<seg id="887">Diabetics should therefore always have grape sugar, sweets, biscuits or sugary fruit juice. • Heavy hypoglycemia associated with deficiencies are treated with an intramuscular or subcutaneous injection of glucagon (0.5 to 1.0 mg) or by glucose that is given intravenously by the doctor.</seg>
<seg id="888">"" "" "" "the effect begins within half an hour, the effective maximum is reached within 2 to 8 hours and the total dose is up to 24 hours." "" "" ""</seg>
<seg id="889">Resorption The resorption profile is based on the fact that it is a mixture of insulin products with fast or delayed absorption.</seg>
<seg id="890">A number of split (hydrolysis) places on the human insulin molecule were considered; none of the metabolites formed by the split is active.</seg>
<seg id="891">"" "" "" "based on the conventional research on safety spatology, toxicity in repeated application, genotoxicity, carcinogenic potential and reproductive toxicity, preclinical data do not reveal any particular danger to humans." "" "" ""</seg>
<seg id="892">It is recommended - after the Actraphane glass bottle is taken out of the refrigerator - to rise the temperature of the insulin at room temperature (not above 25 ° C) before it is resushered according to the operating instructions for the first use.</seg>
<seg id="893">"" "" "" "some patients, in which hypoglycaemic reactions occurred after a change from animal to human insulin, reported that the early warning symptoms of hypoglycemia were less pronounced or different from their previous insulin." "" "" ""</seg>
<seg id="894">"" "" "" "therefore, the doctor must consider possible interactions with the therapy and ask his patients to always consult with other drugs taken by them." "" "" ""</seg>
<seg id="895">"" "" "" "12 Unless hypoglycemia and hyperglycemia, which can occur in a non-controlled diabetes treatment, increase the risk of abnormalities and fertility in utero." "" "" ""</seg>
<seg id="896">"" "" "" "13. an intensification of insulin therapy with abrupt improvement in blood sugar levels can, however, be associated with a temporary worsening of diabetic retinopathy." "" "" ""</seg>
<seg id="897">The terminale half-life (t ½) is therefore rather a measure of absorption as a measure of the elimination per se of the plasma from the plasma (insulin has a t ½ of only a few minutes in the bloodstream).</seg>
<seg id="898">It is recommended - after the Actraphane glass bottle is taken out of the refrigerator - to rise the temperature of the insulin at room temperature (not above 25 ° C) before it is resushered according to the operating instructions for the first use.</seg>
<seg id="899">"" "" "" "some patients, in which hypoglycaemic reactions occurred after a change from animal to human insulin, reported that the early warning symptoms of hypoglycemia were less pronounced or different from their previous insulin." "" "" ""</seg>
<seg id="900">"" "" "" "20 Both hypoglycemia and hyperglycemia, which can occur in a non-controlled diabetes treatment, increase the risk of abnormalities and fertility in utero." "" "" ""</seg>
<seg id="901">"" "" "" "21 The intensification of insulin therapy with abrupt improvement in blood sugar levels can, however, be associated with a temporary worsening of diabetic retinopathy." "" "" ""</seg>
<seg id="902">"" "" "" "degenerative disorders, including generalized skin rash, itching, sweating, gastrointestinal disorders, heart palpitations, low blood pressure and impotence / unconsciousness." "" "" ""</seg>
<seg id="903">Cartridges may only be used together with products compatible with them and ensure a safe and effective cartridge function.</seg>
<seg id="904">It is recommended - after Actraphane Penfill is taken out of the refrigerator - to rise the temperature of the insulin at room temperature (not above 25 ° C) before it is resushered according to the operating instructions for the first use.</seg>
<seg id="905">"" "" "" "some patients, in which hypoglycaemic reactions occurred after a change from animal to human insulin, reported that the early warning symptoms of hypoglycemia were less pronounced or different from their previous insulin." "" "" ""</seg>
<seg id="906">"" "" "" "28 Unless hypoglycemia and hyperglycemia, which can occur in a non-controlled diabetes treatment, increase the risk of abnormalities and fertility in utero." "" "" ""</seg>
<seg id="907">"" "" "" "29 The intensification of insulin therapy with abrupt improvement in blood sugar levels can, however, be associated with a temporary worsening of diabetic retinopathy." "" "" ""</seg>
<seg id="908">"" "" "" "some patients, in which hypoglycaemic reactions occurred after a change from animal to human insulin, reported that the early warning symptoms of hypoglycemia were less pronounced or different from their previous insulin." "" "" ""</seg>
<seg id="909">"" "" "" "36 Unlower hypoglycemia and hyperglycemia, which may occur in a non-controlled diabetes treatment, increase the risk of abnormalities and fertility in utero." "" "" ""</seg>
<seg id="910">"" "" "" "37 The intensification of insulin therapy with abrupt improvement in blood sugar levels can, however, be associated with a temporary worsening of diabetic retinopathy." "" "" ""</seg>
<seg id="911">"" "" "" "44 Unless hypoglycemia and hyperglycemia, which can occur in a non-controlled diabetes treatment, increase the risk of abnormalities and fertility in utero." "" "" ""</seg>
<seg id="912">"" "" "" "45. an intensification of insulin therapy with abrupt improvement in blood sugar levels can, however, be associated with a temporary worsening of diabetic retinopathy." "" "" ""</seg>
<seg id="913">"" "" "" "some patients, in which hypoglycaemic reactions occurred after a change from animal to human insulin, reported that the early warning symptoms of hypoglycemia were less pronounced or different from their previous insulin." "" "" ""</seg>
<seg id="914">"" "" "" "52 Unless hypoglycemia and hyperglycemia, which can occur in a non-controlled diabetes treatment, increase the risk of abnormalities and fertility in utero." "" "" ""</seg>
<seg id="915">"" "" "" "53 The intensification of insulin therapy with abrupt improvement in blood sugar levels can, however, be associated with a temporary worsening of diabetic retinopathy." "" "" ""</seg>
<seg id="916">"" "" "" "before injection, the injection units must be prepared in such a way that the dose regulator drops to zero and a insulin drops appears at the tip of the injection needle." "" "" ""</seg>
<seg id="917">"" "" "" "59 patients whose blood sugar levels have improved significantly, for example, by an intensive insulin therapy, the hypoglycaemia warning symptoms can be changed and should be advised accordingly." "" "" ""</seg>
<seg id="918">"" "" "" "both hypoglycaemia and hyperglycemia, which can occur in a non-controlled diabetes treatment, increase the risk of abnormalities and fertility in utero." "" "" ""</seg>
<seg id="919">"" "" "" "an intensification of insulin therapy with abrupt improvement in blood sugar levels can, however, be associated with a temporary worsening of diabetic retinopathy." "" "" ""</seg>
<seg id="920">"" "" "" "degenerative disorders, including generalized skin rash, itching, sweating, gastrointestinal disorders, heart palpitations, low blood pressure and impotence / unconsciousness." "" "" ""</seg>
<seg id="921">These finished pens must only be used together with products compatible with them and ensure a safe and effective functioning of the finished pens.</seg>
<seg id="922">It is recommended - after Actraphane Novoary was extracted from the refrigerator - the temperature of the insulin at room temperature (not above 25 ° C) before it is resushered according to the operating instructions for the first use.</seg>
<seg id="923">"" "" "" "67 patients whose blood sugar levels have improved significantly, for example, by an intensive insulin therapy, the hypoglycaemia warning symptoms can be changed and should be advised accordingly." "" "" ""</seg>
<seg id="924">"" "" "" "75 patients whose blood sugar levels have improved significantly, for example, by an intensive insulin therapy, the hypoglycaemia warning symptoms can be changed and should be advised accordingly." "" "" ""</seg>
<seg id="925">"" "" "" "83 patients whose blood sugar levels have improved significantly, for example, by an intensive insulin therapy, the hypoglycaemia warning symptoms can be changed and should be advised accordingly." "" "" ""</seg>
<seg id="926">"" "" "" "91 patients whose blood sugar levels have improved significantly, for example, by an intensive insulin therapy, the hypoglycaemia warning symptoms can be changed and should be advised accordingly." "" "" ""</seg>
<seg id="927">"" "" "" "99 patients whose blood sugar levels have improved significantly, for example, by an intensive insulin therapy, the hypoglycaemia warning symptoms can be changed and should be advised accordingly." "" "" ""</seg>
<seg id="928">"" "" "" "any change regarding strength, brand (manufacturer), type of insulin (fast acting, biphasic, long-acting insulin, etc.), type of insulin (animal insulin, human insulin or insulin analogue) and / or production method (recombinant DNA versus insulin origin) can cause a change in dosage." "" "" ""</seg>
<seg id="929">It is recommended - after Actraphane InnoLet is taken from the refrigerator - let the temperature of the insulin rise at room temperature (not above 25 ° C) before it is resushered according to the operating instructions for the first use.</seg>
<seg id="930">It is recommended - after Actraphane FlexPen was taken out of the refrigerator - to increase the temperature of the insulin at room temperature (not above 25 ° C) before it is resushered according to the operating instructions for the first use.</seg>
<seg id="931">"" "" "" "on the packaging supplement of the medicine, the manufacturer's name and address, which is responsible for the approval of the concerned batch, must be stated." "" "" ""</seg>
<seg id="932">Store in the fridge (2 ˚ C - 8 ˚ C) Don't freeze The glass bottle in a box to protect the contents from light after quarry: do not store in the fridge or over 25 ° C</seg>
<seg id="933">Subcutaneous application Penfill cartridges are intended for application with insulin injections made by Novo Nordisk mandates the instructions resuspending packing supplement note Actraphane 10 Penfill may only be used by one person</seg>
<seg id="934">Store in the fridge (2 ˚ C - 8 ˚ C) Do not freeze The cartridge in the box to protect the contents from light After breaking: do not store in the fridge or over 30 ° C</seg>
<seg id="935">Subcutaneous application Penfill cartridges are intended for application with insulin injections mandated by Novo Nordisk. follow the instructions resuspending packages. Actraphane 20 Penfill may only be used by one person</seg>
<seg id="936">Subcutaneous application Penfill cartridges are intended for application with insulin injections made by Novo Nordisk mandates the instructions resuspending packing supplement note Actraphane 30 Penfill may only be used by one person</seg>
<seg id="937">Subcutaneous application Penfill cartridges are intended for application with insulin injections made by Novo Nordisk mandates the instructions resuspending packing supplement note Actraphane 40 Penfill may only be used by one person</seg>
<seg id="938">Subcutaneous application Penfill cartridges are intended for application with insulin injections mandated by Novo Nordisk. follow the instructions resuspending packages. Actraphane 50 Penfill may only be used by one person</seg>
<seg id="939">Subcutaneous application For use with Actraphane 10 Novoary are NovoFine injection needles provided by the instructions resuspending packing supplement note Actraphane 10 NovoLet can only be used by one person</seg>
<seg id="940">Store in the fridge (2 ˚ C - 8 ˚ C) Don't freeze ahead. protect from frost: do not store in the refrigerator or over 30 ° C</seg>
<seg id="941">Subcutaneous application For use with Actraphane 20 Novoary are NovoFine injection needles provided by the instructions resuspending packing supplement note Actraphane 20 NovoLet can only be used by one person</seg>
<seg id="942">Subcutaneous application For use with Actraphane 30 NovoLet NovoFine injections are provided with the instructions resuspending packing supplement note Actraphane 30 NovoLet can only be used by one person</seg>
<seg id="943">Subcutaneous application For use with Actraphane 40 Novoary are NovoFine injection needles provided by the instructions resuspending packing supplement note Actraphane 40 NovoLet can only be used by one person</seg>
<seg id="944">Subcutaneous application For use with Actraphane 50 Novoary are NovoFine injection needles provided by the instructions resuspending packing supplement note Actraphane 50 NovoLet can only be used by one person</seg>
<seg id="945">Subcutaneous application For use with Actraphane 30 InnoLet are NovoFine S injections needles provided by the instructions resuspending packing supplement note Actraphane 30 InnoLet can only be used by one person</seg>
<seg id="946">"" "" "" "this means that about half an hour after you have applied it, your blood sugar begins to sink and that the effect will stop about 24 hours." "" "" ""</seg>
<seg id="947">"" "" "" "► If you are allergic (hypersensitive) to this insulin product, Metacresol or any of the other ingredients (see paragraph 7 For more information)." "" "" ""</seg>
<seg id="948">Pay attention to those under 5 Which side effects are possible? described symptoms of an allergy ► if you feel first signs of hypoglycaemia (symptoms of an undersugar).</seg>
<seg id="949">"" "" "" "if your doctor has initiated a change from an insulin type or brand to another, you may need to adjust the dose by your doctor." "" "" ""</seg>
<seg id="950">"" "" "" "► Check the label, whether it is the right type of insulin, and disinfect the rubber membrane with a medical tiplover." "" "" ""</seg>
<seg id="951">"" "" "" "if this is not completely undamaged, if you get the penetration bottle, put the glass bottle back to your pharmacy (see 6 How to preserve Actraphane?)" "" "" ""</seg>
<seg id="952">"" "" "" "use the injection technique that your doctor or diabetadviser recommended, to ensure that the injection needle is injected under your skin for at least 6 seconds to ensure that the full dose is injected." "" "" ""</seg>
<seg id="953">"" "" "" "the warning signs of a fortification can suddenly appear and may be: cold sweat, cold pale skin, headache, heart rate, nausea, great hunger, temporary blurred vision, anxiety, anxiety, anxiety, concentration difficulties." "" "" ""</seg>
<seg id="954">"" "" "" "tell your relatives, friends and narrow workmates that they will bring you into the stable side situation in case of unconsciousness and need to reach a doctor immediately." "" "" ""</seg>
<seg id="955">"" "" "" "► If a severe fortification is not treated, this may lead to (temporary or permanent) brain damage or even death." "" "" ""</seg>
<seg id="956">You can recover your consciousness quicker if you injected the hormone glucagon from a person familiar with his gift.</seg>
<seg id="957">"" "" "" "this can happen: if you injure too much insulin, if you eat too little or leave a meal, if you do more than otherwise." "" "" ""</seg>
<seg id="958">"" "" "" "increased ururination, thirst, loss of appetite, nausea or vomiting, nausea or fatigue, cured dry skin, dry mouth and fruity (after acetone) smelling breath." "" "" ""</seg>
<seg id="959">• You have forgotten an insulin injections • repeated injecting less insulin than you need • an infection or fever • more food than usual • less physical exercise than usual.</seg>
<seg id="960">"" "" "" "if you often have an injection at the same place, the subcutaneous fatty tissue can shrink or increase (lipohypertrophy)." "" "" ""</seg>
<seg id="961">"" "" "" "if you notice depressions or thickening of your skin at the injection site, tell your doctor or diabetadvisor because these reactions can worsen or affect the absorption of your insulin if you are injected into such a position." "" "" ""</seg>
<seg id="962">"" "" "" "immediately seek a doctor if symptoms of allergy to other parts of the body spread or if you suddenly feel uncomfortable and you have sweat, breathing difficulties, heart rate, or you have the impression of becoming unconscious." "" "" ""</seg>
<seg id="963">You may have a very rare allergic reaction to Actraphane or any of its components (a so-called systemic allergic reaction).</seg>
<seg id="964">"" "" "" "if any of the side effects listed you have significantly impaired or you notice side effects that are not stated in this information, please consult your doctor, your diabetes consultant or your pharmacist." "" "" ""</seg>
<seg id="965">"" "" "" "what Actraphane 30 contains - The active substance produced by recombinant DNA technology is human (30% as a soluble insulin, and 70% as Isophan insulin)." "" "" ""</seg>
<seg id="966">"" "" "" "as Actraphane looks and contents of the pack The injection suspension is delivered as a opaque, white, watery suspension in packs of 1 or 5 ml each 10 ml or a bundle of 5 ml bottles each 10 ml." "" "" ""</seg>
<seg id="967">"" "" "" "use the injection technique that your doctor or diabetadviser recommended, to ensure that the injection needle is injected under your skin for at least 6 seconds to ensure that the full dose is injected." "" "" ""</seg>
<seg id="968">"" "" "" "it is recommended - after it is taken out of the refrigerator - to rise the temperature of the glass bottle at room temperature, before the insulin is resushered according to the operating instructions for the first use." "" "" ""</seg>
<seg id="969">"" "" "" "as Actraphane looks and contents of the pack The injection suspension is delivered as a opaque, white, watery suspension in packs of 1 or 5 ml each 10 ml or a bundle of 5 ml bottles each 10 ml." "" "" ""</seg>
<seg id="970">"" "" "" "► Check the label, whether it is the right type of insulin, and ► Check the penfill cartridge, including gum (stoppers)." "" "" ""</seg>
<seg id="971">"" "" "" "do not use them if any damage is visible or a gap is visible between the rubber piston, and the white belt of the label." "" "" ""</seg>
<seg id="972">"" "" "" "for further information, please refer to the operating instructions of your insulin injector system. ► Use the rubber membrane with a medical tick." "" "" ""</seg>
<seg id="973">"" "" "" "► For insulin infusion pumps, if the fill is damaged or broken, there is a risk of running insulin if it is not stored correctly or frozen (see 6 How to preserve Actraphane?)" "" "" ""</seg>
<seg id="974">"" "" "" "if you are treated with Actraphane 10 Penfill and another insulin in Penfill cartridges, you should use two insulin injections, one for each insulin type." "" "" ""</seg>
<seg id="975">"" "" "" "before inserting the cartridge into the insulin injection system, move it at least 20 times between the positions a and b and ab (see picture), so that the glass ball moves from one end of the cartridge to the other." "" "" ""</seg>
<seg id="976">Use the injection technique described by your doctor or your diabetes adviser and which is described in the operating instructions of your injections. ► Let the injection needle be injected under your skin to ensure that the complete dose was injected.</seg>
<seg id="977">"" "" "" "183 Say your relatives, friends and narrow workmates that they will bring you into the stable side situation in the event of unconsciousness and need to reach a doctor immediately." "" "" ""</seg>
<seg id="978">• You have forgotten an insulin injections • repeated injecting less insulin than you need • an infection or fever • more food than usual • less physical exercise than usual.</seg>
<seg id="979">"" "" "" "if any of the side effects listed you have significantly impaired or you notice side effects that are not stated in this information, please consult your doctor, your diabetes consultant or your pharmacist." "" "" ""</seg>
<seg id="980">"" "" "" "it is recommended - after removing it from the refrigerator - to rise the temperature of the fill cartridge at room temperature, before the insulin is resushered according to the operating instructions for the first use." "" "" ""</seg>
<seg id="981">"" "" "" "185 Keep the cartridges always in box, if you do not use them to protect them from light." "" "" ""</seg>
<seg id="982">"" "" "" "what Actraphane 10 contains - The active substance produced by recombinant DNA technology is human (10% as a soluble insulin, and 90% as Isophan insulin)." "" "" ""</seg>
<seg id="983">"" "" "" "as Actraphane looks and contents of the pack The injection suspension is delivered as a opaque white, watery suspension in packs of 1, 5 or 10 cartridges each 3 ml." "" "" ""</seg>
<seg id="984">"" "" "" "for further information, please refer to the operating instructions of your insulin injector system. ► Use the rubber membrane with a medical tick." "" "" ""</seg>
<seg id="985">"" "" "" "if you are treated with Actraphane 20 Penfill and another insulin in Penfill cartridges, you should use two insulin injections, one for each insulin type." "" "" ""</seg>
<seg id="986">"" "" "" "189 Say your relatives, friends and narrow workmates that they will bring you into the stable side situation in the event of unconsciousness and need to reach a doctor immediately." "" "" ""</seg>
<seg id="987">"" "" "" "if any of the side effects listed you have significantly impaired or you notice side effects that are not stated in this information, please consult your doctor, your diabetes consultant or your pharmacist." "" "" ""</seg>
<seg id="988">"" "" "" "191 Keep the cartridges always in box, if you do not use them to protect them from light." "" "" ""</seg>
<seg id="989">"" "" "" "what Actraphane 20 contains - The active substance produced by recombinant DNA technology is human (20% as a soluble insulin, and 80% as Isophan insulin)." "" "" ""</seg>
<seg id="990">"" "" "" "as Actraphane looks and contents of the pack The injection suspension is delivered as a opaque white, watery suspension in packs of 1, 5 or 10 cartridges each 3 ml." "" "" ""</seg>
<seg id="991">"" "" "" "for further information, please refer to the operating instructions of your insulin injector system. ► Use the rubber membrane with a medical tick." "" "" ""</seg>
<seg id="992">"" "" "" "if you are treated with Actraphane 30 Penfill and another insulin in Penfill cartridges, you should use two insulin injections, one for each insulin type." "" "" ""</seg>
<seg id="993">"" "" "" "195 Tell your relatives, friends and narrow workmates that they will bring you in the event of unconsciousness to the stable side situation and immediately notify a doctor." "" "" ""</seg>
<seg id="994">"" "" "" "if any of the side effects listed you have significantly impaired or you notice side effects that are not stated in this information, please consult your doctor, your diabetes consultant or your pharmacist." "" "" ""</seg>
<seg id="995">"" "" "" "197 Keep the cartridges always in box, if you do not use them to protect them from light." "" "" ""</seg>
<seg id="996">"" "" "" "manufacturer The manufacturer can be identified using the batch designation, which is printed on the flap of the box and on the label:" "" "" ""</seg>
<seg id="997">"" "" "" "if at the second and third place of Chargen designation, the character combination W5, S6, P5, K7 or ZF, the manufacturer Novo Nordisk A / S, Novo Allé, DK- 2880 Bagsvaerde, Denmark" "" "" ""</seg>
<seg id="998">"" "" "" "if in the second and third place of Chargen designation the drawing combination H7 or T6 appears, the manufacturer Novo Nordisk Production SAS, 45, Avenue d'Orléans, F-28002 Chartres, France." "" "" ""</seg>
<seg id="999">"" "" "" "for further information, please refer to the manual of your Insul ininjektion system. ► Use a new injection needle for each injection to avoid contamination." "" "" ""</seg>
<seg id="1000">"" "" "" "if you are treated with Actraphane 40 Penfill and another insulin in Penfill cartridges, you should use two insulin injections, one for each insulin type." "" "" ""</seg>
<seg id="1001">"" "" "" "201 Say your relatives, friends and narrow workmates that they will bring you into the stable side situation in case of unconsciousness and need to reach a doctor immediately." "" "" ""</seg>
<seg id="1002">"" "" "" "if any of the side effects listed you have significantly impaired or you notice side effects that are not stated in this information, please consult your doctor, your diabetes consultant or your pharmacist." "" "" ""</seg>
<seg id="1003">"" "" "" "203 Keep the cartridges always in box, if you do not use them to protect them from light." "" "" ""</seg>
<seg id="1004">"" "" "" "what Actraphane 40 contains - The active substance produced by recombinant DNA technology is human (40% as a soluble insulin, and 60% as Isophan insulin)." "" "" ""</seg>
<seg id="1005">"" "" "" "for further information, please refer to the manual of your Insul ininjektion system. ► Use a new injection needle for each injection to avoid contamination." "" "" ""</seg>
<seg id="1006">"" "" "" "if you are treated with Actraphane 50 Penfill and another insulin in Penfill cartridges, you should use two insulin injections, one for each insulin type." "" "" ""</seg>
<seg id="1007">"" "" "" "before using the fill cartridge in the insulin injection system, move it at least 20 times between the positions a and b and ab (see illustration), so that the glass ball moves from one end of the cartridge to the other." "" "" ""</seg>
<seg id="1008">"" "" "" "207 Say your relatives, friends and narrow workmates that they will bring you in the event of unconsciousness to the stable side situation and immediately notify a doctor." "" "" ""</seg>
<seg id="1009">"" "" "" "if any of the side effects listed you have significantly impaired or you notice side effects that are not stated in this information, please consult your doctor, your diabetes consultant or your pharmacist." "" "" ""</seg>
<seg id="1010">"" "" "" "209 Keep the cartridges always in box, if you do not use them to protect them from light." "" "" ""</seg>
<seg id="1011">"" "" "" "what Actraphane 50 contains - The active substance produced by recombinant DNA technology is human (50% as a soluble insulin, and 50% as Isophan insulin)." "" "" ""</seg>
<seg id="1012">"" "" "" "oral antidiabetic agents (ACE inhibitors), beta inhibitors, acetylsalicylic acid, anabolic steroids, thyroid hormones, beta-hormones, beta releases, octreotide or lanreotid." "" "" ""</seg>
<seg id="1013">"" "" "" "► For each injection, ► Check a new injection needle to avoid contamination." "" "" ""</seg>
<seg id="1014">► in insulin infusion pumps ► if the Novoary dropped damaged or broken up there is the risk of running insulin if it was not properly kept or frozen (see 6 How to preserve Actraphane?) ►</seg>
<seg id="1015">"" "" "" "the warning signs of a fortification can suddenly appear and may be: cold sweat, cold pale skin, headache, heart rate, nausea, great hunger, temporary blurred vision, anxiety, anxiety, anxiety, concentration difficulties." "" "" ""</seg>
<seg id="1016">"" "" "" "214 If any of the side effects listed you have significantly impaired or you notice side effects that are not stated in this information, please consult your doctor, your diabetes consultant or your pharmacist." "" "" ""</seg>
<seg id="1017">"" "" "" "in use, NovoLet's ready-to-use pens and those who are used soon or as a replacement are not stored in the refrigerator." "" "" ""</seg>
<seg id="1018">"" "" "" "it is recommended - after removing from the refrigerator - let the temperature of the Novoary finished pens rise at room temperature, before the insulin is resushered according to the instructions for the first use." "" "" ""</seg>
<seg id="1019">"" "" "" "let the closing cap of your Novoary finished pens always put on, if Novoary is not in use to protect the insulin from light." "" "" ""</seg>
<seg id="1020">"" "" "" "as Actraphane looks and contents of the pack The injection suspension is delivered as cloudy, white, watery suspension in packs of 5 or 10 finished pens each 3 ml." "" "" ""</seg>
<seg id="1021">"" "" "" "before each injection, check if there are at least 12 units of insulin remaining in the cartridge to ensure an even mixture." "" "" ""</seg>
<seg id="1022">Proceed as follows to avoid the injection of air and ensure correct dosage: • Keep Actraphane 10 Novoary with the injection needle upwards • knock a few times with your finger against the cartridge.</seg>
<seg id="1023">"" "" "" "as soon as you keep the injection needle upwards, press the button in the direction of the arrow (Figure D) • Now, from the tip of the injection needle, drop a drop of insulin." "" "" ""</seg>
<seg id="1024">"" "" "" "• Connect the cap back to the finished pen, that the digit 0 is opposite the metering brand (figure E) • Check that the push button is fully pressed." "" "" ""</seg>
<seg id="1025">"" "" "" "if not, turn the cap until the push button is fully pressed • Keep your Actraphane 10 Novoary horizontal." "" "" ""</seg>
<seg id="1026">"" "" "" "if the push button cannot move outward, insulin is pressed out of the injection needle • The scale on the cap shows 0, 2, 4, 6, 8, 10, 14, 16 and 18 units." "" "" ""</seg>
<seg id="1027">"" "" "" "the push button moves outward while you rotate the closing cap • The scale underneath the push button shows 20, 40 and 60 units." "" "" ""</seg>
<seg id="1028">"" "" "" "review a set dose • Record the number on the cap directly next to the dosage marker • Record the highest number you can see on the pushbutton • If you have set a wrong dose, simply turn the cap forward or backward until you have adjusted the correct number of units." "" "" ""</seg>
<seg id="1029">"" "" "" "otherwise insulin will escape from the injection needle and the prescribed dose will not be correct • If you have been mistaken, set a dose of more than 78 units, follow these steps:" "" "" ""</seg>
<seg id="1030">"" "" "" "then remove the cap and set it up again, so that the 0 of the metering brand is over." "" "" ""</seg>
<seg id="1031">"" "" "" "take care not to press the button during the injection. • Keep the push button after the injection, until the injection needle is pulled out of the skin." "" "" ""</seg>
<seg id="1032">"" "" "" "if not, turn the cap until the press button is fully pressed and then proceed as described before use • Finally, you can hear a clicketing noise when pressing the press button." "" "" ""</seg>
<seg id="1033">It may be incorrect • You cannot set a dose that is higher than the number of units remaining in the cartridge • You can use the remaining amount of scale to estimate how much insulin is still left.</seg>
<seg id="1034">"" "" "" "oral antidiabetic agents (ACE inhibitors), beta inhibitors, acetylsalicylic acid, anabolic steroids, thyroid hormones, beta-hormones, beta releases, octreotide or lanreotid." "" "" ""</seg>
<seg id="1035">"" "" "" "224 If any of the side effects listed you have significantly impaired or you notice side effects that are not stated in this information, please consult your doctor, your diabetes consultant or your pharmacist." "" "" ""</seg>
<seg id="1036">"" "" "" "226 Before each injection, check if there are at least 12 units of insulin remaining in the cartridge to ensure an even mixture." "" "" ""</seg>
<seg id="1037">Proceed as follows to avoid the injection of air and ensure correct dosage: • Keep Actraphane 20 Novoary with the injection needle upwards • knock a few times with your finger against the cartridge.</seg>
<seg id="1038">"" "" "" "as soon as you keep the injection needle upwards, press the button in the direction of the arrow (Figure D) • Now, from the tip of the injection needle, drop a drop of insulin." "" "" ""</seg>
<seg id="1039">"" "" "" "if not, turn the cap until the push button is fully pressed • Keep your Actraphane 20 Novoary horizontal." "" "" ""</seg>
<seg id="1040">"" "" "" "oral antidiabetic agents (ACE inhibitors), beta inhibitors, acetylsalicylic acid, anabolic steroids, thyroid hormones, beta-hormones, beta releases, octreotide or lanreotid." "" "" ""</seg>
<seg id="1041">"" "" "" "234 If any of the side effects listed you have significantly impaired or you notice side effects that are not stated in this information, please consult your doctor, your diabetes consultant or your pharmacist." "" "" ""</seg>
<seg id="1042">"" "" "" "236 Before each injection, check if there are at least 12 units of insulin remaining in the cartridge to ensure an even mixture." "" "" ""</seg>
<seg id="1043">Proceed as follows to avoid the injection of air and ensure correct dosage: • Keep Actraphane 30 Novoary with the injection needle upwards • knock a few times with your finger against the cartridge.</seg>
<seg id="1044">"" "" "" "if air bubbles are present, they will move up in the cartridge - While you keep Actraphane 30 NovoLet continue with the injection needle, press the push button in the direction of the arrow (figure D) • Now, from the tip of the injection needle, push a drop of insulin." "" "" ""</seg>
<seg id="1045">"" "" "" "if not, turn the cap until the push button is fully pressed • Keep your Actraphane 30 Novoary horizontal." "" "" ""</seg>
<seg id="1046">"" "" "" "oral antidiabetic agents (ACE inhibitors), beta inhibitors, acetylsalicylic acid, anabolic steroids, thyroid hormones, beta-hormones, beta releases, octreotide or lanreotid." "" "" ""</seg>
<seg id="1047">"" "" "" "244 If any of the listed side effects are significantly impaired or you notice side effects that are not stated in this information, please consult your doctor, your diabetes consultant or your pharmacist." "" "" ""</seg>
<seg id="1048">"" "" "" "246 Before each injection, check if there are at least 12 units of insulin remaining in the cartridge to ensure an even mixture." "" "" ""</seg>
<seg id="1049">Proceed as follows to avoid the injection of air and ensure correct dosage: • Keep Actraphane 40 Novoary with the injection needle upwards • knock a few times with your finger against the cartridge.</seg>
<seg id="1050">"" "" "" "as soon as you keep the injection needle upwards, press the button in the direction of the arrow (Figure D) • Now, from the tip of the injection needle, drop a drop of insulin." "" "" ""</seg>
<seg id="1051">"" "" "" "if not, turn the cap until the push button is fully pressed • Keep your Actraphane 40 Novoary horizontal." "" "" ""</seg>
<seg id="1052">"" "" "" "oral antidiabetic agents (ACE inhibitors), beta inhibitors, acetylsalicylic acid, anabolic steroids, thyroid hormones, beta-hormones, beta releases, octreotide or lanreotid." "" "" ""</seg>
<seg id="1053">"" "" "" "254 If any of the listed side effects are significantly impaired or you notice side effects that are not stated in this information, please consult your doctor, your diabetes consultant or your pharmacist." "" "" ""</seg>
<seg id="1054">"" "" "" "it is recommended - after removing from the refrigerator - let the temperature of the Novoary finished pens rise at room temperature, before the insulin is resushered according to the instructions for the first use." "" "" ""</seg>
<seg id="1055">"" "" "" "256 Before each injection, check if there are at least 12 units of insulin remaining in the cartridge to ensure an even mixture." "" "" ""</seg>
<seg id="1056">Proceed as follows to avoid the injection of air and ensure correct dosage: • Keep Actraphane 50 Novoary with the injection needle upwards • knock a few times with your finger against the cartridge.</seg>
<seg id="1057">"" "" "" "as soon as you keep the injection needle upwards, press the button in the direction of the arrow (Figure D) • Now, from the tip of the injection needle, drop a drop of insulin." "" "" ""</seg>
<seg id="1058">"" "" "" "if not, turn the cap until the push button is fully pressed • Keep your Actraphane 50 Novoary horizontal." "" "" ""</seg>
<seg id="1059">"" "" "" "oral antidiabetic agents (ACE inhibitors), beta inhibitors, acetylsalicylic acid, anabolic steroids, thyroid hormones, beta-hormones, beta releases, octreotide or lanreotid." "" "" ""</seg>
<seg id="1060">► in insulin infusion pumps ► if the innoLet is dropped or broken down there is the risk of running insulin ► if it is not properly kept or frozen (see 6 How to preserve Actraphane?) ►</seg>
<seg id="1061">"" "" "" "the warning signs of a fortification can suddenly appear and may be: cold sweat, cold pale skin, headache, heart rate, nausea, great hunger, temporary blurred vision, anxiety, anxiety, anxiety, concentration difficulties." "" "" ""</seg>
<seg id="1062">"" "" "" "264 If any of the listed side effects you have significantly impaired or you notice side effects that are not stated in this use information, please consult your doctor, your diabetes consultant or your pharmacist." "" "" ""</seg>
<seg id="1063">"" "" "" "in use, InnoLet's ready-to-use pens and those who are used in short or as a replacement are not stored in the refrigerator." "" "" ""</seg>
<seg id="1064">"" "" "" "it is recommended - after it is taken out of the refrigerator - let the InnoLet's temperature rise at room temperature, before the insulin is resushered according to the instructions for the first use." "" "" ""</seg>
<seg id="1065">"" "" "" "let the closing cap of your InnoGo finished pens always set, if InnoLet is not in use to protect the insulin from light." "" "" ""</seg>
<seg id="1066">"" "" "" "as Actraphane looks and contents of the pack The injection suspension is delivered as a opaque white, watery suspension in packs of 1, 5 or 10 finished pens each 3 ml." "" "" ""</seg>
<seg id="1067">"" "" "" "the movement must be repeated until the liquid looks evenly white and cloudy • After the resuspening, perform all the following steps of the injection without delay." "" "" ""</seg>
<seg id="1068">• Refect the rubber membrane with a medicinal tampon • Use a new injection needle to avoid contamination • Remove the protective flap straight and firmly on Actraphane 30 InnoLet (figure 1B) • Withdraw the large external injection needle and the inner injection needle.</seg>
<seg id="1069">"" "" "" "• If the push button is fully pressed and the dose knob is set to zero, place the number of units you have injected by turning the dose regulator clockwise (Figure 2)." "" "" ""</seg>
<seg id="1070">"" "" "" "do not use the residual quantity scale to measure your insulin dose, you hear a click noise for each unit individually adjusted." "" "" ""</seg>
<seg id="1071">"" "" "" "perform the injection technique, which your doctor has shown to you • Specify the dose by pressing the button in the full (Figure 3)." "" "" ""</seg>
<seg id="1072">The dose regulator has to be reduced to zero and you hear click noise • The injection needle must remain under the skin after injection • Do not block the dose regulator during injection as you push the dose regulator to zero if you press on the push button • Remove the injection needle after injection.</seg>
<seg id="1073">"" "" "" "medical staff, family members and other supervisors must observe general precautions to remove and dispose of the injection needles to avoid unintentional stitches with the injection needle." "" "" ""</seg>
<seg id="1074">"" "" "" "oral antidiabetic agents (ACE inhibitors), beta inhibitors, acetylsalicylic acid, anabolic steroids, thyroid hormones, beta-hormones, beta releases, octreotide or lanreotid." "" "" ""</seg>
<seg id="1075">► In insulin infusion pumps ► if the flexPen is dropped or damaged it is the risk of running insulin if it is not properly kept or frozen (see 6 How to preserve Actraphane?) ►</seg>
<seg id="1076">"" "" "" "if you notice depressions or thickening of your skin at the injection site, tell your doctor or diabetadvisor because these reactions can worsen or affect the absorption of your insulin if you are injected into such a position." "" "" ""</seg>
<seg id="1077">"" "" "" "274 If any of the side effects listed you have significantly impaired or you notice side effects that are not stated in this information, please consult your doctor, your diabetes consultant or your pharmacist." "" "" ""</seg>
<seg id="1078">"" "" "" "in use, flexPen finished pens and those that are used in short or as a replacement are not stored in the refrigerator." "" "" ""</seg>
<seg id="1079">"" "" "" "it is recommended - after it is taken out of the refrigerator - to rise the temperature of the flexPen finished pens at room temperature, before the insulin is resushered according to the operating instructions for the first use." "" "" ""</seg>
<seg id="1080">"" "" "" "keep the closing cap of your flexPen finished pens, if FlexPen is not in use to protect the insulin from light." "" "" ""</seg>
<seg id="1081">"" "" "" "as Actraphane looks and contents of the pack The injection suspension is delivered as a opaque white, watery suspension in packs of 1, 5 or 10 finished pens each 3 ml." "" "" ""</seg>
<seg id="1082">"" "" "" "manufacturer The manufacturer can be identified using the batch designation, which is printed on the flap of the box and on the label:" "" "" ""</seg>
<seg id="1083">"" "" "" "if in the second and third place of Chargen designation the character combination W5, S6, P5, K7 or ZF appears, the manufacturer Novo Nordisk Production SAS, 45, Avenue d'Orléans, F- 28002 Chartres, France." "" "" ""</seg>
<seg id="1084">"" "" "" "B Move the finished pen between positions 1 and 2 twenty times and off, so that the glass ball moves from one end of the cartridge to the other." "" "" ""</seg>
<seg id="1085">"" "" "" "move the finished pen at least 10 times between positions 1 and 2, until the liquid appears uniform and opaque." "" "" ""</seg>
<seg id="1086">"" "" "" "• To reduce the risk of inadvertent needle stitches, never put the inner shell back onto the needle after you once removed it." "" "" ""</seg>
<seg id="1087">"" "" "" "279 G Keep the flexPen upwards and knock a few times with the finger against the cartridge, so that existing air bubbles accumulate in the cartridge." "" "" ""</seg>
<seg id="1088">"" "" "" "the dose can be corrected both upwards and downwards by turning the dose dial into the appropriate direction, until the correct dose is against the marking of the indication." "" "" ""</seg>
<seg id="1089">This document is a summary of the European Public Health Report (EPAR) in which explains how the Committee for Medicinal Products (CHMP) evaluated the conducted studies to make recommendations concerning the application of the medicine.</seg>
<seg id="1090">"" "" "" "the inactive ingredient in Actrapid, insulin human (rDNA) is produced using the method of" recombinant technology. "" "" "" ""</seg>
<seg id="1091">(44-20) 74 18 84 00 Fax (44-20) 74 18 86 68 E-mail: mail @ emea.europa.eu http: / / distribution of this document is Authorised for non business purposes only provided the EMEA is acknowledged How was Actrapid investigated?</seg>
<seg id="1092">"" "" "" "Actrapid may not be used in patients who are possibly hypersensitive to insulin human (rDNA), or any of the other components." "" "" ""</seg>
<seg id="1093">"" "" "" "in addition, acetabpid cans need to be adjusted if it is administered together with a number of other medicines that can affect blood sugar." "" "" ""</seg>
<seg id="1094">"" "" "" "in October 2002, the European Commission granted the company Novo Nordisk A / S a permit for the placing of Actrapid in the European Union." "" "" ""</seg>
<seg id="1095">"" "" "" "when two types of insulin are mixed, the amount of quickly acting insulin needs to be wound up first, then the amount of long-acting insulin." "" "" ""</seg>
<seg id="1096">"" "" "" "3 If a dose adjustment is required when changing to Actrapid, it may be necessary at the first dosage or during the first weeks or months after the conversion." "" "" ""</seg>
<seg id="1097">"" "" "" "when travelling over several time zones, the patient should be advised to collect the advice of his physician, as such trips may lead to insulin and meals to be used or taken at other times." "" "" ""</seg>
<seg id="1098">"" "" "" "5 General conditions and complaints at the injection site During insulin therapy local hypersensitivity reactions (redness, swelling, itching, pain and haematoma at the injection site) can occur." "" "" ""</seg>
<seg id="1099">Diabetics should therefore always have grape sugar, sweets, biscuits or sugary fruit juice. • Heavy hypoglycemia associated with deficiencies are treated with an intramuscular or subcutaneous injection of glucagon (0.5 to 1.0 mg) or by glucose that is given intravenously by the doctor.</seg>
<seg id="1100">A clinical trial in an intensive care unit for the treatment of hyperglycemia (blood sugar over 10 mmol / l) with 204 diabetic and 1344 non-diabetic patients showed that an intravenous-induced macglycemia (blood sugar 4.3 - 6.1 mmol / l) reduced mortality by 42% (8% compared to 4.6%).</seg>
<seg id="1101">"" "" "" "the effect begins within half an hour, the effective maximum is reached within 1.5 to 3.5 hours and the total dose is approximately 7 to 8 hours." "" "" ""</seg>
<seg id="1102">Children and adolescents The pharmacokinetic profile of Actrapid was studied at a smaller number (n = 18) diabetic children (aged between 6 and 12) and juvenile (aged between 13 and 17).</seg>
<seg id="1103">"" "" "" "the data is limited, but suggests that pharmacokinetic profile in children and adolescents is similar to that of adults." "" "" ""</seg>
<seg id="1104">Infusion systems with acetabpid in concentrations of 0.05 I.E. / ml - 1.0 I.E. / ml insulin with 40 mmol / l potassium chloride are stable at room temperature for 24 hours at room temperature.</seg>
<seg id="1105">"" "" "" "11 If a dose adjustment is required when changing to Actrapid, it may be necessary at the first dosage or during the first weeks or months after the conversion." "" "" ""</seg>
<seg id="1106">"" "" "" "when travelling over several time zones, the patient should be advised to collect the advice of his physician, as such trips may lead to insulin and meals to be used or taken at other times." "" "" ""</seg>
<seg id="1107">"" "" "" "13 General conditions and complaints at the injection site During insulin therapy local hypersensitivity reactions (redness, swelling, itching, pain and haematoma at the injection site) can occur." "" "" ""</seg>
<seg id="1108">Diabetics should therefore always have grape sugar, sweets, biscuits or sugary fruit juice. • Heavy hypoglycemia associated with deficiencies are treated with an intramuscular or subcutaneous injection of glucagon (0.5 to 1.0 mg) or by glucose that is given intravenously by the doctor.</seg>
<seg id="1109">Children and adolescents The pharmacokinetic profile of Actrapid was studied at a smaller number (n = 18) diabetic children (aged between 6 and 12) and juvenile (aged between 13 and 17).</seg>
<seg id="1110">"" "" "" "the intravenous application of acetabpid from finished pens or cartridges should be an exception, and only occur in situations where no mixing bottles are available." "" "" ""</seg>
<seg id="1111">"" "" "" "if a dose adjustment is required when changing to Actrapid, it may be necessary during the first dosage or during the first weeks or months after the conversion." "" "" ""</seg>
<seg id="1112">21 Diseases of the skin and skin tissue tissue jelly - Lipodystrophy At the injection site can arise a lipodystrophy if failed to switch the instituting within the injection area.</seg>
<seg id="1113">Children and adolescents The pharmacokinetic profile of Actrapid was studied at a smaller number (n = 18) diabetic children (aged between 6 and 12) and juvenile (aged between 13 and 17).</seg>
<seg id="1114">29 Diseases of the skin and skin tissue tissue jelly - Lipodystrophy At the injection site can arise a lipodystrophy if failed to switch the instituting within the injection area.</seg>
<seg id="1115">"" "" "" "degenerative disorders, including generalized skin rash, itching, sweating, gastrointestinal disorders, heart palpitations, low blood pressure and impotence / unconsciousness." "" "" ""</seg>
<seg id="1116">Children and adolescents The pharmacokinetic profile of Actrapid was studied at a smaller number (n = 18) diabetic children (aged between 6 and 12) and juvenile (aged between 13 and 17).</seg>
<seg id="1117">"" "" "" "degenerative disorders, including generalized skin rash, itching, sweating, gastrointestinal disorders, heart palpitations, low blood pressure and impotence / unconsciousness." "" "" ""</seg>
<seg id="1118">38 A clinical trial in an intensive care unit for the treatment of hyperglycemia (blood sugar over 10 mmol / l) with 204 diabetic and 1344 non-diabetic patients showed that an intravenous-induced macglycemia (blood sugar 4.3 - 6.1 mmol / l) reduced mortality by 42% (8% compared to 4.6%).</seg>
<seg id="1119">"" "" "" "degenerative disorders, including generalized skin rash, itching, sweating, gastrointestinal disorders, heart palpitations, low blood pressure and impotence / unconsciousness." "" "" ""</seg>
<seg id="1120">46 A clinical trial in an intensive care unit for the treatment of hyperglycemia (blood sugar over 10 mmol / l) with 204 diabetic and 1344 non-diabetic patients showed a 42% reduction of mortality by 42% (8% compared to 4.6%).</seg>
<seg id="1121">Store in the fridge (2 ° C - 8 ° C) Don't freeze The glass bottle in a box to protect the contents from light. store: do not store in the fridge or over 25 ° C</seg>
<seg id="1122">Subcutaneous application Penfill cartridges are intended to be used with Novo Nordisk insulin injections. Actrapid Penfill may only be used by one person</seg>
<seg id="1123">Store in the fridge (2 ° C - 8 ° C) Don't freeze The cartridge in the box to protect the contents from light. store: do not store in the fridge or over 30 ° C</seg>
<seg id="1124">"" "" "" "subcutaneous application For use with Actrapid NovoLet, NovoFine injection pins are provided with an acetate novel Let only be used by one person." "" "" ""</seg>
<seg id="1125">Store in the fridge (2 ° C - 8 ° C) Do not freeze before light. do not freeze in the fridge or over 30 ° C</seg>
<seg id="1126">"" "" "" "subcutaneous application For use with Actrapid InnoLet, NovoFine S injection pins are provided with an acetabid InnoLet be used only by one person" "" "" ""</seg>
<seg id="1127">"" "" "" "this means that about half an hour after you have applied it, your blood sugar begins to sink and that the effect will stop about 8 hours." "" "" ""</seg>
<seg id="1128">► Check the label to see if it is the right type of insulin. ► Desinfect the rubber membrane with a medical acupiter.</seg>
<seg id="1129">"" "" "" "if this is not entirely unspoiled, if you get the penetration bottle, put the glass bottle back to your pharmacy (see 6 How to preserve Actrapid?) ► if it doesn't look like water and colourless." "" "" ""</seg>
<seg id="1130">"" "" "" "use the injection technique that your doctor or diabetadviser recommended, to ensure that the injection needle is injected under your skin for at least 6 seconds to ensure that the full dose is injected." "" "" ""</seg>
<seg id="1131">"" "" "" "83 Say your relatives, friends and narrow workmates that they will bring you into the stable side situation in the event of unconsciousness and need to reach a doctor immediately." "" "" ""</seg>
<seg id="1132">You may have a very rare allergic reaction to Actrapid or any of its components (a so-called systemic allergic reaction).</seg>
<seg id="1133">"" "" "" "the injection solution is delivered as a clear, colorless, aqueous solution in packs of 1 or 5 ml bottles each 10 ml or a bundle of 5 ml bottles each 10 ml." "" "" ""</seg>
<seg id="1134">"" "" "" "89 See your relatives, friends and narrow workmates that they will bring you into the stable side situation in case of unconsciousness and need to reach a doctor immediately." "" "" ""</seg>
<seg id="1135">"" "" "" "► Check the label to see if it is the right type of insulin, ► Check the cartridge including gum (stopper)." "" "" ""</seg>
<seg id="1136">"" "" "" "► For insulin infusion pumps, if the fill contains, damaged or crushed, the risk of leak failure ► if it is not properly kept or frozen (see 6 How is Actrapid protected?)" "" "" ""</seg>
<seg id="1137">"" "" "" "if you are treated with Actrapid Penfill and another insulin in Penfill cartridges, you should use two insulin injections, one for each insulin type." "" "" ""</seg>
<seg id="1138">Use the injection technique described by your doctor or your diabetes adviser and which is described in the manual of your injections system ► Let the injection needle be injected under your skin for at least 6 seconds to make sure that the complete dose is injected.</seg>
<seg id="1139">"" "" "" "• If on the second and third place of Chargen designation, the character combination W5, S6, P5, K7 or ZF, is the manufacturer Novo Nordisk A / S, Novo Allé, DK-2880 Bagsvaerde, Denmark" "" "" ""</seg>
<seg id="1140">"" "" "" "• If on the second and third place of Chargen designation, the drawing combination H7 or T6 appears, the manufacturer Novo Nordisk Production SAS, 45, Avenue d'Orléans, F- 28002 Chartres, France." "" "" ""</seg>
<seg id="1141">"" "" "" "oral antidiabetic agents (ACE inhibitors), beta inhibitors, acetylsalicylic acid, anabolic steroids, thyroid hormones, beta-hormones, beta releases, octreotide or lanreotid." "" "" ""</seg>
<seg id="1142">► Check the label to see if it is the right type of insulin. ► Use a new needle for each injection to avoid contamination.</seg>
<seg id="1143">"" "" "" "► in insulin infusion pumps ► if the Novoary dropped, damaged or broken; there is the risk of running insulin, if it was not properly kept or frozen (see 6 How to preserve Actrapid?)" "" "" ""</seg>
<seg id="1144">"" "" "" "this can happen: if you injure too much insulin, if you eat too little or leave a meal • if you are more than likely to exercise physically." "" "" ""</seg>
<seg id="1145">"" "" "" "let the closing cap of your Novoary finished pens always be set, if it is not in use to protect it from light." "" "" ""</seg>
<seg id="1146">Remove the protective membrane from a NovoFine injection needle • Use a new injection needle to avoid contamination. • Remove the protective flap from a NovoFine injection needle • Remove the injection needle straight and firmly on Actrapid NovoLet (Figure A) • Remove the large outer cap of the injection needle and the inner cap of the injection needle.</seg>
<seg id="1147">Proceed as follows to avoid the injection of air and ensure correct dosage: • Keep Actrapid Novoary with the injection needle upwards • knock a few times with your finger against the cartridge.</seg>
<seg id="1148">"" "" "" "as soon as the injection needle continues upwards, press the button in the direction of the arrow (Figure C) • While the injection needle continues to rise upwards, press the push button in the direction of the arrow (figure C) • Now, a drop of insulin must be extracted from the tip of the injection needle." "" "" ""</seg>
<seg id="1149">"" "" "" "• Connect the cap back to the finished pen, that the digit 0 is opposite the metering token (Figure D) • Check that the push button is fully pressed." "" "" ""</seg>
<seg id="1150">"" "" "" "if the push button cannot move freely, insulin is pressed out of the injection needle • The scale on the cap shows 0, 2, 4, 6, 8, 10, 14, 16 and 18 units." "" "" ""</seg>
<seg id="1151">"" "" "" "the push button moves outward while you rotate the closing cap • The scale underneath the push button (pushbutton scale) shows 20, 40 and 60 units." "" "" ""</seg>
<seg id="1152">"" "" "" "107 • Record the highest number you can see on the pushbutton scale • Adadd the two numbers to get the prescribed dose • If you have set a wrong dose, simply turn the cap forward or backward until you have adjusted the correct number of units." "" "" ""</seg>
<seg id="1153">"" "" "" "rotate it until the push button is at the bottom, and you will feel any resistance." "" "" ""</seg>
<seg id="1154">"" "" "" "make sure to press the press button during the injection, press the button after the injection, until the injection needle is pulled out of the skin." "" "" ""</seg>
<seg id="1155">"" "" "" "it may be incorrect • You cannot set a dose that is higher than the number of units remaining in the cartridge to estimate how much insulin is still left, but you can not use it to adjust your dose or select." "" "" ""</seg>
<seg id="1156">"" "" "" "oral antidiabetic agents (ACE inhibitors), beta inhibitors, acetylsalicylic acid, anabolic steroids, thyroid hormones, beta-hormones, beta releases, octreotide or lanreotid." "" "" ""</seg>
<seg id="1157">"" "" "" "► in insulin infusion pumps ► if the innoLet is dropped, damaged or broken; there is the risk of running insulin ► if it is not properly kept or frozen (see 6 How to preserve Actrapid?)" "" "" ""</seg>
<seg id="1158">"" "" "" "let the closing cap of your Innocent finished pens always be set, if it is not in use to protect it from light." "" "" ""</seg>
<seg id="1159">• Refect the rubber membrane with a medicinal tampon • Use a new injection needle for each injection to avoid contamination. • Remove the protective flap straight and firmly on Actrapid InnoLet (figure 1A) • Remove the large outer cap of the injection needle and the inner cap of the injection needle.</seg>
<seg id="1160">The dose regulator has to be reduced to zero and you hear click noise • The injection needle must remain below the skin for at least 6 seconds after injection. • Do not freeze the dose regulator during injection as you press on the push button • Remove the injection needle after each injection.</seg>
<seg id="1161">"" "" "" "oral antidiabetic agents (ACE inhibitors), beta inhibitors, acetylsalicylic acid, anabolic steroids, thyroid hormones, beta-hormones, beta releases, octreotide or lanreotid." "" "" ""</seg>
<seg id="1162">"" "" "" "(see, how is Actrapid saved?) ► When it's not clear how water and colourless look like." "" "" ""</seg>
<seg id="1163">"" "" "" "if any of the side effects listed you have significantly impaired or you notice side effects that are not stated in this information, please consult your doctor, your diabetes consultant or your pharmacist." "" "" ""</seg>
<seg id="1164">"" "" "" "keep the closing cap of your flexPen finished pens permanently, if it is not in use to protect it from light." "" "" ""</seg>
<seg id="1165">"" "" "" "F Keep the FlexPen to the top and knock a few times with the finger against the cartridge, so that existing air bubbles accumulate in the cartridge." "" "" ""</seg>
<seg id="1166">The dose can be corrected both upwards and downwards by turning the dose dial into the appropriate direction until the correct dose is against the marking of the dose indicator.</seg>
<seg id="1167">Adenuric is used in patients who already exhibit signs of crystalline rock including arthritis (pain and inflammation in joints) or gimmicks ("stones" i.e. greater urine-crystal deposits that can lead to joint and bone damage).</seg>
<seg id="1168">"" "" "" "if the uric acid level is still above 6 mg per deciliter after two to four weeks, the dose can be increased to 120 mg once a day." "" "" ""</seg>
<seg id="1169">"" "" "" "during the first treatment months, there may still be rheumatism; therefore, it is recommended that at least during the first six months of treatment with adenuric, further medicines are used to prevent rheumatism." "" "" ""</seg>
<seg id="1170">"" "" "" "the medicine is not recommended in children and for patients who had an organ transplant, as it was not examined for these groups." "" "" ""</seg>
<seg id="1171">"" "" "" "in the first study involving 1 072 patients, the efficacy of three different adenalic doses (once daily 80, 120 and 240 mg) was compared to a placebo (pseudo drugs) and allopurinol (another drug used to treat hyperthyroid)." "" "" ""</seg>
<seg id="1172">"" "" "" "in the second study, two doses of adenuric (once daily 80 and 120 mg) were compared to 762 patients each with allopurinol." "" "" ""</seg>
<seg id="1173">"" "" "" "in both studies, Allopurinol was used in a dose of once daily 300 mg; patients with kidney problems received only 100 mg per day." "" "" ""</seg>
<seg id="1174">"" "" "" "the main indicator of efficacy was the number of patients whose urine acid levels were at 6 mg / dl during the last three measurements." "" "" ""</seg>
<seg id="1175">"" "" "" "in the first study, 48% (126 of 262) of patients with a daily dose of 80 mg (175 of 269) had a uric acid level in the blood of less than 6 mg / dl." "" "" ""</seg>
<seg id="1176">"" "" "" "in comparison, this was 22% (60 out of 268) of the patients under Allopurinol and none of the 134 patients under placebo." "" "" ""</seg>
<seg id="1177">"" "" "" "the most common side effects of adenuric (observed in 1 to 10 of 100 patients) are headaches, diarrhea, nausea (nausea), rash and abnormal liver enzymes." "" "" ""</seg>
<seg id="1178">"" "" "" "in particular, in patients with heart problems in the prehistory, there may also be an increased risk of certain side effects that affect the heart and blood vessels." "" "" ""</seg>
<seg id="1179">"" "" "" "the Commission for Medicinal Products (CHMP) concluded that Adenuric was more effective in lowering the uric acid level in the blood than allopurinol, but also a higher risk of side effects related to the heart and blood vessels." "" "" ""</seg>
<seg id="1180">"" "" "" "treatment of chronic hyperurikaemia in diseases that have already led to urination (including a disease known from the patient's history, and / or arthritis)." "" "" ""</seg>
<seg id="1181">"" "" "" "after 2-4 weeks, if the serum levels are still &gt; 6 mg / dl (357 µl / l), a dose increase can be taken into account at ADENURIC 120 mg 1 x daily." "" "" ""</seg>
<seg id="1182">"" "" "" "in patients with severe kidney function restriction, efficacy and safety have not been fully investigated until now (Kreatin- Clearance &lt; 30 ml / min, see Section 5.2)." "" "" ""</seg>
<seg id="1183">"" "" "" "since there are no experiences in children and adolescents, the use of Febuxostat in this patient group is not recommended." "" "" ""</seg>
<seg id="1184">"" "" "" "if there are no experiences in organ transplant recipients, the use of Febuxostat in this patient group is not recommended (see Section 5.1)." "" "" ""</seg>
<seg id="1185">Cardiovascular disease In patients with ischemic heart disease or decompensated heart failure treatment with Febuxostat is not recommended (see Section 4.8).</seg>
<seg id="1186">"" "" "" "as with other drugs, it may result in acute rheumatism during the beginning of the treatment because the reduction of serum levels can initially mobilize uric acid deposits in the tissues." "" "" ""</seg>
<seg id="1187">"" "" "" "B. in malignant diseases and their treatment, Lesch- Nyhan syndrome) increase the absolute concentration of Xanthin in the urine in rare cases so far that it comes to a storage in the urinary tract." "" "" ""</seg>
<seg id="1188">"" "" "" "during Phase 3 clinical trials, light abnormalities of liver function were observed in patients treated with Febuxostat (3.5%)." "" "" ""</seg>
<seg id="1189">"" "" "" "therefore, it is recommended to carry out a liver function test before starting the febuxoary treatment and subsequent clinical findings (see Section 5.1)." "" "" ""</seg>
<seg id="1190">Theophyllin Zwas not performed any interaction studies to Febuxostat but it is known that the XO hibition can lead to an increase in theophylline level (a hibition of the metabolism of theophylline was also reported for other XO inhibitors).</seg>
<seg id="1191">The simultaneous application of Febuxostat and naproxen was 250 mg 2 times daily with an increase in Febuxostat Exposure (CMAx 28% and AUC 41% and t1 / 2 26%).</seg>
<seg id="1192">"" "" "" "in clinical trials, the application of naproxen or other NSAR / Cox-2 inhibitors was not associated with a clinically significant increase in adverse events." "" "" ""</seg>
<seg id="1193">Colchicin / Indometacin / Hydrochlorthiazide / warfarin Febuxostat can be applied together with colchicin or indometacin without a dose adjustment for Febuxostat or the other active ingredient required at the same time.</seg>
<seg id="1194">In a study involving subjects 120 mg ADENURIC 1 x showed an average 22% increase in AUC of desipramine a CYP2D6 substrate which indicates a possible weak inhibitory effect of Febuxostat on the CYP2D6 enzyme in vivo.</seg>
<seg id="1195">"" "" "" "Antazida It could be shown that simultaneous intake of a calcium hydroxide and aluminum hydroxide, the absorption of Febuxostat (around 1 hour) is delayed and a decline of the CMAx by 32%, but no significant changes in AUC." "" "" ""</seg>
<seg id="1196">Pregnancy data over a very limited number of exposed pregnancies do not include any side effects of Febuxostat on pregnancy or the health of the fetus / newborn.</seg>
<seg id="1197">"" "" "" "animal experiments do not include direct or indirect harmful effects on pregnancy, embryonic and fetal development or birth (see Section 5.3)." "" "" ""</seg>
<seg id="1198">"" "" "" "patients should be careful when controlling a vehicle, serving machines or exercising dangerous activities until they can be reasonably secure that ADENURIC does not adversely affect their performance." "" "" ""</seg>
<seg id="1199">A numerical higher incidence of cardiac events reported by the investigator observed cardiovascular events in the pivotal study of Phase 3 (1.3 versus 0.7 events per 100 patient years) and in long-term long-term studies (1.4 versus 0.7 events per 100 patient years) although no statistically significant differences were found and no causal correlation with Febuxostat could be detected.</seg>
<seg id="1200">The risk factors identified in these patients were arteriosclerosis and / or a myocardial infarction or a decompensated heart failure in the patient's history.</seg>
<seg id="1201">Common (≥ 1 / 100 to &lt; 1 / 100) and rare (≥ 1 / 1000 to &lt; 1 / 100) and rare (≥ 1 / 1000 to &lt; 1 / 1000) side effects that could be detected in the treatment groups with the medicine and which were reported in all Febuxostat treatment groups more than once were mentioned below.</seg>
<seg id="1202">"" "" "" "diarrhea, nausea and vomiting are more common in patients who are treated at the same time with Colchicin. * * In the clinical trials no serious rashes or serious hypersensitivity reactions have been observed." "" "" ""</seg>
<seg id="1203">"" "" "" "7 Offene long-term extension studies In the open long-term extension studies, 906 patients were treated with Febuxostat 80 mg / 120 mg for up to 2 years." "" "" ""</seg>
<seg id="1204">"" "" "" "the events related to long-term and long-term studies were similar to those reported in Phase 3 studies (see table 1)." "" "" ""</seg>
<seg id="1205">Following treatment-related events were reported in all Febuxostat treatment groups more than once and occurred in patients who received Febuxostat 80 mg / 120 mg in long-term extension studies (up to 4 years with an exposure time of &gt; 1.900 patient years).</seg>
<seg id="1206">"" "" "" "the following treatment-related events were either not reported at all in the pivotal studies of Phase 3, or at a lower frequency:" "" "" ""</seg>
<seg id="1207">"" "" "" "diabetes, hyperlipidemia, sleeplessness, hypaesthesia, rash, bursitis, protein uria, kidney insufficiency, kidney failure, decrease in lymphocytes, decrease in the number of white blood cells." "" "" ""</seg>
<seg id="1208">"" "" "" "the effect mechanism of uric acid is the final product of Purinmetabolites in humans, resulting in the reaction process called Hypoxanthin → Xanthin → Juric acid." "" "" ""</seg>
<seg id="1209">Febuxostat is a non-Purin-selective inhibitor of the XO (NP-SIxO) with a Ki value for in vitro-inhibiting that is below the nanomolar area.</seg>
<seg id="1210">Clinical study results The efficacy of ADENURIC was demonstrated in two pivotal studies of Phase 3 (APEX study and FACT study as described below) that were conducted with 1.832 patients with hyperspikaemia and gout.</seg>
<seg id="1211">"" "" "" "in each study, the primary efficacy endpoint was the proportion of patients with serum levels of &lt; 6.0 mg / dl (357 µl / l)." "" "" ""</seg>
<seg id="1212">Placebo (n = 134) and ADENURIC 80 mg 1 x daily (n = 269) and ADENURIC 240 mg 1 x daily (n = 269) for patients with a serum increment value at the beginning of studies of &gt; 1.5 mg / dl and ≤ 2.6 mg / dl.</seg>
<seg id="1213">The APEX study showed a statistically significant superiority in the treatment with ADENURIC 80 mg 1 x daily as well as with ADENURIC 120 mg 1 x daily compared to the treatment with conventional doses of Allopurinol 300 mg (n = 258) / 100 mg (n = 10).</seg>
<seg id="1214">The FACT study showed a statistically significant superiority in the treatment with ADENURIC 80 mg 1 x daily as well as with ADENURIC 120 mg 1 x daily compared to treatment with the conventional dose of Allopurinol 300 mg.</seg>
<seg id="1215">Patients with serum increment values &gt; 1.5 and ≤ 0.2 mg / dl) or 300 mg 1 x daily (n = 509) were consolidated for the analyses. * p &lt; 0.001 versus Allopurinol; # p &lt; 0.001 versus 80 mg</seg>
<seg id="1216">Lowering the serum levels to &lt; 6.0 mg / dl (357 µmol / l) was observed during the visit of the doctor in week 2 and persisted throughout the treatment.</seg>
<seg id="1217">"" "" "" "509 patients received allopurinol 300 mg 1 x daily, 10 patients with serum increment values &gt; 1.5 and &lt; 2,0 mg / dl received 100 mg 1 x daily." "" "" ""</seg>
<seg id="1218">Primary endpoint in the subgroup of patients with renal function. the APEX study evaluated the efficacy in 40 patients with renal function restriction (D).</seg>
<seg id="1219">"" "" "" "with ADENURIC, the primary efficacy endpoint was 44% (80 mg 1 x daily), 45% (120 mg 1 x daily) and 60% (240 mg 1 x daily) of the patients." "" "" ""</seg>
<seg id="1220">There were no clinically significant differences in the percentage of serum concentrations in subjects regardless of their renal function (58% in the group with normal renal function and 55% in the group with severe kidney function disorders).</seg>
<seg id="1221">Primary endpoint in the subgroup of patients with serum levels ≥ 10 mg / dl Etwa 40% of patients (APEX- and FACT study) had at the beginning of studies (baseline) a serum concentration of ≥ 10 mg / dl.</seg>
<seg id="1222">The results of the open extension study of Phase 3 demonstrated that less than 3% of patients needed a treatment against rheumatism in the months 16 to 24 (i.e. more than 97% of patients no treatment against rheumatism).</seg>
<seg id="1223">"" "" "" "this was associated with a reduction in the size of the glitter, which resulted in a complete disappearance of the top notes by month 24 in 54% of patients." "" "" ""</seg>
<seg id="1224">Increased SHE values (&gt; 5.5 µW / ml) were observed in patients who received long-term treatment with Febuxostat (5.0%) in patients who received allopurinol (5.8%) in open long-term extension studies (see Section 4.4).</seg>
<seg id="1225">"" "" "" "in healthy subjects, the maximum plasma concentrations (CMAx) and the surface below the plasma concentration time curve (AUC) of Febuxostat increased proportionally by 10 mg to 120 mg dosisdisproportionately." "" "" ""</seg>
<seg id="1226">"" "" "" "for cases of between 120 mg and 300 mg, an increase in AUC is observed for Febuxostat, which is greater than the dose-proportional increase." "" "" ""</seg>
<seg id="1227">"" "" "" "after ingesting simple or multiple oral doses of 80 and 120 mg 1 x daily, the CMAx is about 2.8-3,2 µg / ml and 5.0-5.3 μg / ml." "" "" ""</seg>
<seg id="1228">"" "" "" "however, no clinically significant change was observed in the percentage decrease in serum concentrations observed (multiple doses of 80 mg)." "" "" ""</seg>
<seg id="1229">Distribution The apparent Steady state distribution volume (Vss / F) of Febuxostat is located in the range from 29 to 75 l after taking doses of 10-300 mg.</seg>
<seg id="1230">The plasma bonding of Febuxostat amounts to approximately 99.2% (primary binding of albumin) and is constant over the concentration width which is reached with doses of 80 and 120 mg.</seg>
<seg id="1231">In vitro studies in human liver microcosms showed that these oxidative metabolites are mainly formed by CYP1A1, CYP1A2 or CYP2C9 and that Febuxostaglucuronid is mainly caused by UGT 1A1 and 1A8 and 1A9.</seg>
<seg id="1232">After taking an 80 mg dose of 14C-markedly Febuxostat approximately 49% of the dose in the urine was found as unmodified Febuxostat (3%) and its known oxidative metabolites and their conjugate (13%) as well as other unknown metabolites (3%).</seg>
<seg id="1233">"" "" "" "in addition to excretion across the urine, approximately 45% of the dose was found in the stool as unmodified (12%), Acylglucuronid of the active substance (25%) and other unknown metabolites (7%)." "" "" ""</seg>
<seg id="1234">Specific patient groups of kidney failure After taking multiple doses of 80 mg ADENURIC in patients with mild to moderate or severe kidney failure the CMAx of Febuxostat did not change in relation to subjects with normal renal function.</seg>
<seg id="1235">The mean total AUC of Febuxostat increased by about 1.8-times of 7.5 μ of alh / ml in the group with normal renal function at 13.2 μ y / ml in the group with severe kidney function.</seg>
<seg id="1236">12 Liver function restriction After taking multiple doses of 80 mg ADENURIC in patients with mild (Child- Pugh classification B) liver function restriction changed the CMAx and AUC of Febuxostat and its metabolites did not significantly compared to subjects with normal liver function.</seg>
<seg id="1237">No significant changes were observed with regard to the AUC of Febuxostat or its metabolites after taking multiple oral doses of ADENURIC in older patients compared to younger subjects.</seg>
<seg id="1238">"" "" "" "carcinogenesis, mutagenesis, impairment of fertility In male rats, a statistically significant increase of bladder tumors (transition cell papillomas and carcinomas) was found only in connection with Xanthin stones in the highly doses treated group." "" "" ""</seg>
<seg id="1239">"" "" "" "these findings are seen as a result of specific Purinmetabolization and urine composition, and considered not relevant for clinical use." "" "" ""</seg>
<seg id="1240">It has been noted that Febuxostat has no effect on fertility and reproductive capacity of male and female rats in oral doses of up to 48 mg / kg / day.</seg>
<seg id="1241">"" "" "" "at high doses, which were approximately the 4.3-fold of human-therapeutic exposure, maternal toxicity occurred which was associated with lowering the upward performance and a developmental retardation in the offspring of rats." "" "" ""</seg>
<seg id="1242">"" "" "" "Teratological studies in carrying rats with exposures, approximately the 4.3-fold and in carrying rabbits with exposures, which fertilised about 13-times of human-therapeutic exposure, yielded no teratogenic effects." "" "" ""</seg>
<seg id="1243">Colchicin / Indometacin / Hydrochlorthiazide / warfarin Febuxostat can be applied together with colchicin or indometacin without a dose adjustment for Febuxostat or the other active ingredient required at the same time.</seg>
<seg id="1244">"" "" "" "diarrhea, nausea and vomiting are more common in patients who are treated at the same time with Colchicin. * * In the clinical trials no serious rashes or serious hypersensitivity reactions have been observed." "" "" ""</seg>
<seg id="1245">"" "" "" "in the open long-term extension studies, 906 patients were treated with Febuxostat 80 mg / 120 mg for up to 2 years." "" "" ""</seg>
<seg id="1246">"" "" "" "in each study, the primary efficacy endpoint was the proportion of patients with serum levels of &lt; 6.0 mg / dl (357 µl / l)." "" "" ""</seg>
<seg id="1247">The results of the open extension study of Phase 3 demonstrated that less than 3% of patients needed a treatment against rheumatism in the months 16 to 24 (i.e. more than 97% of patients no treatment against rheumatism).</seg>
<seg id="1248">26 as unchanged Febuxostat (3%) and Acylglucuronid of the active substance (30%) as well as known oxidative metabolites and their conjugate (13%) as well as other unknown metabolites (3%).</seg>
<seg id="1249">The CMAx and AUC of Febuxostat and its metabolites did not significantly change in comparison to subjects with normal liver function.</seg>
<seg id="1250">"" "" "" "carcinogenesis, mutagenesis, impairment of fertility In male rats, a statistically significant increase of bladder tumors (transition cell papillomas and carcinomas) was found only in connection with Xanthin stones in the highly doses treated group." "" "" ""</seg>
<seg id="1251">"" "" "" "the owner of the authorisation for placing the drug has to make sure that a pharmacovigilance system, as described in Version 2.0 module 1.8.1, is ready before the drug is brought into circulation and is available as long as the medicine is brought into circulation." "" "" ""</seg>
<seg id="1252">"" "" "" "according to the CHMP Guideline, an updated RMP can be submitted to risk management systems for human drugs with the next Periodic Safety Update Report (PSUR)." "" "" ""</seg>
<seg id="1253">"" "" "" "in addition, an update of the RMP is required • if new information is available which have an impact on safety data, the pharmacovigilance plan or risk management activities • within 60 days of reaching important milestones (Pharmacovigilance or risk minimization) • at request of EMEA" "" "" ""</seg>
<seg id="1254">"" "" "" "in some people, the uric acid accumulates in the blood and can reach concentrations that are so high that uric acid becomes insoluble." "" "" ""</seg>
<seg id="1255">"" "" "" "when you keep the uric acid concentration low by the 1 x daily intake of ADENURIC, the crystal formation is prevented and thus reached with time a reduction of the discomfort." "" "" ""</seg>
<seg id="1256">Should not be taken if you are hypersensitive (allergic) to the active ingredient Febuxostat or any of the other components of ADENURIC.</seg>
<seg id="1257">Inform your doctor before you start taking this medicine • if you have a heart weakness or suffer from any other heart problem. • if you suffer from a high uric acid concentration as a result of a cancer or the Lesch-Nyhan syndrome (a rare congenital condition in which there is too much uric acid in the blood).</seg>
<seg id="1258">"" "" "" "if you have a rheumatism at the moment (sudden appearance of severe pain, pressure sensitivity, redness, heat sensation and joint swelling), wait until the plasty attack starts before you begin with ADENURIC treatment." "" "" ""</seg>
<seg id="1259">"" "" "" "this does not have to be the case with everyone, but may also occur with you, especially during the first weeks of treatment or - months, if you are taking ADENURIC." "" "" ""</seg>
<seg id="1260">"" "" "" "if necessary, your doctor will prescribe other medicines to prevent rheumatic attack or to treat the symptoms associated with it (such as pain and joint swelling)." "" "" ""</seg>
<seg id="1261">"" "" "" "please tell your doctor or pharmacist if you are taking other medicines / applying it or applying it recently, even if it is not prescription medicine." "" "" ""</seg>
<seg id="1262">It is particularly important that you inform your doctor or pharmacist if you are using drugs that may appear one of the following substances because interactions with ADENURIC may occur and your doctor may consider necessary measures. • Mercaptopurin (for the treatment of asthma) • Warfarin (for the treatment of asthma) • Warfarin (for blood dilution in heart disease)</seg>
<seg id="1263">There were no studies on the effects of ADENURIC on the transport tightness and the ability to serve machines.</seg>
<seg id="1264">"" "" "" "therefore, please take ADENURIC only after consultation with your doctor if you are aware that you suffer from a intolerance to certain sugars." "" "" ""</seg>
<seg id="1265">"" "" "" "on the back of the blister pack, the individual weekdays are printed so that you can check if you have taken one tablet every day. • The tablets must be swallowed and can be taken with or without food." "" "" ""</seg>
<seg id="1266">"" "" "" "if you have unintentionally taken overdose, contact your doctor or the nearest hospital." "" "" ""</seg>
<seg id="1267">"" "" "" "if you forgot ADENURIC, take it as soon as possible unless the next dose is imminent." "" "" ""</seg>
<seg id="1268">"" "" "" "when you break ADENURIC, your uric acid concentration may rise again, and your discomfort can worsen because new elemental crystals can form in your joints and kidneys as well as their environment." "" "" ""</seg>
<seg id="1269">"" "" "" "frequent side effects (more than 1 of 100 treatment, but less than 1 out of 10 dentists): • Several liver tests • diarrhea • headache • rash-nausea" "" "" ""</seg>
<seg id="1270">"" "" "" "rare side effects (more than 1 of 10,000 patients, but less than 1 of 1,000 treated): • weakness • nervousness • During feeling • palpitations" "" "" ""</seg>
<seg id="1271">Inform your doctor or pharmacist if any of the side effects listed you have considerably impaired or you notice side effects that are not stated in this use information.</seg>
<seg id="1272">ADENURIC is available in 2 blister packs each with 14 tablets each with 14 tablets each with 14 tablets each with 14 tablets (Pack of 84 tablets).</seg>
<seg id="1273">Review Ipsen Pharma 24 rue Erlanger F-75781 Paris Cedex 16 France Tél: + 33 - 1 - 44 96 13 13</seg>
<seg id="1274">Danmark Norge, Suomi / Finland; Sverige-Ísland Institut manufactures synthèse (IPSEN) AB Kista Science Tower Farogatan 33 SE - 164 51 Kista Sverige / Backotsi / Puh / Puh / Sími: + 46 8 588 370 70</seg>
<seg id="1275">ADROVANCE is used to treat osteoporosis (a disorder where the bones are brittle) in women after menopause where there is a risk of low vitamin D levels.</seg>
<seg id="1276">"" "" "" "the patient must take the tablet with a full glass of water (no mineral water) at least 30 minutes before eating, drinking or taking other medicines (including antacids, calcium and vitamin supplements)." "" "" ""</seg>
<seg id="1277">"" "" "" "in order to avoid irritation of the esophagus, the patient must not lie down until after the first food intake of the day, which should take place at the earliest 30 minutes after taking the tablet." "" "" ""</seg>
<seg id="1278">"" "" "" "as Alendronate and vitamin D3 are already being used separately in pharmaceuticals approved in the European Union, the company prescribes data originating from earlier studies and published literature." "" "" ""</seg>
<seg id="1279">The company also conducted a study of 35 men and 682 postmenopausal women with osteoporosis in order to demonstrate the effectiveness of ADROVANCE in relation to increased vitamin D levels.</seg>
<seg id="1280">"" "" "" "after a 15-week treatment, the proportion of patients with low vitamin D levels in patients treated with ADROVANCE was lower (11%) than those who solely received alendronate (32%)." "" "" ""</seg>
<seg id="1281">"" "" "" "the company also stipulates that the alendronat dose contained in ADROVANCE is exactly the dose, required for preventing bone loss." "" "" ""</seg>
<seg id="1282">"" "" "" "the most common side effects (observed in 1 to 10 of 100 patients) are headaches, pains of the musculoskeletal, constipation, diarrhea (diarrhea), ulcers (ulcera), abnormalities (swallowed abdomen) and oxygen rise." "" "" ""</seg>
<seg id="1283">"" "" "" "in patients with any hypersensitivity to alendronate, vitamin D3 or any of the other ingredients, ADROVANCE may not be used." "" "" ""</seg>
<seg id="1284">It may not be used in cases of esophagus in patients with hypocalcemia (low calcium level) or in patients who cannot stand or sit for at least 30 minutes.</seg>
<seg id="1285">"" "" "" "in January 2007, the European Commission issued Merck Sharp & Dohme Ltd. approval for the placing of ADROVANCE in the European Union." "" "" ""</seg>
<seg id="1286">"" "" "" "capsule form, white to broken white tablets, marked with the outline of a bone on one side and" 710 "on the other side." "" "" ""</seg>
<seg id="1287">"" "" "" "ADROVANCE is only to take with water (not with mineral water) at least 30 minutes before the first meal, drink or intake of medicines (including antacids, calcium and vitamin supplements) for the day." "" "" ""</seg>
<seg id="1288">"" "" "" "follow these instructions carefully to reduce the risk of esophageal irritation and associated side effects (see section 4.4)," "" "" ""</seg>
<seg id="1289">• ADROVANCE should be swallowed only with a full glass of water (at least 200 ml) after the day. • The patients should not chew the tablet or take the tablet in the mouth. • The patients should not lie before the first food intake of the day that should take place at the earliest 30 minutes after taking the tablet.</seg>
<seg id="1290">"" "" "" "B. peptic ulcer, active gastrointestinal bleedings or surgical procedures in the upper gastrointestinal tract except pyloroplasty should be given only with special caution (see Section 4.3)." "" "" ""</seg>
<seg id="1291">"" "" "" "esophageal reactions, such as oesophagitis, esophageal ulcerations, rarely followed by esophageal striktures, were reported in patients taking Alendronate (some were severe and required hospitalisation)." "" "" ""</seg>
<seg id="1292">The doctor should therefore draw attention to any signs and symptoms that indicate possible lesophageal irritation such as dysphage or pain in swallowing or retrostaral pain or new or worsening heartburn.</seg>
<seg id="1293">"" "" "" "3 The risk of serious breophageal side effects appears to be elevated in patients who do not take the medicine correctly and / or, after the appearance of symptoms, that refer to a breophageal irritation." "" "" ""</seg>
<seg id="1294">It is very important that all dosage instructions are transmitted to the patient and understood by the patient (see section 4.2).</seg>
<seg id="1295">"" "" "" "during large-scale clinical trials with alendronate no increased risk was detected, including some severe and complications (see Section 4.8)." "" "" ""</seg>
<seg id="1296">"" "" "" "osteonecrosis of the jaw, usually associated with a tooth extraction and / or a local infection (including osteomyelitis) was reported in cancer patients whose therapy regimen predominantly intravenously administered bisphosphonate." "" "" ""</seg>
<seg id="1297">"" "" "" "there is no data available to give evidence, whether the rejection of bisphosphonate therapy in patients who need a orthodontic intervention reduces the risk of osteoarthritis of the jaw." "" "" ""</seg>
<seg id="1298">"" "" "" "the clinical evaluation by the doctor treating physician is decisive for therapy planning in each patient, based on an individual benefit-risk assessment." "" "" ""</seg>
<seg id="1299">"" "" "" "patients should be instructed that when taking a dose of ADROVANCE, they should take the tablet next morning after noticing their failure." "" "" ""</seg>
<seg id="1300">"" "" "" "you should not take two tablets the same day, but continue taking one tablet per week as planned on the day of the week." "" "" ""</seg>
<seg id="1301">Other diseases affecting the mineral metabolism (such as vitamin D deficiency and hypoparathyreoidism) should also be treated adequately before beginning of treatment with ADROVANCE.</seg>
<seg id="1302">"" "" "" "alendronate foods and beverages (including mineral water), calcium supplements, antacids and some oral medicines may affect the absorption of alendronate if taken at the same time." "" "" ""</seg>
<seg id="1303">"" "" "" "after taking Alendronat, patients must wait at least 30 minutes before using other medicines (see Sections 4.2 and 5.2)." "" "" ""</seg>
<seg id="1304">"" "" "" "although specific interaction studies were not conducted, Alendronate was taken together with a variety of commonly prescribed medicines without clinically relevant interactions." "" "" ""</seg>
<seg id="1305">"" "" "" "ADROVANCE is only intended for use in postmenopausal women, and is therefore not to be used during pregnancy or by breastfeeding women." "" "" ""</seg>
<seg id="1306">Animal studies with alendronate leave no indication of directly harmful effects with regard to pregnancy that recognize embryonic / fetal or postnatal development.</seg>
<seg id="1307">"" "" "" "osteonecrosis of the jaw was reported in patients with bisphosphonates, most of the reports stem from cancer patients." "" "" ""</seg>
<seg id="1308">Nevertheless concentrations of serum calcium up to &lt; 8.0 mg / dl (2.0 mmol / l) and serum levels of ≤ 0.2 mg / dl (0.65 mmol / l) were observed in both treatment groups with similar incidence.</seg>
<seg id="1309">"" "" "" "alendronate Insequence of an oral overdose may occur Hypocalcemia, hypophosphatemia and side effects in the upper gastrointestinal tract such as stomach upset, heartburn, osophagitis, gastritis or ulcera." "" "" ""</seg>
<seg id="1310">"" "" "" "colecalciferol (vitamin D3) vitamin D3 is produced in the skin by UV light, over the transformation of 7-Dehydrock to vitamin D3." "" "" ""</seg>
<seg id="1311">"" "" "" "the main action of 1.25 DihydroxyB2 D3 is to increase the intestinal absorption of calcium and phosphate, as well as the regulation of calcium and phosphate, bone formation and bone resorption." "" "" ""</seg>
<seg id="1312">"" "" "" "in severe cases, a lack of secondary hyperparathyreoidism, hypophosphatemia, weakness of proximal musculature and osteomalazie can lead to increased risk of falls and fractures across osteoporosis." "" "" ""</seg>
<seg id="1313">"" "" "" "Bone mineral density) of spine or hip, 2.5 standard deviations below the mean value for a normal, young population, or regardless of bone density as present pathological fracture." "" "" ""</seg>
<seg id="1314">Patients received ADROVANCE in lower strength (70 mg / 2,800 I.U.) (n = 350) or Fosamax (Alendronat) 70 mg once a week (n = 332); other vitamin D supplements were prohibited.</seg>
<seg id="1315">After 15 weeks of treatment the average serum levels of 25-hydroxyB2 D were significantly higher (26%) in the group of ADROVANCE (70 mg / 2,800 I.U.) than in the group under alendronate alone (46 nmol / l [18.2 ng / ml]).</seg>
<seg id="1316">ADROVANCE (70 mg / 2,800 I.U.) significantly lowered the proportion of patients with vitamin D insufficiency (serum value of 25-hydroxyB2 D &lt; 37.5 nmol / l [&lt; 15 ng / ml]) by 62.5% compared to alendronate alone (12% vs.</seg>
<seg id="1317">Alendronate studies with alendronate once weekly 70 mg (n = 519) and alendronat 10 mg daily (n = 370) was demonstrated in a one-year multi-center study of postmenopausal women with osteoporosis.</seg>
<seg id="1318">The effects of alendronate on bone mass and fracturincidence in postmenopausal women were studied in two phase III studies of identical design (n = 944) and fracture intervention study (FIT: n = 6.459).</seg>
<seg id="1319">In phase III studies the average incline of BMD with alendronate amounts to 10 mg / day in relation to placebo after 3 years 8.8% on the vertebral column 5.9% on femur and 7.8% at the trochanter.</seg>
<seg id="1320">"" "" "" "in the group treated with alendronate, a 48% reduction (alendronat 3.1%) compared to placebo group was achieved with the percentage of patients who suffered one or more fractures." "" "" ""</seg>
<seg id="1321">"" "" "" "in the two-year extension of these studies, the BMD of spine and trochanter persisted; the BMD of the femur and the entire body was also maintained." "" "" ""</seg>
<seg id="1322">"" "" "" "fit consisted of two plazeboding studies, where Alendronate was taken daily (5 mg daily for 2 years and then 10 mg daily, either over 1 or 2 years):" "" "" ""</seg>
<seg id="1323">"" "" "" "in this study, the daily application of alendronate reduced the appearance of at least one new vertebral fracture by 47% (alendronat 7.9% compared to placebo 15.0%)." "" "" ""</seg>
<seg id="1324">Resorption Based on an intravenous reference dose the average oral bioavailability of alendronate in women was 0.64% for doses between 5 and 70 mg after nocturnal fasting and two hours before a standardized breakfast.</seg>
<seg id="1325">Bioavailability amounts to about 0.46% and 0.39% when Alendronat was taken one or half an hour before a standardized breakfast.</seg>
<seg id="1326">"" "" "" "in osteoporosis, alendronate was effective when it was taken at least 30 minutes before the first meal or drink of the day." "" "" ""</seg>
<seg id="1327">In healthy subjects the gift of oral prednisone (20 mg three times daily over five days) led to no clinically significant change in oral bioavailability of alendronate (increase in the range from 20% to 44%).</seg>
<seg id="1328">"" "" "" "9 distribution studies on rats revealed that Alendronate temporarily distributes itself after intravenous administration of 1 mg / kg, but then quickly spread into the bones or excreted with the urine." "" "" ""</seg>
<seg id="1329">"" "" "" "excretion After a single dose of 14C-alendronate, about 50% of the radioactivity was excreted within 72 hours with the urine and no radioactivity was found in the feces." "" "" ""</seg>
<seg id="1330">"" "" "" "after intravenous application of a single dose of 10 mg, the renal clearance of alendronate was 71 ml / min and the systemic clearing did not exceed 200 ml / min." "" "" ""</seg>
<seg id="1331">"" "" "" "in rats, alendronate is not excreted by the acid or alkaline transport system of the kidneys, and therefore it is not assumed that it influences the elimination of other medicines by these transport systems." "" "" ""</seg>
<seg id="1332">Resorption In healthy adult subjects (women and men) after nightly fasting and two hours before taking a meal the mean surface below the serum concentration time curve (AUC0-120 h) for vitamin D3 296.4 ng • h / ml (without taking into account endogenous vitamin D3 levels).</seg>
<seg id="1333">The mean maximum concentration in serum (CMAx) of vitamin D3 was 5.9 ng / ml and median time until the maximum serum concentration (Tmax) 12 hours.</seg>
<seg id="1334">"" "" "" "biotransformation vitamin D3 is rapidly absorbed in the liver to 25-hydroxyB2 D3 HydroxyB2 and then in the kidney to 1,25 DihydroxyB2 D3, the bioactive form, metabolized." "" "" ""</seg>
<seg id="1335">"" "" "" "excretion In the application of radioactively marinated vitamin D3 to healthy volunteers, the medial excretion of radioactivity in the urine amounted to 2.4% in the urine after 4 days 4.9%." "" "" ""</seg>
<seg id="1336">Characteristics in patients "pre-clinical studies have shown that the portion of alendronate that is not deposited in the bone quickly excretes over the urine.</seg>
<seg id="1337">"" "" "" "although no clinical data is available, it is expected that the renal elimination of alendronate as in animal experiments will also be reduced in patients with reduced kidney function." "" "" ""</seg>
<seg id="1338">"" "" "" "in patients with reduced kidney function, a slightly increased cumulation of alendronate can be expected in the bone (see Section 4.2)." "" "" ""</seg>
<seg id="1339">"" "" "" "Alendronate's non-clinical data on the basis of conventional trials for safety harmacology, chronic toxicity, gene toxicity and the pathogenic potential do not reveal any particular danger to humans." "" "" ""</seg>
<seg id="1340">Studies on rats showed that the gift of alendronate was accompanied by pregnant rats with the occurrence of dystoia in maternity that was due to hypocalcemia.</seg>
<seg id="1341">Microcrystalline cellulose (E 460) Lactose medium-chain triglyceride Gelatin croscarlet High disperses Siliciumdioxide Magnesium Sucrose (Ph.Eur.) (E 321) Strength (Ph.Eur.) (E 321) Strength and modified (corn) alumsilica silicate (E 554)</seg>
<seg id="1342">"" "" "" "case with sealed aluminium / aluminium blister packs (2 tablets), 4 (1 case with 4 tablets), 6 (3 cases with 4 tablets), 12 (3 cases with 4 tablets) or 40 (10 case with 4 tablets) tablets." "" "" ""</seg>
<seg id="1343">EU / 1 / 06 / 364 / 001 - 2 tablets EU / 1 / 06 / 364 / 003 - 6 tablets EU / 1 / 06 / 364 / 004 - 12 tablets EU / 1 / 06 / 364 / 005 - 40 tablets</seg>
<seg id="1344">"" "" "" "rectangular, white and white tablets, marked with the outline of a bone on one side and" 270 "on the other side." "" "" ""</seg>
<seg id="1345">13 • Patients should not lie after taking ADROVANCE for at least 30 minutes. • ADROVANCE should not be taken before bedtime or before the first day of the day.</seg>
<seg id="1346">"" "" "" "the risk of serious breophageal side effects seems to be increased in patients who do not take the medicine correctly and / or, after the appearance of symptoms, that refer to a breophageal irritation." "" "" ""</seg>
<seg id="1347">"" "" "" "during large-scale clinical trials with alendronate no increased risk was detected, including some severe and complications (see Section 4.8)." "" "" ""</seg>
<seg id="1348">"" "" "" "18 colecalciferol (vitamin D3) vitamin D3 is produced in the skin by UV light, over the transformation of 7-Dehydrock to vitamin D3." "" "" ""</seg>
<seg id="1349">Patients received ADROVANCE in lower strength (70 mg / 2,800 I.U.) (n = 350) or Fosamax (Alendronat) 70 mg once a week (n = 332); other vitamin D supplements were prohibited.</seg>
<seg id="1350">Vitamin D3 (the amount of vitamin D3 in the higher dose of ADROVANCE) once weekly corresponds to a 24-week extension study with osteoporosis in a 24-week extension study.</seg>
<seg id="1351">After 24 weeks of treatment the average serum levels of 25-hydroxyB2 D were significantly higher in the 5.600-I.U. S. vitamin D3 group (69 nmol / l [27,6 ng / l [27,6 ng / ml]) than in the 2.800-I.E vitamin D3 group (64 nmol / l [255 ng / ml]).</seg>
<seg id="1352">There was no statistically significant difference between treatment groups in the proportion of patients with Hypercalciurie at the end of the 24-week extension.</seg>
<seg id="1353">"" "" "" "3.1% of the total hip in the group with 70 mg once a week, or at 10 mg. daily." "" "" ""</seg>
<seg id="1354">"" "" "" "in this study, the daily application of alendronate reduced the appearance of at least one new vertebral fracture by 47% (alendronat 7.9% compared to placebo 15.0%)." "" "" ""</seg>
<seg id="1355">Bioavailability amounts to about 0.46% and 0.39% when alendronate half an hour before a standardized breakfast</seg>
<seg id="1356">"" "" "" "distribution studies on rats have shown that Alendronate temporarily distributes itself after intravenous administration of 1 mg / kg, but then quickly spread into the bones or excreted with the urine." "" "" ""</seg>
<seg id="1357">Resorption In healthy adult subjects (women and men) after consuming ADROVANCE (70 mg / 5.600 I.U.) after nightly fasting and two hours before taking a meal the middle area below the serum concentration time curve (AUC0-80 h) for vitamin D3 490.2 ng • h / ml (without taking into account endogenous vitamin D3 levels).</seg>
<seg id="1358">The mean maximum concentration in serum (CMAx) of vitamin D3 was 12.2 ng / ml and the median time until reaching the maximum serum concentration (Tmax) 10.6 hours.</seg>
<seg id="1359">"" "" "" "smaller amounts are distributed in fat and muscle tissue, and are stored there as vitamin D3 to be released later in the circulation." "" "" ""</seg>
<seg id="1360">"" "" "" "21 Vitamin D3 is quickly absorbed in the liver to contain 25-hydroxyvitamin D3 hydroxylic acid and then, in the kidney to 1,25-DihydroxyB2 D3, the bioactive form, metabolized." "" "" ""</seg>
<seg id="1361">There were no indication of satiety of the absorption capacity of the bone after long-term dose of cumulative intravenous dosages up to 35 mg / kg in animals.</seg>
<seg id="1362">"" "" "" "case with sealed aluminium / aluminium blister packs (1 case with 2 tablets), 4 (1 case with 4 tablets), 12 (3 cases with 4 tablets) or 40 (10 case with 4 tablets) tablets." "" "" ""</seg>
<seg id="1363">Pharmacovigilance system The owner of approval for placing the drug has to make sure that a pharmacovigilance system as described in version 2 module 1.8.1 of the approval documents is ready before the drug is brought into circulation and so long is available as the marketed medicine is brought into circulation.</seg>
<seg id="1364">Risk Management Plan The owner of approval for placing on the market commits itself to carry out trials and other pharmaceutical vigilance activities of the pharmacovigilance plan which are described in detail in the risk management plan (RMP) and its relevant updates according to version 1 module 1.8.2 of the approval documents.</seg>
<seg id="1365">"" "" "" "according to the CHMP Guideline, an updated RMP can be submitted to risk management systems for human drugs with the next periodic Saftey update report (PSUR)." "" "" ""</seg>
<seg id="1366">"" "" "" "in addition, an update of the RMP is required − when new information is available which have an impact on the safety data, pharmacovigilance plan or risk management activities − in response to EMEA" "" "" ""</seg>
<seg id="1367">Take an ADROVANCE tablet after getting up and before eating and drinking before taking any other medicines by swallowing the tablet with a full glass of water (not chewing and chilling).</seg>
<seg id="1368">"" "" "" "if you have any further questions, please contact your doctor or pharmacist. • This medicine was personally prescribed for you." "" "" ""</seg>
<seg id="1369">"" "" "" "in menopause, ovaries do not produce female hormones, estrogen, and more that help to get the skeletal of women healthy." "" "" ""</seg>
<seg id="1370">"" "" "" "the fractures usually arise on hip, spine or wrist and can cause considerable problems such as bent posture (" Witwenbuckel ") and a loss of mobility." "" "" ""</seg>
<seg id="1371">"" "" "" "ADROVANCE not only prevents the loss of bone mass, but also helps to balance bone loss and reduce the risk of spine and hip fractures." "" "" ""</seg>
<seg id="1372">Constriction of oesophagus or swallowing disorders (3) if it is not possible for you to sit or stand for at least 30 minutes (4) if your doctor has noticed that your calcium content is lower in the blood.</seg>
<seg id="1373">"" "" "" "40 • If you have problems swallowing or digesting, • if you have cancer, • if you have cancer, • if you have chemotherapy or radiation treatment • if you do not routinely attend dental provisioning." "" "" ""</seg>
<seg id="1374">"" "" "" "these complaints can occur in particular, if patients do not take the ADROVANCE tablet with a full glass of water and / or sit back before the expiration of 30 minutes after taking." "" "" ""</seg>
<seg id="1375">"" "" "" "taking ADROVANCE with other medicines Calcium supplements, antacids and some other medicines to intake ADROVANCE may interfere with the efficacy of ADROVANCE while taking concurrent." "" "" ""</seg>
<seg id="1376">"" "" "" "certain medicines or food additives may impede the absorption of vitamin D contained in the body, including artificial fat substitute, mineral oils, orlistat and cholesterol-lowering drugs cholestyramine and colestipol." "" "" ""</seg>
<seg id="1377">"" "" "" "please tell your doctor or pharmacist if you are taking other medicines / applying it or applying it recently, even if it is not prescription medicine" "" "" ""</seg>
<seg id="1378">"" "" "" "after consultation with your doctor, please consult your doctor if you are aware that you suffer from a intolerance to certain sugars." "" "" ""</seg>
<seg id="1379">Please follow the instructions 2) (3) (4) and 5) to facilitate the transport of the ADROVANCE tablet into the stomach and to reduce possible irritation of the esophagus (esophagus - the tube that connects your mouth with the stomach).</seg>
<seg id="1380">"" "" "" "(2) Take the ADROVANCE tablet after the first appearance and before taking any foods or drinks, as well as taking any other medicines only with a full glass (with or without carbonic acid)." "" "" ""</seg>
<seg id="1381">"" "" "" "(3) Do not lie down - stay fully erect (sitting, standing or walking) - at least 30 minutes after taking the tablet." "" "" ""</seg>
<seg id="1382">"" "" "" "(5) If difficulties or pains occur when swallowing, pain behind the sternum, restarting or worsening heartburn, set ADROVANCE and seek your doctor." "" "" ""</seg>
<seg id="1383">"" "" "" "(6) Check for at least 30 minutes after swallowing your ADROVANCE tablet before taking your first food, beverages or other medicines such as antacids, calcium or vitamin supplements this day." "" "" ""</seg>
<seg id="1384">"" "" "" "should you accidentally take too many tablets at once, drink a full glass of milk and contact your doctor immediately." "" "" ""</seg>
<seg id="1385">"" "" "" "if you miss taking a tablet, just take one tablet the next morning after you have noticed your failure." "" "" ""</seg>
<seg id="1386">"" "" "" "• Biesophagus - pain in swallowing; tumors of the esophagus (oesophagus - the tube that connects your mouth with your stomach), pain in the chest, heartburn, and / or joint pain; diarrhea; bloating; headache." "" "" ""</seg>
<seg id="1387">"" "" "" "occasionally: nausea; vomiting, irritation and inflammation of the esophagus (oesophagus - the tube that connects your mouth with your stomach) or the stomach mucosa, • black or teerless chair; skin rash; itching; cured skin." "" "" ""</seg>
<seg id="1388">"" "" "" "following introduction, the following side effects were reported (frequency not known): • (Changing) dizziness, • Joint Swinging, • Pain Problems (osteoarthritis) in combination with delayed wound healing and infections, often after pulling teeth, swelling on hands or legs." "" "" ""</seg>
<seg id="1389">"" "" "" "43 Dabei is helpful when you note the complaints you had when they started, and how long they stopped." "" "" ""</seg>
<seg id="1390">"" "" "" "other components are microcrystalline cellulose (E 460), lactose, medium-chain triglycerides, gelatine, Croscareciree sodium, magnesium stearate (Ph.Eur.) (E 321), starch, modified (corn), and alumalate silicate (E 554)." "" "" ""</seg>
<seg id="1391">The tablets are available in Etuis with sealed aluminium / aluminium blister packs in packs: • 2 tablets (1 Etui with 2 tablets in aluminium blister packs) • 6 tablets (1 Etui with 4 tablets in aluminium blister packs) • 40 tablets (10 Etuis each with 4 tablets in aluminium blister packs) • 40 tablets (10 tablets each with 4 tablets in aluminium blister packs).</seg>
<seg id="1392">"" "" "" "in menopause, ovaries do not produce female hormones, estrogen, and more that help to get the skeletal of women healthy." "" "" ""</seg>
<seg id="1393">"" "" "" "if you have cancer, if you have cancer, • if you have cancer, • if you have cancer or radiation treatment, if you do not routinely attend dental provisioning." "" "" ""</seg>
<seg id="1394">"" "" "" "taking ADROVANCE with other medicines Calcium supplements, antacids and some other medicines to intake ADROVANCE may interfere with the efficacy of ADROVANCE while taking concurrent." "" "" ""</seg>
<seg id="1395">2) Take the ADROVANCE tablet after the first stand and before taking any foods or drinks as well as taking any other medicines only with a full glass (at least 200 ml) water (not with mineral water). • Do not take with mineral water (with or without carbonic acid). • Do not take with juice or milk.</seg>
<seg id="1396">"" "" "" "3) Do not lie down - stay fully erect (sitting, standing or walking) - at least 30 minutes after taking the tablet." "" "" ""</seg>
<seg id="1397">"" "" "" "5) If difficulties or pains occur when swallowing, pain behind the sternum, restarting or worsening heartburn, set ADROVANCE and seek your doctor." "" "" ""</seg>
<seg id="1398">"" "" "" "6) Check for at least 30 minutes after swallowing your ADROVANCE tablet before taking your first food, beverages or other medicines such as antacids, calcium or vitamin supplements this day." "" "" ""</seg>
<seg id="1399">"" "" "" "• (rotary) dizziness, • Joint swelling, • tiredness, • Hair loss, • Pain problems (osteoarthritis) in combination with delayed wound healing and infections, often after pulling teeth, swelling on hands or legs." "" "" ""</seg>
<seg id="1400">"" "" "" "tablets are available as rectangular, white or broken white tablets, marked with the outline of a bone on one side and" 270 "on the other side." "" "" ""</seg>
<seg id="1401">"" "" "" "" "" "" "" "Advagraf is administered to adult patients with kidney or liver transplanted to prevent transplanted organ transplanted by the immune system." "" "" ""</seg>
<seg id="1402">"" "" "" "since Tacrolimus and Prograf / Prograft are already used in the EU, the company has presented the results from previously carried out studies with Prograf / Prograft and data from published literature." "" "" ""</seg>
<seg id="1403">"" "" "" "furthermore, the results of a clinical trial were presented to 668 patients with kidney transplant, and the application of Advagraf with Prograf / Prograft or Ciclosporin was compared." "" "" ""</seg>
<seg id="1404">"" "" "" "the main indicator of efficacy was the number of patients with which the transplant was repelled after one year (for example, by examining how often a re-organ transplant or recovery of dialysis was necessary)." "" "" ""</seg>
<seg id="1405">"" "" "" "in addition, more than 119 patients with kidney transplantation and 129 patients with liver transplant were conducted and investigated, such as Advagraf, compared to Prograf / Prograft." "" "" ""</seg>
<seg id="1406">"" "" "" "tremor (trembling), headache, nausea / vomiting, diarrhoea (diarrhoea), kidney problems, increased blood sugar levels (hypertension), high blood pressure (hypertension) and insomnia (insomnia)." "" "" ""</seg>
<seg id="1407">"" "" "" "in patients with any hypersensitivity to tacrolimus, macro lid antibiotics (such as erythromycin) or any of the other ingredients may not be applied." "" "" ""</seg>
<seg id="1408">"" "" "" "patients and physicians must be careful if other (especially some herbal) medicines should be taken at the same time as a supplement, as the dose or dose of the medication taken at the same time needs to be adjusted accordingly." "" "" ""</seg>
<seg id="1409">"" "" "" "hard capsules, retarded yellow-orange gelatine capsules, printed in red ink on the bright yellow cap top with" "" "" "" "0.5 mg" "" "" "" "; they contain white powder." "" "" ""</seg>
<seg id="1410">Only doctors who are familiar with immunosuppressive therapy and the treatment of transplant patients should prescribe this medicine or make changes in immunosuppressive therapy.</seg>
<seg id="1411">"" "" "" "due to clinically relevant differences in systemic exposure of Tacrolimus, this can lead to graft rejection or increased incidence of side effects, including under- or overimmunosuppression." "" "" ""</seg>
<seg id="1412">Patients should always maintain the same tacrolimus formulation and the corresponding daily dose; changes to the formulation or the regime should only be performed under close-meshed control of a physician experienced in transplant (see Sections 4.4 and 4.8).</seg>
<seg id="1413">"" "" "" "as a result of switching to an alternative formulation, therapeutic drug monitoring and appropriate dose adjustments must be carried out in order to ensure that the systemic exposure of tacrolimus remains." "" "" ""</seg>
<seg id="1414">"" "" "" "the dosage of Advagraf should primarily depend on the clinical evaluation of rejection and tolerability in individual cases, and on blood level provisions (see below" "" "" "" "Recommendations" "" "" ""</seg>
<seg id="1415">"" "" "" "after switching from Prograf to Advagraf, the Tacrolimus Talks should be inspected before switching over and over two weeks after conversion." "" "" ""</seg>
<seg id="1416">"" "" "" "in day 4, systemic exposure was comparable with both formulations in both kidney and liver transplant patients." "" "" ""</seg>
<seg id="1417">Careful and repeated controls of the Tacrolimus Talks are recommended during the first two weeks following the transplantation in Advagraf to ensure proper substance exposition in the immediate stage of the night.</seg>
<seg id="1418">"" "" "" "since Tacrolimus is a low-Clearance substance, an adjustment of the anagraf dose schemes can take several days until steady state is reached." "" "" ""</seg>
<seg id="1419">"" "" "" "if the patient's condition is not permitted in the first postoperative period, the Tacrolimus treatment can be initiated intravenously (Prograf 5 mg / ml concentrate for the production of an infusion solution) with a dose of ca." "" "" ""</seg>
<seg id="1420">"" "" "" "in order to suppress graft rejection, immunosuppression has to be maintained; consequently, a maximum duration of oral therapy cannot be specified." "" "" ""</seg>
<seg id="1421">Dose recommendations - kidney transplant prophylaxis of transplant rejection The oral advent therapy should start with 0.20 - 0.30 mg / kg / day as daily gift in the morning.</seg>
<seg id="1422">"" "" "" "further dose adjustments can later be necessary, as the pharmacokinetics of Tacrolimus can change after transplantation." "" "" ""</seg>
<seg id="1423">Dosage recommendations - liver transplant prophylaxis of transplant rejection The oral advent therapy should start with 0.10 - 0.20 mg / kg / day as daily gift in the morning.</seg>
<seg id="1424">Dosage recommendation - switch from Prograf to Advagraf Mould a transplant recipient of twice daily doses of Prograf should be converted to one once daily intake of Advagraph so this conversion in relation 1: 1 (mg: mg) has to take place in relation to the entire daily dose.</seg>
<seg id="1425">"" "" "" "after switching from other immunosuppressants to Advagraph once a day, the treatment with the recommended oral initial dose for the prophylaxis of transplant rejection must begin once a day." "" "" ""</seg>
<seg id="1426">"" "" "" "heart transplant In adult patients, which are converted to Advagraf, an oral initial dose of 0.15 mg / kg / day is taken once a day." "" "" ""</seg>
<seg id="1427">Other transplant recipients did not have clinical experience with Advagraf in pulmonary, pancreatic and intestine transplanted patients in an oral initial dose of 0.2 mg / kg / day and in colorectal transplanted patients in an oral initial dose of 0.3 mg / kg / day.</seg>
<seg id="1428">"" "" "" "in patients with severe liver function disorders, dosage adjustments in patients with reduced liver function can be a reduction of the dose." "" "" ""</seg>
<seg id="1429">"" "" "" "patients with reduced kidney function, since the renal function does not affect the pharmacokinetic of tacrolimus, can be assumed that a dose adjustment is not required." "" "" ""</seg>
<seg id="1430">"" "" "" "however, due to the nephrotoxic potential of tacrolimus, a careful monitoring of the renal function (including regular determination of serum levels and a monitoring of urinary volume) is recommended." "" "" ""</seg>
<seg id="1431">Changeover from Ciclosporin to Advagraph When switching from a Ciclosporin- to a Tacrolimus-based therapy is advisable (see Sections 4.4 and 4.5).</seg>
<seg id="1432">"" "" "" "the dose should be based primarily on the clinical evaluation of repulsion and tolerability in individual cases, using full blood tacrolimus talmirrors controls." "" "" ""</seg>
<seg id="1433">"" "" "" "it is recommended to perform frequent checks of tacrolimus feat levels during the first two weeks following transplant, followed by periodic controls during maintenance therapy." "" "" ""</seg>
<seg id="1434">Blood-Talks of Tacrolimus should also be controlled after switching from Prograf to Advagraf. dose adjustment changes of immunosuppressive therapy or simultaneous use of substances that could change the Tacrolimus whole blood concentration (see section 4.5).</seg>
<seg id="1435">"" "" "" "since Advagraf is a medicine with a low clearance, adjustments of the dose may require several days before the Steady State has entered." "" "" ""</seg>
<seg id="1436">"" "" "" "the data in clinical trials suggest that successful treatment is possible in most cases, if the blood level in the blood does not exceed 20 ng / ml." "" "" ""</seg>
<seg id="1437">"" "" "" "in clinical practice, treatment levels of Tacrolimus are usually associated with liver transplantation in the area of 5 - 20 ng / ml and in patients with heart transplants at 10 - 20 ng / ml." "" "" ""</seg>
<seg id="1438">"" "" "" "during the subsequent maintenance therapy of liver, kidney and heart transplant receivers, blood concentrations in the range of 5 - 15 ng / ml were generally used." "" "" ""</seg>
<seg id="1439">"" "" "" "this has led to serious adverse events, including transplant rejection or other side effects, which can occur in a row of tacrolimus under- or overexposure." "" "" ""</seg>
<seg id="1440">Patients should always maintain the same tacrolimus formulation and the corresponding daily dose; changes to the formulation or the regime should only be performed under close-meshed control of an experienced physician (see Sections 4.2 and 4.8).</seg>
<seg id="1441">"" "" "" "5 In the treatment of adult patients with graft rejection, which proved to be therapy resistant to other immunosuppressants, no clinical data is available for the retarded formulation of Advent." "" "" ""</seg>
<seg id="1442">No clinical data for the retarded formulation of Advagraf are available for prophylaxis of graft rejection in adult cardiac transplant receivers and transplant receivers in childhood.</seg>
<seg id="1443">Taking herbal supplements which may lead to a lowering of the Tacrolimus in the blood and a weakening of the clinical effect of tacrolimus is to avoid taking herbal supplements (Hypericum perforatum) or other plant remedies during a treatment with Advagraf (see section 4.5).</seg>
<seg id="1444">"" "" "" "in patients with diarrhoea, a particularly careful observation of the Tacrolimus concentrations in the blood is required as the Tacrolimus blood mirrors can be subject to considerable variations under such circumstances." "" "" ""</seg>
<seg id="1445">"" "" "" "in rare cases, a chamber or septum hypertrophy described as cardiomyopathy was to be observed, which can therefore also occur under Advagraf." "" "" ""</seg>
<seg id="1446">"" "" "" "other factors that increase the risk of such clinical disorders are an already existing heart disease, a treatment with corticosteroids, high blood pressure, kidney or liver function disorders, infections, fluid loading and edema." "" "" ""</seg>
<seg id="1447">"" "" "" "as with other immunosuppressants, exposure to sunlight or UV light should be limited due to the possible risk of malignant skin changes by suitable clothing or use of a sunscreen with a high protection factor." "" "" ""</seg>
<seg id="1448">"" "" "" "if patients who are taking Tacrolimus, symptoms for PRES like headache, altered state of consciousness, convulsions and blurred vision, should be a radiological examination (e.g.." "" "" ""</seg>
<seg id="1449">"" "" "" "since we offer hard capsules, retarded lactose, lactose, lactose, lactose, lactose, lactose, lactose, lactose intolerance, lactose intolerance, lactose intolerance, lactose intolerance, lactose intolerance and lactose intolerance." "" "" ""</seg>
<seg id="1450">The simultaneous application of medicines or herbal remedies known as inhibitors or inductors of CYP3A4 can influence the metabolism of tacrolimus and thus increase or lower blood values of tacrolimus.</seg>
<seg id="1451">It is therefore advisable to monitor the Tacrolimus blood levels while simultaneously offering substances that can change the CYP3A metabolism and adjust the Tacrolimus dose to maintain uniform concentrations (see Sections 4.2 and 4.4).</seg>
<seg id="1452">A strongly distinct interaction was performed with antimycotics such as ketoconazole and fluconazole and Voriconazole as well as with the Macropan antibiotic Erythromycin and HIV proteasinhibitors (z.</seg>
<seg id="1453">"" "" "" "pharmacokinetics studies revealed that the increase in blood levels mainly resulted from the increased oral bioavailability of tacrolimus, caused by the hibition of gastrointestinal metabolism." "" "" ""</seg>
<seg id="1454">"" "" "" "highly dozed prednisolone or methylprednisolone, as used in acute rejection reactions, can increase or lower the concentration of tacrolimus in the blood." "" "" ""</seg>
<seg id="1455">The effect of tacrolimus on the metabolism of other medicines Tacrolimus is known as CYP3A4 inhibitor; therefore the simultaneous application of tacrolimus with medicines which are metabolized by CYP3A4 can compromise their metabolism.</seg>
<seg id="1456">"" "" "" "since tacrolimus can reduce the balance of steroid contraceptives and thus increase hormone exposure, it is particularly cautious when decisions about contraception measures are taken." "" "" ""</seg>
<seg id="1457">The results of animal experiments have shown that tacrolimus can potentially reduce the Clearance of pentobarbital and phenazon and prolong their half-life.</seg>
<seg id="1458">The results of a low number of transplant patients do not provide an indication that under tacrolimus in comparison to other immunosuppressants there is an increased risk of adverse events with regard to the course and outcome of pregnancy.</seg>
<seg id="1459">"" "" "" "in utero exposure, a monitoring of the newborn is recommended for possible adverse effects of tacrolimus (especially regarding its effect on the kidneys)." "" "" ""</seg>
<seg id="1460">"" "" "" "there is the risk of premature birth (&lt; week 37) and a hypercalemia of the newborn (incidence 8 of 111 newborns, i.e.:" "" "" ""</seg>
<seg id="1461">The side effects of immunosuppressant immunosuppressants can often be identified precisely because of the health of the patient and the simultaneous treatment with a variety of other medicines.</seg>
<seg id="1462">"" "" "" "often (≥ 1 / 100, ≤ 1 / 100), rarely (≥ 1 / 10, ≤ 1 / 100), very rare (≥ 1 / 10), very rare (≥ 1 / 10), very rare (incidence on the basis of available data is not appreciated)." "" "" ""</seg>
<seg id="1463">Ischemic disorders of coronary arteries; tachycardia chamber arrhythmia and cardiac insufficiency; cardiac insufficiency and cardiac arrhythmia and supraventricular arrhythmias; palpitatio and anomalies in the ECG; abnormal heart rate and pulse rate</seg>
<seg id="1464">"" "" "" "diarrhoea, nausea gastrointestinal inflammation, gastrointestinal ulcers and irritations, gastrointestinal signs and symptoms, obstipation, flatulence, flatulence, flatulence, bloating and symptoms in the gastrointestinal area" "" "" ""</seg>
<seg id="1465">"" "" "" "infections and parasitic diseases As well as known to other highly effective immunosuppressants is frequently elevated in patients treated with Tacrolimus, the susceptibility to infections (viral, bacterial, mycotic, protozoal)." "" "" ""</seg>
<seg id="1466">Cases of BK-virus-associated nephropathy and JC virus-associated progressive multifocal corneal cephalopathy (PML) were reported in patients with immunosuppression therapy including therapy with Advagraf.</seg>
<seg id="1467">"" "" "" "it was reported about benign or malignant neoplasms, including EBV-associated lymphoproliferative diseases and skin tumors in combination with tacrolimus treatment." "" "" ""</seg>
<seg id="1468">"" "" "" "due to its high molecular weight, its low water solubility and the high binding of erythrocytes and plasma proteins it can be assumed that tacrolimus is not dialysis." "" "" ""</seg>
<seg id="1469">The effects of tacrolimus can be mediated by its binding to a cytosolitic protein (FKBP12) which is responsible for enriching the connection in the nucleus.</seg>
<seg id="1470">"" "" "" "this leads to a calciument inhibition of signal transductions in the T cell, thus preventing the transcription of a number of lymphokin genes." "" "" ""</seg>
<seg id="1471">"" "" "" "tacrolimus suppresses the activation of the T cells and the proliferation of the B cells, the formation of lymphocytes (like interleukin-2, interleukin-3 and gamma-interferon) as well as the expression of the interleukin-2 receptor." "" "" ""</seg>
<seg id="1472">12 confirmed acute rejection was 32.6% within the first 24 weeks of the Advent group (N = 237) and 29.3% in the Prograf Group (N = 234).</seg>
<seg id="1473">The patient survival rates after 12 months were 89.2% for Advagraf and 90.8% for Prograf; in the Anagraf arm 25 (14 females and 11 men) and the Prograf arm 24 (5 females and 19 men) died.</seg>
<seg id="1474">Kidney transplantation The effectiveness and safety of Advagraf and Prograf was compared in combination with mycophenolate mofetil (MMF) and corticosteroids; in 667 de novo kidney transplant receivers.</seg>
<seg id="1475">Patients survival rates after 12 months were 96.9% for Advagraf and 97.5% for Prograf; in the Anagraf arm 10 (3 women, 7 men) and in Prograf arm 8 (3 females).</seg>
<seg id="1476">"" "" "" "the efficacy and safety of Prograf, Ciclosporin and Advagraf, in combination with Basiliximab-antibodies, MMF and corticosteroids, were compared with 638 de novo kidney transplant receivers." "" "" ""</seg>
<seg id="1477">The incidence of therapy failure after 12 months (defined as death and transplant loss) was 14.0% in the RESEF group (N = 212) and 15.1% in the Prograf Group (N = 212) and 17.0% in the Ciclosporin group (N = 212).</seg>
<seg id="1478">The difference in treatment was -3.0% (Advagraph Ciclosporin) (5.0%) for Advagraf vs Ciclosporin and -1.9% (Prograf-Ciclosporin) (5.0% reduction interval [-8.9% [-8.9%]) for Prograf vs Ciclosporin.</seg>
<seg id="1479">"" "" "" "in the Sagraf arm, 3 (men), in the Prograf arm 10 (3 females, 7 men) and in the Ciclosporin arm 6 (3 females, 3 men)." "" "" ""</seg>
<seg id="1480">Primary immunosuppression with Tacrolimus in the form of prograf tablets applied twice a day after other primary organ transplants Prograf has developed into a recognized primary immunosuppressant according to pancreas, lung and intestinal transplantation.</seg>
<seg id="1481">"" "" "" "175 patients, in 475 patients undergoing pancreatic transplants, were used as primary immunosuppressant in 630 patients." "" "" ""</seg>
<seg id="1482">"" "" "" "overall, the safety profile of oral prograf in these published studies was consistent with observed in large studies where prograf was used for primary immunosuppression in liver, kidney and heart transplant receivers." "" "" ""</seg>
<seg id="1483">Lung transplantation in an interim analysis of a recent multi-center study with oral prograf reports over 110 patients who received either Tacrolimus or Ciclosporin within 1: 1 randomisation.</seg>
<seg id="1484">"" "" "" "in the first year following the transplant, chronic transplant rejection was less frequent after transplantation (2.86% versus 8.57%)." "" "" ""</seg>
<seg id="1485">"" "" "" "the survival rate after one year was 80.8% in the Tacrolimus- and 83% in the Ciclosporin Group (Treede et al., 3rd ICI San Diego, USA, 2004; abstract 22)." "" "" ""</seg>
<seg id="1486">"" "" "" "compared to 38.0% Ciclosporin (p = 0,025) compared to 38.0% of patients treated with Tacrolimus." "" "" ""</seg>
<seg id="1487">The number of cases where Ciclosporin had to be changed to Tacrolimus was significantly larger (p = 0.02) than the number of patients coated by tacrolimus on Ciclosporin (n = 2) (Keenan et al.) Ann Thoracic Surg 1995; 60: 580).</seg>
<seg id="1488">The number of cases in which there was no acute graft rejection was after 6 months (57.7% versus 45.8%) and after 1 year (50% versus 33.2%) and after 1 year (50% versus 33.3%) patients of the Tacrolimus Group (J Heart Lung Transplant 2001; 20: 511).</seg>
<seg id="1489">"" "" "" "in a study, the incidence of a bronchiolitis obliter- syndroms in patients treated with Tacrolimus was significantly lower." "" "" ""</seg>
<seg id="1490">Pancreatic Plantation A multicenter study with oral prograf was carried out in 205 patients with pancreatic and kidney transplantation which resulted in a randomised trial tacrolimus (n = 103) or Ciclosporin (n = 102).</seg>
<seg id="1491">The oral initial dose (per protocol) of tacrolimus was 0.2 mg / kg / day and was then reached for reaching the target level of 8 to 15 ng / ml on 5.</seg>
<seg id="1492">"" "" "" "in 155 patients (65 only intestine, 75 liver and intestine and 25 multivisceral transplants), 155 patients (65 only intestine, 75 liver and intestine and 25 multivisceral transplants) showed an up-to-date survival rate of 75% after 5 years and 42% after 10 years." "" "" ""</seg>
<seg id="1493">Methods for early detection of Epstein-Barr (EBV) - and CMV infections; bone marmentation; additional talent of the interleukin-2 antagonist Daclizumab leading to lower initial doses of Tacrolimus and recent graft irradiation (Abu-Elmagd et al.) Ann Surg 2001; 234: 404).</seg>
<seg id="1494">Factors such as a low haematokrite level and low protein concentrations lead to an increase in the bound group of tacrolimus or a reinforcement of the metabolism led by treatment with corticosteroids should be responsible for the higher clearances observed after transplantation.</seg>
<seg id="1495">"" "" "" "this suggests that tacrolimus is almost completely metabolized before excretion, whereby excretion takes place mainly through bile." "" "" ""</seg>
<seg id="1496">The systemic exposure of Tacrolimus (AUC0-24) was approximately 10% lower than under Prograf (mg: mg: mg: mg: mg: mg once daily) at a rate of 1: 1 (mg: mg) in relation to 1: 1 (mg: mg).</seg>
<seg id="1497">"" "" "" "it is recommended to perform frequent checks of tacrolimus feat levels during the first two weeks following transplant, followed by periodic controls during maintenance therapy." "" "" ""</seg>
<seg id="1498">"" "" "" "21 For the treatment of adult patients with graft rejection, which proved to be therapy resistant against other immunosuppressants, no clinical data is available for the retarded formulation of Advent." "" "" ""</seg>
<seg id="1499">"" "" "" "other factors that increase the risk of such clinical disorders are an already existing heart disease, a treatment with corticosteroids, high blood pressure, kidney or liver function disorders, infections, fluid loading and edema." "" "" ""</seg>
<seg id="1500">28 confirmed acute rejection was 32.6% within the first 24 weeks of the Advent group (N = 237) and 29.3% in the Prograf Group (N = 234).</seg>
<seg id="1501">"" "" "" "the efficacy and safety of Prograf, Ciclosporin and Advagraf, in combination with Basiliximab-antibodies, MMF and corticosteroids, were compared with 638 de novo kidney transplant receivers." "" "" ""</seg>
<seg id="1502">"" "" "" "hard capsules, retarded Gräublrot-orange gelatine capsules, printed in red ink on the ruminous red capsule bottom with" "" "" "" "000687" "" "" "", "they contain white powder." "" "" ""</seg>
<seg id="1503">"" "" "" "it is recommended to perform frequent checks of tacrolimus feat levels during the first two weeks following transplant, followed by periodic controls during maintenance therapy." "" "" ""</seg>
<seg id="1504">"" "" "" "37 For the treatment of adult patients with graft rejection, which proved to be therapy resistant against other immunosuppressants, no clinical data is available for the retarded formulation of Advent." "" "" ""</seg>
<seg id="1505">"" "" "" "other factors that increase the risk of such clinical disorders are an already existing heart disease, a treatment with corticosteroids, high blood pressure, kidney or liver function disorders, infections, fluid loading and edema." "" "" ""</seg>
<seg id="1506">44 confirmed acute rejection was 32.6% within the first 24 weeks of the Advent group (N = 237) and 29.3% in the Prograf Group (N = 234).</seg>
<seg id="1507">"" "" "" "the efficacy and safety of Prograf, Ciclosporin and Advagraf, in combination with Basiliximab-antibodies, MMF and corticosteroids, were compared with 638 de novo kidney transplant receivers." "" "" ""</seg>
<seg id="1508">"" "" "" "in total 34 patients from Ciclosporin were converted to Tacrolimus, while only 6 Tacrolimus patients needed another therapy (Bechstein et al., transplantation 2004; 77: 1221)." "" "" ""</seg>
<seg id="1509">"" "" "" "in 155 patients (65 only intestine, 75 liver and intestine and 25 multivisceral transplants), 155 patients (65 only intestine, 75 liver and intestine and 25 multivisceral transplants) showed an up-to-date survival rate of 75% after 5 years and 42% after 10 years." "" "" ""</seg>
<seg id="1510">"" "" "" "this suggests that tacrolimus is almost completely metabolized before excretion, whereby excretion takes place mainly through bile." "" "" ""</seg>
<seg id="1511">Risk management plan The owner of approval for placing on the market is obliged to carry out the studies described in the pharmacovigilance plan and additional pharmacovigilance activities as described in version 3.2 of the Risk Management Plan (RMP) and all further updates of the RMP approved by the CHMP.</seg>
<seg id="1512">"" "" "" "according to the CHMP guideline, the updated RMP must be submitted at the same time with the next periodic safety report (Periodic Safety Update Report, PSUR)." "" "" ""</seg>
<seg id="1513">"" "" "" "you may also receive Advagraf to treat your liver, kidney or heart transplant or other transplanted organ, or because your body's immune response could not be ruled by prior treatment." "" "" ""</seg>
<seg id="1514">"" "" "" "if you use other medicines, please inform your doctor or pharmacist if you have other medicines or have recently taken it, even if it is not prescription medicine or herbal remedy." "" "" ""</seg>
<seg id="1515">"" "" "" "Amiloride, triamier or spironolacton, certain pain killers (known as insteroidal antiphlogistica like ibuprofen), anticoagulants or medicines for the treatment of diabetes mellitus." "" "" ""</seg>
<seg id="1516">"" "" "" "if pregnant or breastfeeding, ask your doctor or pharmacist for advice before taking any medicines." "" "" ""</seg>
<seg id="1517">"" "" "" "traffic tightness and operation of machines must not be set against the wheel of a vehicle, or use tools or machines if you feel dizzy or drowsy after taking in Advent." "" "" ""</seg>
<seg id="1518">"" "" "" "important information about certain other components of Advent Please contact your doctor first after consultation, if you are aware that you suffer from a intolerance to certain sugars." "" "" ""</seg>
<seg id="1519">Make sure you always receive the same tacrolimus medication if you release your prescription unless your specialist has expressly agreed to change the Tacrolimus preparation.</seg>
<seg id="1520">"" "" "" "if you receive a medicine whose appearance is changed from the usual deviation or the dosage instructions, please talk as soon as possible with your doctor or pharmacist, so that you can get the right medicine." "" "" ""</seg>
<seg id="1521">"" "" "" "in order for your doctor to determine the correct dose and be able to adjust from time to time, it must then regularly perform blood tests." "" "" ""</seg>
<seg id="1522">"" "" "" "if you have taken a larger amount of Advagraf than you should have inadvertently taken a larger amount of Advagraf, seek out immediately your doctor or the emergency department of the nearest hospital." "" "" ""</seg>
<seg id="1523">"" "" "" "if you forgot taking this supplement if you forgot to take the capsules, please take this at the same day at the earliest possible time." "" "" ""</seg>
<seg id="1524">"" "" "" "if you cancel the intake of Advent at the end of the treatment with Advagraf, the risk of graft failure can increase." "" "" ""</seg>
<seg id="1525">"" "" "" "Advagraf 0.5 mg of hard capsules, retarded, are hard gelatine capsules, their light yellow top with" 0.5 mg "and their orange bottoms with" "" "" "" "647" "" "" "" "are red and they are filled with white powder." "" "" ""</seg>
<seg id="1526">"" "" "" "Advagraf 1 mg of hard capsules, retarded, are hard gelatine capsules whose white top is labeled with" 1 mg "and their orange bottoms are red in red and filled with white powder." "" "" ""</seg>
<seg id="1527">"" "" "" "Advagraf 5 mg of hard capsules, retarded, are hard gelatine capsules, whose green part with" 5 mg "and their orange bottoms are red, and they are filled with white powder." "" "" ""</seg>
<seg id="1528">România Astellas Pharma Internaţ: Ploieş ti-Ploieş ti-Ploieş ti-Ploieş ti-Ploieş ti-Ploieş ti-Ploieş ti 42-44: Ploieş ti-Ploieş ti Tel: + 40 (0) 21 361 0495</seg>
<seg id="1529">Slovenská republika Astellas Pharma s.r.o., organizač ná zlož ka Galvániho 15 / C SK- 821 04 Bratislava 2 Tel: + 421 2 4444 2157</seg>
<seg id="1530">"" "" "" "advent is used to treat and prevent hemorrhage in patients with hemophilia A (a congenital thrombosis caused by the lack of factor VIII)." "" "" ""</seg>
<seg id="1531">"" "" "" "the dosage and frequency of the application depend on whether it is used for the treatment of bleeding or for the prevention of bleeding, in case of surgical procedures." "" "" ""</seg>
<seg id="1532">"" "" "" "patients with hemophilia A suffer from a factor VIII deficiency, which causes blood clots like bleeding in joints, muscles or internal organs." "" "" ""</seg>
<seg id="1533">"" "" "" "Octocog alfa is not extracted from human plasma, but is produced according to a method known as" recombinant DNA technology. "" "" "" ""</seg>
<seg id="1534">"" "" "" "it is produced by a cell in which a gene (DNA) was placed, which enables it to form the human coagulation factor VIII." "" "" ""</seg>
<seg id="1535">"" "" "" "Advate is similar to another medicine approved in the European Union called Recombinate, but it is made differently so that the medicine contains no proteins of human or animal origin." "" "" ""</seg>
<seg id="1536">"" "" "" "in three additional studies in patients with severe to moderate haemophilia A, including a study with 53 children under six years, the application of the medicine for the prevention of bleeding and surgical procedures was examined." "" "" ""</seg>
<seg id="1537">"" "" "" "in the main study, the efficacy of Advate in the prevention of hemorrhages in 86% of 510 new sepisods with" excellent "or" good "evaluated." "" "" ""</seg>
<seg id="1538">"" "" "" "the most common side effects of Advate (observed in 1 to 10 of 100 patients) are dizziness, headaches, pyrexia (fever) and the formation of antibodies compared to factor VIII." "" "" ""</seg>
<seg id="1539">"" "" "" "Advate may not be applied to patients who are possibly hypersensitive to the human coagulation factor VIII, mouse or hamster protein or one of the other ingredients." "" "" ""</seg>
<seg id="1540">"" "" "" "March 2004, the European Commission issued a permit to the company Baxter AG for the placing of lawyers in the European Union." "" "" ""</seg>
<seg id="1541">"" "" "" "dosage The dosage and duration of the substitution therapy depend on the severity of the factor VIII deficiency, on the place and the extent of bleeding and clinical condition of the patient." "" "" ""</seg>
<seg id="1542">"" "" "" "in the following hemorrhagic events, the factor VIII activity should not fall below the specified plasma levels (in% of the standard or in I.E. / dl)." "" "" ""</seg>
<seg id="1543">Injection every 12-24 hours (8-24 hours in patients under 6 years) for 3-4 days or longer before the pain and acute impairment are removed.</seg>
<seg id="1544">"" "" "" "injection every 8-24 hours (6-12 hours in patients under 6 years), until the risk is over." "" "" ""</seg>
<seg id="1545">"" "" "" "during the treatment process, a proper determination of the factor VIII plasma is recommended for controlling the dose and frequency of injections." "" "" ""</seg>
<seg id="1546">"" "" "" "individual patients can differ in their response to factor VIII, different in vivo recovery and show different half-value times." "" "" ""</seg>
<seg id="1547">3 Prophylaxis For long-term prophylaxis of bleeding in patients with severe hemophilia A doses between 20 and 40 I.U. of factor VIII per kg body weight should be given at intervals of 2-3 days.</seg>
<seg id="1548">"" "" "" "if the expected factor VIII plasma activities are not reached or if the bleeding is not controlled with a reasonable dose, a test must be carried out to prove an inhibitor." "" "" ""</seg>
<seg id="1549">"" "" "" "in patients with high inhibitors, it is possible that the factor VIII therapy is not effective so other therapeutic measures need to be considered." "" "" ""</seg>
<seg id="1550">"" "" "" "the dosage rate should depend on the patient's condition, whereby a maximum injection rate of 10 ml / min should not be exceeded." "" "" ""</seg>
<seg id="1551">The formation of neutralizing antibodies (inhibitors) against factor VIII is a known complication in the treatment of patients with hemophilia A.</seg>
<seg id="1552">These inhibitors are always opposed to the procoagulatory activity of factor VIII directed by IgG immunoglobulins which are quantified in Bethesda units (B.E.) per ml plasma using modified Bethesda assay.</seg>
<seg id="1553">"" "" "" "the risk of developing inhibitors correlates with the magnitude of exposure to factor VIII, whereby the risk is greatest in the first 20 exposures and depends on genetic and other factors." "" "" ""</seg>
<seg id="1554">In pre-treated patients (PTPs) with more than 100 Expositional days and anamnesian known inhibitors development was observed after switching from a recombinant factor VIII to another to reoccur (low-tium) inhibitors.</seg>
<seg id="1555">"" "" "" "due to the rare occurrence of haemophilia A in women, there are no experiences with the use of factor VIII during pregnancy and lactation." "" "" ""</seg>
<seg id="1556">"" "" "" "the ADRs (5 patients) which had previously untreated patients had headaches (5 patients), headache (5 patients), fever and dizziness (3 patients each)." "" "" ""</seg>
<seg id="1557">"" "" "" "very common (≥ 1 / 100 to &lt; 1 / 100), rarely (≥ 1 / 1000 to &lt; 1 / 100), rare (≥ 1 / 10), very rare &lt; 1 / 1000), not known (frequency based on data available)." "" "" ""</seg>
<seg id="1558">A) The percentage of patients was calculated on the basis of the total of the individual patients (234). the unexpected drop in the blood coagulation factor VIII-level occurred postoperatively (10 - 14 postoperatively) in a patient with continuous ADVATE infusion.</seg>
<seg id="1559">"" "" "" "blood clotting was maintained throughout the time, and both the factor VIII- Mirror in the plasma and the clearance rate showed sufficient values again on the 15th postoperative day." "" "" ""</seg>
<seg id="1560">In clinical trials with ADVATE to 145 children and adults 2 with diagnosed severe to moderate haemophilia A (FVIII ≤ 0.2%) and previous exposure to factor VIII- concentrates (≥ 150 days) only one patient showed a low inhibitor (2.4 B.E. in the modified Bethesda approach).</seg>
<seg id="1561">In addition none of the 53 pediatric patients with an age of less than 6 years and diagnosed severe to moderate haemophilia A (FVIII ≤ 0.2%) after previous exposure to factor VIII- concentrates (≥ 50 days) found a FVIII inhibitor.</seg>
<seg id="1562">"" "" "" "in previously untreated patients undergoing a clinical trial, 5 out of 25 (20%) treated with ADVATE showed inhibitors against factor VIII." "" "" ""</seg>
<seg id="1563">"" "" "" "the immune response of the patients to traces of contaminated proteins was analyzed by investigating the antibody titer against these proteins, laboratory parameters and reported side effects." "" "" ""</seg>
<seg id="1564">"" "" "" "a patient showed both a statistically significant upward trend as well as a prolonged peak of antibody level against anti-CHO cell protein, but otherwise no signs or symptoms appeared which were referred to an allergic reaction or hypersensitivity." "" "" ""</seg>
<seg id="1565">"" "" "" "in four patients the incidence of urticaria, pruritus, skin rash and increased number of eosinophiles granulocytes were reported in several repeated product expositions within the study." "" "" ""</seg>
<seg id="1566">"" "" "" "7 As with other intravenous products, ADVATE reported hypersensitivity reactions from the allergic type, including anaphylactic / anaphylactic reactions (frequency not known)." "" "" ""</seg>
<seg id="1567">"" "" "" "the activated factor VIII acts as a co-factor for the activated factor IX and accelerates the formation of activated factor X, factor X." "" "" ""</seg>
<seg id="1568">All Pharmacokinetic studies with ADVATE were performed on pre-treated patients with severe or moderate haemophilia A (base value of factor VIII activity ≤ 2%).</seg>
<seg id="1569">The pharmacokinetic parameters come from a cross-over study with ADVATE in 100 previously treated patients same or &gt; 10 years and are listed in table 3 below.</seg>
<seg id="1570">Table 3 Summary of the pharmacokinetic parameters of ADVATE in 100 patients with severe to moderate haemophilia A (factor VIII &lt; 2%) PK parameters (Pharmacokinetics)</seg>
<seg id="1571">"" "" "" "not clinical data, based on safety spatology studies, acute, repeated and local toxicity and genotoxicity, show no specific risk for humans." "" "" ""</seg>
<seg id="1572">Each pack consists of a glass bottle with powder and a water bottle containing 5 ml solvents (both glass type I with chlorobutyl rubber stoppers) and a device for reconstitution (BAXJECT II).</seg>
<seg id="1573">"" "" "" "if the product is still stored in the refrigerator, remove both glazing bottles with ADVATE powder and solvents from the refrigerator and heat up at room temperature (between 15 and 25 ° C)." "" "" ""</seg>
<seg id="1574">"" "" "" "a significant increase of the pulse rate can usually be lowered immediately by using slow or temporary disruptions of the injection (see Sections 4.4, 4.8)." "" "" ""</seg>
<seg id="1575">14 Prophylaxis For long-term prophylaxis of bleeding in patients with severe hemophilia A doses between 20 and 40 I.U. of factor VIII per kg body weight should be given at intervals of 2-3 days.</seg>
<seg id="1576">"" "" "" "due to the rare occurrence of haemophilia A in women, there are no experiences with the use of factor VIII during pregnancy and lactation." "" "" ""</seg>
<seg id="1577">"" "" "" "3 newborns (aged 0-1 month), infants (aged 1 month - 2 years), children (aged 2-12), adolescents (aged 12-16), adults (over 16 years)" "" "" ""</seg>
<seg id="1578">In clinical trials with ADVATE to 145 children and adults 4 with diagnosed severe to moderate haemophilia A (FVIII ≤ 0.2%) and previous exposure to factor VIII- concentrates (≥ 150 days) only one patient showed a low inhibitor (2.4 B.E. in the modified Bethesda approach).</seg>
<seg id="1579">"" "" "" "18 As with other intravenous products, ADVATE reported hypersensitivity reactions from the allergic type, including anaphylactic / anaphylactic reactions (frequency not known)." "" "" ""</seg>
<seg id="1580">Table 3 Summary of the pharmacokinetic parameters of ADVATE in 100 patients with severe to moderate haemophilia A (factor VIII &lt; 2%) PK parameters (Pharmacokinetics)</seg>
<seg id="1581">"" "" "" "not clinical data, based on safety spatology studies, acute, repeated and local toxicity and genotoxicity, show no specific risk for humans." "" "" ""</seg>
<seg id="1582">25 Prophylaxis For long-term prophylaxis of bleeding in patients with severe hemophilia A doses between 20 and 40 I.U. of factor VIII per kg body weight should be given at intervals of 2-3 days.</seg>
<seg id="1583">"" "" "" "5 infants (aged from 0-1 month), young children (aged 2-12), children (aged 2-12), adults (aged 12-16), adults (over 16 years)" "" "" ""</seg>
<seg id="1584">In clinical trials with ADVATE to 145 children and adults 6 with diagnosed severe to moderate haemophilia A (FVIII ≤ 0.2%) and previous exposure to factor VIII- concentrates (≥ 150 days) only one patient showed a low inhibitor (2.4 B.E. in the modified Bethesda approach).</seg>
<seg id="1585">"" "" "" "29 As with other intravenous products, ADVATE reported hypersensitivity reactions from the allergic type, including anaphylactic / anaphylactic reactions (frequency not known)." "" "" ""</seg>
<seg id="1586">"" "" "" "not clinical data, based on safety spatology studies, acute, repeated and local toxicity and genotoxicity, show no specific risk for humans." "" "" ""</seg>
<seg id="1587">36 Prophylaxis For long-term prophylaxis of bleeding in patients with severe hemophilia A doses between 20 and 40 I.U. of factor VIII per kg body weight should be given at intervals of 2-3 days.</seg>
<seg id="1588">"" "" "" "7 newborns (aged 0-1 month), infants (aged 1 month - 2 years), children (aged 2-12), adolescents (aged 12-16), adults (over 16 years)" "" "" ""</seg>
<seg id="1589">In clinical trials with ADVATE to 145 children and adults 8 with diagnosed severe to moderate haemophilia A (FVIII ≤ 0.2%) and previous exposure to factor VIII- concentrates (≥ 150 days) only one patient showed a low inhibitor (2.4 B.E. in the modified Bethesda approach).</seg>
<seg id="1590">"" "" "" "40 As with other intravenous products, ADVATE reported hypersensitivity reactions from the allergic type, including anaphylactic / anaphylactic reactions (frequency not known)." "" "" ""</seg>
<seg id="1591">"" "" "" "not clinical data, based on safety spatology studies, acute, repeated and local toxicity and genotoxicity, show no specific risk for humans." "" "" ""</seg>
<seg id="1592">"" "" "" "47 Prophylaxis For long-term prophylaxis of bleeding in patients with severe hemophilia A, doses between 20 and 40 I.U. of factor VIII per kg body weight should be given at intervals of 2-3 days." "" "" ""</seg>
<seg id="1593">"" "" "" "9 newborns (aged 0-1 month), infants (aged 1 month - 2 years), children (aged 2-12), adolescents (aged 12-16), adults (over 16 years)" "" "" ""</seg>
<seg id="1594">In clinical trials with ADVATE to 145 children and adults 10 with diagnosed severe to moderate haemophilia A (FVIII ≤ 0.2%) and previous exposure to factor VIII- concentrates (≥ 150 days) only one patient showed a low inhibitor (2.4 B.E. in the modified Bethesda approach).</seg>
<seg id="1595">"" "" "" "51 As with other intravenous products, ADVATE reported hypersensitivity reactions from the allergic type, including anaphylactic / anaphylactic reactions (frequency not known)." "" "" ""</seg>
<seg id="1596">"" "" "" "not clinical data, based on safety spatology studies, acute, repeated and local toxicity and genotoxicity, show no specific risk for humans." "" "" ""</seg>
<seg id="1597">"" "" "" "58 prophylaxis For long-term prophylaxis of bleeding in patients with severe hemophilia A, doses between 20 and 40 I.U. of factor VIII per kg body weight should be given at intervals of 2-3 days." "" "" ""</seg>
<seg id="1598">"" "" "" "11 newborns (aged from 0-1 month), infants (aged 1 month - 2 years), children (aged 2-12), adolescents (aged 12-16), adults (over 16 years)" "" "" ""</seg>
<seg id="1599">In clinical trials with ADVATE to 145 children and adults 12 with diagnosed severe to moderate haemophilia A (FVIII ≤ 0.2%) and previous exposure to factor VIII- concentrates (≥ 150 days) only one patient showed a low inhibitor (2.4 B.E. in the modified Bethesda approach).</seg>
<seg id="1600">"" "" "" "62 As with other intravenous products, ADVATE reported hypersensitivity reactions from the allergic type, including anaphylactic / anaphylactic reactions (frequency not known)." "" "" ""</seg>
<seg id="1601">"" "" "" "not clinical data, based on safety spatology studies, acute, repeated and local toxicity and genotoxicity, show no specific risk for humans." "" "" ""</seg>
<seg id="1602">"" "" "" "pharmaceutical vigilance system The authorisation holder must ensure that a pharmaceutical vigilance system, as described in section 1.1 of chapter 1.8.1 of the authorization approval, has been established and that this system remains in force throughout the period when the product is on the market." "" "" ""</seg>
<seg id="1603">"" "" "" "as defined in the CHMP directive on the risk management plan for human medicine, these updates should be submitted concurrently with the next Periodic Safety Update Report (PSUR)." "" "" ""</seg>
<seg id="1604">"" "" "" "• If new information is available which may have an impact on the valid safety precautions, the pharmacovigilance plan or the risk minimization measures - within 60 days of an important event (with regard to pharmacovigilance or risk minimization)" "" "" ""</seg>
<seg id="1605">"" "" "" "1 cup bottle with ADVATE 500 I.e Octocog alfa, 1 cup bottle with 5 ml sterilised water for injection purposes, 1 BAXJECT II medical product." "" "" ""</seg>
<seg id="1606">"" "" "" "1 cup bottle with ADVATE 1000 i.e Octocog alfa, 1 cup bottle containing 5 ml of sterilised water for injection purposes, 1 BAXJECT II medical product" "" "" ""</seg>
<seg id="1607">Special caution when using ADVATE is necessary you should inform your doctor if you have recently been treated with factor VIII products especially if you have developed inhibitors.</seg>
<seg id="1608">"" "" "" "these symptoms can be early signs of anaphylactic shock which may include the following symptoms: extreme dizziness, loss of consciousness and extreme breathing difficulties." "" "" ""</seg>
<seg id="1609">"" "" "" "if you have other medicines, please inform your doctor if you have other medicines or have recently taken it, even if it is non-prescription medicine." "" "" ""</seg>
<seg id="1610">Your doctor will calculate your dose ADVATE (in international units or I.U.) depending on your physical condition and body weight and whether it is used to prevent or treat bleeding.</seg>
<seg id="1611">"" "" "" "patients who develop factor VIII inhibitors If the anticipated FaktorVIII mirrors cannot be reached in your plasma with ADVATE, or could not be controlled by bleeding, this could lead to the development of factor VIII-" "" "" ""</seg>
<seg id="1612">"" "" "" "in combination with operations catheter infections, lower number of red blood cells, swelling of limbs and joints, extended bleeding after drainage, reduced factor VIII mirrors and postoperative hematomas." "" "" ""</seg>
<seg id="1613">"" "" "" "rare side effects Since the introduction of the drug in the market, some serious and potentially life-threatening reactions (anaphylactic) and other allergic reactions were reported (see above)." "" "" ""</seg>
<seg id="1614">Inform your doctor if any of the listed side effects are significantly impaired or if you notice side effects that are not listed in this packing supplement.</seg>
<seg id="1615">Portugal Baxter Médico Farmacêutica Lda Sintra Business Park Zona Industrial da Abrunheira; Edifício 10 P-2710-089 Sintra phone: + 351 21 925 25 00</seg>
<seg id="1616">"" "" "" "• Don't use BAXJECT II if its sterile barrier is broken, its packaging is damaged or signs of manipulation, as shown in the symbol" "" "" ""</seg>
<seg id="1617">Important note: • Do not administer yourself before you have received the special training from your doctor or nurse. • Check the product on suspended or discoloration prior to administration.</seg>
<seg id="1618">"" "" "" "the solution should be administered slowly with an infusion speed, which is beneficial to the patient and does not exceed 10 ml per minute." "" "" ""</seg>
<seg id="1619">"" "" "" "106 In the case of blood events, the factor VIII-Spiegel should not fall below the indicated plasma activity value (in% or in I.E. / ml)." "" "" ""</seg>
<seg id="1620">"" "" "" "these symptoms can be early signs of anaphylactic shock which may include the following symptoms: extreme dizziness, loss of consciousness and extreme breathing difficulties." "" "" ""</seg>
<seg id="1621">"" "" "" "patients who develop factor VIII inhibitors If the anticipated FaktorVIII mirrors cannot be reached in your plasma with ADVATE, or could not be controlled by bleeding, this could lead to the development of factor VIII-" "" "" ""</seg>
<seg id="1622">"" "" "" "occasional side effects itching, enhanced sweating, unusual taste sensation, heat flushes, diarrhea, nausea, vomiting, short breathe, smoother, eye inflammations, skin rashes, extreme sweating," "" "" ""</seg>
<seg id="1623">"" "" "" "116 In the case of blood events, the factor VIII-Spiegel should not fall below the indicated plasma activity value (in% or in I.E. / ml)." "" "" ""</seg>
<seg id="1624">"" "" "" "these symptoms can be early signs of anaphylactic shock which may include the following symptoms: extreme dizziness, loss of consciousness and extreme breathing difficulties." "" "" ""</seg>
<seg id="1625">"" "" "" "patients who develop factor VIII inhibitors If the anticipated FaktorVIII mirrors cannot be reached in your plasma with ADVATE, or could not be controlled by bleeding, this could lead to the development of factor VIII-" "" "" ""</seg>
<seg id="1626">"" "" "" "126 In case of blood events, the factor VIII-Spiegel should not fall below the indicated plasma activity value (in% or in I.E. / ml)." "" "" ""</seg>
<seg id="1627">"" "" "" "these symptoms can be early signs of anaphylactic shock which may include the following symptoms: extreme dizziness, loss of consciousness and extreme breathing difficulties." "" "" ""</seg>
<seg id="1628">"" "" "" "patients who develop factor VIII inhibitors If the anticipated FaktorVIII mirrors cannot be reached in your plasma with ADVATE, or could not be controlled by bleeding, this could lead to the development of factor VIII-" "" "" ""</seg>
<seg id="1629">"" "" "" "136 in the case of blood events, the factor VIII-Spiegel should not fall below the indicated plasma activity value (in% or in I.E. / ml)." "" "" ""</seg>
<seg id="1630">"" "" "" "these symptoms can be early signs of anaphylactic shock which may include the following symptoms: extreme dizziness, loss of consciousness and extreme breathing difficulties." "" "" ""</seg>
<seg id="1631">"" "" "" "patients who develop factor VIII inhibitors If the anticipated FaktorVIII mirrors cannot be reached in your plasma with ADVATE, or could not be controlled by bleeding, this could lead to the development of factor VIII-" "" "" ""</seg>
<seg id="1632">"" "" "" "146 In the case of blood events, the factor VIII-Spiegel should not fall below the indicated plasma activity value (in% or in I.E. / ml)." "" "" ""</seg>
<seg id="1633">"" "" "" "these symptoms can be early signs of anaphylactic shock which may include the following symptoms: extreme dizziness, loss of consciousness and extreme breathing difficulties." "" "" ""</seg>
<seg id="1634">"" "" "" "patients who develop factor VIII inhibitors If the anticipated FaktorVIII mirrors cannot be reached in your plasma with ADVATE, or could not be controlled by bleeding, this could lead to the development of factor VIII-" "" "" ""</seg>
<seg id="1635">"" "" "" "occasional side effects itching, enhanced sweating, unusual taste sensation, heat flushes, diarrhea, nausea, vomiting, short breathe, smoother, eye inflammations, skin rashes, extreme sweating," "" "" ""</seg>
<seg id="1636">"" "" "" "rare side effects Since the introduction of the drug in the market, some serious and potentially life-threatening reactions (anaphylactic) and other allergic reactions were reported (see above)." "" "" ""</seg>
<seg id="1637">"" "" "" "in the case of blood events, the factor VIII-Spiegel should not fall below the indicated plasma activity value (in% or in I.E. / ml)." "" "" ""</seg>
<seg id="1638">"" "" "" "based on the data available since initial approval, the CHMP continues to evaluate the benefits risk assessment as positive, but considering that the safety profile must be closely monitored for the following reasons:" "" "" ""</seg>
<seg id="1639">"" "" "" "therefore, the CHMP has decided on the basis of ADVATE's safety profile, which makes PSURs necessary every 6 months, to apply for another extension procedure in 5 years." "" "" ""</seg>
<seg id="1640">"" "" "" "in December 2008, Gendux Molecular Limited was officially approved by the Committee for Human Use (CHMP) that the company will withdraw its application for the transfer of Advexin to the treatment of Li-Fraumeni cancer." "" "" ""</seg>
<seg id="1641">"" "" "" "normally, however, breast, brain, bone or soft tissue (tissues that connect, surround and support other structures in the body) are affected." "" "" ""</seg>
<seg id="1642">"" "" "" "this is a kind of virus, which was genetically altered so that it can carry a gene into the cells of the body." "" "" ""</seg>
<seg id="1643">"" "" "" "the virus in Advexin is an" adenovirus, "which has been modified so that it does not produce copies of itself and thus cannot trigger infections in humans." "" "" ""</seg>
<seg id="1644">"" "" "" "advent would have been injected directly into the tumors, enabling the cancer cells to reform the normal p53 protein." "" "" ""</seg>
<seg id="1645">"" "" "" "the p53 protein, which is formed from the non-defective p53 gene in the human body, normally contributes to the recovery of damaged DNA and to kill the cells when the DNA cannot be recovered." "" "" ""</seg>
<seg id="1646">"" "" "" "with Li-Fraumeni-Cancer, in which the p53 gene is defective, the p53 protein does not work properly and the cancer cells can grow and share." "" "" ""</seg>
<seg id="1647">"" "" "" "the company presented data from a study involving a patient with Li-Fraumeni-cancer in the area of the substructure, in the bones and in the brain." "" "" ""</seg>
<seg id="1648">"" "" "" "after the CHMP checked the company's answers to the questions asked, some questions were still unclear." "" "" ""</seg>
<seg id="1649">"" "" "" "based on testing the initially submitted documents, the CHMP creates a list of questions sent to the company on day 120." "" "" ""</seg>
<seg id="1650">"" "" "" "according to the CHMP, it was not sufficiently demonstrated that the injection of Advexin in Li-Fraumeni-tumours has advantages for the patients." "" "" ""</seg>
<seg id="1651">"" "" "" "the Committee also had concerns regarding the processing of the medicine in the body, the type of administration and the safety of the medicine." "" "" ""</seg>
<seg id="1652">"" "" "" "in addition, the company had not sufficiently demonstrated that Advexin can be manufactured in a reliable manner and that it is neither for the environment nor for people who come in close contact with the patient." "" "" ""</seg>
<seg id="1653">"" "" "" "the company does not know whether the withdrawal has consequences for patients, who are currently participating in clinical studies or" compassionate use "programs with Advexin." "" "" ""</seg>
<seg id="1654">"" "" "" "" "" "" "" "altered ingredient release" means that the tablets are so composite that one of the effective components immediately and the other is released slowly over several hours. "" "" "" "</seg>
<seg id="1655">Aerinaze is used to treat symptoms of seasonal allergic rhinitis (hay fever and inflammation of the nasal passages) in patients with nasal mucous membranes (clogged nose).</seg>
<seg id="1656">"" "" "" "for adults and adolescents from 12 years onwards, the recommended dose of Aerinaze is twice a day a tablet that should be taken with a glass of water with or without food." "" "" ""</seg>
<seg id="1657">"" "" "" "the duration of the treatment should be as short as possible and stopped as soon as the symptoms, especially the swelling of the nasal mucosa (clogged nose) are cluttered." "" "" ""</seg>
<seg id="1658">"" "" "" "a treatment duration of more than 10 days is not recommended, because the effects of the drug can be reduced to the constipation of the nose." "" "" ""</seg>
<seg id="1659">"" "" "" "the main efficacy measures were the changes in the severity of the hay fever symptoms, which were reported by the patient before the treatment and during the 15-day treatment." "" "" ""</seg>
<seg id="1660">"" "" "" "during the study, patients carried out their symptoms every 12 hours in a diary and assessed with a standard scala how difficult the symptoms were during the last 12 hours." "" "" ""</seg>
<seg id="1661">"" "" "" "the patients receiving Aerinaze reported a decrease in symptoms by 46.0%, compared with 35.9% in patients receiving pseudoephedrine alone." "" "" ""</seg>
<seg id="1662">"" "" "" "if only the swelling of the nasal mucosa was considered, patients under Aerinaze showed a relief of 37.4% compared to 26.7% in patients receiving desloratadin alone." "" "" ""</seg>
<seg id="1663">"" "" "" "the most common side effects of Aerinaze (observed with 1 to 10 of 100 patients) are tachycardia, oral dry, dizziness, psychomotor hyperactivity (restlessness), headache, fatigue, insomnia (sleepiness), sleep disorders and nervousness." "" "" ""</seg>
<seg id="1664">"" "" "" "Aerinaze may not be used in patients who are possibly hypersensitive to desloratadin, pseudoephedrine or any of the other ingredients, against adrenergic agents or loratadin (other medicines for the treatment of allergies)." "" "" ""</seg>
<seg id="1665">"" "" "" "aerinaze may not be used in patients with hypertonia (hypertension), hypertension (hypertension), hyperthyrosis (hyperthyrosis) or hypertonia (cerebral thrombosis) or a hemorrhagic stroke." "" "" ""</seg>
<seg id="1666">"" "" "" "on 30 July 2007, the European Commission granted the SP Europe company a permit for the transport of Aerinaze throughout the European Union." "" "" ""</seg>
<seg id="1667">"" "" "" "the tablet can be taken with a glass of water, but is to be swallowed whole (i.e. without biting, breaking or chewing)." "" "" ""</seg>
<seg id="1668">"" "" "" "aerinaze should not be used in children under 12 years of age, due to the lack of data for safety and efficacy (see Section 5.1)." "" "" ""</seg>
<seg id="1669">"" "" "" "the duration of the application is as short as possible, and should not be continued after sounding the symptoms." "" "" ""</seg>
<seg id="1670">"" "" "" "it is recommended to limit the duration of use for 10 days, as long-term use can decrease the activity of pseudoephedrine over time." "" "" ""</seg>
<seg id="1671">"" "" "" "after the swelling of the mucous membranes in the upper respiratory tract, the treatment can be continued with desloratadin as monotherapy." "" "" ""</seg>
<seg id="1672">"" "" "" "since Aerinaze contains pseudoephedrine, the medicine is contraindicated in patients treated with a monoamine oxidase (MAO) inhibitor or within 2 weeks of completion of such therapy." "" "" ""</seg>
<seg id="1673">"" "" "" "this is due to alphamimetic activity in combined use of pseudoephedrine with other vasoconstrictors such as bromocripitin, pergolid, exorlephrine, phenylephrine, ephedrine, oxymetazoline, naphaoline etc." "" "" ""</seg>
<seg id="1674">"" "" "" "the safety and efficacy of this combination therapy have not been checked for this patient collective, and the data is not sufficient to express appropriate dosage recommendations." "" "" ""</seg>
<seg id="1675">"" "" "" "the safety and efficacy of Aerinaze were not tested in patients with kidney or liver dysfunction, and the data is not sufficient to express appropriate dosage recommendations." "" "" ""</seg>
<seg id="1676">"" "" "" "patients need to be informed about the treatment of hypertension, tachycardia or palpitations, palpitations, nausea, or any other neurological symptoms (such as headaches or amplification of the headache)." "" "" ""</seg>
<seg id="1677">"" "" "" "patients with hypertonia • patients with hypertonia • patients with a myocardial infarction in anamnesis, diabetes mellitus, bladder halobstruction or bronchospasmus in the anamnesis." "" "" ""</seg>
<seg id="1678">"" "" "" "aerinaze must be suspended at least 48 hours before performing matological tests, since antihistaminika otherwise can prevent positive reactions to indicators for skin reactions or reduce it to its extent." "" "" ""</seg>
<seg id="1679">"" "" "" "in the course of clinical trials involving desloratadin in which erythromycin or ketoconazole were administered, no clinically relevant interactions or changes in the plasma concentration of desloratadin were observed." "" "" ""</seg>
<seg id="1680">"" "" "" "the results of the psychomotor testing showed no significant differences between patients treated with desloratadin and the placebo-treated patients, regardless of whether Desloratadin was taken alone or with alcohol." "" "" ""</seg>
<seg id="1681">"" "" "" "the enzyme responsible for the metabolism of desloratadin has not yet been identified, so that interactions with other medicines cannot be completely excluded." "" "" ""</seg>
<seg id="1682">Desloratadin does not inhibit in vivo CYP3A4 and in-vitro studies have shown that the drug CYP2D6 does not inhibit and neither a substrate nor an inhibitor of the P-glycoproteins.</seg>
<seg id="1683">"" "" "" "the safety of the application of aerinaze during pregnancy is not guaranteed, but experiences from a large number of affected pregnancies revealed no increase in the frequency of abnormalities compared to the frequency of the normal population." "" "" ""</seg>
<seg id="1684">"" "" "" "since reproduction studies on animals are not always transmitted to humans, and due to the vasoconstrictive properties of pseudoephedrine, Aerinaze should not be applied during pregnancy." "" "" ""</seg>
<seg id="1685">"" "" "" "patients should, however, be informed that in very rare cases there may be a presumption that may result in impaired mobility or the ability to operate machinery." "" "" ""</seg>
<seg id="1686">"" "" "" "symptoms may vary between a CNS depression (sedation, apnea, decreased mental alertness, cyanosis, coma, cardiovascular collapse) and CNS stimulation (sleeplessness, hallucinations, tremor, convulsions)." "" "" ""</seg>
<seg id="1687">"" "" "" "headache, anxiety, scary micpletion, muscular weakness and increased muscle tension, euphoria, arousal, breathing insufficiency, nausea, vomiting, precordial pain, dizziness, tinnitus, ataxia, blurred vision or hypotony." "" "" ""</seg>
<seg id="1688">"" "" "" "CNS stimulation is particularly likely in children, as well as atropin-typical symptoms (mouth-dry, pupil rigidity and - dilatation, skin redness, hyperthermia and gastrointestinal symptoms)." "" "" ""</seg>
<seg id="1689">These include the inhibition of the release of pro-inflammatory cytokines such as IL-6 and IL-13 and IL-13 from human mast cells / basophiles as well as the inhibition of the expression of the Adhersionsmolecules P selectin to endothelial cells.</seg>
<seg id="1690">"" "" "" "in a single dose study involving adults, desloratadin showed no influence on standard measured parameters of flight performance, including amplification of subjective drowsiness or the tasks associated with flying." "" "" ""</seg>
<seg id="1691">"" "" "" "in controlled clinical trials, no increased frequency of drowsiness was found at the recommended dose of 5 mg daily compared to placebo." "" "" ""</seg>
<seg id="1692">"" "" "" "the oral application of pseudoephedrine in the recommended dose can cause further symptomatic effects, such as an increase in blood pressure, tachycardia or manifestations of a CNS arousal." "" "" ""</seg>
<seg id="1693">"" "" "" "there were 1,248 patients aged between 12 and 78 years with seasonal allergy rhinitis, with 414 patients receiving Aerinaze tablets." "" "" ""</seg>
<seg id="1694">"" "" "" "in both studies, the histamine antagonistic efficacy of aerinaze tablets was significantly higher than under a monotherapy with pseudoephedrine over the 2-week treatment period." "" "" ""</seg>
<seg id="1695">The efficacy of aerinaze tablets with regard to the swelling effect determined by the nasal mucosa was significantly higher than under a monotherapy with desloratadin over the 2-week treatment period.</seg>
<seg id="1696">"" "" "" "the efficacy of Aerinaze tablets showed no significant differences in terms of gender, age or ethnic origin." "" "" ""</seg>
<seg id="1697">"" "" "" "as part of a single dose study on the pharmacokinetics of Aerinaze, desloratadin is demonstrable within 30 minutes of the application in plasma." "" "" ""</seg>
<seg id="1698">After the peroral application of aerinaze in healthy volunteers over 14 days the floating equilibrium of desloratadin and 3-hydroxydesloratadin and pseudoephedrine was reached in day 10.</seg>
<seg id="1699">"" "" "" "as part of a pharmacokinetic multidose study conducted with the formulation as a tablet in healthy adult subjects, it was noted that four subjects were ill-metabolized desloratadin." "" "" ""</seg>
<seg id="1700">A component interaction study shows that the exposure (CMAx and AUC) of pseudoephedrine is bioequivalent to the application of an aerinaze tablet.</seg>
<seg id="1701">"" "" "" "based on the conventional research on safety spatology, toxicity in repeated application, genotoxicity and reproductive toxicity, the preclinical data with desloratadin can no longer detect any particular danger to humans." "" "" ""</seg>
<seg id="1702">"" "" "" "the combination had no greater toxicity than its individual components, and the observed effects were generally related to the ingredient pseudoephedrine." "" "" ""</seg>
<seg id="1703">In reproductive toxicological studies the combination of Loratadin / pseudoephedrine was not teratogenic in a dose of up to 150 mg / kg / day and in rabbits in a dose of up to 120 mg / kg / day.</seg>
<seg id="1704">"" "" "" "March 2007 and in Module 1.8.1, the regulatory application described is established and works before and while the product is on the market." "" "" ""</seg>
<seg id="1705">"" "" "" "antihistamines contribute to the relief of the allergic symptoms by preventing histamine, a body's own substance, its effect." "" "" ""</seg>
<seg id="1706">"" "" "" "aerinaze tablets relieve symptoms associated with seasonal allergic rhinitis (hay fever), such as sneezing, running or itchy nose and tearing eyes while simultaneous constipation of the nose." "" "" ""</seg>
<seg id="1707">"" "" "" "20 In certain circumstances, you may be particularly sensitive to the swollen drug pseudoephedrine, which is contained in this medicine." "" "" ""</seg>
<seg id="1708">"" "" "" "(diabetes), a stenozing gastric ulcer (ulcer), a closure of the stomach or duodenum (intestinal closure), a bladder neck cap, bronchospasmen in the patient's history (breathing difficulties due to a varicose of the lung musculature), a prostate enlargement or problems with the liver, kidneys or bladder." "" "" ""</seg>
<seg id="1709">"" "" "" "inform your doctor if there are symptoms or diseases diagnosed with you following the application of Aerinaze: • Cardiovascular disease • Cardiac disease • nausea and headache, or a strengthening of existing headache." "" "" ""</seg>
<seg id="1710">"" "" "" "if you are taking aerinaze with other medicines, please tell your doctor or pharmacist if you have other medicines or recently taken, even if it is not prescription medicine." "" "" ""</seg>
<seg id="1711">"" "" "" "transport tightness and operation of machines In the recommended dosage, it is not to be expected that aerinaze results in dizziness or reduced attention." "" "" ""</seg>
<seg id="1712">If you have taken a larger amount of Aerinaze than you should inform immediately your doctor or pharmacist if you have taken a larger amount of Aerinaze than you ought to.</seg>
<seg id="1713">"" "" "" "if you forgot the intake of Aerinaze if you forgot to take a dose in time, take the application as soon as possible and apply the next dose at the scheduled time." "" "" ""</seg>
<seg id="1714">Inform your doctor or pharmacist if any of the side effects listed you have considerably impaired or you notice side effects that are not stated in this use information.</seg>
<seg id="1715">"" "" "" "heart hunting, restlessness with increased physical activity, mouth dry, dizziness, throat pain, loss of appetite, sugar in the urine, increased blood sugar levels, thirst, fatigue, headache, sleep disorders, nervousness and dizziness." "" "" ""</seg>
<seg id="1716">"" "" "" "heart palpitations, cardiac arrhythmia, increased physical activity, redness, nasal irritation, nasal irritation, nasal irritation, nasal irritation, nasal irritation, nasal irritation, throat irritation, irritation, anxiety, anxiety and irritability." "" "" ""</seg>
<seg id="1717">"" "" "" "after the launch of Desloratadin it was rarely reported about cases of severe allergic reactions (breathing difficulties, whistling breathing, itching, hives and swelling) or skin rash." "" "" ""</seg>
<seg id="1718">"" "" "" "about cases of palpitations, heart hunting, abdominal pain, nausea, vomiting, stomach upset, diarrhea, dizziness with increased physical activity, in cases of liver inflammation and about cases of conspicuous liver values was also very seldom reported." "" "" ""</seg>
<seg id="1719">"" "" "" "it is available as a 5 mg tablet, 5 mg- and 5 mg tablets (tablets which dissolve in the mouth), 0.5 mg / ml syrup and 0,5 mg / ml solution." "" "" ""</seg>
<seg id="1720">"" "" "" "for children aged one to five years, the dose is 1.25 mg once a day, in the form of 2.5 ml syrup or fruit." "" "" ""</seg>
<seg id="1721">"" "" "" "for children aged six to eleven, the dose is 2.5 mg once a day, either in the form of 5 ml syrup or." "" "" ""</seg>
<seg id="1722">Aerius was examined in a total of eight studies involving about 4 800 adults and adolescents with allergic rhinitis (among them four studies in seasonal allergic rhinitis and two studies in patients who also had asthma).</seg>
<seg id="1723">"" "" "" "effectiveness was measured by changing the symptoms (itching, number and size of paddles, impairment of sleep and performance on the day) before and after six weeks of treatment." "" "" ""</seg>
<seg id="1724">"" "" "" "further studies were presented to demonstrate that the body uses the syrup, the solution to intake and the tablets in the same way as the tablets and the application in children is harmless." "" "" ""</seg>
<seg id="1725">"" "" "" "in case of allergic rhinitis, when the results of all studies were taken together, the two-week treatment with 5 mg of Aerius resulted in an average decrease in the symptom scores, compared to the decrease of 12 to 26% in the patients who received a placebo." "" "" ""</seg>
<seg id="1726">"" "" "" "in both studies at Urticaria, the decrease in the symptom scores after six weeks of treatment with Aerius 58 and 67%, compared with 40 and 33% in patients treated with placebo." "" "" ""</seg>
<seg id="1727">"" "" "" "Aerius may not be used in patients who are possibly hypersensitive to desloratadin, Loratadin or any of the other ingredients." "" "" ""</seg>
<seg id="1728">"" "" "" "in January 2001, the European Commission granted the SP Europe company a permit for the placing of Aerius in the European Union." "" "" ""</seg>
<seg id="1729">One tablet once a day with one or without a meal to alleviate the symptoms of allergic rhinitis (including intermittent and persisting allergic rhinitis) and urticaria (see section 5.1).</seg>
<seg id="1730">There is limited experience from clinical trials for efficacy in the application of desloratadin in adolescents aged 12 to 17 years (see Sections 4.8 and 5.1).</seg>
<seg id="1731">"" "" "" "the treatment of the intermittent allergic rhinitis (appearance of symptoms for less than 4 days per week or less than 4 weeks) should be done according to the disease progression, and may be resumed and resumed when reappearing." "" "" ""</seg>
<seg id="1732">"" "" "" "in the persisting allergic rhinitis (appearance of symptoms to 4 or more days per week and more than 4 weeks), the patient can be recommended for prolonged treatment." "" "" ""</seg>
<seg id="1733">Clinically relevant interactions were not found in clinical trials involving desloratadin tablets in which erythromycin or ketoconazole were administered in addition (see section 5.1).</seg>
<seg id="1734">"" "" "" "in a clinical pharmacological study, the performance-reducing effect of alcohol was not increased while taking Aerius and alcohol (see Section 5.1)." "" "" ""</seg>
<seg id="1735">"" "" "" "patients should, however, be informed that in very rare cases there may be a presumption that may result in impaired mobility or the ability to operate machinery." "" "" ""</seg>
<seg id="1736">Clinical trials in various indications including allergic rhinitis and chronic idiopathic urticaria were reported at the recommended dose of 5 mg daily 3% more adverse events in patients with Aerius than in patients who were treated with placebo.</seg>
<seg id="1737">Tiredness (1.2%) and mouth-dry (0.8%) and headache (0.6%) were the most frequent reported side effects reported more frequently than in the placebo.</seg>
<seg id="1738">In a clinical study with 578 young patients aged 12 to 17 years the most common side-effect was headaches; this occurred at 5.9% of patients treated with desloratadin and with 6.9% of the patients treated with placebo.</seg>
<seg id="1739">"" "" "" "in a multi-dose study, administered up to 45 mg of desloratadin (nine-fold clinical dose), no clinically relevant effects were observed." "" "" ""</seg>
<seg id="1740">This includes both inhibiting the release of pro-inflammatory cytokines such as IL-6 and IL-13 and IL-13 from human mast cells / basophiles as well as the inhibition of the expression of the Adhersionsmolecules P selectin to endothelial cells.</seg>
<seg id="1741">"" "" "" "as part of a clinical trial with multiple doses administered in the desloratadin in a dose of up to 20 mg daily for over 14 days, no statistically significant or clinically relevant cardiovascular effect was described." "" "" ""</seg>
<seg id="1742">"" "" "" "in a clinical pharmacological study, in which desloratadin was administered at a dose of 45mg daily (the nine times the clinical dose) was administered for ten days, no prolongation of the Qtc interval was shown." "" "" ""</seg>
<seg id="1743">"" "" "" "in a single dose study involving adults, desloratadin showed no influence on standard measured parameters of flight performance, including amplification of subjective drowsiness or the tasks associated with flying." "" "" ""</seg>
<seg id="1744">"" "" "" "in patients with allergic rhinitis, Aerius was effective in relieving symptoms such as sneezing, nasal secretion and itching of the nose, itching, tearing and redness of the eyes as well as itching on the palate." "" "" ""</seg>
<seg id="1745">"" "" "" "in addition to the established classification in seasonal and perennial, allergic rhinitis can be divided into intermittent allergic rhinitis and persistent allergic rhinitis depending on the duration of the symptoms." "" "" ""</seg>
<seg id="1746">Intermittent allergic rhinitis is defined as occurrence of symptoms for less than 4 days a week or less than 4 weeks.</seg>
<seg id="1747">Persistent allergic rhinitis is defined as the occurrence of symptoms in 4 or more days per week and over 4 weeks.</seg>
<seg id="1748">"" "" "" "as demonstrated on the basis of the overall scores of the questionnaire on quality of life in Rhino-conjunctivitis, Aerius effectively diminishes the burden caused by seasonal allergic rhinitis." "" "" ""</seg>
<seg id="1749">"" "" "" "the chronically idiopathic urticaria was investigated for other forms of urticaria, as the underlying pathophysiology of the different forms is similar and chronic patients can be recruited more easily prospectively." "" "" ""</seg>
<seg id="1750">"" "" "" "since the history of histamine is a causative factor in all the urticaria, it is expected that the symptoms of desloratadin occur in other forms of urticaria; this is confirmed by the recommendations of clinical guidelines." "" "" ""</seg>
<seg id="1751">In two placebo-controlled trials over 6 weeks in patients with chronic idiopathic urticaria Aerius was effective in the improvement of pruritus and the reduction of size and number of paddles at the end of the first dose interval.</seg>
<seg id="1752">"" "" "" "as in other studies with antihistaminika in chronically idiopathic urticaria, the minority of patients who did not react to antihistaminika were excluded from the study." "" "" ""</seg>
<seg id="1753">An improvement of the Juckirritations by more than 50% was observed in 55% of patients treated with desloratadin compared to 19% of patients treated with placebo.</seg>
<seg id="1754">"" "" "" "the treatment with Aerius reduced the disorder of sleep and waking, as measured by a 4-point scale to evaluate these variables." "" "" ""</seg>
<seg id="1755">"" "" "" "in a pharmacokinetic study, in which patients with the general seasonal allergy rhinitis population were comparable, 4% of patients achieved higher concentrations of desloratadin." "" "" ""</seg>
<seg id="1756">"" "" "" "there are no indications for clinically relevant cumulation following a daily application of desloratadin (5- 20 mg), over 14 days." "" "" ""</seg>
<seg id="1757">"" "" "" "however, the enzyme responsible for the metabolism of desloratadin has not yet been identified so that interactions with other medicines are not completely excluded." "" "" ""</seg>
<seg id="1758">Desloratadin does not inhibit CYP3A4 and in-vitro studies have shown that the drug CYP2D6 does not inhibit and neither a substrate nor an inhibitor of the P-glycoproteins.</seg>
<seg id="1759">"" "" "" "in a single dose study with desloratadin at a dose of 7.5 mg, meals (fatty, calorie-rich breakfast) did not affect the availability of desloratadin." "" "" ""</seg>
<seg id="1760">The preclinical studies performed with Desloratadin and Loratadin showed no qualitative or quantitative differences in the toxicity profile of Desloratadin and Loratadin.</seg>
<seg id="1761">"" "" "" "based on the conventional research on safety spatology, toxicity in repeated application, genotoxicity and reproductive toxicity, the preclinical data with desloratadin can no longer detect any particular danger to humans." "" "" ""</seg>
<seg id="1762">"" "" "" "color film (contains lactose monohydrate, hypoglycans, titanium dioxide, macro gol 400, Indigocarmin (E 132)), colourless film (contains hypromless, macro gol 400), carnauba wax, bleached wax." "" "" ""</seg>
<seg id="1763">"" "" "" "Aerius can be taken independently of meals, to relieve the symptoms of allergic rhinitis (including intermittent and persisting allergic rhinitis) and urticaria (see section 5.1)." "" "" ""</seg>
<seg id="1764">The prescribing doctor should be aware that most cases of rhinitis in children under 2 years of infection are caused by an infection (see section 4.4) and that there is no data available which support a treatment of an infectious rhinitis with aerius.</seg>
<seg id="1765">"" "" "" "apart from the exclusion of upper respiratory tract infections or anatomical anomalies, anamnesis, physical examinations and corresponding laboratory and skin tests should play a role." "" "" ""</seg>
<seg id="1766">"" "" "" "about 6% of adults and children between 2 and 11 years of age metabolise desloratadin and experience higher substance exposure (see section 5.2)." "" "" ""</seg>
<seg id="1767">"" "" "" "the safety of Aerius Sirup in children between 2 and 11 years, which is restricted to metabolise, is identical to that of children who are normally metabolic." "" "" ""</seg>
<seg id="1768">"" "" "" "this drug contains saccharose and sorbitol; therefore, patients with hereditary problems of fructose intolerance, glucose-caractose absorption or insufficiency should not use this medicine." "" "" ""</seg>
<seg id="1769">Clinically relevant interactions were not observed in clinical trials involving Aerius tablets in which erythromycin or ketoconazole were administered in addition (see section 5.1).</seg>
<seg id="1770">"" "" "" "in a clinical pharmacological study, the performance-reducing effect of alcohol was not increased while taking Aerius tablets and alcohol (see Section 5.1)." "" "" ""</seg>
<seg id="1771">The overall frequency of adverse events in children between 2 and 11 years was similar to the Aerius Sirup group similar to the placebo group.</seg>
<seg id="1772">In clinical trials involving adults and adolescents in various indications including allergic rhinitis and chronic idiopathic urticaria were reported at the recommended dose 3% more adverse events in patients with Aerius were reported as in patients who were treated with placebo.</seg>
<seg id="1773">"" "" "" "in a multi-dose study involving adults and adolescents, up to 45 mg of desloratadin (nine clinical trials) were administered, no clinically relevant effects were observed." "" "" ""</seg>
<seg id="1774">Children aged between 1 and 11 years old who were eligible for an antihistamine therapy received a daily desloratadindose of 1.25 mg (aged between 1 and 5 years) or 2.5 mg (aged between 6 and 11 years).</seg>
<seg id="1775">"" "" "" "because the course of allergic rhinitis / chronic idiopathic urticaria and the profile of desloratadin in adults and children are similar, the efficacy data of desloratadin in adults can be extrapolated to the children's population." "" "" ""</seg>
<seg id="1776">"" "" "" "as part of a clinical trial with multiple doses of adults and adolescents, in the desloratadin in a dose of up to 20 mg daily for over 14 days, no statistically significant or clinically relevant cardiovascular effect was described." "" "" ""</seg>
<seg id="1777">"" "" "" "in a clinical pharmacological study of adults and adolescents, in the desloratadin in a dose of 45 mg daily (the nine times the clinical dose) was used for ten days in adults, no prolongation of the Qtc interval was shown." "" "" ""</seg>
<seg id="1778">"" "" "" "in controlled clinical trials, at the recommended dosage of 5 mg daily for adults and adolescents no increased frequency of sleepiness compared to placebo." "" "" ""</seg>
<seg id="1779">"" "" "" "for a single daily dose of 7,5 mg, Aerius tablets in adults and adolescents in clinical trials do not affect psychomotics." "" "" ""</seg>
<seg id="1780">"" "" "" "in clinical pharmacological studies in adults, the simultaneous consumption of alcohol was neither an increase in alcohol-induced performance impairment nor an increase in drowsiness." "" "" ""</seg>
<seg id="1781">"" "" "" "in adult and adolescent patients with allergic rhinitis, Aerius tablets were effective in relieving symptoms such as sneezing, nasal secretion and itching of the nose, itching, tears of eyes and itching on the palate." "" "" ""</seg>
<seg id="1782">"" "" "" "as demonstrated on the basis of the overall scores of the questionnaire on quality of life in Rhino-conjunctivitis, Aerius tablets effectively alleviate the caused by seasonal allergic rhinitis." "" "" ""</seg>
<seg id="1783">In two placebo-controlled trials over 6 weeks in patients with chronic idiopathic urticaria Aerius was effective in the improvement of pruritus and the reduction of size and number of paddles at the end of the first dose interval.</seg>
<seg id="1784">The spread of this limited metabolic phenotype was comparable to adults (6%) and children between 2 and 11 years (6%) and in both populations bigger with black (18% adults and 16% children) than in Caucasian (2% adults and 3% children).</seg>
<seg id="1785">Similar pharmacokinetic parameters were observed in a pharmacokinetic multi-dose study with syrup formulation in children between 2 and 11 years with allergic rhinitis that limit metabolise.</seg>
<seg id="1786">The strain (AUC) by Desloratadin was about 6 times higher by Desloratadin and the CMAx approximately 3 to 4times higher with a terminal half-life of about 120 hours.</seg>
<seg id="1787">"" "" "" "there are no indications for clinically relevant active ingredient cumulation, after once daily use of desloratadin (5- 20 mg) for 14 days in adults and adolescents." "" "" ""</seg>
<seg id="1788">"" "" "" "12. in various single dose studies, the efficacy of AUC- and CMAx values of desloratadin in pediatric patients were comparable with those of adults who received desloratadin syrup in a dose of 5 mg." "" "" ""</seg>
<seg id="1789">"" "" "" "however, the enzyme responsible for the metabolism of desloratadin has not yet been identified so that interactions with other medicines cannot be completely excluded." "" "" ""</seg>
<seg id="1790">"" "" "" "Aerius syrup is available in type III Braunglass bottles with a child-safe polypropylene seal with 30, 50, 60, 100, 120, 150, 225 and 300 ml." "" "" ""</seg>
<seg id="1791">"" "" "" "equipped with a rigid, transparent polystyrene measuring spoon, calibrated with 2.5 ml and 5 ml or with a application injector for preparations for application with scaling of 2.5 ml and 5 ml (only for the 150 ml bottle)." "" "" ""</seg>
<seg id="1792">A dose of Aerius Lyophilisate to take once a day in the mouth to relieve the symptoms of allergic rhinitis (including intermittent and persisting allergic rhinitis) and urticaria (see section 5.1).</seg>
<seg id="1793">"" "" "" "immediately prior to the application, the blister has to be carefully opened and the dose of the lyophilisate can be taken for taking without damaging them." "" "" ""</seg>
<seg id="1794">Clinically relevant interactions were not found in the framework of clinical trials involving Aerius tablets in which erythromycin or ketoconazole were additionally applied (see section 5.1).</seg>
<seg id="1795">In clinical trials in various indications including allergic rhinitis and chronic idiopathic urticaria were reported at the recommended dose of 5 mg daily 3% more adverse events in patients with Aerius tablets were reported as in patients who were treated with placebo.</seg>
<seg id="1796">"" "" "" "in a multi-dose study, where up to 45 mg of desloratadin (nine-fold clinical dose) were used, no clinically relevant effects were observed." "" "" ""</seg>
<seg id="1797">"" "" "" "in two single dose studies, Aerius's lyophilisate was well tolerated; this was documented by clinical laboratory results, medical examinations, vital signs and ECG interval data." "" "" ""</seg>
<seg id="1798">"" "" "" "as part of a clinical trial with multiple doses in which desloratadin was used for over 14 days a day, no statistically significant or clinically relevant cardiovascular effect was described." "" "" ""</seg>
<seg id="1799">"" "" "" "in a clinical pharmacological study, in the desloratadin in a dose of 45 mg daily (the nine times the clinical dose) was applied for ten days, no prolongation of the Qtc interval was shown." "" "" ""</seg>
<seg id="1800">"" "" "" "in controlled clinical trials, no increased frequency of drowsiness was found at the recommended dose of 5 mg daily compared to placebo." "" "" ""</seg>
<seg id="1801">"" "" "" "in a 17 single dose study involving adults, desloratadin showed no influence on standard measuring parameters of flight performance, including amplification of subjective drowsiness or the tasks associated with flying." "" "" ""</seg>
<seg id="1802">"" "" "" "in patients with allergic rhinitis, Aerius tablets were effective in relieving symptoms such as sneezing, nasal secretion and itching of the nose, itching, tearing and redness of the eyes as well as itching on the palate." "" "" ""</seg>
<seg id="1803">"" "" "" "as demonstrated on the basis of the overall scores of the questionnaire on quality of life in Rhino-conjunctivitis, Aerius effectively diminishes the burden caused by seasonal allergic rhinitis." "" "" ""</seg>
<seg id="1804">"" "" "" "18 In a pharmacokinetic study, in which patients with the general seasonal allergy rhinitis population were comparable, 4% of patients achieved higher concentrations of desloratadin." "" "" ""</seg>
<seg id="1805">Food has no significant influence on AUC and CMAx from Aerius Lyophilisate to take while food Tmax of desloratadin from 2.5 to 4 hours and Tmax of 3-OH desloratadin extended from 4 to 6 hours.</seg>
<seg id="1806">Gelatine Mannitol aspartame (E 951) Polacrilin-potassium colorant Opatint red (contains iron (III) -oxid (E 172) and Hypromless (E 464)) aroma Tutti-Frutti Waterproof Citronenic acid</seg>
<seg id="1807">An Aerius 2.5 mg fusion tablet once daily put in the mouth to relieve the symptoms of allergic rhinitis (including intermittent and persisting allergic rhinitis) and urticaria (see section 5.1).</seg>
<seg id="1808">Two Aerius 2.5 mg melted tablets once daily put in the mouth to alleviate the symptoms of allergic rhinitis (including intermittent and persisting allergic rhinitis) and urticaria (see section 5.1).</seg>
<seg id="1809">There is limited experience from clinical trials for efficacy in the application of desloratadin in adolescents aged 12 to 17 years (see Sections 4.8 and 5.1)</seg>
<seg id="1810">"" "" "" "immediately before applying, the blister has to be carefully opened and the dose of the processed tablet is removed without damaging them." "" "" ""</seg>
<seg id="1811">The efficacy and safety of Aerius 2.5 mg of melting tablets in the treatment of children under 6 years of age have not been proven.</seg>
<seg id="1812">The overall incidence of adverse events between the Gloratadine syrup and the placebo group was the same and did not deviate significantly from the safety profile established in adult patients.</seg>
<seg id="1813">"" "" "" "at the recommended dose, Aerius was used as a bioequivalent to the Aerius 5 mg conventional tablets formulation and the aerius 5 mg lyophilisate for the formulation of desloratadin." "" "" ""</seg>
<seg id="1814">"" "" "" "as part of a clinical trial with multiple doses in which desloratadin was used for over 14 days a day, no statistically significant or clinically proven" "" "" ""</seg>
<seg id="1815">"" "" "" "in a single dose study involving adults, desloratadin showed no influence on standard measuring parameters of flight performance, including amplification of subjective drowsiness or the tasks associated with flying." "" "" ""</seg>
<seg id="1816">The spread of this badly-metabolizing phenotype was comparable to adult (6%) and pediatric patients between 2 and 11 years (6%) and under black (adults 18%) and the safety profile of these patients was not different from that of the general population.</seg>
<seg id="1817">"" "" "" "in single dose crossover studies of Aerius fusion tablet with Aerius 5 mg conventional tablets or anerius 5 mg lyophilisate, the formulations were bioequivalent." "" "" ""</seg>
<seg id="1818">"" "" "" "Aerius 2.5 mg tablets were not studied in pediatric patients, but in combination with the dose studies in children, pharmacokinetic data for Aerius melt tablets support the use of the 2.5 mg dosage in children aged 6 to 11." "" "" ""</seg>
<seg id="1819">Food has no significant influence on AUC and CMAx from Aerius Aerius Lyophilisate to take while food Tmax of desloratadin from 2.5 to 4 hours and Tmax of 3-OH desloratadin extended from 4 to 6 hours.</seg>
<seg id="1820">The overall analysis of preclinical and clinical irritation tests for the melting tablet revealed that this formulation is an unlikely risk for local irritations in clinical use.</seg>
<seg id="1821">Microcrystalline Cellulose Prepared Strength Carboxymethylmethacrylate Copolymer (Ph.Eur.) Cropovidon Natrium Hydrogencarbonate Citronenic acid Oxiumdioxide Iron oxide Mannitol Aspartame (E951) Aroma Tutti Frutti</seg>
<seg id="1822">The plastic film made of polyvinyl chloride (PVC) is laminated onto a polyamide (OPA) film which is laminated onto an aluminium foil and laminated onto a polyvinyl chloride (PVC) film.</seg>
<seg id="1823">An Aerius 5 mg fusion tablet once daily put in the mouth to relieve the symptoms of allergic rhinitis (including intermittent and persisting allergic rhinitis) and urticaria (see section 5.1).</seg>
<seg id="1824">"" "" "" "at the recommended dose, Aerius 5 mg fusion tablet proved bioequivalent to the Aerius 5 mg conventional tablets formulation and the aerius 5 mg lyophilisate for reducing desloratadin." "" "" ""</seg>
<seg id="1825">"" "" "" "as part of a clinical trial with multiple doses in which desloratadin was used for over 14 days a day, no statistically significant or clinically relevant cardiovascular effect was described." "" "" ""</seg>
<seg id="1826">"" "" "" "in a 30 single dose study involving adults, desloratadin showed no influence on standard measuring parameters of flight performance, including amplification of subjective drowsiness or the tasks associated with flying." "" "" ""</seg>
<seg id="1827">"" "" "" "in patients with allergic rhinitis, Aerius tablets were effective in relieving symptoms such as sneezing, nasal secretion and itching of the nose, itching, tearing and redness of the eyes as well as itching on the palate." "" "" ""</seg>
<seg id="1828">In single dose crossover studies of Aerius 5 mg fusion tablet with Aerius 5 mg conventional tablets or Aerius 5 mg lyophilisate for intake the formulations were bioequivalent.</seg>
<seg id="1829">The overall analysis of preclinical and clinical irritation tests for the melting tablet revealed that this formulation is an unlikely risk for local irritations in clinical use.</seg>
<seg id="1830">"" "" "" "the safety of desloratadin in children between 2 and 11 years, which is restricted to metabolise, is identical to that of children who are normally metabolic." "" "" ""</seg>
<seg id="1831">"" "" "" "this drug contains sorbitol; therefore, patients with hereditary problems of fructose intolerance, glucose-caractose absorption or sucroase isomaltase insufficiency should not use this medicine." "" "" ""</seg>
<seg id="1832">The overall incidence of adverse events in children between 2 and 11 years was similar to the disloratadin group similar to the placebo group.</seg>
<seg id="1833">"" "" "" "for infants between 6 and 23 months, the most common adverse events reported more frequently than in the placebo (3.7%), fever (2.3%) and insomnia (2.3%)." "" "" ""</seg>
<seg id="1834">"" "" "" "in an additional study, a single dose of 2.5 mg of desloratadin solution for taking no adverse events in patients between 6 and 11 years was observed." "" "" ""</seg>
<seg id="1835">"" "" "" "at the recommended doses, the plasma concentrations of desloratadin (see section 5.2) were comparable to child and adult population." "" "" ""</seg>
<seg id="1836">"" "" "" "in controlled clinical trials, at the recommended dosage of 5 mg daily for adults and adolescents no increased frequency of sleepiness compared to placebo." "" "" ""</seg>
<seg id="1837">"" "" "" "in addition to the established classification in seasonal and perennial, allergic rhinitis may alternatively also occur in intermittent allergic rhinitis depending on the duration of the symptoms." "" "" ""</seg>
<seg id="1838">"" "" "" "as demonstrated on the basis of the overall scores of the questionnaire on quality of life in Rhino-conjunctivitis, Aerius tablets effectively reduce the burden caused by seasonal allergic rhinitis." "" "" ""</seg>
<seg id="1839">The spread of this limited metabolic phenotype was comparable to adults (6%) and children between 2 and 11 years (6%) and in both populations bigger with black (18% adults and 16% children) than in Caucasian (2% adults and 3% children).</seg>
<seg id="1840">"" "" "" "since the Aerius solution contains the same concentration of desloratadin, no bio equivalence study was required and it is expected that it meets the syrup and the tablets." "" "" ""</seg>
<seg id="1841">"" "" "" "in different single dose studies, the efficacy of AUC- and CMAx values of desloratadin in pediatric patients were comparable with those of adults who received desloratadin syrup in a dose of 5 mg." "" "" ""</seg>
<seg id="1842">"" "" "" "Sorbitol, propylene glycol, Sucralite E 955, hypoallerite E 2910, sodium citrate 2 H2O, natural and artificial flavours (bubble gum), water-free citron acid, sodium edetate (Ph.Eur.), purified water." "" "" ""</seg>
<seg id="1843">"" "" "" "Aerius solution for intake is offered with 30, 50, 60, 100, 120, 150, 225 and 300 ml in type III Braunglass bottles with a child-safe screw cap with a multi-layer polyethylene coating." "" "" ""</seg>
<seg id="1844">"" "" "" "all packet sizes, except the 150 ml package size, are provided with a measuring spoon with markers for dosage of 2.5 ml and 5 ml." "" "" ""</seg>
<seg id="1845">"" "" "" "the 150 ml package size is a measuring spoon, or an application injector for preparations for application with scaling of 2.5 ml and 5 ml." "" "" ""</seg>
<seg id="1846">"" "" "" "following the approval of the approval, the authorisation holder will submit the regularly updated reports on the harmlessness of a drug every two years unless there is something different from the CHMP." "" "" ""</seg>
<seg id="1847">"" "" "" "1 film tablet, 2 film trays, 10 movie trays, 20 movie trays, 50 movie trays, 50 movie trays, 100 movie tablets" "" "" ""</seg>
<seg id="1848">"" "" "" "1 film tablet, 2 film trays, 10 movie trays, 20 movie trays, 50 movie trays, 50 movie trays, 100 movie tablets" "" "" ""</seg>
<seg id="1849">Syrup 30 ml with 1 measuring spoon of 60 ml with 1 measuring spoonful of 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 300 ml with 1 measuring spoon.</seg>
<seg id="1850">30 ml with 1 measuring spoonful of 50 ml with 1 measuring spoonful of 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 300 ml with 1 measuring spoon</seg>
<seg id="1851">1 dose of lyophilisate to intake 2 doses of lyophilisate to take in the intake of 21 doses of lyophilisate for the intake of 21 doses of lyophilisate for taking over 30 doses of lyophilisate for taking over 100 cans of lyophilisate to take up 100 doses of lyophilisate.</seg>
<seg id="1852">"" "" "" "5 melting tablets, 10 melt tablets, 20 melt tablets, 50 melt tablets, 50 melt tablets" "" "" ""</seg>
<seg id="1853">Solution for intake 30 ml with 1 measuring spoon 60 ml with 1 measuring spoonful of 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 300 ml with 1 measuring spoon.</seg>
<seg id="1854">"" "" "" "during pregnancy and lactation, ask your doctor or pharmacist for advice during pregnancy and lactation." "" "" ""</seg>
<seg id="1855">"" "" "" "transport tightness and operation of machines In the recommended dosage, it is not expected that Aerius will lead to dizziness or decrease the attention." "" "" ""</seg>
<seg id="1856">"" "" "" "if you have been told by your doctor that you have an intolerance against certain sugars, consult your doctor before you take this medicine." "" "" ""</seg>
<seg id="1857">"" "" "" "regarding the duration of treatment, your doctor will determine the type of allergic rhinitis you suffer and will then determine how long you should take Aerius." "" "" ""</seg>
<seg id="1858">"" "" "" "if your allergic rhinitis is intermittent (the symptoms will occur less than 4 weeks per week or less than 4 weeks), your doctor will recommend you a treatment scheme that depends on your illness." "" "" ""</seg>
<seg id="1859">"" "" "" "if your allergic rhinitis is persistent (the symptoms may occur in 4 or more days per week and more than 4 weeks), your doctor may recommend you a longer lasting treatment." "" "" ""</seg>
<seg id="1860">"" "" "" "if you forgot taking Aerius if you forgot to take your dose in time, take it as soon as possible and then follow the normal treatment schedule again." "" "" ""</seg>
<seg id="1861">"" "" "" "71 After the introduction of Aerius was very rarely reported about cases of severe allergic reactions (difficulty breathing, whistling breathing, itching, hives and swelling) and rash." "" "" ""</seg>
<seg id="1862">"" "" "" "over cases of palpitations, heart hunting, abdominal pain, nausea, vomiting, stomach upset, diarrhea, dizziness, ansomnia, muscle pains, hallucinations, diarrhea, and unusual liver function is also very seldom reported." "" "" ""</seg>
<seg id="1863">"" "" "" "tablet coating consists of coloured film (contains lactose monohydrate, hypromless, titanium dioxide, macro gol 400), colorless film (contains hypoderless, macro gol 400), carnauba wax, bleached wax." "" "" ""</seg>
<seg id="1864">"" "" "" "Aerius 5 mg film tablets are packaged individually in blister packs with 1, 2, 3, 5, 7, 10, 15, 20, 30, 50, 90 or 100 tablets." "" "" ""</seg>
<seg id="1865">"" "" "" "Aerius Sirup is indicated for children aged 1-11, adolescents (12 years and older) and adults, older people included." "" "" ""</seg>
<seg id="1866">"" "" "" "important information about certain other ingredients of Aerius you should not take Aerius Sirup, if you are allergic to the dye E 110." "" "" ""</seg>
<seg id="1867">"" "" "" "if your doctor tells you that you have a intolerance to some sugars, consult your doctor before taking this medicine." "" "" ""</seg>
<seg id="1868">"" "" "" "when the syrup is attached to the application with scaling, you can alternatively use it to take the appropriate amount of syrup." "" "" ""</seg>
<seg id="1869">"" "" "" "regarding the duration of treatment, your doctor will determine the type of allergic rhinitis you suffer and will then determine how long you should take Aerius syrup." "" "" ""</seg>
<seg id="1870">"" "" "" "however, in children under 2 years diarrhoea, fever and insomnia were frequent side effects, while in adults fatigue, mouth-drought and headaches were reported more often than placebo." "" "" ""</seg>
<seg id="1871">"" "" "" "after the introduction of Aerius was very rarely reported about cases of severe allergic reactions (difficulty breathing, whistling breathing, itching, hives and swelling) and rash." "" "" ""</seg>
<seg id="1872">"" "" "" "77 Aerius syrup is available in bottles with a childproof cap with 30, 50, 60, 100, 120, 150, 225 and 300 ml." "" "" ""</seg>
<seg id="1873">"" "" "" "Aerius Lyophilisate improves symptoms of allergic rhinitis (inflammation of nasal passages caused by allergy), such as hay fever or house dust mite allergy." "" "" ""</seg>
<seg id="1874">Taking Aerius Lyophilisate to take along with food and drinks Aerius Lyophilisate does not need to be taken with water or other liquids.</seg>
<seg id="1875">"" "" "" "regarding the duration of treatment, your doctor will determine the type of allergic rhinitis you suffer and will then determine how long you should take Aerius Lyophilisate." "" "" ""</seg>
<seg id="1876">"" "" "" "81 If you forgot taking Aerius Lyophilisate to take your dose in time, take it as soon as possible and then follow the normal treatment schedule again." "" "" ""</seg>
<seg id="1877">"" "" "" "after the introduction of Aerius was very rarely reported about cases of severe allergic reactions (difficulty breathing, whistling breathing, itching, hives and swelling) and rash." "" "" ""</seg>
<seg id="1878">"" "" "" "Aerius Lyophilisate for intake is packaged singly in blister packs with 1, 2, 3, 5, 7, 10, 15, 20, 21, 30, 50 or 100 cans of the lyophilisate." "" "" ""</seg>
<seg id="1879">"" "" "" "Aerius Melting tablet improves symptoms of allergic rhinitis (allergic inflammation of nasal passages, such as hay fever or house dust mite allergy)." "" "" ""</seg>
<seg id="1880">"" "" "" "when taking Aerius fusion tablet together with food and drinks, Aerius Melting tablet does not need to be taken with water or another liquid." "" "" ""</seg>
<seg id="1881">"" "" "" "regarding the duration of treatment, your doctor will determine the type of allergic rhinitis you suffer and will then determine how long you should take Aerius Melting tablets." "" "" ""</seg>
<seg id="1882">"" "" "" "86 If you forgot taking Aerius Melting tablet if you forgot to take your dose in time, take it as soon as possible and then follow the normal treatment schedule again." "" "" ""</seg>
<seg id="1883">"" "" "" "Aerius Melting tablet is individually packaged in blister packs of 5, 6, 10, 12, 15, 18, 20, 30, 50, 60, 90 and 100 cans." "" "" ""</seg>
<seg id="1884">"" "" "" "when taking Aerius fusion tablet together with food and drinks, Aerius Melting tablet does not need to be taken with water or another liquid." "" "" ""</seg>
<seg id="1885">"" "" "" "if you forgot taking Aerius Melting tablet if you forgot to take your dose in time, take it as soon as possible and then follow the normal treatment schedule again." "" "" ""</seg>
<seg id="1886">"" "" "" "after the introduction of Aerius was very rarely reported about cases of severe allergic reactions (difficulty breathing, whistling breathing, itching, hives and swelling) and rash." "" "" ""</seg>
<seg id="1887">"" "" "" "Aerius solution for intake is indicated for children between 1 and 11 years, adolescents (12 years and older) and adults, older people included." "" "" ""</seg>
<seg id="1888">"" "" "" "if the solution for taking up an application injector for preparations for setting up with scaling, you can use this alternative to take the appropriate amount of solution." "" "" ""</seg>
<seg id="1889">"" "" "" "regarding the duration of treatment, your doctor will determine the type of allergic rhinitis you suffer and will then determine how long you should take Aerius solution for taking." "" "" ""</seg>
<seg id="1890">"" "" "" "however, in children under 2 years diarrhoea, fever and insomnia were frequent side effects while adults fatigue, mouth-drought and headaches were reported more often than placebo." "" "" ""</seg>
<seg id="1891">"" "" "" "97 Aerius solution for intake is available in bottles with childproof closing cap with 30, 50, 60, 100, 120, 150, 225 and 300 ml." "" "" ""</seg>
<seg id="1892">"" "" "" "the 150 ml package size is a measuring spoon, or an application injector fût preparations for accepting 2.5 ml- and 5 ml dosages." "" "" ""</seg>
<seg id="1893">June 2008 Novartis Vaccines and Diagnostics S.r.l. acknowledged the Committee for Medicinal Products (CHMP) for the approval of Aflunov for the prevention of aviary H5N1 Influenza in adults and elderly people.</seg>
<seg id="1894">Aflunov should be used in adults and elderly people for protection against influenza caused by the strain (type) H5N1 of the influenza A virus.</seg>
<seg id="1895">This is a special type of vaccine that should protect against a strain of the flu virus that could cause a future pandemic.</seg>
<seg id="1896">"" "" "" "a flu pandemic breaks out when a new strain of the flu virus appears, which can easily be spread from humans to humans, because humans have no immunity (no protection) against it." "" "" ""</seg>
<seg id="1897">"" "" "" "after the vaccine is administered, the immune system recognises the parts of the flu virus as" "" "" "" "alien" "" "" "" "and forms antibodies against it." "" "" ""</seg>
<seg id="1898">"" "" "" "as a result, the immune system is able to train fast antibodies in a contact with a flu virus." "" "" ""</seg>
<seg id="1899">"" "" "" "subsequently, the membrane cover of the virus with the" surface antigens "(proteins on the membrane surface that recognizes the human body as alien) is purified and used as a component of the vaccine." "" "" ""</seg>
<seg id="1900">An inspection of some of the study centres showed that the study was not carried out in accordance with the "good clinical practice" (GCP).</seg>
<seg id="1901">"" "" "" "as a result, the scope of the clinical data base was not sufficient to evaluate the safety of the vaccine, in order to meet the requirements of the EMEA guidelines for preventive vaccines." "" "" ""</seg>
<seg id="1902">"" "" "" "should you take part in a clinical examination and need further information about your treatment, please contact your doctor." "" "" ""</seg>
<seg id="1903">"" "" "" "for more information on the basis of the CHMP recommendations, please read the scientific discussion (also included in EPAR)." "" "" ""</seg>
<seg id="1904">It is used in combination with other antiviral medicines used to treat adults and children over four years using the human immunodeficiency virus type 1 (HIV-1) which causes the acquired immunodeficiency syndrome (AIDS).</seg>
<seg id="1905">"" "" "" "for patients who cannot swallow the capsules, Agenerase is available as a solution, but this cannot be taken along with Ritonavir as the safety of this combination has not been studied." "" "" ""</seg>
<seg id="1906">"" "" "" "Agenerase should be prescribed only if the doctor has examined the antiviral drugs used by the patient before, and the likelihood that the virus is addressed to the medicine." "" "" ""</seg>
<seg id="1907">"" "" "" "the recommended dose for patients over twelve years is 600 mg twice a day, which are taken together with twice daily 100 mg of Ritonavir and other antiviral medicines." "" "" ""</seg>
<seg id="1908">"" "" "" "for children between four and twelve years and in patients with a body weight of less than 50 kg, the recommended dose of Agenerase is based on body weight." "" "" ""</seg>
<seg id="1909">"" "" "" "in combination with other antiviral medicines, Agenerase decreases the HIV quantity in the blood and keeps it at a low level." "" "" ""</seg>
<seg id="1910">"" "" "" "aids can not cure AIDS, but can delay the damage of the immune system and thus also the development of associated infections and illnesses." "" "" ""</seg>
<seg id="1911">"" "" "" "in combination with other antiviral medicines, Agenerase was studied in two main studies with 736 HIV infected adults who had previously not been treated with protease inhibitors." "" "" ""</seg>
<seg id="1912">"" "" "" "the medicine Agenerase, which was used with low dose, was compared to other protease inhibitors in 206 adults who used to take proteasinhibitors." "" "" ""</seg>
<seg id="1913">"" "" "" "the main indicator of efficacy was the proportion of patients with non-demonstrable concentrations of HIV in the blood (viral load), or the changes in the viral load after treatment." "" "" ""</seg>
<seg id="1914">"" "" "" "in the studies with patients who had previously not taken proteasinhibitors, more patients had a viral load less than 400 copies / ml than placebo, but Agenerase was less effective than indinavir." "" "" ""</seg>
<seg id="1915">"" "" "" "in children, Agenerase also reduced the viral load, but only very few of the children who had previously been treated with protease inhibitors." "" "" ""</seg>
<seg id="1916">"" "" "" "in the study with adults treated earlier with proteasinhibitors, the medicines Agenerase strengthened the viral load after 16-week treatment as effectively as other proteasinhibitors:" "" "" ""</seg>
<seg id="1917">"" "" "" "in the patients with HIV, which was resistant to four other proteasinhibitors, there was a more severe decrease in the viral load after four weeks compared to the patients who continued their previous Proteasinhibitors:" "" "" ""</seg>
<seg id="1918">"" "" "" "the most common side effects of Agenerase (observed in more than 1 out of 10 patients) are headaches, diarrhoea, nausea, vomiting, rash and fatigue (fatigue)." "" "" ""</seg>
<seg id="1919">"" "" "" "2 / 3 Agenerase may not be applied to patients, who may be hypersensitive to amniotic or any of the other ingredients." "" "" ""</seg>
<seg id="1920">"" "" "" "asgenerase may also not be used in patients, including currants (a herbal supplement for treating depression) or medicines which are broken down in the same way as amemase and are harmful to health in high blood concentrations." "" "" ""</seg>
<seg id="1921">"" "" "" "as with other medicines against HIV, there is a risk of a lipodystrophy (changes in the distribution of body fat), osteoarthritis (symptoms of infection caused by the recovery of the immune system)." "" "" ""</seg>
<seg id="1922">The Committee for Medicinal Products (CHMP) concluded that the benefits of Agenerase in combination with other antiretroviral medicines used to treat HIV-1 infected adults and children over four years compared to the risks.</seg>
<seg id="1923">"" "" "" "asgenerase is usually taken together with the pharmacokinetic amplifier Ritonavir, but the committee found that the benefits of amoases in combination with Ritonavir were not detected." "" "" ""</seg>
<seg id="1924">"" "" "" "asgenerase was originally licensed under extraordinary circumstances, as limited information was available at the time of approval for scientific reasons." "" "" ""</seg>
<seg id="1925">"" "" "" "October 2000, the European Commission granted Glaxo Group Limited approval for the placing of amals across the European Union." "" "" ""</seg>
<seg id="1926">"" "" "" "in combination with other antiretroviral medicines used to treat HIV-1 infected, proteasinhibitors (PI) -pretreated adults and children from 4 years onwards." "" "" ""</seg>
<seg id="1927">"" "" "" "usually, nasazure capsules for pharmacokinetic boosters should be administered along with low doses of Ritonavir (see Sections 4.2 and 4.5)." "" "" ""</seg>
<seg id="1928">The use of ammonites should take place in consideration of the individual viral resistance pattern and the pretreatment of the patient (see Section 5.1).</seg>
<seg id="1929">The bioavailability of ammonites as a solution for intake is 14% less than from amateavir as a capsule; therefore nasgenerase capsules and solution for intake on a milligram per milligram base are not interchangeable (see paragraph 5.2).</seg>
<seg id="1930">"" "" "" "the recommended dose for Agenerase capsules is 600 mg of amateavir twice a day along with 100 mg of Ritonavir, twice a day in combination with other antiretroviral medicines." "" "" ""</seg>
<seg id="1931">"" "" "" "2 If nasacriase capsules are applied without the intensifying additive of kronavir (boosters), higher doses must be applied to asgenerase (1200 mg twice daily)." "" "" ""</seg>
<seg id="1932">The recommended dose for Agenerase Capsules is 20 mg of amonavir / kg bodyweight twice a day in combination with other antiretroviral medicines up to a daily maximum of 2400 mg of ammonite that should not be exceeded (see section 5.1).</seg>
<seg id="1933">"" "" "" "pharmacokinetics, efficacy and safety of acrease in combination with low doses of Ritonavir or other proteasants were not studied in children." "" "" ""</seg>
<seg id="1934">"" "" "" "Agenerase is not recommended for use in children under 4 years of age, due to lack of data for safety and efficacy (see Section 5.2)." "" "" ""</seg>
<seg id="1935">"" "" "" "based on pharmacokinetic data, the dose of Agenerase capsules in adult patients with moderate liver dysfunction should be reduced to 450 mg twice daily and in patients with severe liver dysfunction at 300 mg twice daily." "" "" ""</seg>
<seg id="1936">"" "" "" "in patients with severe liver dysfunction, it is contraindicated in patients with severe liver dysfunction (see Section 4.3)." "" "" ""</seg>
<seg id="1937">Acrease may not be given simultaneously with medicines that have a low therapeutic width and also present substrates of the Cytochrome P450-Isoenzyme 3A4 (CYP3A4).</seg>
<seg id="1938">Herbal preparations containing St. John's wort (Hypericum perforatum) may not be applied because of the risk of reduced plasma concentrations and a reduced therapeutic effect of ammonites during the ingestion of ammonites (see section 4.5).</seg>
<seg id="1939">Patients should be advised that amoase or any other antiretroviral therapy does not lead to a cure of HIV infection and that they can continue to develop opportunistic infections or other complications of HIV infection.</seg>
<seg id="1940">"" "" "" "the current antiretroviral therapy, including treatment with asgenerase, does not prevent the risk of transmission from HIV to others through sexual contact or contamination with blood." "" "" ""</seg>
<seg id="1941">"" "" "" "usually, Agenerase capsules should be used together with low doses of Ritonavir and in combination with other antiretroviral medicines (see section 4.2)." "" "" ""</seg>
<seg id="1942">Patients suffering from chronic hepatitis B or C and treated with antiretroviral combination therapies have an increased risk of severe liver side effects with potentially fatal course.</seg>
<seg id="1943">"" "" "" "for a simultaneous antiviral treatment of hepatitis B or C, please refer to the specialist information for this medicine." "" "" ""</seg>
<seg id="1944">"" "" "" "patients with pre-existing liver function, including chronic hepatitis, show an increased frequency of liver dysfunction under an antiretroviral combination therapy and should be monitored according to clinical practice." "" "" ""</seg>
<seg id="1945">Simultaneous use of Agenerase and Ritonavir with fluticason or other glucocosteroids that are metabolized via CYP3A4 is not recommended unless the possible benefits of treatment outweigh the risk of systemic corticosteroid effects including Morbus Cushing and Suppression of the adrenal function (see section 4.5).</seg>
<seg id="1946">Since the metabolism of the HMG-CoA-reductase inhibitor Lovastatin and Simvastatin strongly dependent on CYP3A4 a simultaneous administration of amnasal and Simvastatin is not recommended because of the increased risk of myopathies including Rhabdomyolysis.</seg>
<seg id="1947">"" "" "" "4 For some medicines that can cause serious or life-threatening adverse effects, such as carbamazepine, phenytoin, tricyclic antidepressants and warfarin (under supervision of the International Norised Ratio), methods for determining the concentration of active substances are available." "" "" ""</seg>
<seg id="1948">"" "" "" "for patients who use this medicine at the same time, amoases can be less effective because of reduced plasma levels of ammonites (see section 4.5)." "" "" ""</seg>
<seg id="1949">"" "" "" "because of the possibility of metabolic interactions with ammonites, the efficacy of hormonal contraceptives can be altered, however, the information is not sufficient to assess the kind of interactions." "" "" ""</seg>
<seg id="1950">"" "" "" "if methadone is given simultaneously with ammonites, the patients should therefore be monitored at opium withdrawal symptoms, especially if there are even low doses of kronavir." "" "" ""</seg>
<seg id="1951">"" "" "" "because of the possible risk of toxicity due to the high propylglycolcontent of the Agenerase solution, this formulation is contraindicated in children under an age of four years and should be used with caution in certain other patient populations." "" "" ""</seg>
<seg id="1952">"" "" "" "if a rash of systemic or allergic symptoms is accompanied or the mucous membranes are involved (see section 4.8), Agenerase should be suspended for a duration of 5." "" "" ""</seg>
<seg id="1953">"" "" "" "patients receiving antiretroviral therapy including proteasinhibitors were reported on the occurrence of diabetes mellitus, hyperglycemia or an existing diabetes mellitus." "" "" ""</seg>
<seg id="1954">"" "" "" "many of the patients had other diseases that were needed to therapy drugs, which were associated with the development of diabetes mellitus or hyperglycemia." "" "" ""</seg>
<seg id="1955">"" "" "" "B. a higher age, and associated with drug dependent factors, such as prolonged antiretroviral treatment and associated metabolic disorders." "" "" ""</seg>
<seg id="1956">"" "" "" "in hemophilic patients (Type A and B) treated with proteasinhibitors, reports about an increase in bleeding including spontaneous cutaneous hematomas and hemorrhosis occur." "" "" ""</seg>
<seg id="1957">"" "" "" "at the time of initiating an antiretroviral combination therapy (ART), HIV-infected patients can develop inflammatory responses to asymptomatic or residual opportunistic infections leading to severe clinical conditions or worsening of symptoms." "" "" ""</seg>
<seg id="1958">"" "" "" "although a multifactorial ethology was adopted (including application of corticosteroids, alcohol use, heavy immunosuppression, higher body mass index), cases of osteoarthritis were reported in particular in patients with advanced HIV disease and / or long-term use of an antiretroviral combination therapy (ART)." "" "" ""</seg>
<seg id="1959">CYP3A4 substrates with low therapeutic width can not be given simultaneously with medicines that have a low therapeutic width and also present substrates of the Cytochrome P450-Isoenzyme 3A4 (CYP3A4).</seg>
<seg id="1960">CYP2D6 substrates with low therapeutic width asgenerase may not be combined with medicines whose agents are metabolized mainly via CYP2D6 and are associated with serious and / or life-threatening side effects.</seg>
<seg id="1961">"" "" "" "it has been shown that Rifampicin causes a 82% reduction in AUC of ammonites, which can lead to a virological failure and resistance development." "" "" ""</seg>
<seg id="1962">"" "" "" "in attempting to compensate the dehumed plasma levels by a dose increase of other protease inhibitors in combination with Ritonavir, adverse reactions to the liver were frequently observed." "" "" ""</seg>
<seg id="1963">Johanniskraut (Hypericum perforatum) The serum levels of ammonites can be degraded by the simultaneous application of herbal preparations with Johanniskraut (Hypericum perforatum).</seg>
<seg id="1964">"" "" "" "if a patient has already enrolled Johanniskraut, the ammonia virus and, if possible, to check the viral load and reduce the St. John's wort." "" "" ""</seg>
<seg id="1965">A dose adjustment for one of the medicines is not necessary if nelfinavir is administered together with ammonium avir (see also Efavirenz below).</seg>
<seg id="1966">"" "" "" "increased 508%, for CMAx to be reduced by 30% if Ritonavir (100 mg twice daily) was administered in combination with Amoplastic Capsules (600 mg twice daily)." "" "" ""</seg>
<seg id="1967">"" "" "" "in clinical trials, doses of 600 mg of amateavir were twice daily and Ritonavir 100 mg twice daily, demonstrating the efficacy and safety of this treatment scheme." "" "" ""</seg>
<seg id="1968">52% humiliated if ammonite (750 mg twice daily) was administered in combination with Kaletra (400 mg Lopinavir + 100 mg of Ritonavir twice a day).</seg>
<seg id="1969">The Cmin values of Amonavir in the plasma that were achieved with Kaletra (600 mg twice daily) with Kaletra (600 mg twice daily) are approximately 40 to 50% lower than if ammonium avir (600 mg twice daily) is administered twice daily in combination with 100 mg of Ritonavir.</seg>
<seg id="1970">"" "" "" "dosage recommendations for simultaneous administration of ammonites and Kaletra can not be given, however, there is a close monitoring recommended since the efficacy and safety of this combination is not known." "" "" ""</seg>
<seg id="1971">"" "" "" "no pharmacokinetical study was carried out in combination with Didanosin, but due to the antazic component of Didanosin it is recommended that the revenues of Didanosin and Agenerase are at least one hour apart (see Antazida below)." "" "" ""</seg>
<seg id="1972">Therefore in combination with amateavir (600 mg twice daily) and Rittonavir (100 mg twice daily) no dose adjustment is required.</seg>
<seg id="1973">Treatment with Efavirenz in combination with amateavir and saquinavir is not recommended as the exposition of both proteasinhibitors would lower.</seg>
<seg id="1974">The effect of Nevirapin on other proteasants and existing limited data suggests that Nevirapin could possibly sunk the serum concentration of ammonites.</seg>
<seg id="1975">"" "" "" "if these drugs should be used at the same time, caution is advisable since Delaviris could be less effective because of the reduced or possibly subtherapeutic plasma level." "" "" ""</seg>
<seg id="1976">If these drugs are used together caution is advisable; a thorough clinical and virological monitoring should be carried out since an exact prediction of the effect of the combination of amonavir and Ritonavir on Delavirus is difficult.</seg>
<seg id="1977">The simultaneous application of ammonite and rifabutin lead to an increase in the plasma concentrations (AUC) by Rifabutin by 193% and thus to a rise in the side effects associated with rfabutin.</seg>
<seg id="1978">"" "" "" "when it is necessary for clinical reasons, when it is necessary to administer the variase, a minimum of half of the recommended dose is recommended, although there are no clinical data available for this." "" "" ""</seg>
<seg id="1979">"" "" "" "pharmacokinetic studies in combination with erythromycin were not performed, but the plasma levels of both drugs could be increased in the case of simultaneous administration." "" "" ""</seg>
<seg id="1980">Simultaneous application of twice daily 700mg of Fosamblown avir and 100 mg of ketoconazole with 200 mg of ketoconazole resulted in an increase of the CMAx of ketoconazole in the plasma by 25% and the AUC (0-Cluster) once daily without simultaneous use of Fosamblown avir with Ritonavir.</seg>
<seg id="1981">"" "" "" "other medicines that are listed below, including substrates, inhibitors or inductors from CYP3A4, may result in interactions with Agenerase." "" "" ""</seg>
<seg id="1982">"" "" "" "patients should therefore be monitored for toxic reactions associated with these drugs, when used in combination with asgenerase." "" "" ""</seg>
<seg id="1983">"" "" "" "based on the data of other proteasinhibitors, it is advisable that antacids are not taken at the same time as acrease as it can cause resorption problems." "" "" ""</seg>
<seg id="1984">Simultaneous application of anticonvulsants known as enzyme inductors (phenytoin, phenobarbital and carbamazepine) can lead to degradation of the ammonion plasma level.</seg>
<seg id="1985">"" "" "" "the serum concentrations of calcium channel blockers such as amlodipine, diltiazem, nifedipine, nidipine, nidipine, nidipine, nidipine, nidipine, nifedipine and Verapamil may increase the activity and toxicity of these medicines." "" "" ""</seg>
<seg id="1986">"" "" "" "simultaneous intake with dorase can increase their plasma concentrations and intensify associated side effects including hypotension, vision disorders and priapism associated with PDE5 inhibitors (see section 4.4)." "" "" ""</seg>
<seg id="1987">In a clinical study conducted in the Ritonavir 100 mg capsules twice a day along with 50 µg fluticasonpropionate intranasal (4 times a day) the fluorocasonpropionate plasma levels increased significantly while the endogenous cortisol decreased by about 86% (90% confidence interval 82 to 89%).</seg>
<seg id="1988">"" "" "" "as a result, the simultaneous gift of acrease with kronavir along with these glucocosteroids is not recommended unless the possible benefits of treatment outweigh the risk of systemic corticosteroid effects (see Section 4.4)." "" "" ""</seg>
<seg id="1989">"" "" "" "for HMG-CoA-reductase inhibitors such as Lovastatin and Simvastatin, whose metabolism is strongly dependent on CYP3A4, pronounced increases in the plasma level can be expected at the same time administration of Agenerase." "" "" ""</seg>
<seg id="1990">As plasma increases of these HMG-CoA-reductase inhibitors can lead to myopathy including rhabdomyolysis the combined use of these drugs with ambleavir is not recommended.</seg>
<seg id="1991">"" "" "" "it is recommended for more frequent monitoring of therapeutic concentrations to stabilize the levels, as the plasma concentrations of cyclosporine, rapamycin and tacrolimus can be increased with simultaneous administration of ammonites (see section 4.4)." "" "" ""</seg>
<seg id="1992">"" "" "" "therefore, Agenerase may not be applied together with oral midazolam (see Section 4.3) while caution is advisable while applying Agenerase with parenteral midazolam." "" "" ""</seg>
<seg id="1993">Data on simultaneous use of parenteral midazolam with other proteinase inhibitors point to a possible increase in the plasma level of Midazolam by 3 to 4 faeces.</seg>
<seg id="1994">"" "" "" "if methadone is administered together with ammonites, the patients should therefore be monitored at opium withdrawal symptoms, especially if there are even low doses of kronavir." "" "" ""</seg>
<seg id="1995">"" "" "" "due to the low reliability of historical comparisons, no recommendation is given at the moment, such as the ammonite dose can be adjusted if ammonite is administered simultaneously with methadone." "" "" ""</seg>
<seg id="1996">Simultaneous administration of Varfarin or other oral anticoagulants along with asgenerase is recommended for increased control of the INR (International Norised Ratio) because of the possibility of weakening or reinforcing the antithrombotic effect (see section 4.4).</seg>
<seg id="1997">"" "" "" "the effect of an additional administration of kronavir on hormonal contraceptives is not predictable, therefore alternate methods for contraception are recommended." "" "" ""</seg>
<seg id="1998">Careful monitoring of therapeutic effects and side effects of tricyclic antidepressants (for example desipramine and nortryptilin) is also recommended by Agenerase (see section 4.4).</seg>
<seg id="1999">"" "" "" "during pregnancy, this medicine may only be used after careful weighing of possible benefits for the mother in comparison to the possible risks for the fetus." "" "" ""</seg>
<seg id="2000">"" "" "" "in the milk of lactic rats, ammonite-related substances have been detected, but it is not known if ammonites are transferred into breast milk in humans." "" "" ""</seg>
<seg id="2001">"" "" "" "a reproduction study of vile rats, which was administered by the disarmament in the uterus up to the end of lactation, showed a decreased increase in the 12 body weight during breastfeeding." "" "" ""</seg>
<seg id="2002">"" "" "" "further development of seed, including fertility and reproductive capacity, was not affected by the administration of ammonites to the dam." "" "" ""</seg>
<seg id="2003">The harmlessness of asgenerase was studied in adults and children aged 4 years in controlled clinical trials in combination with different antiretroviral medicines.</seg>
<seg id="2004">"" "" "" "most of the side effects associated with the Agenerase treatment were mild to moderate, early on and rarely lead to treatment rupture." "" "" ""</seg>
<seg id="2005">"" "" "" "in many of these events, it is not clear whether or not they are associated with the intake of Agenerase or another medication used simultaneously for HIV treatment, or whether they are a consequence of the underlying disease." "" "" ""</seg>
<seg id="2006">"" "" "" "most of the side effects mentioned below are two clinical studies (PROAB3001, PROAB3006), in which patients with proteasinhibitors received 1200 mg of Agenerase twice a day." "" "" ""</seg>
<seg id="2007">"" "" "" "events (Grade 2 to 4), which were assessed by the investigators as in connection with the study medication and performed in more than 1% of the patients, as well as the changes occurring in the treatment (Grade 3 to 4)." "" "" ""</seg>
<seg id="2008">Antiretroviral combination therapy was associated with a redistribution of body fat (lipodystrophy) in HIV patients including a loss of peripheral and bilateral fatty tissue; increased intraabdominal and visceral adipose tissue (hypertension) and dorsocervical fat accumulation.</seg>
<seg id="2009">"" "" "" "under 113 antiretroviral, not pre-treated subjects treated with ammonia in combination with lamivudin / zidovudin, only one case (Stiernacken) was observed (&lt; 1%)." "" "" ""</seg>
<seg id="2010">In the study PROAB 3006 in 245 NRTI- pre-treated patients under amateavir 7 cases (11%) compared to 27 cases (11%) in 241 patients under Indinavir in combination with different NRTIs over a mean duration of 56 weeks (p &lt; 0.001).</seg>
<seg id="2011">"" "" "" "skin rashes were usually mild to moderate, erythema migrans or makulopapulous nature, with or without itching and spontaneously disappeared during the second treatment week and disappeared spontaneously within two weeks without the treatment with ammonites had to be stopped." "" "" ""</seg>
<seg id="2012">Cases of osteoarthritis were reported in particular in patients with generally known risk factors such as advanced HIV disease or long-term use of an antiretroviral combination therapy (ART).</seg>
<seg id="2013">"" "" "" "at the time of initiating an antiretroviral combination therapy (ART), HIV-infected patients can develop inflammatory responses to asymptomatic or residual opportunistic infections (see Section 4.4)." "" "" ""</seg>
<seg id="2014">With PI pre-treated patients who received 600 mg of amgenerase twice daily along with low-dose Ritonavir (Grade 3 and 4) were comparable; the exception provided increases of triglycerid and CPK levels (Grade 3 and 4) that were observed in patients who received angenerase along with low-dose kritonavir.</seg>
<seg id="2015">"" "" "" "in the case of overdosing, the patient can observe signs of intoxication (see Section 4.8) if necessary, to initiate necessary supporting measures." "" "" ""</seg>
<seg id="2016">Amammavir binds to the active center of HIV-1 protease and thereby prevents the process of viral gene and gag polystyrene with the result of a formation of immature and non infectious viral particles.</seg>
<seg id="2017">Antiviral activity in vitro against HIV-1 IIIB was investigated on acute and chronic lymphoblastic cell lines (MT-4, CEM-CCRF, H9) and peripheral blood lymphocytes.</seg>
<seg id="2018">The 50% Hemmconcentration (IC50) of amateavir is in the range from 0,012 to 0.08 µM in acutely infected cells and is 0.41 µM in chronically infected cells.</seg>
<seg id="2019">The connection between the activity of ammonites against HIV-1 in vitro and the inhibition of HIV-1 replication in humans is not yet defined.</seg>
<seg id="2020">"" "" "" "in the treatment of antiretroviral non-pretreated patients with the currently approved fossil-avir / Ritonavir dosage, the described mutations were rarely observed with proteaseinase inhibitors." "" "" ""</seg>
<seg id="2021">In sixteen out of 434 antiretroviral patients who received 700mg of fossils with 100mg of Ritonavir twice a day in the study ESS100732 a virological failure occurred up to week 48 with 14 isolates genotypically examined.</seg>
<seg id="2022">Genotypic analysis of isolates of 13 out of 14 children in which a virological failure occurred within 59 patients with proteasinhibitors showed resistance patterns that were similar to those in adults.</seg>
<seg id="2023">"" "" "" "L10F / I / V, V11I, I13V, V32V, M36V, I54V, I54V, I54V, V84V, I84V, I84V, I84V, L90M and I93L / M." "" "" ""</seg>
<seg id="2024">In the study APV30003 and its extension APV3005 (700 mg of Fosamblown avir / 100 mg of chionavir twice a day: n = 107) patients with virological failure occurred in patients with virological failure over 96 weeks following the following proteasinhibitors mutations:</seg>
<seg id="2025">Genotypic resistance tests based on genotypic resistance tests can be used to estimate the activity of amateavir / Ritonavir / Ritonavir / Ritonavir in patients with proteasinhibitors-resistant insulates.</seg>
<seg id="2026">The current (July 2006) ANRS-AC-11-algorithm for fossils V32I + 147a / V or I50V or at least 4 of the following mutations L10F + 147a / V; I54A / C / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M /</seg>
<seg id="2027">"" "" "" "the conclusions concerning the relevance of certain mutations or mutation patterns can be subject to additional data, and it is recommended to always extract the current interpretation systems for the analysis of the results of resistance tests." "" "" ""</seg>
<seg id="2028">Phenotypic data analysis systems based on phenotypic resistance tests can be used in conjunction with genotypic data for estimating the activity of amateavir / Ritonavir / Ritonavir in patients with proteasinhibitors-resistant insulates.</seg>
<seg id="2029">Companies that distribute diagnostic resistance tests have developed clinically phenotypical cut-offs (separation points) for FPV / RTV which can be applied to interpret results of a resistance test.</seg>
<seg id="2030">"" "" "" "each of these four with a reduced sensitivity to ammuniavir associated genetic patterns produces a certain cross resistance against Ritonavir, the sensitivity to indinavir, nelfinavir and saquinavir remains in general." "" "" ""</seg>
<seg id="2031">"" "" "" "there are currently data for resistance resistance between ammonites and other proteasants for all 4 types of fossil-resistance pathways, either alone or in combination with other mutations." "" "" ""</seg>
<seg id="2032">On the basis of twenty-five antiretroviral treatment pathways (one of 25 insulates) and sacaviavir / Ritonavir (three out of 25 isolates) and sacaviavir / Ritonavir (three out of 24 isolates) and animal pranayr / Ritonavir (four out of 24 isolates) appear.</seg>
<seg id="2033">"" "" "" "conversely, ammonite retains its activity against some other proteasant-resistant insulates; the preservation of this activity appears to be dependent on the number and type of resistance mutations in the isolates." "" "" ""</seg>
<seg id="2034">Early departing of a failing therapy is recommended to hold the accumulation of a variety of mutations within limits that can affect subsequent treatment adversely.</seg>
<seg id="2035">The proof of the effectiveness of Agenerase in combination with Ritonavir 100 mg twice daily is based on the study PRO30017; a randomised open trial with PI pretreated (600 mg twice daily) and a standard of care (SOC) with a PI mainly with low-dose kritonavir.</seg>
<seg id="2036">"" "" "" "one hundred threescore and sixty (n = 163) patients with proven virus sensitivity to Agenerase, at least one other PI and at least one NRTI were included in the A of PRO30017 study study." "" "" ""</seg>
<seg id="2037">The primary analysis revealed the non-inferiority of APV / Ritonavir versus time-adjusted average changes in the viral load (HIV-1 RNA) in the viral load (HIV-1 RNA) in the plasma after 16 weeks with a non-stop threshold of 0.4log10 copies / ml.</seg>
<seg id="2038">"" "" "" "the evidence of the efficacy of unroasted Agenerase is based on two uncontrolled trials involving 288 HIV infected children aged 2 to 18, of which 152 were treated with PI." "" "" ""</seg>
<seg id="2039">"" "" "" "in the studies, the Agenerase solution was taken twice daily, 20 mg / kg three times a day, 20 mg / kg twice daily and 22.5 mg / kg twice a day, whereby the majority of patients received 20 mg / kg twice a day." "" "" ""</seg>
<seg id="2040">No low-dose Ritonavir was given at the same time; the majority of patients treated with PI had at least one (78%) or two (42%) of the NRTIs administered together with Agenerase.</seg>
<seg id="2041">After 48 weeks approximately 25% of the patients enrolled in the study had a plasma HIV 1 RNA concentration &lt; 10.000 copies / ml and 9% &lt; 400 copies / ml with a median increase in CD4 cell count of 26 cells / mm ³ (n = 74) compared to the baseline.</seg>
<seg id="2042">"" "" "" "19 Based on this data, consideration should be taken into consideration in therapy optimisation with PI pre-treated children of the expected benefits of" "" "" "" "unbridled" "" "" "". "" "" "" ""</seg>
<seg id="2043">"" "" "" "after oral administration, the average duration (max) to the maximum serum concentration of ammonites is approximately 1 to 2 hours for the capsule and approximately 0.5 to 1 hour for the solution." "" "" ""</seg>
<seg id="2044">"" "" "" "increased 508%, for CMAx by 30%, when Ritonavir (100 mg twice daily) was administered together with Amoplastic (600 mg twice daily)." "" "" ""</seg>
<seg id="2045">"" "" "" "the administration of ammonites with a meal leads to a 25% decrease in AUC, but has no effect on the concentration of ammonites 12 hours after dosage (C12)." "" "" ""</seg>
<seg id="2046">"" "" "" "therefore, minimum concentration in the Steady state (Cmin, ss) was unaffected by food intake, although the simultaneous intake of food influences the extent and rate of resorption." "" "" ""</seg>
<seg id="2047">"" "" "" "the apparent distribution volume amounts to approximately 430 l (6 l / kg at a weight of 70 kg) and allows a large distribution volume, as well as an unimpeded penetration of ammonites from the bloodstream into the tissue." "" "" ""</seg>
<seg id="2048">"" "" "" "this change leads to a decrease in the overall concentration of the active substance in the plasma, with the amount of unbound ammunition that represents the active part, probably remains unchanged." "" "" ""</seg>
<seg id="2049">"" "" "" "while absolute concentration of unbound ammunition remains constant, the percentage share of the free active ingredient during the dosing interval varies depending on the overall dosage in the Steady state via the area of CMAx, ss to Cmin, ss." "" "" ""</seg>
<seg id="2050">"" "" "" "therefore, medicines that induce or inhibit CYP3A4 or a substrate of CYP3A4 must be administered with caution when given simultaneously with asgenerase (see Sections 4.3, 4.4 and 4.5)." "" "" ""</seg>
<seg id="2051">"" "" "" "the gift of amgeneric capsules, either 20 mg / kg twice or 15 mg / kg three times a day, leads to a similar daily ammonite exposure as in adults with a dose of 1200 mg twice daily." "" "" ""</seg>
<seg id="2052">"" "" "" "from the solution, ammonite is 14% less bioavailability than from the capsules; therefore, Agenerase Solution and Agenerase capsules are not replaceable on a milligram basis." "" "" ""</seg>
<seg id="2053">"" "" "" "the renal clearance of Ritonavir is also negligible, so the effect of renal dysfunction should be limited to the elimination of ammonites and chionavir." "" "" ""</seg>
<seg id="2054">"" "" "" "these treatment schemes lead to amateavir plasma levels, comparable to those obtained at healthy volunteers after a dose of 1,200 mg of amateavir twice a day without simultaneous use of Ritonavir." "" "" ""</seg>
<seg id="2055">In long-term studies on the carcinogenicity of mice and rats in male animals benigne hepatocellular adenomas occurred in male animals containing the 2.0-times (mice) or 3.8- times (rat) of the human exposure after twice daily gift of 1200 mg amammavir.</seg>
<seg id="2056">"" "" "" "the 21 underlying mechanism for the formation of hepatocellular adenomas and carcinomas was not yet elucidated, and the relevance of these observed effects for humans is unclear." "" "" ""</seg>
<seg id="2057">"" "" "" "however, from the present exposure data on humans, both from clinical trials and the therapeutic application, there was little evidence of the clinical relevance of these findings." "" "" ""</seg>
<seg id="2058">"" "" "" "in a standard battery of In-vivo- and in-vitro Genotoxicity tests, the bacterial reverse mutation tests, mice-lymphom test, microkernel tests on human peripheral lymphocytes, was neither presumed nor genotoxic." "" "" ""</seg>
<seg id="2059">"" "" "" "this liver toxicity can be monitored and detected in the clinical daily life by measuring AST, ALT and the activity of alkaline phosphatase." "" "" ""</seg>
<seg id="2060">"" "" "" "until now, no significant liver toxicity in patients has been observed in clinical trials, neither during oral administration nor after the end of treatment." "" "" ""</seg>
<seg id="2061">"" "" "" "studies on the toxicity of young animals, which were treated from an age of 4 days, showed a high mortality in both the control and the treated animals." "" "" ""</seg>
<seg id="2062">Systemic plasma exposure significantly below (rabbits) or not significantly higher (rats) than the expected exposure under therapeutic dosage in humans however were observed a number of minor changes including thymus ongation and minor skeletal changes that indicate a delayed development.</seg>
<seg id="2063">"" "" "" "24 When Agenerase capsules are applied without the intensifying additive of kronavir (boosters), higher doses of amniase (1200 mg twice daily) must be applied." "" "" ""</seg>
<seg id="2064">The recommended dose for Agenerase Capsules is 20 mg of amonavir / kg bodyweight twice a day in combination with other antiretroviral medicines up to a daily maximum of 2400 mg of ammonite that should not be exceeded (see section 5.1).</seg>
<seg id="2065">"" "" "" "in patients with severe liver dysfunction, it is contraindicated (see Section 4.3)." "" "" ""</seg>
<seg id="2066">"" "" "" "26 For some medicines that can cause serious or life-threatening adverse effects, such as carbamazepine, phenytoin, tricyclic antidepressants and warfarin (under supervision of the International Norised Ratio), methods for determining the concentration of active substances are available." "" "" ""</seg>
<seg id="2067">"" "" "" "Agenerase should be removed in duration 27, if a skin rash is accompanied by systemic or allergic symptoms or the mucous membranes are involved (see section 4.8)." "" "" ""</seg>
<seg id="2068">"" "" "" "an increased risk for a lipodystrophy was associated with individual factors, such as higher age, and drug dependent factors such as a longer lasting antiretroviral treatment and associated metabolic disorders." "" "" ""</seg>
<seg id="2069">"" "" "" "it has been shown that Rifampicin causes a 82% reduction in AUC of ammonites, which can lead to a virological failure and resistance development." "" "" ""</seg>
<seg id="2070">"" "" "" "increased 508%, for CMAx to be reduced by 30% if Ritonavir (100 mg twice daily) was administered in combination with Amoplastic Capsules (600 mg twice daily)." "" "" ""</seg>
<seg id="2071">The Cmin values of Amonavir in the plasma that were achieved with Kaletra (600 mg twice daily) with Kaletra (600 mg twice daily) are approximately 40 to 50% lower than if ammonium avir (600 mg twice daily) is administered twice daily in combination with 100 mg of Ritonavir.</seg>
<seg id="2072">"" "" "" "dosage recommendations for simultaneous administration of ammonites and Kaletra can not be given, however, there is a close monitoring recommended since the efficacy and safety of this combination is not known." "" "" ""</seg>
<seg id="2073">Treatment with Efavirenz in combination with amateavir and saquinavir is not recommended as the exposition of both proteasinhibitors would lower.</seg>
<seg id="2074">If these drugs are used together caution is advisable; a thorough clinical and virological monitoring should be carried out since an exact prediction of the effect of the combination of amonavir and Ritonavir on Delavirus is difficult.</seg>
<seg id="2075">"" "" "" "if it is necessary for clinical reasons, to administer the variutin along with asgenerase, at least half of the recommended dose is recommended, although no clinical data is available for this." "" "" ""</seg>
<seg id="2076">"" "" "" "the serum concentrations of calcium channel blockers such as amlodipine, diltiazem, nifedipine, nidipine, nidipine, nidipine and diapamil can be increased by ammonium, thereby increasing the activity and toxicity of these medicines." "" "" ""</seg>
<seg id="2077">In a clinical study conducted in the Ritonavir 100 mg capsules twice a day along with 50 µg fluticasonpropionate intranasal (4 times a day) the fluorocasonpropionate plasma levels increased significantly while the endogenous cortisol decreased by about 86% (90% confidence interval 82 to 89%).</seg>
<seg id="2078">Simultaneous administration of Varfarin or other oral anticoagulants along with asgenerase is recommended for increased control of the INR (International Norised Ratio) because of the possibility of weakening or reinforcing the antithrombotic effect (see section 4.4).</seg>
<seg id="2079">The simultaneous administration of ortho-novum 1 / 35 (0.035 mg Ethinylestradiol plus 1.0 mg Norethindron) led to a decline in AUC and Cmin of ammonites by 22% or respectively.</seg>
<seg id="2080">"" "" "" "during pregnancy, this medicine may only be used after careful weighing of possible benefits for the mother in comparison to the possible risks for the foetus." "" "" ""</seg>
<seg id="2081">"" "" "" "a reproduction study of vile rats, which was administered by the disarmament in the uterus up to the end of lactation, showed a diminished increase in body weight in posterity." "" "" ""</seg>
<seg id="2082">The harmlessness of asgenerase was studied in adults and children aged 4 years in controlled clinical trials in combination with different antiretroviral medicines.</seg>
<seg id="2083">"" "" "" "in the case of overdosing, the patient can observe signs of intoxication (see Section 4.8) if necessary, to initiate necessary supporting measures." "" "" ""</seg>
<seg id="2084">Antiviral activity in vitro against HIV-1 IIIB was investigated on acute and chronic lymphoblastic cell lines (MT-4, CEM-CCRF, H9) and peripheral blood lymphocytes.</seg>
<seg id="2085">The 50% Hemmconcentration (IC50) of amateavir is in the range from 0,012 to 0.08 µM in acutely infected cells and is 0.41 µM in chronic infected cells (1 µM = 0.50 µg / ml).</seg>
<seg id="2086">"" "" "" "conversely, ammonite retains its activity against some other proteasant-resistant insulates; the preservation of this activity appears to be dependent on the number and type of resistance mutations in the isolates." "" "" ""</seg>
<seg id="2087">"" "" "" "based on these data, the anticipated benefits of" "" "" "" "unbridged" "" "" "" "should be considered in therapy optimisation." "" "" ""</seg>
<seg id="2088">"" "" "" "while absolute concentration of unbound ammunition remains constant, the percentage share of the free active ingredient during the dosing interval varies depending on the overall dosage in the Steady state via the area of CMAx, ss to Cmin, ss.." "" "" ""</seg>
<seg id="2089">"" "" "" "therefore, medicines that induce or inhibit CYP3A4 or a substrate of CYP3A4 must be administered with caution when given simultaneously with asgenerase (see Sections 4.3, 4.4 and 4.5)." "" "" ""</seg>
<seg id="2090">"" "" "" "the renal clearances of Ritonavir are also negligible, therefore the effect of renal dysfunction should be limited to the elimination of ammonites and chionavir." "" "" ""</seg>
<seg id="2091">"" "" "" "in long-term studies on the carcinogenicity of mice and rats, malignant hepatocellular adenomas occurred in male animals, responding to 2.0-times (mice) or 3,8- times (rat) of human exposure after twice daily gift of 1200 mg." "" "" ""</seg>
<seg id="2092">The underlying mechanism for the formation of hepatoo-cellular adenomas and carcinomas was not yet elucidated and the relevance of these observed effects for humans is unclear.</seg>
<seg id="2093">"" "" "" "however, there was little evidence of the clinical relevance of these findings from the present exposure data on humans, both from clinical studies and the therapeutic application." "" "" ""</seg>
<seg id="2094">"" "" "" "in a standard battery of In-vivo- and in-vitro Genotoxicity tests, the bacterial reverse mutation test, mice-lymphom test, microkernel tests on human peripheral lymphocytes, was neither presumed nor genotoxic." "" "" ""</seg>
<seg id="2095">"" "" "" "studies on the toxicity of young animals, which were treated from an age of 4 days, showed a high mortality in both the control and the treated animals." "" "" ""</seg>
<seg id="2096">"" "" "" "these results suggest that the metabolisation routes are not fully mature in young animals, so that amateavir or other critical components of the formulation (z) are excluded." "" "" ""</seg>
<seg id="2097">"" "" "" "in combination with other antiretroviral medicines used to treat HIV-1 infected, proteasinhibitors (PI), adults and children from 4 years old are indicated." "" "" ""</seg>
<seg id="2098">"" "" "" "the benefits of using Ritonavir" "" "" "" "roooster" "" "" "" "solution for inclusion of patients with PI were not treated with PI pretreated patients." "" "" ""</seg>
<seg id="2099">The bioavailability of ammonites as a solution for intake is 14% less than from amateavir as a capsule; therefore nasgenerase capsules and solution for intake on a milligram per milligram base are not interchangeable (see paragraph 5.2).</seg>
<seg id="2100">"" "" "" "patients should, once they are able to swallow the capsules, stop taking the solution (see section 4.4)." "" "" ""</seg>
<seg id="2101">The recommended dose for Agenerase solution is 17 mg (1.1 ml) Amonavir / kg bodyweight three times a day in combination with other antiretroviral medicines up to a daily dose of 2800 mg of amateavir which should not be exceeded (see section 5.1).</seg>
<seg id="2102">"" "" "" "in addition, because no dose recommendation can be given for the simultaneous use of the Agenerase solution for accepting and low-dose knights, this combination can be avoided in these patient populations." "" "" ""</seg>
<seg id="2103">"" "" "" "although a dose adjustment for ammonites is not considered necessary, an application of angenerase solution is contraindicated in patients with kidney failure (see Section 4.3)." "" "" ""</seg>
<seg id="2104">"" "" "" "due to the potential risk of a toxic reaction as a result of high propylene glycolin content, the Agenerase solution is contraindicated in pregnant women, in patients with reduced liver function or liver failure and in patients with kidney failure." "" "" ""</seg>
<seg id="2105">The simultaneous administration may lead to a competitive inhibition of the metabolism of these medicines and potentially cause serious and / or life-threatening adverse effects such as cardiac arrhythmia (z.</seg>
<seg id="2106">Patients should be advised that amoase or any other antiretroviral therapy does not lead to a cure of HIV infection and that they continue to develop opportunistic infections or other complications of HIV infection.</seg>
<seg id="2107">"" "" "" "the current antiretroviral therapy, including treatment with asgenerase, does not prevent the risk of dying from HIV to others through sexual contact or contamination with blood." "" "" ""</seg>
<seg id="2108">"" "" "" "for some medicines that can cause serious or life-threatening adverse effects, such as carbamazepine, phenytoin, tricyclic antidepressants and warfarin (under supervision of the International Norised Ratio), methods for determining the concentration of active substances are available." "" "" ""</seg>
<seg id="2109">"" "" "" "asgenerase should be suspended in the long term, if a skin rash is accompanied by systemic or allergic symptoms or the mucous membranes are involved (see section 4.8)." "" "" ""</seg>
<seg id="2110">"" "" "" "an increased risk for a lipodystrophy was associated with individual factors, such as higher age, and with drugs - 49 dependent factors such as a longer lasting antiretroviral treatment and associated metabolic disorders." "" "" ""</seg>
<seg id="2111">"" "" "" "in hemophilic patients (Type A and B) treated with proteasinhibitors, reports about an increase in bleeding including spontaneous cutaneous hematomas and hemorrhosis occur." "" "" ""</seg>
<seg id="2112">"" "" "" "it has been shown that Rifampicin causes a 82% reduction in AUC of ammonites, which can lead to a virological failure and resistance development." "" "" ""</seg>
<seg id="2113">"" "" "" "increased 508%, for CMAx to be reduced by 30% if Ritonavir (100 mg twice daily) was administered in combination with Amoplastic Capsules (600 mg twice daily)." "" "" ""</seg>
<seg id="2114">"" "" "" "simultaneous intake with dorase can significantly increase their plasma concentrations and lead to associated side effects including hypotension, blurred vision and priapism (see section 4.4)." "" "" ""</seg>
<seg id="2115">"" "" "" "based on the data of 54 other CYP3A4 inhibitors, Midazolam produces significantly higher plasma concentrations of Midazolam." "" "" ""</seg>
<seg id="2116">The potential risk for humans is not known. Agenerase solution for intake may not be used during pregnancy due to possible toxic reactions of the fetus to the contained Propylene glycol (see Section 4.3).</seg>
<seg id="2117">"" "" "" "in the milk of lactic rats, ammonite-related substances have been detected, but it is not known if ammonites are transferred into breast milk in humans." "" "" ""</seg>
<seg id="2118">"" "" "" "a reproduction study of vile rats, which was administered from the insertion into the uterus up to the end of lactation, showed a decreased 55 body weight during breastfeeding." "" "" ""</seg>
<seg id="2119">The harmlessness of asgenerase was studied in adults and children aged 4 years in controlled clinical trials in combination with different antiretroviral medicines.</seg>
<seg id="2120">"" "" "" "in many of these events, it is not clear whether or not they are associated with the intake of Agenerase or another medication used simultaneously for HIV treatment, or whether they are a consequence of the underlying disease." "" "" ""</seg>
<seg id="2121">"" "" "" "in the treatment of antiretroviral non-pretreated patients with the currently approved fossil-avir / Ritonavir dosage, the described mutations were rarely observed with proteaseinase inhibitors." "" "" ""</seg>
<seg id="2122">Early departing of a failing 60 therapy is recommended to hold the accumulation of a variety of mutations within limits that can affect subsequent treatment adversely.</seg>
<seg id="2123">"" "" "" "62 Based on this data, consideration should be taken into consideration in therapy optimisation with PI pre-treated children of the expected benefits of" "" "" "" "unbridled" "" "" "". "" "" "" ""</seg>
<seg id="2124">"" "" "" "the apparent distribution volume amounts to approximately 430 l (6 l / kg at a weight of 70 kg) and can be closed to a large cousin volume, and an unimpeded penetration of ammonites from the bloodstream into the tissue." "" "" ""</seg>
<seg id="2125">"" "" "" "the underlying mechanism for the formation of hepatocellular adenomas and carcinomas was not elucidated, and the relevance of these observed effects for humans is unclear." "" "" ""</seg>
<seg id="2126">Systemic plasma exposure significantly below (rabbits) or not significantly higher (rats) than the expected exposure under therapeutic dosage in humans however were observed a number of minor changes including thymus ongation and minor skeletal changes that indicate a delayed development.</seg>
<seg id="2127">"" "" "" "- If you have any further questions, please contact your doctor or pharmacist." "" "" ""</seg>
<seg id="2128">"" "" "" "if any of the side effects listed you have considerably impaired or you notice side effects that are not stated in this information, please inform your doctor or pharmacist." "" "" ""</seg>
<seg id="2129">"" "" "" "your doctor will usually instruct you to apply Agenerase Capsules along with low doses of knionavir, in order to increase the effect of Agenerase." "" "" ""</seg>
<seg id="2130">"" "" "" "the use of Agenerase will be based on the individual viral resistance test carried out by your doctor, and your treatment history." "" "" ""</seg>
<seg id="2131">Inform your doctor if you are suffering from any of the above conditions or taking any of the above drugs.</seg>
<seg id="2132">"" "" "" "if your doctor has recommended that you take Agenerase Capsules along with low doses of Ritonavir to strengthen the effect (boosters), make sure you have read the use information about Ritonavir before starting treatment." "" "" ""</seg>
<seg id="2133">"" "" "" "also, there is no sufficient information to recommend the use of Agenerase Capsules along with Ritonavir for the efficacy of children aged 4 to 12 years or generally in patients under 50 kg of body weight." "" "" ""</seg>
<seg id="2134">"" "" "" "therefore, it is important that you read the section" When taking Agenerase with other medicines "before you start taking Aregeneration." "" "" ""</seg>
<seg id="2135">"" "" "" "- In patients receiving antiretroviral combination therapy, a redistribution, accumulation or loss of body fat may occur." "" "" ""</seg>
<seg id="2136">"" "" "" "if you can perform certain medicines that can cause serious side effects, such as carbamazepine, phenytoin, lidotoin, rapamycin, tricyclic antidepressants and warfarin, at the same time as Agenerase, your doctor may perhaps carry out additional blood tests to minimize possible security problems." "" "" ""</seg>
<seg id="2137">"" "" "" "it is recommended that HIV positive women should breastfeed their children under any circumstances, in order to avoid the transmission of HIV." "" "" ""</seg>
<seg id="2138">"" "" "" "traffic tightness and operation of machines No studies have been carried out on the impact of the aura on the driving ability, or the ability to operate machinery." "" "" ""</seg>
<seg id="2139">"" "" "" "after consultation with your doctor, please consult your doctor if you are aware that you suffer from a intolerance to certain sugars." "" "" ""</seg>
<seg id="2140">"" "" "" "if you take Didanosin), it is advisable that you take this more than one hour before or after acrease, otherwise the effects of amoases may be diminished." "" "" ""</seg>
<seg id="2141">Dose of Agenerase Capsules is 600 mg twice daily along with 100 mg Ritonavir twice daily in combination with other antiretroviral medicines.</seg>
<seg id="2142">"" "" "" "if your doctor decides that taking Ritonavir is not suitable for you, you will need to take higher doses (1200 mg ammonica twice daily)." "" "" ""</seg>
<seg id="2143">"" "" "" "85 Damit Agenerase benefits as much as possible, it is very important that you take the total daily dose you prescribed for your doctor." "" "" ""</seg>
<seg id="2144">"" "" "" "if you have taken a larger amount of angenerase than you should have taken, if you have taken more than the prescribed dose of Agenerase, you should contact your doctor or pharmacist immediately." "" "" ""</seg>
<seg id="2145">"" "" "" "if you have forgotten taking Aregeneration, take it once you think about it and then continue taking it as before." "" "" ""</seg>
<seg id="2146">"" "" "" "in treating HIV infection, it is not always possible to say whether any side effects can be caused by amusing, by other medicines that are taken simultaneously or by the HIV disease itself." "" "" ""</seg>
<seg id="2147">"" "" "" "headache, fatigue, diarrhea, sickness sensation, vomiting, bloating skin rash (redness, blisters or itching) - occasionally the rash may be serious in nature and force you to stop taking this medicine." "" "" ""</seg>
<seg id="2148">"" "" "" "mood, depression, sleep disorders, loss of appetite tingling in the lips and in the mouth, uncontrollable movements pain, discomfort or overacidic stomach, soft chairs, increase of certain liver enzymes called the pancreas named Amylase" "" "" ""</seg>
<seg id="2149">"" "" "" "elevated blood glucose levels for sugar or cholesterol (a certain blood fat) Increased blood values of a substance called Bilirubin swelling of the face, lips and tongue (angioedema)." "" "" ""</seg>
<seg id="2150">"" "" "" "this can include fat loss on legs, arms and face, fat increase in the abdomen and in other internal organs, breast augmentation and fat growths in the neck (" Stiber ")." "" "" ""</seg>
<seg id="2151">Inform your doctor or pharmacist if any of the side effects listed you have considerably impaired or you notice side effects that are not stated in this use information.</seg>
<seg id="2152">"" "" "" "therefore, it is important that you read the section" When taking Agenerase with other medicines "before you start taking Aregeneration." "" "" ""</seg>
<seg id="2153">"" "" "" "in some patients receiving antiretroviral combination treatment, osteoarthritis (weakening of bone tissue as a result of inadequate blood supply of the bone) may develop bone disease." "" "" ""</seg>
<seg id="2154">"" "" "" "if you take Didanosin), it is advisable that you take this more than one hour before or after acrease, otherwise the effects of amoases may be diminished." "" "" ""</seg>
<seg id="2155">"" "" "" "94 So that Agenerase benefits as much as possible, it is very important that you take the total daily dose you prescribed for your doctor." "" "" ""</seg>
<seg id="2156">"" "" "" "if you have forgotten taking Aregeneration, take it once you think about it and then continue taking it as before." "" "" ""</seg>
<seg id="2157">"" "" "" "headache, fatigue, diarrhea, sickness sensation, vomiting, bloating skin rash (redness, blisters or itching) - occasionally the rash may be serious in nature and force you to stop taking this medicine." "" "" ""</seg>
<seg id="2158">Inform your doctor or pharmacist if any of the side effects listed you have considerably impaired or you notice side effects that are not stated in this use information.</seg>
<seg id="2159">Dose of Agenerase Capsules is 600 mg twice daily along with 100 mg Ritonavir twice daily in combination with other antiretroviral medicines.</seg>
<seg id="2160">"" "" "" "so that Agenerase benefits as much as possible, it is very important that you take the entire daily dose that your doctor has prescribed." "" "" ""</seg>
<seg id="2161">"" "" "" "if you have taken more than the prescribed dose of Agenerase, you should contact your doctor or pharmacist immediately." "" "" ""</seg>
<seg id="2162">"" "" "" "the benefits of the" "" "" "" "biased" "" "" "" "nasolavir" "" "" "" "solution were not covered with proteasinhibitors in pre-treated patients." "" "" ""</seg>
<seg id="2163">"" "" "" "for the application of low doses of kronavir (commonly used to strengthen the effect [boopadding] of asgenerase capsules) together with Agenerase solution for intake, no dosage recommendations can be given." "" "" ""</seg>
<seg id="2164">"" "" "" "use the Ritonavir solution, or use propylenglycol while taking Agenerase solution (see also Agenerase may not be taken)." "" "" ""</seg>
<seg id="2165">"" "" "" "your doctor may observe you possibly on side effects associated with the Propylene glycolcontent of the Agenerase Solution for interfering in, especially if you have kidney or liver illness." "" "" ""</seg>
<seg id="2166">"" "" "" "111 If you can perform certain medicines that can cause serious side effects, such as carbamazepine, phenytoin, lidotoin, rapamycin, tricyclic antidepressants and warfarin, at the same time as Agenerase, your doctor may perhaps carry out additional blood tests to minimize possible security problems." "" "" ""</seg>
<seg id="2167">"" "" "" "kronavir solution (intake) or supplemental glycol, while taking Agenerase (see Agenerase may not be taken)." "" "" ""</seg>
<seg id="2168">"" "" "" "important information about certain other components of the Agenerase solution for intake The solution for intake contains propylene glycol, which can cause side effects in high doses." "" "" ""</seg>
<seg id="2169">"" "" "" "propylenglycol may cause a number of side effects including varicose, dizziness, heart rate and the reduction of the red blood cells (see also Agenerase may not be taken, special precautions are needed)." "" "" ""</seg>
<seg id="2170">"" "" "" "if you have forgotten taking Aregeneration, take it once you think about it and then continue taking it as before." "" "" ""</seg>
<seg id="2171">"" "" "" "headache, fatigue, diarrhea, sickness sensation, vomiting, bloating skin rash (redness, blisters or itching) - occasionally the rash may be serious in nature and force you to stop taking this medicine." "" "" ""</seg>
<seg id="2172">"" "" "" "this can include fat loss on legs, arms and face, fat increase in the abdomen and in other internal organs, breast augmentation and fat growths in the neck (" Stiber ")." "" "" ""</seg>
<seg id="2173">"" "" "" "other ingredients are propylene glycol, methrin 400 (polyethylene glycol 400), acetylenglycol 400, saccharine sodium, natural peppermint aroma, lemonenthol, citric acid, sodium citrate dihydrat, purified water." "" "" ""</seg>
<seg id="2174">The frequency and duration of the treatment with aldara depend on the disease to be treated. • In case of small basal cell carcinomas it is up to 16 weeks to apply five times a week. • In case of small basal cell carcinomas it is repeated five weeks a week during one or two weeks of treatment with four weeks of pause between the treatment cycles.</seg>
<seg id="2175">"" "" "" "before bedtime, the cream is thin-layered onto the affected skin areas so that it remains sufficiently long (about eight hours) on the skin before it is washed." "" "" ""</seg>
<seg id="2176">In all studies Aldara was compared with a placebo (same cream but without the active substance). • Aldara was tested in four main studies at 923 patients with warts in the genital area each for 16 weeks.</seg>
<seg id="2177">The main indicator of efficacy was the number of patients with complete healing of treated warts. • Aldara was also studied in 724 patients with small basal cell carcinomas in two studies in which the patients were treated six weeks or placebo either daily or five times a week.</seg>
<seg id="2178">The main indicator for efficacy was the number of patients with complete healing of tumors after 12 weeks. • Aldara was also tested in two studies involving 505 patients with actinic keratosis.</seg>
<seg id="2179">In all studies Aldara was more effective than the placebo. • The total healing rate in all four main studies was 15% to 52% in patients treated with placebo. • The results of the two studies on basal cell carcinomas demonstrated a complete healing rate of 66% to 80% compared to 0% to 3% in the placebo group.</seg>
<seg id="2180">The most common side effects of aldara (observed in more than 1 out of 10 patients) are reactions to the application point of the cream (pain or itching).</seg>
<seg id="2181">"" "" "" "clinically typical, non hypertrophic, non hypertrophic keratosis (AKs) in the face or on the scalp in immunocompetent adults, if the size or number of lesions limit the effectiveness and / or acceptance of cryotherapy and other topical treatment options are contraindicated or less suitable." "" "" ""</seg>
<seg id="2182">"" "" "" "open Monday, Wednesday and Friday or Tuesday, Thursday and Saturday before bedtime and leave for 6 to 10 hours on the skin." "" "" ""</seg>
<seg id="2183">"" "" "" "the treatment with imiquimod cream can continue until all visible genital warts have disappeared in the genital or pericanal area, or up to a maximum of 16 weeks per treatment period." "" "" ""</seg>
<seg id="2184">"" "" "" "an interruption in the treatment procedure described above should be considered when intensive local inflammatory reactions occur (see section 4.4), or if an infection is observed in the treatment area." "" "" ""</seg>
<seg id="2185">"" "" "" "if during follow-up examination 4 to 8 weeks after the second treatment period, the treated lesions were only completely healed, another therapy should be started (see section 4.4)." "" "" ""</seg>
<seg id="2186">"" "" "" "when a dose is omitted, the patient should apply the cream as soon as he notices it and then proceed with the usual therapy plan." "" "" ""</seg>
<seg id="2187">"" "" "" "apply Imiquimod cream in a thin layer and rub in the cleaned, moistened skin area until the cream is completely covered." "" "" ""</seg>
<seg id="2188">"" "" "" "in these patients, it should take place between the benefits of a treatment with imiquimod and the risk associated with a possible worsening of their autoimmune disease." "" "" ""</seg>
<seg id="2189">"" "" "" "it should take place in these patients between the benefits of a treatment with imiquimod and the risk associated with possible organ rejection, or graft vs. host reaction." "" "" ""</seg>
<seg id="2190">"" "" "" "in other studies, in which no daily prosthesis was performed, two cases of serious phimosis were observed and a case with a stripe leading to circumcision." "" "" ""</seg>
<seg id="2191">For an application of imiquimod cream in higher than the recommended doses there is an increased risk of severe local skin irritation (see section 4.2.) In rare cases heavy local skin irritation (see section 4.2.) In rare cases has also been observed under proper application severe local skin irritation that have made a treatment and / or have led to temporary physical impairment.</seg>
<seg id="2192">"" "" "" "in cases where such reactions occurred at the exit of the urethra, some women had difficulty passing urine which necessitated emergency catheterisation and treatment of the affected area." "" "" ""</seg>
<seg id="2193">"" "" "" "for the use of imiquimod cream immediately following a treatment with other cutaneous means for the treatment of external genital warts in the genital and periphine area, no clinical experiences have occurred." "" "" ""</seg>
<seg id="2194">"" "" "" "limited data may indicate an increased rate of contraction reductions in HIV-positive patients, Imiquimod cream has demonstrated a lower effectiveness in this patient population." "" "" ""</seg>
<seg id="2195">"" "" "" "treatment of basal cell carcinoma with imiquimod within 1 cm around the eyelids, nose, lips, or hair attachment was not examined." "" "" ""</seg>
<seg id="2196">"" "" "" "local skin reactions are common, but the intensity of these reactions generally decreases during therapy or the reactions form after completion of the treatment with imiquimod cream." "" "" ""</seg>
<seg id="2197">"" "" "" "if it is necessary due to the discomfort of the patient or due to the severity of local skin reactions, a treatment break may be made several days." "" "" ""</seg>
<seg id="2198">"" "" "" "after the regeneration of the treated skin, the clinical outcome of the treatment may be judged about 12 weeks after the end of the treatment." "" "" ""</seg>
<seg id="2199">"" "" "" "since there is currently no data available for long-term recovery rates of more than 36 months after the treatment, other suitable forms of therapy should be considered." "" "" ""</seg>
<seg id="2200">"" "" "" "in patients with recurrent and pre-treated BCCs there are no clinical experiences, therefore the application is not recommended for pre-treated cancer." "" "" ""</seg>
<seg id="2201">Data from an open clinical study indicate that there is a lower probability of response to Imiquimod therapy in large tumors (&gt; 7.25 cm2).</seg>
<seg id="2202">"" "" "" "Imiquimod was not investigated for treatment of actinic keratosis on eyelids, inside the nose or the ears or on the lip area within the lip." "" "" ""</seg>
<seg id="2203">"" "" "" "only very limited data are available on the use of imiquimod for treatment of actinic keratoses in anatomical places outside the face, and the scalp." "" "" ""</seg>
<seg id="2204">"" "" "" "the available data on the actinic keratosis on forearms and hands do not support the effectiveness of this application, therefore such an application is not recommended." "" "" ""</seg>
<seg id="2205">"" "" "" "local skin reactions occur frequently, but these reactions usually decrease in intensity in the course of therapy or go back after the treatment with Imiquimod cream." "" "" ""</seg>
<seg id="2206">"" "" "" "if local skin reactions cause great discomfort or are very strong, treatment may be exposed for a few days." "" "" ""</seg>
<seg id="2207">"" "" "" "from the data of an open clinical study, patients with more than 8 minor lesions showed a lower overall healing rate than patients with fewer than 8 lesions." "" "" ""</seg>
<seg id="2208">"" "" "" "due to the immune-stimulation properties, imiquimod cream should be used with caution in patients receiving an immunosuppressive treatment (see 4.4)." "" "" ""</seg>
<seg id="2209">"" "" "" "from animal studies no direct or indirect harmful effects go to pregnancy, embryonic / fetal development, fetching or postnatal development (see 5.3)." "" "" ""</seg>
<seg id="2210">"" "" "" "although non-recurring serum levels (&gt; 5ng / ml) were achieved, no recommendation is given to the application during breastfeeding." "" "" ""</seg>
<seg id="2211">The most commonly shared and possibly or possibly with the application of Imiquimod cream in related side effects in studies with three times weekly treatment were local reactions in the place of treatment of crackers (33.7% of patients treated with imiquimod).</seg>
<seg id="2212">"" "" "" "among the most commonly reported and probably or possibly with the application of the imiquimod cream in the related side effects include discomfort at the application site, with a frequency of 28.1%." "" "" ""</seg>
<seg id="2213">The side effects reported by 185 with Imiquimod spread out of a placebo-controlled clinical trial of Phase III reported side effects are shown below.</seg>
<seg id="2214">"" "" "" "in these studies, the most common, possibly or possibly with the application of the imiquimod cream in relation to the application site (22% of patients treated with imiquimod)." "" "" ""</seg>
<seg id="2215">The side effects reported by 252 in placebo-controlled clinical trials of Phase III with Imiquimod cream treated patients with actinic keratosis are listed below.</seg>
<seg id="2216">This review of clinical signs indicated that these placebo-controlled clinical trials with Imiquimod crème often resulted in local skin reactions including erythema (61%) and erode (23%) and edema (23%) and edema (see section 4.4).</seg>
<seg id="2217">"" "" "" "according to the study plan, this study showed that in these studies five times weekly treatment with Imiquimod cream often resulted in serious erytopics (31%), severe atrophy (13%) and severe casualties (19%)." "" "" ""</seg>
<seg id="2218">"" "" "" "in clinical trials investigating the application of imiquimod for the treatment of actinic keratosis, alopecia was observed with a frequency of 0.4% (5 / 1214) at the treatment center or in the surrounding area." "" "" ""</seg>
<seg id="2219">"" "" "" "the accidental orale absorption of 200 mg Imiquimod, which corresponds to the contents of approximately 16 bags, could lead to nausea, vomiting, headache, myalgia and fever." "" "" ""</seg>
<seg id="2220">"" "" "" "the clinically serious side effect, which occurred after several oral doses of &gt; 200 mg, consisted of hypotony, normalized after oral or intravenous fluid." "" "" ""</seg>
<seg id="2221">"" "" "" "in a pharmacokinetic examination, increasing systemic concentrations of alpha interferons and other cytokines were detected after the topical application of Imiquimodine." "" "" ""</seg>
<seg id="2222">"" "" "" "in 3 pivotal Phase 3 efficacy studies, it was shown that efficacy in relation to complete healing of the crampons in an Imiquimod treatment was clearly superior over 16 weeks of placebo treatment." "" "" ""</seg>
<seg id="2223">"" "" "" "in 60% of the patients treated with imiquimod patients, the patients were completely cured; this was the case with 20% of the 105 patients who were treated with placebo (95% CI):" "" "" ""</seg>
<seg id="2224">A complete healing was achieved in 23% of 157 with Imiquimodine treated male patients compared to 5% of 161 in placebo-treated male patients (95% CI):</seg>
<seg id="2225">"" "" "" "the effectiveness of Imiquimod with five weeks of application per week over 6 weeks was examined in two double-blind, placebo-controlled clinical trials." "" "" ""</seg>
<seg id="2226">The target tumors were histologically confirmed single primary supernatural basal cell carcinomas with a minimum size of 0.5 cm2 and a maximum diameter of 2 cm.</seg>
<seg id="2227">"" "" "" "the data presented from an open, uncontrolled long-term study after four years showed that approximately 79.3% [95% CI (73.7%, 84.9%)] of all treated patients clinically healed and this remained for 48 months." "" "" ""</seg>
<seg id="2228">"" "" "" "Imiquimod's efficacy in one or two treatment periods of 4 weeks, interrupted by a four-week, treatment-free period, was examined in two double-blind, placebo-controlled clinical trials." "" "" ""</seg>
<seg id="2229">"" "" "" "patients had clinically typical, visible, discrete, non hypertrophic lesions in a contiguous 25 cm2 treatment area on the uncomfortable scalp or face." "" "" ""</seg>
<seg id="2230">The single-year data from two combined monitoring studies show a recurrence rate of 27% (35 / 128 patients) after one or two treatment periods.</seg>
<seg id="2231">"" "" "" "the permitted indications of external feignices, actinic keratosis and supernatural basal cell carcinoma do not usually occur in paediatric patients and were therefore not examined." "" "" ""</seg>
<seg id="2232">"" "" "" "Aldara Creme was studied in four randomised, double-blind placebo-controlled trials in children aged 2 to 15 years with Molluscum contagiosum (Imiquimod n = 576, placebo n = 313)." "" "" ""</seg>
<seg id="2233">"" "" "" "the efficacy of Imiquimod could not be shown in these studies at the dosages studied there (3x / week for a period of ≤ 16 weeks, respectively)." "" "" ""</seg>
<seg id="2234">Minimal systemic absorption of the 5% Imiquimod cream by the skin of 58 patients with actinic keratosis was observed during the three weeks weekly application during 16 weeks.</seg>
<seg id="2235">"" "" "" "the highest drug concentrations in serum at the end of the week 16 were observed between 9 and 12 hours and betted 0.1, 0.2 and 1.6 ng / ml in the face (25 mg, 2 bags) and on the hands / arms (75 mg, 6 bags)." "" "" ""</seg>
<seg id="2236">The calculated apparent half-life time was about 10 times higher than the 2h half-life after the subcutaneous application in an earlier study; this indicates an extended retention of the drug in the skin.</seg>
<seg id="2237">Systemic exposure data showed that the resorption of imiquimod to topical application on MC-diseased skin was low and comparable to that in healthy adults and adults with actinic keratosis or supernatural basal cell carcinoma.</seg>
<seg id="2238">"" "" "" "in a four-month study, doses of 0.5 and 2.5 mg / kg KG lead to significantly reduced body weight and increased spleen weight; a study carried out for four months resulted in no similar effects with the mouse." "" "" ""</seg>
<seg id="2239">"" "" "" "a two-year study on carcinogenicity in mice, in three days a week, did not induce tumours on the application site." "" "" ""</seg>
<seg id="2240">"" "" "" "the mechanism is not known, but since Imiquimod possesses only a low system absorption of human skin and is not mutagen, there is a risk for humans to be regarded as very low due to systemic exposure." "" "" ""</seg>
<seg id="2241">"" "" "" "the tumors occurred in the group of mice treated with the substance-free cream, earlier and in larger numbers than in the control group with low UVR." "" "" ""</seg>
<seg id="2242">"" "" "" "if any of the side effects listed you have considerably impaired or you notice side effects that are not stated in this information, please inform your doctor or pharmacist." "" "" ""</seg>
<seg id="2243">● Feignizen (Condylomata acuminata) formed on the skin in the area of genitals (sexual organs) and the anus (anus) - superficial basal cell carcinoma This is a frequently encountered, slow growing type of skin cancer with very low probability of spread to other parts of the body.</seg>
<seg id="2244">"" "" "" "if left untreated, it may result in hiring, especially in the face - so early detection and treatment is important." "" "" ""</seg>
<seg id="2245">"" "" "" "actinic keratoses are rough areas of the skin, which occur in people who were exposed to exposure to sunlight during their previous life." "" "" ""</seg>
<seg id="2246">Aldara should only be used for flat actinic keratoses in the face and on the scalp in patients with a healthy immune system where your doctor has decided that Aldara is the most suitable treatment for you.</seg>
<seg id="2247">"" "" "" "Aldara Creme supports your body's immune system in the production of natural substances that help your body to combat the superficial basal cell carcinoma, the actinic keratosis or the virus responsible for the infection." "" "" ""</seg>
<seg id="2248">"" "" "" "O If you have used Aldara cream or any other similar preparations before you start treatment, consult your doctor if you have problems with your immune system. o Avoid contact with eyes, lips and nasal mucosa." "" "" ""</seg>
<seg id="2249">"" "" "" "after applying Aldara cream not inwardly. o If reactions occur in the treated area, which will give you strong discomfort, wash the cream with a mild soap and water." "" "" ""</seg>
<seg id="2250">"" "" "" "once the reactions are subsided, you can continue the treatment process. o Inform your doctor if they do not have a normal blood pattern" "" "" ""</seg>
<seg id="2251">"" "" "" "if this daily cleaning is not carried out under the foreskin, swelling of the skin or difficulties during withdrawal of the foreskin can be expected with increased occurence of skin constrictions." "" "" ""</seg>
<seg id="2252">"" "" "" "do not use Aldara cream in the urethra, in the vagina (vagina), the cervix (cervix) or within the anus (anus)." "" "" ""</seg>
<seg id="2253">"" "" "" "if other drugs have serious problems with your immune system, you should not use this medication for more than one treatment cycle." "" "" ""</seg>
<seg id="2254">"" "" "" "if you have intercourse with genital warts during the genital area, the treatment with Aldara cream after intercourse (not before) perform." "" "" ""</seg>
<seg id="2255">"" "" "" "please inform your doctor or pharmacist if you use other medicines or have recently applied, even if it is not prescription medicine." "" "" ""</seg>
<seg id="2256">"" "" "" "breastfeed your baby during treatment with Aldara Cream, since it is not known whether Imiquimod enters the breast milk." "" "" ""</seg>
<seg id="2257">"" "" "" "the frequency and duration of treatment are different in case of crackers, basal cell carcinoma and actinic keratosis (see specific instructions for each application area)." "" "" ""</seg>
<seg id="2258">"" "" "" "apply a thin layer of Aldara cream to the clean, dry skin area with the crackers and rub the cream gently on the skin until the cream is completely covered." "" "" ""</seg>
<seg id="2259">Males with gradients under the foreskin must withdraw the foreskin every day and wash the skin area underneath (see section 2 "What must you consider before using Aldara cream?).</seg>
<seg id="2260">Please talk to your doctor or pharmacist if you have the impression that the effect of Aldara is too strong or too weak.</seg>
<seg id="2261">"" "" "" "for 6 weeks each week, 5 days a week a sufficient amount of Aldara cream apply to cover the affected area and 1 cm around this area." "" "" ""</seg>
<seg id="2262">"" "" "" "frequent side effects (expecting more than 1 out of 10 patients) common side effects (in less than 1 out of 100 patients) can expect rare side effects (in less than 1 out of 10 patients) Very rare side effects (in case of less than 1 out of 10,000 patients)" "" "" ""</seg>
<seg id="2263">Tell your doctor or pharmacist about it immediately if you do not feel comfortable while using Aldara cream.</seg>
<seg id="2264">"" "" "" "if your skin reacts too strongly to the treatment with Aldara cream, you should not use the cream further, wash the affected skin area with water and a mild soap and notify your doctor or your pharmacist." "" "" ""</seg>
<seg id="2265">"" "" "" "a degraded number of blood cells can make you more vulnerable to infections; it can cause you to get a blue stain faster, or it can cause fatigue." "" "" ""</seg>
<seg id="2266">Inform your doctor or pharmacist if any of the listed side effects you have significantly impaired or you notice side effects that are not stated in this use information.</seg>
<seg id="2267">"" "" "" "in addition, you can experience itching (32% of patients), burning (26% of patients) or pain in the areas you have applied to Aldara cream (8% of patients)." "" "" ""</seg>
<seg id="2268">"" "" "" "usually it is easier skin reactions, which end up again within about 2 weeks after the treatment has been removed." "" "" ""</seg>
<seg id="2269">"" "" "" "occasionally some patients notice changes in the location of the application (wound secretion, inflammation, swelling, skin formation, bladder, dermatitis) or irritability, nausea, dry mouth, flu-like symptoms and tiredness." "" "" ""</seg>
<seg id="2270">"" "" "" "occasionally some patients suffer from changes in the place of application (bleeding, inflammation, wound secretion, sensitivity, swelling, skin irritation, swelling of the eyelids, throat, facial swelling, ulcers, body aches, fever, weakness or chills." "" "" ""</seg>
<seg id="2271">Aldurazyme is used for the enzyme replacement therapy in patients with assured diagnosis of a Mucopolysaccharidosis I (MPS I; α-Iduronidase deficiency) to treat the non-neurological manifestations of the disease (the symptoms that are not related to brain or nerves).</seg>
<seg id="2272">"" "" "" "this means that certain substances (glycosaminoglycans, gags) are not broken down and accumulate in most organs in the body and damage them." "" "" ""</seg>
<seg id="2273">"" "" "" "the following non neurological symptoms of the MPS I can occur: enlarged liver, stiff joints, the movements complicate, reduced lung volume, heart and eye diseases." "" "" ""</seg>
<seg id="2274">"" "" "" "the treatment with Aldurazyme should be monitored by a doctor, which possesses experience in treating patients with MPS I or other hereditary metabolic diseases." "" "" ""</seg>
<seg id="2275">"" "" "" "the administration of Aldurazyme should take place in a hospital or clinic with revitation devices, and patients may need appropriate medicines prior to the administration to prevent an allergic reaction." "" "" ""</seg>
<seg id="2276">(44-20) 74 18 84 00 Fax (44-20) 74 18 86 68 E-mail: mail @ emea.europa.eu http: / / distribution of this document is Authorised for non business purposes only provided the EMEA is acknowledged How does Aldurazyme work?</seg>
<seg id="2277">"" "" "" "in the study, the safety of the drug was mainly studied, but its effectiveness was also measured (by examining its effect regarding the reduction of GAG concentrations in the urine and in relation to the size of the liver)." "" "" ""</seg>
<seg id="2278">"" "" "" "in children under the age of five, Aldurazyma lowered the GAG concentrations in the urine by about 60%, and half of the treated children had a normal large liver at the end of the study." "" "" ""</seg>
<seg id="2279">"" "" "" "the most common side effects of aldurazyme in patients aged over five years (observed in more than 1 out of 10 patients) are headaches, nausea, abdominal pain, skin rash, arthropathy (joint pain), heat sensation, fever and reactions at the infusion site." "" "" ""</seg>
<seg id="2280">"" "" "" "frequent side effects in patients under the age of five are elevated blood pressure, reduced oxygen saturation (a measure of lung function), tachycardia (accelerated heart rate), fever and chills." "" "" ""</seg>
<seg id="2281">Aldurazyme may not react to patients suffering from hypersensitivity to laronidase or any of the other components (anaphylactic reaction).</seg>
<seg id="2282">"" "" "" "every year, the European Medicines Agency (EMEA) will review all new information that may be known, and, if necessary, update this summary." "" "" ""</seg>
<seg id="2283">"" "" "" "the manufacturer of aldurazyma is used to observe aldurazyms, in terms of reactions to infusion and development of antibodies." "" "" ""</seg>
<seg id="2284">"" "" "" "in June 2003, the European Commission granted the European Commission to Genzyme Europe B.V. a permit for the placing of Aldurazyme throughout the European Union." "" "" ""</seg>
<seg id="2285">Laronidase is a recombinant form of the human α-L-Iduronidase and is produced using recombinant DNA technology using CHO mammal cell cultures (Chinese hamster Ovary from Chinese hamsters).</seg>
<seg id="2286">Aldurazyme is indicated for long-term enzyme replacement therapy in patients with assured diagnosis of a Mucopolysaccharidosis I (MPS I, α-Iduronidase deficiency) in order to treat the non-neurological manifestations of the disease (see Section 5.1).</seg>
<seg id="2287">"" "" "" "treatment with Aldurazyme should be carried out by a doctor, who possesses experience in treating patients with MPS I or other hereditary metabolic diseases." "" "" ""</seg>
<seg id="2288">"" "" "" "the initial infusion rate of 2 E / kg / h can, if the patient wears this, increased every 15 minutes in single steps to a maximum dose of 43 E / kg / h." "" "" ""</seg>
<seg id="2289">"" "" "" "the safety and efficacy of aldurazyms in adults over 65 years has not been determined, and no dosage schedule can be recommended for these patients." "" "" ""</seg>
<seg id="2290">"" "" "" "the safety and efficacy of aldurazyms in patients with kidney or liver failure was not determined, and no dosage schedule can be recommended for these patients." "" "" ""</seg>
<seg id="2291">Patients treated with Aldurazyme can develop infusion-related reactions which are defined as any side effect that occurs during infusion or until the end of the infusion day (see Section 4.8).</seg>
<seg id="2292">"" "" "" "for this reason, especially those patients should continue to be closely monitored, and the infusion of aldurazyms should only be carried out in an appropriate clinical environment where recovery facilities are immediately available for medical emergencies." "" "" ""</seg>
<seg id="2293">"" "" "" "due to the clinical phase 3 study, it is expected that almost all patients form IgG antibodies against laronidase, usually within 3 months from the beginning of treatment." "" "" ""</seg>
<seg id="2294">Patients who develop antibodies or symptoms of infusion-related reaction must be treated with caution when applying Aldurazyme (see Sections 4.3 and 4.8).</seg>
<seg id="2295">"" "" "" "since there is little experience in restarting treatment after a longer break, it has to be cautiously advised because of the risk of hypersensitivity reactions after an interruption of the treatment." "" "" ""</seg>
<seg id="2296">"" "" "" "60 minutes before the start of infusion with medications (antihistaminika and / or antipyents), to minimize the potential occurrence of infusion-related reactions." "" "" ""</seg>
<seg id="2297">"" "" "" "in case of mild or moderate infusion, treatment with antihistaminika and paracetamol / ibuprofen should be considered and / or reduction of infusion rate to half of the infusion rate in which the reaction has occurred." "" "" ""</seg>
<seg id="2298">"" "" "" "in case of a single, severe infusion-related reaction the infusion must be stopped until the symptoms are reduced, a treatment with antihistaminika and paracetamol / ibuprofen must be considered." "" "" ""</seg>
<seg id="2299">"" "" "" "fusion can be resumed with a reduction of infusion rate to 1 / 2 - 1 / 4 of the infusion rate, where the reaction has occurred." "" "" ""</seg>
<seg id="2300">3. (antihistaminika and paracetamol / ibuprofen / ibuprofen and / or corticosteroids) and a reduction of infusion rate to 1 / 2 - 1 / 4 of the infusion rate in which the previous reaction has occurred.</seg>
<seg id="2301">"" "" "" "Aldurazyme should not be applied simultaneously with chloroquin or procaine, because there is a potential risk of interference with the intracellular absorption of laronidase." "" "" ""</seg>
<seg id="2302">"" "" "" "animal experiments do not lead to direct or indirect harmful effects on the pregnancy, embryonic and fetal development, birth and postnatal development (see Section 5.3)." "" "" ""</seg>
<seg id="2303">"" "" "" "since there is no data on newborns exposed to laronidase over mother's milk, it is recommended not to breastfeed with Aldurazyme." "" "" ""</seg>
<seg id="2304">Adverse events in clinical trials were mainly classified as infusion-related reactions which were observed in 53% of patients in the Phase 3 study (treatment duration up to 4 years) and 35% of patients in the study involving participants under 5 years (treatment duration up to 1 year).</seg>
<seg id="2305">Adverse drug reactions related to Aldurazyma that were observed during the phase 3 study and their extension in a total of 45 patients at the age of 5 years or older during a treatment period of up to 4 years are performed in the following table following the following frequency: very common (≥ 1 / 100 to &lt; 1 / 10).</seg>
<seg id="2306">"" "" "" "in some patients with severe MPS-I-related involvement of upper respiratory passages and lungs in the prehistory, severe reactions occurring, including bronchospasmus, breathing stills and edema (see section 4.4)." "" "" ""</seg>
<seg id="2307">"" "" "" "children Undesirable Drug Effects related to Aldurazyme, which were reported during a phase 2 study involving a total of 20 patients aged under 5 years, with predominantly severe form and duration of treatment up to 12 months, are listed in the table." "" "" ""</seg>
<seg id="2308">"" "" "" "100 E / kg IV once a week (recommended dose), 200 E / kg intravenously once a week, 200 E / kg intravenously every 2 weeks or 300 E / kg intravenously every 2 weeks." "" "" ""</seg>
<seg id="2309">In most patients it occurred within 3 months after the onset of treatment to a seroconversion with a severe form of serocarditis mostly within one month to a seroconversion (on average after 26 days versus 45 days in patients aged 5 years and older).</seg>
<seg id="2310">"" "" "" "up to the end of the Phase 3 study (or up to a premature departure from the study), no detectable antibodies were detected in 13 / 45 patients, including 3 patients with no Seroconversion." "" "" ""</seg>
<seg id="2311">Patients with a lack of low antibody levels showed a robust reduction of the GAG mirror in urine while in patients with high antibody titers a variable reduction of GAG in urine was observed.</seg>
<seg id="2312">Four patients (three in phase 3 study and one in phase 2 study) showed a marginal to low neutralizing inhibitory effect on enzymatic Laronidase- activity in vitro which seemed to impair clinical efficacy and / or reduction of GAG in Harn.</seg>
<seg id="2313">"" "" "" "the presence of antibodies did not appear to be associated with the incidence of adverse drug reactions, although the occurrence of adverse drug reactions typically coincided with the formation of IgG antibodies." "" "" ""</seg>
<seg id="2314">"" "" "" "the reason for the enzyme replacement therapy is for the hydrolysis of the accumulated substrate, and the prevention of further accumulation of adequate enzyme activity." "" "" ""</seg>
<seg id="2315">"" "" "" "after IV infusion, laronidase is quickly removed from the circulation and absorbed by cells into the lysosomes, most likely via Mannose-6-phosphate receptors." "" "" ""</seg>
<seg id="2316">"" "" "" "the safety and efficacy of aldurazyms were studied in a randomised, double-blind, placebo-controlled Phase 3 study to 45 patients aged 6 to 43." "" "" ""</seg>
<seg id="2317">"" "" "" "although patients were recruited to study the entire disease spectrum, the majority of patients were of the mean phenotype and only one patient showed the serious phenotype." "" "" ""</seg>
<seg id="2318">Patients were recruited if they had a forced expiratory volume (FEV) of less than 80% of the expected value and they had to be able to stand 6 minutes and walk 5 meters.</seg>
<seg id="2319">The primary endpoints for efficacy were the percentage change of FEV to be expected and the total distance in the 6-minute walk test.</seg>
<seg id="2320">All patients were subsequently recruited for an open-label extension study where they received 100 E / kg Aldurazyme every week (182 weeks) every week.</seg>
<seg id="2321">"" "" "" "after 26 weeks of therapy, the patients treated with Aldurazyme demonstrated an improvement in lung function and ability in the following table." "" "" ""</seg>
<seg id="2322">An open extension study showed an improvement and / or maintenance of these effects of up to 208 weeks in the Aldurazyme / Aldurazyme group and from 182 weeks in the placebo / Aldurazyme group as emerged from the following table.</seg>
<seg id="2323">"" "" "" "the decrease in the expected percentage FEV is clinically not significant during this period, and the absolute lung volume increases further proportionally to the height of growing children." "" "" ""</seg>
<seg id="2324">"" "" "" "of the 26 patients with a Hepatomegaly before treatment, 22 (85%) reached a normal liver size until the end of the study." "" "" ""</seg>
<seg id="2325">"" "" "" "within the first 4 weeks, a clear decrease in the GAG levels in the urine (µg / mg of creatine) was established, which remained constant until the end of the study." "" "" ""</seg>
<seg id="2326">In general an improvement in 26 patients (58%) was generally an improvement in 26 patients (58%) and no change in 10 patients (22%) and a decrease in 9 patients (20%).</seg>
<seg id="2327">A one-year open phase 2 study was carried out in which the safety and pharmacokinetics of Aldurazyme was examined in 20 patients at the time of their inclusion in the study under 5 years of age (16 patients with severe follow-up form and 4 with the middle follow-up form).</seg>
<seg id="2328">"" "" "" "in four patients, the dosage was increased to 200 E / kg because of increased Gag- Mirror in Harn in week 22." "" "" ""</seg>
<seg id="2329">In several patients a size growth (n = 7) and a weight gain (n = 3) found a normal mental developmental speed after the Z-score (&lt; 2.5 years) and all 4 patients with the mean follow-up form showed a normal mental developmental speed.</seg>
<seg id="2330">"" "" "" "in a phase 4 study, examinations on pharmacogenic effects of various Aldurazyme dosing schemata were carried out on the GAG mirror in urine, liver volume and the 6-minute walking test." "" "" ""</seg>
<seg id="2331">"" "" "" "100 E / kg IV once a week (recommended dose), 200 E / kg intravenously once a week, 200 E / kg intravenously every 2 weeks or 300 E / kg intravenously every 2 weeks." "" "" ""</seg>
<seg id="2332">The dosage schedule with 200 E / kg intravenous every 2 weeks can represent a substitute alternative in patients who have difficulties with weekly infusions; however it is not proven that the long-term clinical effectiveness of these two dosing schemes is equivalent.</seg>
<seg id="2333">"" "" "" "the European Medicines Agency (EMEA) will evaluate any new information available annually, and if necessary, the summary of the characteristics of the medicine will be updated." "" "" ""</seg>
<seg id="2334">"" "" "" "the pharmacokinetic profile in patients at the age of 5 was similar, as was the case with elderly and less strongly affected patients." "" "" ""</seg>
<seg id="2335">"" "" "" "based on the conventional research on safety spatology, toxicity in repeated application, toxicity in repeated application and reproductive toxicity, preclinical data do not reveal any particular danger to humans." "" "" ""</seg>
<seg id="2336">"" "" "" "since no feasibility studies have been carried out, this drug may not be mixed with other medicines unless specified under 6,6." "" "" ""</seg>
<seg id="2337">"" "" "" "if the ready-to-use preparation is not used immediately, it is no longer to be stored for 24 hours at 2 ° C - 8º C unless the dilution was controlled under controlled and validated aseptic conditions." "" "" ""</seg>
<seg id="2338">5 ml concentrate for the production of a solution in a glass bottle (type I-glass) with stoppers (silicone butbutyl rubber) and sealing (aluminium) with tear-off cap (polypropylene).</seg>
<seg id="2339">10 preparation of the Aldurazyme infusion (using aseptic technique) • Depending on the body weight of the individual patient first the number of diluent penetration bottles.</seg>
<seg id="2340">"" "" "" "within the specified period, the holder of authorization for the placing of goods has completed the following study programme whose results are the basis for the annual evaluation report on the benefit-risk ratio." "" "" ""</seg>
<seg id="2341">"" "" "" "in the long term, this register will detect safety and efficacy information on patients treated with aldurazyms and data on the natural progression of the disease in patients without this treatment." "" "" ""</seg>
<seg id="2342">"" "" "" "in patients suffering from MPS I, an enzyme called α -L-Iduronidase, which splits certain substances in the body (Glycosaminoglykane), is completely absent or totally absent." "" "" ""</seg>
<seg id="2343">"" "" "" "if you are allergic (hypersensitive) to any of the components of Aldurazyme, or if you have encountered a serious allergic reaction to laronidase." "" "" ""</seg>
<seg id="2344">Infusion-related reaction is each side effect that occurs during infusion or until the end of the infusion day (see section 4 "Which side effects are possible").</seg>
<seg id="2345">"" "" "" "if you use Aldurazyme with other medicines, tell your doctor if you are taking medicines that contain chloroquin or procaine because there is a potential risk of a diminished effect of Aldurazyme." "" "" ""</seg>
<seg id="2346">"" "" "" "please tell your doctor or pharmacist if you have other medicines or recently taken, including prescription drugs." "" "" ""</seg>
<seg id="2347">Tips for handling - dilution and application The concentrate for the production of an infusion solution must be diluted prior to use and is intended for intravenous application (see information for doctors and medical professionals).</seg>
<seg id="2348">"" "" "" "the initial infusion rate of 2 E / kg / h can, if the patient wears this, gradually increased to a maximum dose of 43 E / kg / h every 15 minutes." "" "" ""</seg>
<seg id="2349">"" "" "" "in some patients with severe MPS-I- unconditional involvement of upper respiratory passages and lungs in the past, severe reactions occurred, including bronchospasmus, breathing stills and facial oils." "" "" ""</seg>
<seg id="2350">"" "" "" "very common (occurrence with more than 1 out of 10 patients): • headache • nausea, joint pain, joint pain, back pain, pain in arms and legs • Reflected • hypertension • less oxygen in the blood • Reaction at the infusion site" "" "" ""</seg>
<seg id="2351">"" "" "" "the European Medicines Agency (EMEA) will evaluate any new information available annually, and if necessary, the packaging supplement will be updated." "" "" ""</seg>
<seg id="2352">"" "" "" "if the ready-to-use preparation is not used immediately, it is no longer to be stored for 24 hours at 2 ° C - 8º C unless the dilution was controlled under controlled and validated aseptic conditions." "" "" ""</seg>
<seg id="2353">"" "" "" "prepare the Aldurazyme infusion (using aseptic technique) • Depending on the body weight of the individual patient, the number of fluid-thinning bottles to be diluted." "" "" ""</seg>
<seg id="2354">Alimta is used together with Cisplatin (another drug for cancer) in patients who have no chemotherapy (drugs against cancer) and "malign" (malignant - cancer has already spread to other parts of the body) and is likely to spread easily onto other parts of the body.</seg>
<seg id="2355">"" "" "" "Alimta is used in patients who have not been treated before, in combination with cisplatin and in patients who have previously received chemotherapy before chemotherapy alone." "" "" ""</seg>
<seg id="2356">"" "" "" "in order to reduce side effects, the patients should receive corticosteroid and folic acid (a vitamin) during the treatment with Alimta and receive injections of vitamin B12." "" "" ""</seg>
<seg id="2357">"" "" "" "when administered with cisplatin together with cisplatin, a" anti-emetic "(medicine against vomiting) and liquids (to prevent fluid deficiency) should be given before or after the gift of Cisplatin." "" "" ""</seg>
<seg id="2358">"" "" "" "in patients whose blood pattern changes or any other side effects occur, the treatment should be postponed, removed or reduced." "" "" ""</seg>
<seg id="2359">"" "" "" "thus, the active form of pemetrexed slows down the formation of DNA and RNA and prevents the cells from sharing." "" "" ""</seg>
<seg id="2360">"" "" "" "the transformation of Pemetremixed into its active form is easier in cancer cells than in healthy cells, leading to higher concentrations of the active form of the medicine and a longer time of operation in cancer cells." "" "" ""</seg>
<seg id="2361">"" "" "" "for the treatment of malignant pleural othelioma, Alimta was examined in a major study of 456 patients who had previously not received chemotherapy for their disease." "" "" ""</seg>
<seg id="2362">"" "" "" "in the treatment of non-small cell lung cancer, the effects of Alimta were compared with the effects of docetaxel (another drug against cancer) in 571 patients with local advanced or metastatic disease." "" "" ""</seg>
<seg id="2363">"" "" "" "Alimta was also compared with gemcitabine (another drug against cancer), both in combination with cisplatin in 1 725 patients who had previously not received chemotherapy for lung cancer." "" "" ""</seg>
<seg id="2364">Patients treated with Alimta and Cisplatin were an average of 12.1 months compared to 9.3 months when performing Cisplatin.</seg>
<seg id="2365">"" "" "" "in patients who had previously received chemotherapy, the average survival time with Alimta was 8.3 months compared to 7.9 months at docetaxel." "" "" ""</seg>
<seg id="2366">"" "" "" "however, in both studies patients with whom the cancer did not attack the squamous epithelial cells, during the administration of Alimta prolonged survival compared to the previous drug." "" "" ""</seg>
<seg id="2367">"" "" "" "in September 2004, the European Commission granted the approval of Eli Lilly Nederland B.V. to approve the placing of Alimta in the European Union." "" "" ""</seg>
<seg id="2368">"" "" "" "each glass bottle has to be dissolved with 4.2 ml 0.9% sodium chloride injection solution (9 mg / ml), which results in a solution of 25 mg / ml." "" "" ""</seg>
<seg id="2369">"" "" "" "the adequate volume of the necessary dosage is taken from the penetration bottle and diluted with 0,9% sodium chloride injection solution (9 mg / ml) to 100 ml (see section 6.6)." "" "" ""</seg>
<seg id="2370">ALIMTA is shown in combination with Cisplatin for first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer except for the predominant plate epithelial histology (see Section 5.1).</seg>
<seg id="2371">ALIMTA in Monotherapy is indicated for the treatment in second-line treatment of patients with LO- Kal advanced or metastatic non-small cell lung cancer except for overwhelming panel epithelial histology (see Section 5.1).</seg>
<seg id="2372">The recommended dose of ALIMTA 500 mg / m ² body surface area (KOF) is administered as intravenous infusion over a period of 10 minutes on the first day of every 21 day treatment cycle.</seg>
<seg id="2373">The recommended dose of Cisplatin is 75 mg / m ² of KOF as infusion over a period of 2 hours approximately 30 minutes after completion of the Pemetrexed- infusion on the first day of every 21 day treatment cycle.</seg>
<seg id="2374">In patients with non-small bronchial carcinoma after previous chemotherapy the recommended dose of ALIMTA 500 mg / m ² KOF is administered as intravenous infusion over a period of 10 minutes on the first day of every 21 day treatment cycle.</seg>
<seg id="2375">"" "" "" "to reduce the frequency and severity of skin reactions, a Korticosteroid must be given on the day before and on the day of the Pemetrexed-Gift as well as on the day after treatment." "" "" ""</seg>
<seg id="2376">"" "" "" "during the seven days before the first dose of Pemetremixed, at least 5 doses of folic acid must be taken and the intake must be continued throughout the treatment period and for another 21 days after the last pemetrexed- dose." "" "" ""</seg>
<seg id="2377">Patients must also receive an intramuscular injection of vitamin B12 (1000 micrograms) in the week prior to the first pemetremixed dose and after each third treatment cycle.</seg>
<seg id="2378">"" "" "" "in patients who receive pemetremixed, a complete blood pattern should be created before each gift, including a differentiation of the leukocytes and a thrombocyte count." "" "" ""</seg>
<seg id="2379">The alkaline phosphatase (AP) and aspartame transaminase (AST or SGOT) and Alanin transaminase (ALT or SGPT) should be ≤ 3 times the upper limit value.</seg>
<seg id="2380">"" "" "" "at the beginning of a new treatment cycle, a dose examination will take place in the presence of the blood image or the maximum non-haematological toxicity of the previous therapy cycles." "" "" ""</seg>
<seg id="2381">"" "" "" "after recovery, patients need to be treated according to the indications in tables 1, 2 and 3 that are suitable for ALIMTA as monotherapy or in combination with cisplatin." "" "" ""</seg>
<seg id="2382">These criteria correspond to the definition of the National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998) ≥ CTC degree 2 bleeding.</seg>
<seg id="2383">"" "" "" "should patients not develop hematological toxicity ≥ 3 (except neurotoxicity), the therapy must be interrupted with ALIMTA until the patient adjusts the value before treatment" "" "" ""</seg>
<seg id="2384">Treatment with ALIMTA must be stopped when in patients after 2 canned foods a hematological toxicity or non-haematological toxicity level 3 or 4 occurs or so - at the occurrence of degree 3 or 4 neurotoxicity.</seg>
<seg id="2385">"" "" "" "clinical studies showed no indication that in patients at the age of 65, or in comparison to patients at the age of 65, there is an increased side effect risk." "" "" ""</seg>
<seg id="2386">"" "" "" "ALIMTA is not recommended for use in children under 18 years of age, due to insufficient safety and efficacy." "" "" ""</seg>
<seg id="2387">"" "" "" "in clinical trials, no dose adjustments were necessary in patients with a Kreatinin-Clearance of ≥ 45 ml / min." "" "" ""</seg>
<seg id="2388">"" "" "" "the data base in patients with a Kreatinin-Clearance of less than 45 ml / min was not sufficient, therefore the application is not recommended (see section 4.4)." "" "" ""</seg>
<seg id="2389">"" "" "" "however, patients with a liver function restriction of &gt; 1.5-times of the upper limit value and / or transaminase values of &gt; 5.0-times of the upper limit value (for the presence of liver metastases) were not studied specifically in the studies." "" "" ""</seg>
<seg id="2390">"" "" "" "patients need to be monitored in terms of bone mariner and Pemetrexed should not be given to patients before their absolute neutrology number has reached a value of ≥ 1500 cells / mm ³, and the thrombocyte number has reached a value of ≥ 100,000 cells / mm ³." "" "" ""</seg>
<seg id="2391">A dose reduction for further cycles is based on the Nadir of the absolute neutrophilanthropic number and maximum non-haematological toxicity as seen in the previous treatments (see section 4.2).</seg>
<seg id="2392">A lower toxicity and a reduction of the degree 3 / 4 hematologic and non-matological toxicity such as neutropenia and febrile neutropenia and infection with degree 3 / 4 neutropenia was observed if a pre-treatment with folic acid and vitamin B12 had taken place.</seg>
<seg id="2393">"" "" "" "therefore, all patients with Pemetrexed need to be instructed to apply folic acid and vitamin B12 as prophylactic measure to reduce treatment-related toxicity (see Section 4.2)." "" "" ""</seg>
<seg id="2394">Patients with mild to medium renal insufficiency (creatinin-Clearance 45 to 79 ml / min) must avoid simultaneous seizure of nonsteroidal anti-phlogistika (NSAIDs) for at least 2 days prior to the therapy and at least 2 days after the therapy with Pemetrexed (see section 4.5).</seg>
<seg id="2395">All patients for the treatment with Pemetrexed need to avoid taking NSAIDs with a long half-life time for at least 5 days prior to the therapy and at least 2 days after the therapy with Pemetrexed (see section 4.5).</seg>
<seg id="2396">"" "" "" "many patients in which these events occurred had appropriate risk factors for the occurrence of renal events, including dehydration, prevalent high blood pressure or diabetes." "" "" ""</seg>
<seg id="2397">"" "" "" "therefore, in patients with clinically significant fluid accumulation in the transcellular space, a drainage of the effusion before the pemetremixed treatment is to be considered." "" "" ""</seg>
<seg id="2398">5 Several cardiovascular events including myocardial infarction and cerebrovascular events were occasionally reported in clinical trials involving Pemetrexed in combination with a different cytotoxic agent.</seg>
<seg id="2399">"" "" "" "for this reason, the simultaneous application of attenuated life vaccines (except yellow fever, this vaccination is contraindicated) is not recommended (see Section 4.3 and 4.5)." "" "" ""</seg>
<seg id="2400">"" "" "" "since the possibility of an irreversible reproduction of the reproductive capacity by Pemetrexed, men should be advised in front of the treatment procedure to obtain counseling on sperm conservation." "" "" ""</seg>
<seg id="2401">In patients with normal kidney function (creatinin-Clearance ≥ 80 ml / min) high doses of nonsteroidal anti-phlogistika (≥ 1.3 g per day) and acetylsalicylic acid (≥ 1.3 g per day) can result in reduced Pemetremixed excretion.</seg>
<seg id="2402">"" "" "" "therefore, caution is advisable when treating high doses of NSAIDs or Ace- tylsalicylic acid in high doses in patients with normal renal function (creatinin-Clearance ≥ 80 ml / min)." "" "" ""</seg>
<seg id="2403">Ibuprofen) or acetylsalicylic acid at a high dosage for at least 2 days before the therapy and at least 2 days after therapy with Pemetrexed (see section 4.4).</seg>
<seg id="2404">Because there is no data concerning the interaction potential with NSAIDs with long half-life like Piro- xicam or Rofecoxib the simultaneous application with Pemetrexed must be avoided at least 5 days before the therapy and at least 2 days after the treatment with Pemetre- fixed.</seg>
<seg id="2405">The large intra-individual variability of the coagulation status during the disease and the possibility of interactions between oral anticoagulants and antine oplastic chemotherapy requires an increased monitoring frequency of INR (International Norised Ratio) when the decision was made to treat the patient with oral anticoagulants.</seg>
<seg id="2406">"" "" "" "there are no data for using Pemetrexed in pregnant women, but as with ande- ren antimetabolites, heavy birth defects are expected in pregnancy." "" "" ""</seg>
<seg id="2407">"" "" "" "Pemetrexed should not be applied during pregnancy, unless absolutely required and after careful weighing of the benefits for the mother and the risk of fetus (see Section 4.4)." "" "" ""</seg>
<seg id="2408">"" "" "" "as the possibility of an irreversible damage to reproductive capacity is due to Pemetrexed, men should be advised prior to the start of the treatment to bring in consultation with regard to the blocking of the sperm." "" "" ""</seg>
<seg id="2409">"" "" "" "it is not known whether Pemetrexed surpasses the mother's milk, and undesirable effects on the breastfed baby cannot be excluded." "" "" ""</seg>
<seg id="2410">The following table shows the frequency and severity of adverse effects reported in &gt; 5% of 168 patients with mesothelioma and the randomised cisplatin and Pemetremixed - and 163 patients with mesothelioma who were randomized cisplatin as monotherapy.</seg>
<seg id="2411">"" "" "" "side effects Frequency data: very common (≥ 1 / 100 and &lt; 1 / 100), rarely (≥ 1 / 1000 and &lt; 1 / 100), very rare (≥ 1 / 1000 and &lt; 1 / 100)." "" "" ""</seg>
<seg id="2412">* * * * Beeducated at National Cancer Institute CTC (v2.0; NCI 1998) is reported to be reported as a level 1 or 2 loss of taste and hair loss. * * * Beeducated at National Cancer Institute CTC (v2.0; NCI 1998).</seg>
<seg id="2413">"" "" "" "for this table, a threshold of 5% was specified for the inclusion of all events in which the report doctor held a connection with Pemetrexed and Cisplatin." "" "" ""</seg>
<seg id="2414">Clinically relevant CTC toxicity which were reported at &lt; 1% (occasionally) of the patients who were randomized cisplatin and Pemetrexed received arrhythmia and motor neuropathy.</seg>
<seg id="2415">The following table shows the frequency and severity of unwanted effects that were reported in &gt; 5% of 265 patients randomised as monotherapy with gifts of folacidic and vitamin B12 and 276 patients who were randomized to docetaxel as monotherapy.</seg>
<seg id="2416">* * Regulated at National Cancer Institute CTC version 2 for any toxicity degree. * * Beared at National Cancer Institute CTC (v2.0; NCI 1998) should report hair loss only as Level 1 or 2.</seg>
<seg id="2417">"" "" "" "for this table, a threshold of 5% was specified for the inclusion of all events in which the report doctor held a connection with Pemetrexed for possible." "" "" ""</seg>
<seg id="2418">"" "" "" "clinically relevant CTC toxicity, which were reported at &lt; 1% (occasionally) of the patients who were randomized, were randomised to supraventricular arrhythmias." "" "" ""</seg>
<seg id="2419">The clinically relevant laboratory toxicity level 3 and 4 was similar to the combined results of three single Pemetremixed-monotherapy studies (n = 164) in phase 2 (12.8% compared with 5.3%) and an increase in alanine transaminase (15.2% compared with 1.9%).</seg>
<seg id="2420">These differences are likely to lead to differences in the patient population as the Pha- se 2 studies included both chemonaive and clearly pre-treated breast cancer patients with existing liver metastases and / or abnormal basal values of liver function tests.</seg>
<seg id="2421">The following table shows the frequency and severity of adverse effects that could be possible in connection with the study medication; they were randomised to receive Cisplatin and Pemetremixed and 830 patients with NSCLC who were randomized cisplatin and gemcitabine.</seg>
<seg id="2422">* * * Regulated at National Cancer Institute CTC (v2.0; NCI 1998) for any toxicity degree. * * * Beeducated at National Cancer Institute CTC (v2.0; NCI 1998) should report taste dysfunction and hair loss only as Level 1 or 2.</seg>
<seg id="2423">"" "" "" "for this table, a threshold of 5% was specified for the inclusion of all events in which the reconfessional physician held a connection with Pemetrexed and Cisplatin." "" "" ""</seg>
<seg id="2424">"" "" "" "clinically relevant toxicity, reported in ≥ 1% and ≤ 5% (common) of patients who were randomised to receive cisplatin and Pemetremixed, included:" "" "" ""</seg>
<seg id="2425">Clinically relevant toxicity reported at &lt; 1% (occasionally) of the patients who were ran- domized cisplatin and Pemetremixed was:</seg>
<seg id="2426">"" "" "" "severe cardiovascular and cerebrovascular events, including myocardial infarction, angina pectoris, cerebrovascular insulin and transitory ischemic attacks were occasionally reported in combination with a different cytotoxic substance." "" "" ""</seg>
<seg id="2427">"" "" "" "clinical trials reported cases of coli- tis (including intestinal and rectal bleeding, sometimes fatal, intestinal perfo- ration, intestinal necrosis and typhlitis)." "" "" ""</seg>
<seg id="2428">"" "" "" "in patients with Pemetremixed treatment, cases of sometimes fatal interstitial pneumonitis with respiratory failure were reported in patients with Pemetremixed treatment." "" "" ""</seg>
<seg id="2429">There have been reported cases of acute kidney failure in Pemetremixed monotherapy or in combination with other chemotherapy agents (see section 4.4).</seg>
<seg id="2430">"" "" "" "there have been reported cases of radiation pneumonitis in patients before, during or after their pemetrexed therapy (see section 4.4)." "" "" ""</seg>
<seg id="2431">"" "" "" "ALIMTA (Pemetremixed) is an antineoplastic antifolate, which performs its effect by interrupting weight-sensitive metabolic processes that are necessary for cell replication." "" "" ""</seg>
<seg id="2432">In vitro studies showed that Pemetrexed works as antifolate with several points of attack by blocking thymidylatynthase (DHFR) and Glycinamidribonucleotidfor- myltransferase (GARFT) and thymidin- and Purinnucleotides folate-dependent enzymes.</seg>
<seg id="2433">EMPHACIS: a multicenter randomised single-blind Phase 3 study of ALIMTA plus Cisplatin versus Cisplatin in chemonaiven patients with malignant pleuramesothelioma showed a clinically significant benefit to survival compared to patients that were treated with cisplatin only with cisplatin.</seg>
<seg id="2434">"" "" "" "the primary analysis of this study was carried out in the population of all patients, who received the test medication (randomized and treated)." "" "" ""</seg>
<seg id="2435">A statistically significant improvement of the clinically relevant symptoms (pain and dyspnoe) in connection with the malignant pleural endothelioma was shown in the use of the LLIMTA / Cisplatin arm (212 patients) compared to the common Cispine arm (218 Patients).</seg>
<seg id="2436">The differences between the two treatment arms resulted in improved lung function parameters in the ALIMTA / Cisplatin arm and a worsening of lung function over time in the control room.</seg>
<seg id="2437">A median survival time of 8.3 months in patients treated with ALIMTA (Intent to treat Population n = 283) and from 7.9 months in with docetaxel treated patients (ITT n = 288) treated with docetaxel.</seg>
<seg id="2438">An analysis of the influence of histology on the overall survival benefit of ALIMTA in patients with NSCLC with a predominantly non-disk epithelial histology (n = 172; 6.2 versus 7.4 months; adjusted HR = 1.56; 95% CI = 1.08-2.26; p = 0.018).</seg>
<seg id="2439">Limited data from a randomised controlled Phase 3 study showed that efficacy data (survival and progression-free survival) for Pemetremixed between patients with (n = 41) and without (n = 540) pre-treatment by docetaxel are similar.</seg>
<seg id="2440">The efficacy analyses of the PQ population are consistent with the analyses of the ITT population and support the non-supremacy of the ALIMTA Cisplatin combination compared to gemcitabine Cisplatin combination.</seg>
<seg id="2441">Mean PFS was 4.8 months for the combination of ALIMTA Cisplatin versus 5.1 months for the combination of gemcitabine Cisplatin versus 28,2% (95% CI = 25.0 - 31.4) for the combination gemcitabine Cisplatin.</seg>
<seg id="2442">"" "" "" "the analysis of the influence of NSCLC histology on survival revealed clinically relevant differences according to histology, see table below." "" "" ""</seg>
<seg id="2443">CI = confidence interval; ITT = intento-to-treat; N = size of the total population a statistically for non-inferiority; with a total confidence interval for HR (= Hazard ratio) clearly below the non-submission threshold of 1.17645 (p &lt; 0.001).</seg>
<seg id="2444">Patients treated with ALIMTA and Cisplatin required less transfusions (16.4% versus 28,9%; p &lt; 0.001) and thrombocyte transfusions (1.8% versus 4.5%; p = 0.002).</seg>
<seg id="2445">Patients also needed less and less the gift of erythropopoetin / darbopoetin (10.4% versus 18.1%, p &lt; 0.001) and G-CSF / GM-CSF (3.0% versus 7.0%; p = 0.021).</seg>
<seg id="2446">The pharmacokinetic properties of Pemetrexed as a monotherapist were examined in 426 cancer patients with various solid tumours in doses ranging from 0.2 to 838 mg / m ² in infusion zones over a period of 10 minutes.</seg>
<seg id="2447">"" "" "" "Pemetremixed is mainly excreted in the urine, and 70% to 90% of the administered dose is found in the urine within 24 hours after the application." "" "" ""</seg>
<seg id="2448">Pemetremixed has a total of 91.8 ml / min and the half-life in the plasma amounts to 3.5 hours in patients with normal renal function (creatinin-Clearance 90 ml / min).</seg>
<seg id="2449">"" "" "" "in a study with Beagle-dogs, which had been given intravenous Bolus injections for 9 months, Tesimitary changes were observed (degene- ration / necrosis of the seminiferous epithelial tissue)." "" "" ""</seg>
<seg id="2450">"" "" "" "if not neglected, the retention times and conditions after the preparation are in the responsibility of the user and should not exceed 24 hours at 2 to 8 ° C unless the preparation / dilution has taken place under controlled and validated aseptic conditions." "" "" ""</seg>
<seg id="2451">Dissolve the content of the 100 mg / ml milk bottles with 4.2 ml 0.9% sodium chloride injection solution (9 mg / ml) without any preservatives. this results in a solution with a concentration of about 25 mg / ml Pemetremixed.</seg>
<seg id="2452">"" "" "" "the resulting solution is clear and the coloring ranges from colourless to yellow or greenish, without compromising the quality of the product." "" "" ""</seg>
<seg id="2453">"" "" "" "each glass bottle has to be dissolved with 20 ml 0.9% sodium chloride injection solution (9 mg / ml), which results in a solution of 25 mg / ml." "" "" ""</seg>
<seg id="2454">23 Several cardiovascular events including myocardial infarction and cerebrovascular events were occasionally reported in clinical trials involving Pemetrexed in combination with a different cytotoxic agent.</seg>
<seg id="2455">* * * Beeducated at National Cancer Institute CTC (v2.0; NCI 1998) is reported to be reported as a level 1 or 2 for any toxicity degree. * * * Beeducated at National Cancer Institute CTC (v2.0; NCI 1998).</seg>
<seg id="2456">"" "" "" "for this table, a threshold of 5% was specified for the inclusion of all events in which the correction doctor held a connection with Pemetrexed and Cisplatin." "" "" ""</seg>
<seg id="2457">* * Regulated at National Cancer Institute CTC version 2 for any toxicity degree. * * Beared at National Cancer Institute CTC (v2.0; NCI 1998) should report hair loss only as Level 1 or 2.</seg>
<seg id="2458">* * * Regulated at National Cancer Institute CTC (v2.0; NCI 1998) for any toxicity degree. * * * Beeducated at National Cancer Institute CTC (v2.0; NCI 1998) should only be reported as Grade 1 or 2.</seg>
<seg id="2459">Clinically relevant toxicity reported at &lt; 1% (occasionally) of the patients who were ran- domized cisplatin and Pemetremixed was:</seg>
<seg id="2460">An analysis of the influence of histology on the overall survival benefit of ALIMTA in patients with NSCLC with a predominantly non-disk epithelial his- tological type (n = 172; 6.2 versus 7.4 months; adjusted HR = 1.56; 95% CI = 1.08-2.26; p = 0.018).</seg>
<seg id="2461">Dissolve the contents of 500 mg / ml milk bottles with 20 ml 0.9% sodium chloride injection solution (9 mg / ml) without any preservatives. this results in a solution with a concentration of about 25 mg / ml Pemetremixed.</seg>
<seg id="2462">"" "" "" "the resulting solution is clear and the coloring ranges from colourless to yellow or greenish, without compromising the product quality." "" "" ""</seg>
<seg id="2463">"" "" "" "pharmacovigilance system The owner of authorization for placing on the market has to worry that the pharmaceutical covigilance system, as described in Version 2.0, is ready and ready for use as soon as the product is brought into circulation and while the product is in the market." "" "" ""</seg>
<seg id="2464">Risk Management Plan The owner of approval for placing on the market commits the studies and additional pharmaceutical vigilance activities according to the Pharmacovigilance plan as agreed in the version 1.2 of the Risk Management Plan (RMP) in module 1.8.2. the approval for placing on the market and all the following updates of the MP approved by the CHMP.</seg>
<seg id="2465">According to "CHMP Guideline on Risk Management Systems for" products for human use "an updated RMP must be submitted simultaneously with the next" Periodic Safety Update Report "(PSUR).</seg>
<seg id="2466">"" "" "" "in addition, an updated RMP must be submitted • If new information is available which could have an impact on the current safety specifications, the pharmacovigilance plan or risk management activities • Inquiry by EMEA" "" "" ""</seg>
<seg id="2467">ALIMTA 100 mg powder for the production of a concentrate for the production of an ALIMTA 500 mg powder for the production of a concentrate to produce an infusion solution</seg>
<seg id="2468">"" "" "" "ALIMTA is used in patients who have no previous chemotherapy used for the treatment of malignant pleural endothelioma (malignant disease of the rib) in combination with Cisplatin, another drug for the treatment of cancer." "" "" ""</seg>
<seg id="2469">"" "" "" "if you have a kidney disease or earlier one, please discuss this with your doctor or hospital pharmacy as you may not be allowed to receive ALIMTA." "" "" ""</seg>
<seg id="2470">"" "" "" "before any infusion blood tests will be carried out, it checks whether your kidney and liver function is sufficient and if you have sufficient blood cells to receive ALIMTA to 49." "" "" ""</seg>
<seg id="2471">"" "" "" "your doctor may possibly change the dose or stop treatment if it requires your general condition, and if your blood values are too low." "" "" ""</seg>
<seg id="2472">"" "" "" "if you are also receiving Cisplatin, your doctor will ensure that your body contains sufficient water and you will receive the necessary medicines to prevent vomiting before and after cisplatin." "" "" ""</seg>
<seg id="2473">"" "" "" "if you have liquid accumulation around the lungs, your doctor may decide to remove this liquid before you receive ALIMTA." "" "" ""</seg>
<seg id="2474">"" "" "" "if you wish to receive a child during treatment or during the first 6 months of treatment, please contact your doctor or pharmacist." "" "" ""</seg>
<seg id="2475">"" "" "" "interact with other medicines Please tell your doctor if you are using drugs for pain or inflammation (swelling), including medicines that are not prescription (like ibuprofen)." "" "" ""</seg>
<seg id="2476">"" "" "" "depending on the planned development of your ALIMTA infusion and / or the extent of your renal function, your doctor will tell you which other medicines you can take, and when." "" "" ""</seg>
<seg id="2477">"" "" "" "please tell your doctor or pharmacist if you have other medicines or recently taken, even if it is not prescription medication Han- delt." "" "" ""</seg>
<seg id="2478">"" "" "" "a hospital pharmacy, nursing staff or a doctor will mix the ALIMTA powder with sterile 0.9% sodium chloride injection solution (9 mg / ml) before it is applied." "" "" ""</seg>
<seg id="2479">"" "" "" "your doctor will prescribe cortisone tablets (according to 4 mg dexama- son two times a day), which you must take on the day before, during and the day following the application of ALIMTA." "" "" ""</seg>
<seg id="2480">"" "" "" "your doctor will prescribe folic acid (a vitamin) for taking or multivitamins which contain folic acid (350 to 1000 micrograms), which you have to take daily during the application of ALIMTA." "" "" ""</seg>
<seg id="2481">"" "" "" "in the week before the application of ALIMTA and about every 9 weeks (according to 3 cycles of treatment with ALIMTA), you will also receive an injection of Vi- tamin B12 (1000 micrograms)." "" "" ""</seg>
<seg id="2482">"" "" "" "in this utility information, a side effect as" very often "is described, this means that it was reported by at least 1 out of 10 patients." "" "" ""</seg>
<seg id="2483">"" "" "" "if a side effect is described as" frequently, "this means that it was reported by at least 1 of 100 patients but reported less than 1 out of 10 patients." "" "" ""</seg>
<seg id="2484">"" "" "" "if a side effect is described as" occasionally, "this indicates that it is reported by at least 1 of 1,000 but less than 1 out of 100 patients." "" "" ""</seg>
<seg id="2485">"" "" "" "fever or infection (frequent): if you have a body temperature of 38 ° C or above, sweating or other signs of infection (because you may have less white blood cells than normal which is very common)." "" "" ""</seg>
<seg id="2486">"" "" "" "if you feel tired or weak, get into shortness of breath or look pale (because you might have fewer hemoglobin than normal which is very common)." "" "" ""</seg>
<seg id="2487">"" "" "" "when you notice a bleeding of the gums, nose or mouth or another bleeding that does not come to a standstill, or have a reddish or pink urine or unexpected blood sugar (because you may have fewer platelets than normal which is very common)." "" "" ""</seg>
<seg id="2488">Occasionally (occurs at least 1 out of 1000 patients but less than 1 of 100 patients) increased pulse rate colitis (inflammation of the inner lining of the colon that may be associated with bleeding in the intestines and endgut) Interstitial pneumonitis (narrowing of the lung vesicles) edema (discharge of water into the body tissue that leads to swelling).</seg>
<seg id="2489">"" "" "" "rare (occurs in more than 1 out of 10,000 patients but less than 1 out of 1,000 patients)" Radiation Recall "(a rash resembling a severe sunburn), appearance on the skin that was previously exposed (a few days to years) of radiotherapy." "" "" ""</seg>
<seg id="2490">"" "" "" "occasionally occurred in patients ALIMTA, usually in combination with other cancer patients, received a stroke or stroke with minor damage." "" "" ""</seg>
<seg id="2491">"" "" "" "in patients receiving radiation treatment before, during or after their ALIMTA treatment, radiation of the lung tissue (scarring of the lung vesicles that is related to radiation treatment) can occur." "" "" ""</seg>
<seg id="2492">52 Check your doctor or pharmacist if any of the listed side effects are uplifting or if you notice side effects that are not listed in this packing supplement.</seg>
<seg id="2493">"" "" "" "as prescribed by law, the chemical and physical stability of the diluted and infusion solution for storage in the refrigerator or at 25 ° C was proven for 24 hours." "" "" ""</seg>
<seg id="2494">O 359 2 491 41 40 Česká republika ELI LILLY Česká republika ELI LILLY ČR.</seg>
<seg id="2495">Tel: + 420 234 664 111 Danmark Eli Lilly Danmark A / S Tlf: + 45 45 26 6100 Germany Lilly Postmark A / S Tlf: + 49 45 26 6100 Germany Lilly Germany GmbH Tel. + 49- (0) 6172 273 2222 Eesti Eli Lilly Danmark Tel: + 49- (0) 6172 273 2222</seg>
<seg id="2496">Tel: + 34-91-623-1732 France Lilly France SAS Tél: + 33- (0) 1 55 49 34 34 Ireland Eli Lilly and Company (0) 1 661 4377 Ísland Icepharma hf.</seg>
<seg id="2497">Particulars: + 357 22 715000 Latvija Eli Lilly Holdings Limited pā rstovybė. Tel: + 371 67364000 Lietuva Eli Lilly Holdings Limited atstovybė Tel. + 370 (5) 2649600</seg>
<seg id="2498">Tel.: + 48 (0) 22 440 33 00 Portugal Lilly Portugal - produtos Farmacêuticos Lda Tel: + 351-21-4126600 România Eli Lilly România S.R.L.</seg>
<seg id="2499">Eli Lilly Sweden AB Tel: + 46- (0) 8 7378800 United Kingdom Eli Lilly and Company Limited Tel: + 44- (0) 1256 315999</seg>
<seg id="2500">Dissolve the content of the 100 mg / ml milk tanks with 4.2 ml 0.9% sodium chloride injection solution (9 mg / ml) without any preservatives which results in a solution with a concentration of about 25 mg / ml Pemetremixed.</seg>
<seg id="2501">Dissolve the contents of 500 mg / ml milk bottles with 20 ml 0.9% sodium chloride injection solution (9 mg / ml) without any preservatives which results in a solution with a concentration of about 25 mg / ml Pemetremixed.</seg>
<seg id="2502">"" "" "" "the resulting solution is clear, and the coloring ranges from colourless to yellow or greenish without compromising the quality of the products." "" "" ""</seg>
<seg id="2503">"" "" "" "it is used in overweight adults with a body mass index (BMI) of ≥ 28 kg per square meter in conjunction with a low-calorie, reduced fat diet." "" "" ""</seg>
<seg id="2504">"" "" "" "patients who are allergic to Alli and have no weight loss after 12 weeks, should consult their doctor or pharmacist." "" "" ""</seg>
<seg id="2505">"" "" "" "if these enzymes are inhibited, they can't break down some fats in the food, causing about a quarter of the fats added to the food ingests the intestines." "" "" ""</seg>
<seg id="2506">"" "" "" "in a third study, 391 patients were compared with a BMI between 25 and 28 kg / m2 with placebo." "" "" ""</seg>
<seg id="2507">"" "" "" "in the two studies in patients with a BMI of ≥ 28 kg / m2, patients receiving Alli 60 mg had an average weight loss of 4.8 kg, compared to 2.3 kg when taking placebo." "" "" ""</seg>
<seg id="2508">"" "" "" "in the study with alli in patients with a BMI between 25 and 28 kg / m2, no relevant weight loss could be observed for patients." "" "" ""</seg>
<seg id="2509">"" "" "" "the most common side effects of alli (observed in more than 1 out of 10 patients) are oily stains at after, flatus (winch) with hailage, greasy / oily chair, draught (winch), flatulence (winch) and soft chairs." "" "" ""</seg>
<seg id="2510">It may not be used in patients who are treated with Ciclosporin (to prevent organ rejection in graft patients) or with medicines such as warfarin to prevent blood clots.</seg>
<seg id="2511">It may also not be used in patients suffering from a long-term malabsorption syndrome (where not enough nutrients are absorbed from the digestive tract) or to cholestase (a liver disease) and for pregnant or breastfeeding mothers.</seg>
<seg id="2512">"" "" "" "July 2007, the European Commission granted Glaxo Group Limited approval for the placing of orlistat GSK in the European Union." "" "" ""</seg>
<seg id="2513">Alli is indicated for weight reduction of adults with overweight (body mass index BMI ≥ 28 kg / m2) and should be used in conjunction with a slightly hypocaloric acid-reduced diet.</seg>
<seg id="2514">"" "" "" "alli should not be used by children and young people under 18, because there is not enough data for efficacy and safety." "" "" ""</seg>
<seg id="2515">"" "" "" "since orlistat is absorbed only minimally, in elderly and in patients with reduced liver and / or kidney function no adjustment of the dosage is necessary." "" "" ""</seg>
<seg id="2516">• Oversensitivity to the active ingredient or any of the other ingredients • Simultaneous treatment with Ciclosporin (see section 4.6) • Premature treatment with warfarin or other oral anticoagulants (see section 4.6) • Simultaneous treatment with warfarin or other oral anticoagulants (see Section4.5 and 4.8)</seg>
<seg id="2517">The likelihood of occurrence of gastrointestinal symptoms (see section 4.8) may increase if alli is taken together with a low-fat single meal or high-fat diet.</seg>
<seg id="2518">"" "" "" "as the weight reduction in diabetes can be associated with improved metabolic control, patients who take a medicine against diabetes should consult a doctor or pharmacist before starting a therapy with alli if necessary." "" "" ""</seg>
<seg id="2519">"" "" "" "patients receiving alli as well as medicines for high blood pressure or increased cholesterol should consult their doctor or pharmacist, whether the dosage of these drugs must be adjusted." "" "" ""</seg>
<seg id="2520">"" "" "" "in the event of severe diarrhoea, it is recommended to prevent possible failure of oral contraception (see Section 4.5)." "" "" ""</seg>
<seg id="2521">Both in a study on drug interactions and in several cases with simultaneous application of orlistat and ciclosporin a decrease of the iclosporin plasma gas was observed.</seg>
<seg id="2522">"" "" "" "when applying Warfarin or other oral anticoagulants in combination with orlistat, the Quick values (international normal ratio, INR) could be influenced (see Section 4.8)." "" "" ""</seg>
<seg id="2523">"" "" "" "in most patients who were treated with orlistat in clinical trials up to 4 full years, concentrations of vitamins A, D, E and K remained in the normal range." "" "" ""</seg>
<seg id="2524">"" "" "" "however, the patient should be advised to take a supplement of the Multivitamin supplement before bedtime to ensure sufficient vitaminic intake (see Section 4.4)." "" "" ""</seg>
<seg id="2525">"" "" "" "following the gift of a single dose Amiodarone, a marginal decrease of the Amiodarone plasma concentration was observed in a limited number of volunteers." "" "" ""</seg>
<seg id="2526">"" "" "" "animal experiments showed no direct or indirect harmful effects on pregnancy, embryonic / fetal development, birth or postnatal development (see Section 5.3)." "" "" ""</seg>
<seg id="2527">"" "" "" "the side effects of orlistat are mainly gastrointestinal nature and are associated with the pharmacological effect of the drug, since the absorption of taken fat is prevented." "" "" ""</seg>
<seg id="2528">The gastrointestinal side effects were obtained from clinical studies with orlistat 60 mg over a duration of 18 months to 2 years and were generally mild and temporary.</seg>
<seg id="2529">"" "" "" "the frequencies are defined as follows: very common (≥ 1 / 100, &lt; 1 / 100), rarely (≥ 1 / 1000) and very rare (≥ 1 / 1000), not known (frequency based on the data available)." "" "" ""</seg>
<seg id="2530">"" "" "" "the frequency of known side effects noted after the launch of orlistat is not known, as these events voluntarily were reported from a population of some extent." "" "" ""</seg>
<seg id="2531">"" "" "" "† It is plausible, that the treatment with alli can lead to anxiety regarding possible or actual gastrointestinal side effects." "" "" ""</seg>
<seg id="2532">Single doses of 800 mg orlistat and multiple doses of up to 400 mg three times a day were administered over a period of 15 days to normal and obese subjects without significant clinical findings.</seg>
<seg id="2533">"" "" "" "in the majority of cases reported after the market launch of orlistat overdosing, no side effects or similar side effects were reported as at the recommended dose of orlistat." "" "" ""</seg>
<seg id="2534">"" "" "" "based on studies on humans and animals, a fast reformation of any systemic effects can be traced back to the antibacterial properties of orlistat." "" "" ""</seg>
<seg id="2535">The therapeutic effect decreases in the lumen of the stomach and the upper small intestine by covalent bonding to the active serin-remainder of the gastric and pankreatic lipases.</seg>
<seg id="2536">"" "" "" "from clinical studies, it was derived that 60 mg orlistat was taken three times a day, blocking the absorption of about 25% of the dietary fat." "" "" ""</seg>
<seg id="2537">"" "" "" "two double-blind, randomised, placebo-controlled trials in adults with a BMI ≥ 28 kg / m2 substantiate the efficacy of 60 mg orlistat, which was taken three times a day in combination with a hypocalori, reduced fat diet." "" "" ""</seg>
<seg id="2538">The primary parameter that changes the body weight compared to the baseline (at the time of randomization) was evaluated as follows: as a change in body weight in the course of study (Table 1) and as part of those study participants who have lost more than 5% or more than 10% of their weight (table 2).</seg>
<seg id="2539">"" "" "" "although the weight reduction was observed over 12 months in both studies, the greatest weight loss occurred in the first six months." "" "" ""</seg>
<seg id="2540">The average change in the total cholesterol was 60 mg -2.4% (baseline 5.20 mmol / l) and with placebo + 2.8% (baseline 5.26 mmol / l).</seg>
<seg id="2541">The average change in LDL cholesterol was with orlistat 60 mg -3.5% (initial value 3.30 mmol / l) and with placebo + 3.8% (initial value 3.41 mmol / l).</seg>
<seg id="2542">With waist circumference the average change was -4.5 cm with orlistat 60 mg (initial value 103.7 cm) and with placebo -3.6 cm (starting value 103.5 cm).</seg>
<seg id="2543">Plasma concentrations of non-metabolized orlistat were not measurable for 8 hours after oral administration of 360 mg orlistat (&lt; 5 ng / ml).</seg>
<seg id="2544">"" "" "" "7 In general, non-metabolized orlistat in the plasma could only be sporadic and at very low concentrations (&lt; 10 ng / ml or 0.02 µmol) and without signs of an accumulation." "" "" ""</seg>
<seg id="2545">"" "" "" "in a study with adipous patients receiving the minimal systemic absorption, two primary metabolites were identified, namely, M1 (in position 4 hydrolyzed Lactonring) and M3 (M1 after splitting the N-Formyl-leucine group)." "" "" ""</seg>
<seg id="2546">"" "" "" "based on the conventional studies on safety spatology, toxicity in repeated application, genotoxicity, hurricanogenic potential and reproductive toxicity, pre-clinical data do not reveal any particular danger to humans." "" "" ""</seg>
<seg id="2547">"" "" "" "pharmacovigilance system The owner of approval for placing on the market must make sure that the pharmacovigilance system, according to the version of July 2007, is described and worked before and while the product is available on the market." "" "" ""</seg>
<seg id="2548">Risk management planning The owner of approval for the placing on the market is obliged to perform the trials and additional pharmaceutical vigilance activities as described in the Pharmacovigilance Plan and to adhere to the RMPs's risk management plan as well as all further updates of the RMPs to be agreed with the Committee for Human Use (CHMP).</seg>
<seg id="2549">"" "" "" "according to the CHMP guidelines for risk management systems for human drugs, the updated RMP must be submitted simultaneously with the next PSUR (Periodic Safety Update Report)." "" "" ""</seg>
<seg id="2550">"" "" "" "furthermore, an updated RMP should be submitted: • If new information is available, comply with current security policies, pharmacovigilance or risk management activities • within 60 days of reaching an important milestone • European Medicines Agency (EMEA)" "" "" ""</seg>
<seg id="2551">"" "" "" "12 PSURs First year after the Commission's decision about the extension of approval for the alli 60 mg of hard capsules PSURs, every six months, every three years." "" "" ""</seg>
<seg id="2552">If you are pregnant or breastfeeding if you are hypersensitive to orlistat or any of the other ingredients • if you are hypersensitive to orlistat or any of the other ingredients • if you suffer from cholestase (disease of the liver where the bile discharge is disturbed) • if you have problems with food intake (chronic malabsorption syndrome).</seg>
<seg id="2553">"" "" "" "• Take one capsule with water three times a day, including fat, take one capsule with water. • You should take one capsule once a day, before bedtime, a multivitamin tablet (with vitamins A, D, E and K)." "" "" ""</seg>
<seg id="2554">"" "" "" "use: take one capsule with water three times a day with each main meal. • Do not take more than three capsules per day. • You should take a multivitamin tablet once a day (vitamins A, D, E and K)." "" "" ""</seg>
<seg id="2555">"" "" "" "ask your doctor or pharmacist if you need further information or advice. if you have not reached any weight reduction after 12 weeks of alli, consult a doctor or pharmacist for advice." "" "" ""</seg>
<seg id="2556">"" "" "" "if any of the listed side effects you are significantly impaired or you notice side effects that are not stated in this information, please inform your doctor or pharmacist." "" "" ""</seg>
<seg id="2557">What do you need to consider before taking alli? • alli should not be used • Special precaution when taking alli with other medicines • For intake of alli along with food and drinks • Pregnancy and feeding times • Transport tightness and operation of machines 3.</seg>
<seg id="2558">How can you prepare your weight loss? O Choose your starting date o Setzen you goals for your calorie and fat intake • How long should you take alli? Oh if you have taken alli in too large quantities o if you forgot the intake of alli 4.</seg>
<seg id="2559">What side effects are possible? • Several side effects • Frequent side effects • Frequent side effects • Effects on blood tests • How can you control nutritional deficiencies?</seg>
<seg id="2560">More information • What alli contains • How alli looks and contents of the package • Pharmaceutical entrepreneurs and manufacturers • More helpful information</seg>
<seg id="2561">Alli is used for weight reduction and is used for overweight adults aged 18 years with a body mass index (BMI) of 28 or above. alli should be used in conjunction with a low-fat and low-calorie diet.</seg>
<seg id="2562">"" "" "" "the BMI helps you determine whether you have a normal weight in relation to your height, or are overweight." "" "" ""</seg>
<seg id="2563">"" "" "" "even if these diseases do not initially cause you to feel uncomfortable, you should nevertheless ask your doctor for a check-up." "" "" ""</seg>
<seg id="2564">"" "" "" "for a weight of 2 kg, weight loss, you can lose an additional kilogram with the help of alli." "" "" ""</seg>
<seg id="2565">"" "" "" "please tell your doctor or pharmacist if you have other medicines or recently taken, even if it is not prescription medicine." "" "" ""</seg>
<seg id="2566">Ciclosporin is used after transplants in severe rheumatoid arthritis and certain severe skin diseases. • Warfarin or other medicines that have a blood thinning effect.</seg>
<seg id="2567">Oral contraceptives and alli • The effect of orally increasing means of contraception (pill) may be weakened or canceled if you have strong diarrhoea (diarrhea).</seg>
<seg id="2568">"" "" "" "before taking alli, please consult your doctor or pharmacist if you are:" "" "" "" "Amiodarone for the treatment of heart rhythms." "" "" ""</seg>
<seg id="2569">"" "" "" "ask your doctor or pharmacist if you take any medicine, and if you need drugs for high blood pressure, the dosage may be adjusted." "" "" ""</seg>
<seg id="2570">"" "" "" "how to set your calorie and fat boundaries, see further helpful information on the blue pages in section 6." "" "" ""</seg>
<seg id="2571">"" "" "" "if you leave a meal or a meal contains no fat, take no capsule. alli can only act if the food contains fat." "" "" ""</seg>
<seg id="2572">"" "" "" "if you are taking the capsule in conjunction with a meal that contains too much fat, you risk nutritional deficiencies (see section 4)." "" "" ""</seg>
<seg id="2573">"" "" "" "to get used to your body in new eating habits, start the first capsule intake with a calorie and fat-reduced diet." "" "" ""</seg>
<seg id="2574">"" "" "" "dietary kerchiefs are effective as you can understand what you eat, how much you eat and it will likely be easier to change your dietary habits." "" "" ""</seg>
<seg id="2575">"" "" "" "in order to achieve your target weight, you should set two daily targets in advance: one for the calories and one for fat." "" "" ""</seg>
<seg id="2576">"" "" "" "• dietary fat is reduced, in order to reduce the likelihood of nutritional deficiencies (see section 4). • Try to move more before you start taking the capsules." "" "" ""</seg>
<seg id="2577">"" "" "" "remember to ask your doctor in advance, if you are not used to physical activity." "" "" ""</seg>
<seg id="2578">"" "" "" "• alli should not be taken longer than 6 months. • If you can't notice any reduction in weight after 12 weeks of application by alli, ask your doctor or pharmacist for advice." "" "" ""</seg>
<seg id="2579">"" "" "" "you may need to stop taking alli. • When taking a successful weight loss, it is not about switching the diet quickly and then back to old habits." "" "" ""</seg>
<seg id="2580">"" "" "" "• If less than one hour has passed since the last meal, grab the capsule intake. • If more than one hour has passed since the last meal, take no capsule." "" "" ""</seg>
<seg id="2581">"" "" "" "flatulence with and without oily exit, sudden or increased studiness and soft chair) can be attributed to the mechanism of action (see section 1)." "" "" ""</seg>
<seg id="2582">"" "" "" "allergic reactions • severe allergic reactions • severe allergic reactions can be seen in the following changes: severe breath, sweat eruptions, skin rashes, itching in the face, heart rate, circulatory rupture." "" "" ""</seg>
<seg id="2583">29 Very frequent side effects These can occur in more than 1 out of 10 people who are alli. • Bflatulence (flatulence) with and without oily exit • Bothful or oily chair • Weicher chair Inform your doctor or pharmacist if any of these side effects amplified or you significantly impaired.</seg>
<seg id="2584">Frequent side effects These can occur at 1 out of 10 people who are alli. • Magento (abdominal) pain; • Incontinence (chair) • aqueous / liquid chair • Increased studldvings • Reforms your doctor or pharmacist if any of these side effects amplified or you significantly impaired.</seg>
<seg id="2585">Implications for blood tests It is not known how often these effects occur. • Increase blood clotting in patients who use warfarin or other blood diluted (anticoagulation) medicines.</seg>
<seg id="2586">Inform your doctor or pharmacist if any of the side effects listed you have considerably impaired or you notice side effects that are not stated in this use information.</seg>
<seg id="2587">"" "" "" "the most common side effects are related to the mode of action of the capsules, resulting in increased fat from the body." "" "" ""</seg>
<seg id="2588">"" "" "" "these side effects usually occur within the first few weeks of treatment, since you may not have consistently reduced the fat content in your diet." "" "" ""</seg>
<seg id="2589">"" "" "" "with the following basic rules, you can learn to minimize nutrition-related side effects: • Start a few days, or better a week before taking capsules with a fat-reduced diet." "" "" ""</seg>
<seg id="2590">"" "" "" "if you know exactly how much you eat, the likelihood that you exceed your fat limit decreases." "" "" ""</seg>
<seg id="2591">"" "" "" "save the amount of calories and fat you can take per meal, not to take it in the form of a fat rich main court or a substantial dessert, as you may possibly have done with other programs for weight reduction." "" "" ""</seg>
<seg id="2592">• Keep out of the reach of children. • Keep out of reach of children after the expiry date stated on the box. • Keep container tightly closed to protect the contents from moisture. • The bottle contains two white sealed containers with silicones which serve to keep the capsules dry.</seg>
<seg id="2593">"" "" "" "do not swallow it. • You can carry out your daily dose alli in the blue transport box (Shuttle), which is included in this pack." "" "" ""</seg>
<seg id="2594">"" "" "" "FAMAR, 190 11 Avlona, Greece Catalent UK Packaging Limited, Sedge Close, Headway, Great Oakley, Corby, Northamptonshire NN18 8HS, United Kingdom" "" "" ""</seg>
<seg id="2595">"" "" "" "obesity has an impact on your health and increases the risk of developing different serious diseases, such as: • hypertension • diabetes • heart disease • stroke • Certain cancers • Osteoarthritis Please contact your doctor about your risk of these diseases." "" "" ""</seg>
<seg id="2596">"" "" "" "permanent weight loss, for example by improving diet and more exercise, can prevent serious diseases and have a positive impact on your health." "" "" ""</seg>
<seg id="2597">"" "" "" "choose meals that contain a wide range of nutrients, and gradually learn to nourish yourself permanently healthy." "" "" ""</seg>
<seg id="2598">"" "" "" "energy is also measured in kilojoules, which you can also find in food packaging. • The recommended calorie intake indicates how many calories you should take maximum per day." "" "" ""</seg>
<seg id="2599">Note the below tables below. • The recommended fat intake in grams is the maximum amount of fat you should take with each meal.</seg>
<seg id="2600">"" "" "" "which quantity is suitable for you, take out the information below that indicates the number of calories that is suitable for you." "" "" ""</seg>
<seg id="2601">"" "" "" "if you take the same amount of fat as before, this may mean that your body cannot process this amount of fat." "" "" ""</seg>
<seg id="2602">"" "" "" "with recommended fat intake, you can maximize weight loss while at the same time reduce the likelihood of nutritional deficiencies." "" "" ""</seg>
<seg id="2603">"" "" "" "34 This reduced calorie intake should allow you to gradually lose weight at approximately 0.5 kg per week, without frustration and disappointments." "" "" ""</seg>
<seg id="2604">"" "" "" "•" Low-calorie physical activity "means that you burn 150 kcal daily, i.e. by 3 km walking, 30- to 45 minute gardening or 2 km running in 15 minutes." "" "" ""</seg>
<seg id="2605">"" "" "" "• For lasting weight loss, it is necessary to set up realistic calorie and fat targets and to comply with it. • Sense to move more before you start taking alli." "" "" ""</seg>
<seg id="2606">The alli program to support weight loss combines the capsules with a diet plan and a large number of other information materials that can help you eat calori- and fatty alcohol and give guidelines to become physically active.</seg>
<seg id="2607">"" "" "" "in combination with a program tailored to your type, this information can help you develop a healthier lifestyle and achieve your target weight." "" "" ""</seg>
<seg id="2608">"" "" "" "Alois is used in chemotherapies that are strong triggers for nausea and vomiting (like cisplatin), as well as chemotherapies, which are excessive nausea and vomiting (such as cyclophosphamide, doxorubicin or carboplatin)." "" "" ""</seg>
<seg id="2609">The effectiveness of Alois can be increased by the additional gift of a corticosteroid (a drug which can be used as an antiemetic).</seg>
<seg id="2610">"" "" "" "the application for patients under 18 years of age is not recommended, because there is not enough information about the effects in this age group." "" "" ""</seg>
<seg id="2611">"" "" "" "this means that the active agent prevents the binding of a chemical substance in the body, 5-hydroxytryptamin (5HT, also known as serotonin), to the receptors in the intestines." "" "" ""</seg>
<seg id="2612">"" "" "" "Aloxi was examined in three main studies involving 1 842 adults who received chemotherapy, which are strong or moderate triggers for nausea and vomiting." "" "" ""</seg>
<seg id="2613">"" "" "" "in chemotherapy alone, 59% of patients treated with Alois showed no vomiting (132 of 223) compared to 57% of patients treated with ondansetron (126 of 221)." "" "" ""</seg>
<seg id="2614">"" "" "" "in chemotherapy alone, 81% of patients treated with Alois showed no vomiting (153 of 189) compared to 69% of patients treated with ondansetron (127 of 185)." "" "" ""</seg>
<seg id="2615">In comparison with Dolasetron these values were 63% for Aloxi (119 of 189 patients) and 53% for Dolasetron (101 out of 191 patients).</seg>
<seg id="2616">"" "" "" "March 2005, the European Commission granted approval to the company of Helsinki Birex Pharmaceuticals Ltd." "" "" ""</seg>
<seg id="2617">"" "" "" "aloxi is indicated: for prevention of acute nausea and vomiting in strong emetoid chemotherapy, due to a cancer and for preventing nausea and vomiting related to chemotherapy." "" "" ""</seg>
<seg id="2618">"" "" "" "the effectiveness of aloxi to prevent nausea and vomiting, which is induced by a strong emetoed chemotherapy, can be enhanced by adding a corticosteroids given before chemotherapy." "" "" ""</seg>
<seg id="2619">"" "" "" "since Palonosetron can extend the colon assay, patients with anamnesty or signs of a subacute Ileus should be closely monitored after injection." "" "" ""</seg>
<seg id="2620">"" "" "" "as with other 5HT3 antagonists, however, caution is advisable while simultaneous application of palonosetron with medicines that extend the QT interval or in patients where the Qt interval is extended or those tend to such an extension." "" "" ""</seg>
<seg id="2621">"" "" "" "in addition to chemotherapy, Aloxi is not used to treat or treat nausea and vomiting in the days following chemotherapy." "" "" ""</seg>
<seg id="2622">"" "" "" "in preclinical studies, palonosetron did not inhibit the targeted activity of the five chemotherapeutics (Cisplatin, cyclophosphamide, cytarabin, doxorubicin and mitomycin C)." "" "" ""</seg>
<seg id="2623">In a clinical study no significant pharmacokinetic interaction between a one-time intravenous dose of Palonosetron and a Steady State- Concentration oralen Metoclopramids - a CYP2D6 inhibitor.</seg>
<seg id="2624">In a pharmacokinetic analysis based on a population the simultaneous application of CYP2D6 inductors (Dexamethasone and Rifampicin) as well as CYP2D6 inhibitors (dexterine, paroxetine, sertraline and terbinafin) did not have a significant effect on the Clearance of Palonosetron.</seg>
<seg id="2625">"" "" "" "in case of pregnant women, palonosetron should not be used in pregnant pregnancies, unless it is deemed necessary by the treating physician." "" "" ""</seg>
<seg id="2626">"" "" "" "in clinical trials, the most common side effects were observed at a dose of 250 micrograms (a total of 633 patients), which could at least be associated with Alois (9%) and Obstipation (5%)." "" "" ""</seg>
<seg id="2627">"" "" "" "very rare cases (&lt; 1 / 10,000) of hypersensitivity reactions and reactions to the destination (burning, hardening, complaints and pain) were reported in post marketing reports." "" "" ""</seg>
<seg id="2628">"" "" "" "in the group with the highest dosage there were similar frequencies of adverse events, as in the other dosing groups; there were no dose-active relationships observed." "" "" ""</seg>
<seg id="2629">"" "" "" "dialysis studies were not carried out, but a dialysis is probably not an effective therapy for aloxi- overdosage." "" "" ""</seg>
<seg id="2630">In two randomised double-blind studies a total of 1.132 patients receiving a moderately emetoed chemotherapy with ≤ 50 mg / m2 of cyclophosphamide and &gt; 25 mg / m2 of cyclophosphamide and 250 mg / m2 of cyclophosphamide and 250 mg / m2 were given intravenously to day 1 without dexamethasone.</seg>
<seg id="2631">In a randomised double-blind study a total of 667 patients who received a strong emetoed chemotherapy with ≥ 60 mg / m2 cyclophosphamide and Dacarbazine as well as 250 or 750 micrograms of Palonosetron received the 32 mg ondansetron received on day 1 intravenously.</seg>
<seg id="2632">"" "" "" "results of studies with chemotherapy-based chemotherapy, and the study with strong emetoid chemotherapy, are summarized in the following tables." "" "" ""</seg>
<seg id="2633">"" "" "" "in clinical trials for indication chemotherapy-induced nausea and vomiting (CINV) the effects of palonosetron were comparable to blood pressure, heart rate and ECG parameters including the corresponding effects of ondansetron and dolasetron." "" "" ""</seg>
<seg id="2634">"" "" "" "according to clinical examinations, Palonosetron possesses the ability to block the ion channels involved in ventricular de- and repolarization and extend the duration of the action potential." "" "" ""</seg>
<seg id="2635">"" "" "" "the objective of the study conducted at 221 healthy subjects was to evaluate the ECG effects of intravenous palonosetron in single doses of 0,25, 0.75 and 2,25 mg." "" "" ""</seg>
<seg id="2636">Resorption After an intravenous gift follows an initial decrease in plasma concentrations a slow elimination of the body with an average terminal half-life of about 40 hours.</seg>
<seg id="2637">The average maximum plasma concentration (CMAx) and the area below the concentration time curve (AUC0- ∞) are generally in the entire dose range from 0.- 90 μ y / kg in patients and cancer patients dosisdisproportionately.</seg>
<seg id="2638">"" "" "" "after intravenous application of palonosetron 0,25 mg every second day for a total of 3 doses, the mediocosetron plasma concentration was measured at 42 ± 34% between day 1 and day 5." "" "" ""</seg>
<seg id="2639">Pharmacokinetic simulations indicate that at once daily intravenous administration of 0.25 mg palonosetron was comparable to 3 consecutive days (AUC0- ∞) with which after one-time intravenous administration of 0.75 mg was comparable; however the CMAx was higher after the one-off dose of 0.75 mg.</seg>
<seg id="2640">About 40% are eliminated by the kidneys and about 50% are converted into two primary metabolites that have less than 1% of the antagonistic effect on the 5HT3 receptor.</seg>
<seg id="2641">"" "" "" "in-vitro studies for metabolism have shown that CYP2D6 and, in a lesser degree, the Isoenzyme CYP3A4 and CYP1A2 on the metabolism of palonosetron are involved." "" "" ""</seg>
<seg id="2642">Elimination After an intravenous single dose of 10 micrograms / kg [14C] -palonosetron were found about 80% of the dose within 144 hours in the urine. palonosetron as unaltered agent made about 40% of the given dose.</seg>
<seg id="2643">"" "" "" "after a one-time intravenous bolus injection, the overall body was 173 ± 73 ml / min and the renal Clearance 53 ± 29ml / min." "" "" ""</seg>
<seg id="2644">"" "" "" "in patients with severe liver dysfunction, the terminal elimination time and the average systemic exposure to palonosetron are increased, however, reducing the dose is not justified." "" "" ""</seg>
<seg id="2645">"" "" "" "in preclinical studies, effects were observed only after exposures, which are considered sufficient above the maximum humanist exposure, suggesting low relevance for clinical use." "" "" ""</seg>
<seg id="2646">10 From preclinical studies evidence indicates that Palonosetron can only block ion channels in very high concentrations which are involved in ventricular de- and repolarisation and extend the duration of action.</seg>
<seg id="2647">"" "" "" "high doses of palonosetron (each dose was equivalent to 30ples of therapeutic exposure to humans), which were given daily for two years, resulted in increased frequency of liver tumors, endocrine neoplasms, pancreas, adrenal glands, and skin tumors." "" "" ""</seg>
<seg id="2648">"" "" "" "the underlying mechanisms are not fully known, but due to the high dosage and since Alois is intended for one-time application, relevance of these results will be minimized for humans." "" "" ""</seg>
<seg id="2649">"" "" "" "" "" "" "" "the holder of this authorisation for the placing of information must inform the European Commission on the plans for the placing of the medicines approved within this decision." "" "" ""</seg>
<seg id="2650">"" "" "" "• If any of the side effects listed you have significantly impaired or you notice side effects that are not stated in this information, please consult your doctor." "" "" ""</seg>
<seg id="2651">• Alois is a clear and colorless injection solution for injection into a vein. • The active ingredient (palonosetron) is a group of drugs called serotonin which may cause nausea and vomiting. • Alois is used to prevent nausea and vomiting associated with chemotherapy for cancer.</seg>
<seg id="2652">"" "" "" "21 If you use Alois with other medicines, tell your doctor if you are taking other medicines / applying it or applying it recently, even if it is not prescription medicine." "" "" ""</seg>
<seg id="2653">"" "" "" "if you are pregnant or believe to be pregnant, your doctor will not give you aloxi unless it is clearly required." "" "" ""</seg>
<seg id="2654">"" "" "" "before taking any medicines, ask your doctor or pharmacist for advice if you are pregnant or believe to become pregnant." "" "" ""</seg>
<seg id="2655">"" "" "" "in some very rare cases, allergic reactions to aloxi or burning or pain at the incision site occurred." "" "" ""</seg>
<seg id="2656">"" "" "" "like aloxi looks and contents of the pack Aloxi Injection Solution is a clear, colorless solution and is available in a package of 1 glass bottle containing 5 ml of solution." "" "" ""</seg>
<seg id="2657">A re-diaphragm by a scanning of a new aspiration to be a member of a diaphragm. a number of aspirations to be defined by a mediahost.: + 359 2 975 13 95 (6)</seg>
<seg id="2658">Latvija Pharma Swiss Latvia SIA 54-5 - Speaking in the street of the Street Riga LV-1011 Tel: + 37167502185 Lietuva UAB Pharma Swiss Š eimyniš kids.</seg>
<seg id="2659">United Kingdom IS Pharmaceuticals Ltd Office Village Chester Business Park Chester CH4 9QZ - UK Tel: + 44 1244 625 152</seg>
<seg id="2660">"" "" "" "June 2006, the Committee for Medicinal Products (CHMP) approved a negative report in which Alpheon's approval for the treatment of hepatitis C was recommended by Alpheon 6 million IE / ml injection solution." "" "" ""</seg>
<seg id="2661">"" "" "" "this means that Alpheon should resemble a biological drug called Roferon-A, called Roferon-A, which is already approved in the EU (also known as the" reference drug ")." "" "" ""</seg>
<seg id="2662">"" "" "" "alpheon should be used for the treatment of adult patients with chronic (long-lasting) hepatitis C (a liver illness, which is caused by viral infection)." "" "" ""</seg>
<seg id="2663">"" "" "" "in the case of a microscopic examination, the liver tissue damages damage; moreover, the values of the Liver enzyme Alanine aminotransferase (ALT) are elevated in the blood." "" "" ""</seg>
<seg id="2664">"" "" "" "it is produced by a yeast produced by a gene (DNA), which stimulates the formation of the active ingredient." "" "" ""</seg>
<seg id="2665">"" "" "" "the manufacturer of Alpheon submitted data proving the comparison of Alpheon with Roferon-A (substance structure, composition and purity of the drug, effects, safety and efficacy in hepatitis C)." "" "" ""</seg>
<seg id="2666">"" "" "" "in the study of patients with Hepatitis C, the efficacy of alpheon was compared with the efficacy of the reference drug to 455 patients." "" "" ""</seg>
<seg id="2667">"" "" "" "in the study, measured how many patients after 12 of 48 treatment weeks and 6 months after the treatment had been adjusted to the drug (i.e. no signs of the virus in the blood)." "" "" ""</seg>
<seg id="2668">(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail @ emea.eu.int http: / / www.emea.eu.int © EMEA is reproduction and / or distribution of this document is Authorised for non business purposes only provided the CHMP to forbid the authorization for placing on the market?</seg>
<seg id="2669">"" "" "" "furthermore, concerns have also been expressed that the data on the stability of the drug and the drug to be marketed will not suffice." "" "" ""</seg>
<seg id="2670">"" "" "" "the number of patients with hepatitis C, responding to the treatment with Alpheon and Roferon-A, was similar in the clinical trial." "" "" ""</seg>
<seg id="2671">"" "" "" "after setting the treatment with Alpheon, the disease returned to more patients than the reference drug, and Alpheon had more side effects." "" "" ""</seg>
<seg id="2672">"" "" "" "apart from this, the test used in the study to investigate the extent to which the drug develops an immune response (i.e. the body produces antibodies - special proteins - against the medicine), is not adequately validated." "" "" ""</seg>
<seg id="2673">"" "" "" "it can be used for the treatment of impetigo (a skin infection associated with crusts) and small infected areas (crack or cutting wounds), abrasions and sewn wounds." "" "" ""</seg>
<seg id="2674">Altargo should not be used to treat infections that have been proven or possibly caused by methicillinresistant Staphylococcus aureus (MRSA) because alarm goes against this type of infection possibly not.</seg>
<seg id="2675">"" "" "" "Altargo can be applied to patients aged nine months, but patients under 18 years of age may not exceed 2% of the body's surface." "" "" ""</seg>
<seg id="2676">"" "" "" "if the patient does not respond to treatment after two or three days, the doctor should examine the patient again and consider alternative treatments." "" "" ""</seg>
<seg id="2677">It works by blocking the bacterial ribosomes (the parts of the bacterial cell in which proteins are produced) and thereby inhibiting the growth of bacteria.</seg>
<seg id="2678">"" "" "" "in all five studies, the main indicator of efficacy was the proportion of patients whose infection was clung to the end of the treatment." "" "" ""</seg>
<seg id="2679">119 (85.6%) of the 139 patients under Altargo and 37 (52.1%) of 71 patients under placebo discussed the treatment.</seg>
<seg id="2680">"" "" "" "in the treatment of infected skin lesions, Altargo and Cefalexin showed similar rates of response: when the results of both studies were taken together at home customers, about 90% of both groups participated in the treatment." "" "" ""</seg>
<seg id="2681">"" "" "" "in these two studies, however, it was noted that Altargo was not effective enough in treating abscess (eiterfilled cavities in the body tissue) or from infections that were demonstrably or probably caused by MRSA." "" "" ""</seg>
<seg id="2682">The most common side-effect with Altargo (which was observed from 1 to 10 of 100 patients) is an irritation at the place of the order.</seg>
<seg id="2683">"" "" "" "the Commission for Medicinal Products (CHMP) concluded that the benefits of Altargo weigh in the short-term treatment of the following superficial skin infections: • Impetigo, • infected small detoxification, abrasions or wound wounds." "" "" ""</seg>
<seg id="2684">"" "" "" "in May 2007, the European Commission issued Glaxo Group Ltd. approval for the placing of Altargo throughout the European Union." "" "" ""</seg>
<seg id="2685">"" "" "" "patients with no improvement within two or three days should be examined again, and an alternative therapy should be considered (see Section 4.4)." "" "" ""</seg>
<seg id="2686">"" "" "" "in the event of a sensitization or serious local irritation due to the application of retinapamulin ointment, the treatment should be stopped, the ointment carefully wipes off and an appropriate alternative therapy of infection commenced." "" "" ""</seg>
<seg id="2687">"" "" "" "Retapamulin should not be used for treatment of infections, where MRSA is known as pathogen or suspected (see Section 5.1)." "" "" ""</seg>
<seg id="2688">In clinical trials of secondary infected open wounds the efficacy of retinapamulin was insufficient in patients with infections caused by a methicillin-resistant Staphylococcus aureus (MRSA).</seg>
<seg id="2689">"" "" "" "an alternative therapy should be considered, if after a 2- or 3-day treatment no improvement or worsening of the infected position occurs." "" "" ""</seg>
<seg id="2690">The effect of the simultaneous application of retinapamulin and other topical treatments on the same skin area has not been studied and the simultaneous application of other topical medicines is not recommended.</seg>
<seg id="2691">A clinically relevant inhibition in vivo is not to be expected due to the low plasma concentrations encountered in the skin or infected superficial wounds in humans (see Section 5.2).</seg>
<seg id="2692">3 The mean Retapamulin AUC (0-24) and CMAx after topical application of 1% Retapamulin Salbe increased by 81% after topical application of 1% Retapamulin Salbe.</seg>
<seg id="2693">"" "" "" "due to the low systemic exposure to topical treatment in patients, dose adjustments are not required when topical retinapamulin is used during systemic treatment with CYP3A4 inhibitors." "" "" ""</seg>
<seg id="2694">Animal studies have shown a reproductive toxicity after oral consumption and are insufficient regarding a statement regarding effect on the birth and the fetal / postnatal development (see Section 5.3).</seg>
<seg id="2695">Retapamulin Salbe should only be used during pregnancy if a topical antibacterial therapy is clearly indicated and the application of retinapamulin is preferable to the administration of a systemic antibiotic.</seg>
<seg id="2696">"" "" "" "when deciding whether breastfeeding continues or should be continued or terminated with Altargo, it is necessary to consider between the benefits of breastfeeding for the infant and the benefit of the Altargo therapy for the woman." "" "" ""</seg>
<seg id="2697">"" "" "" "in clinical trials involving 2150 patients with superficial skin infections, the Altargo reported was the most frequently reported side-effect irritation on the administration site, which affects approximately 1% of the patients." "" "" ""</seg>
<seg id="2698">Mode Effect Retapamulin is a semi-synthetic derivative of Pleuromutilin; a substance isolated by fermentation from Clitopilus passabeckerianus (formerly pleurotus passanerianus).</seg>
<seg id="2699">The mode of action of retinapamulin is based on selective inhibition of bacterial protein synthesis by interaction at a specific binding point of the 50S subunit of the bacterial ribosome which differs from the binding sites of other ribosomal interacting antibacterial substances.</seg>
<seg id="2700">Data indicates that the binding site ribosomal protein L3 is involved and is located in the region of the ribosomal P-binding site and the peptidyltransferase centre.</seg>
<seg id="2701">"" "" "" "binding to this binding site, Pleuromutiline inhibits the peptide transfer, block partial P-binding interactions and prevent normal formation of active 50S ribosomal subunits." "" "" ""</seg>
<seg id="2702">"" "" "" "if the application of Retapamulin should appear critically at least some infection forms due to the local prevalence of resistance, a consultation should be targeted by experts." "" "" ""</seg>
<seg id="2703">"" "" "" "there were no differences in the in-vitro activity of retinapamulin compared to S.aureus, regardless of whether the isolates were sensitive or resistant to methicillin." "" "" ""</seg>
<seg id="2704">In the event of failure on the treatment at S.aureus the presence of strains with additional virulence factors (such as PVL = Panton-Valentine Leucocidin) should be considered.</seg>
<seg id="2705">Resorption In a study involving healthy adults 1% Retapamulin Salbe was applied daily under occlusion on intact and striped skin for up to 7 days.</seg>
<seg id="2706">"" "" "" "of 516 patients (adults and children), which received 1% Retapamulin Salbe twice a day for 5 days for topical treatment of secondary traumatic wounds, individual plasma samples were obtained." "" "" ""</seg>
<seg id="2707">"" "" "" "the sampling was performed on days 3 or 4 in the adult patients, before the medication and the children between 0-12 hours after the last application." "" "" ""</seg>
<seg id="2708">However the maximum individual systemic absorption in people after topical application of 1% ointment to 200 cm2 of reduced skin (CMAx = 22 ng / ml; AUC (0-24) = 238 ng · h / ml) 660 times lower than the Retapamulin IC50 for PGP-inhibiting.</seg>
<seg id="2709">Metabolism The in vitro oxidative metabolism of retinapamulin in human liver microcosms was primarily mediated by CYP3A4 and lower participation of CYP2C8 and CYP2D6 (see section 4.5).</seg>
<seg id="2710">"" "" "" "in trials of oral toxicity in rats (50, 150 or 450 mg / kg), which were carried out over 14 days, there were signs of adaptive liver and thyroid changes." "" "" ""</seg>
<seg id="2711">In-vitro testing of gene mutation and / or chromosomal effects in the mouse-lympoma test or in cultures of human peripheral blood lymphocytes and in the rats-micro-core test for in-vivo investigation of chromosomal effects.</seg>
<seg id="2712">"" "" "" "there was neither male nor female rats signs of restricted fertility with oral dosages of 50, 150 or 450 mg / kg / day, which has reached up to 5 times higher exposure than the highest estimated exposure to humans (topical application on 200 cm2 skimped skin):" "" "" ""</seg>
<seg id="2713">In an embryotoxicity study of rats at oral dosages of ≥ 150 mg / kg / day (corresponding to the ≥ 3-fold of estimated human exposure (see above)) development stoxicity (reduced body weight of the fetus and delayed Ossification) and maternal toxicity.</seg>
<seg id="2714">The owner of the authorisation for placing on the market must ensure that a pharmacovigilance system (Version 6.2) is present and works before the product is marketed and as long as the marketing product is being marketed.</seg>
<seg id="2715">"" "" "" "the owner of the authorisation procedure is obliged to carry out detailed studies and additional pharmaceutical vigilance activities in the pharmacovigilance plan, as described in Version 1 of the Risk Management Plan (RMP) and all additional RMP updates agreed with the CHMP." "" "" ""</seg>
<seg id="2716">"" "" "" "as described in the" CHMP "Guideline on Risk Management Systems for" products for human use, "the updated RMP should be submitted at the same time with the next periodic Safety Update Report." "" "" ""</seg>
<seg id="2717">Irritation or other signs and symptoms in the treated area will show you the application of Altargo and speak to your doctor.</seg>
<seg id="2718">"" "" "" "do not apply any other ointments, creams or lotions on the surface treated with Altargo unless specifically prescribed by your doctor." "" "" ""</seg>
<seg id="2719">"" "" "" "it may not be used in the eyes, in the mouth or on the lips, in the nose or in the female genital area." "" "" ""</seg>
<seg id="2720">"" "" "" "if the ointment is on one of these surfaces, wash the place with water and ask your doctor for advice if problems arise." "" "" ""</seg>
<seg id="2721">"" "" "" "after applying the ointment, cover the affected area with a sterile dressing or a Gaza strip unless your doctor has advised you not to cover the area." "" "" ""</seg>
<seg id="2722">"" "" "" "it is offered in an aluminum tube with a plastic cap containing 5, 10 or 15 grams of ointment, or in an aluminium pouch that contains 0.5 g ointment." "" "" ""</seg>
<seg id="2723">Ambirix is used to protect against hepatitis A and hepatitis B (diseases affecting the liver) in children aged between one and fifteen years that are not immune to these two diseases.</seg>
<seg id="2724">"" "" "" "ambirix is used as a vaccination plan consisting of two doses, whereas a protection against Hepatitis B may not be reached until the second dose is administered." "" "" ""</seg>
<seg id="2725">"" "" "" "for this reason, Ambirix may be used only if there is a low risk of hepatitis B infection during the immunization, and it is ensured that the vaccination plan consists of two doses." "" "" ""</seg>
<seg id="2726">"" "" "" "if a refresher dose for hepatitis A or B is desirable, Ambirix or other hepatitis A or B vaccine can be given." "" "" ""</seg>
<seg id="2727">"" "" "" "vaccines work by contributing to the immune system (the natural defence of the body)," "" "" "" "as it can fight against a disease." "" "" ""</seg>
<seg id="2728">"" "" "" "after obtaining the vaccine, the immune system detects viruses and surface antigens as" alien "and creates antibodies against it." "" "" ""</seg>
<seg id="2729">"" "" "" "Ambirix contains the same components as the vaccine that has been approved since 1996, and has been the authorized vaccine of Twinrix children since 1997." "" "" ""</seg>
<seg id="2730">"" "" "" "the three vaccines are used to protect the same illnesses, but Twinrix adults and Twinrix children are administered within three doses." "" "" ""</seg>
<seg id="2731">"" "" "" "because ambirix and Twinrix adults contain identical ingredients, some of the data that support the use of Twinrix adults were also used as proof for the application of ambirix." "" "" ""</seg>
<seg id="2732">"" "" "" "the main indicator of efficacy was the proportion of vaccinated children, which had developed a protective anti-antibody concentration one month after injection." "" "" ""</seg>
<seg id="2733">"" "" "" "in an additional study of 208 children, the efficacy of the vaccine was compared with a six months and a 12 month gap between the two injections." "" "" ""</seg>
<seg id="2734">Ambirix performed between 98 and 100% of vaccinated children a month after the last injection to develop protective anti-antibody concentrations against hepatitis A and B.</seg>
<seg id="2735">The additional study showed that ambirix's degree of protection was similar to a six-month gap between the injections.</seg>
<seg id="2736">"" "" "" "the most common side effects of Ambirix (observed in more than 1 out of 10 vaccine doses) are headache, loss of appetite, pain at the injection point, redness, fatigue, and irritability." "" "" ""</seg>
<seg id="2737">"" "" "" "ambirix may not be used in patients who are possibly hypersensitive to the active ingredients, any of the other ingredients or neomycin (an antibiotic)." "" "" ""</seg>
<seg id="2738">"" "" "" "in August 2002, the European Commission granted GlaxoSmithKline Biologicals s.a. a permit for the placing of ambirix in the whole." "" "" ""</seg>
<seg id="2739">"" "" "" "the standardization plan for primed vaccination with Ambirix consists of two doses, and the first dose is given at the date of choice and the second dose between six and twelve months after the first dose." "" "" ""</seg>
<seg id="2740">"" "" "" "if a collection formulation is desired for hepatitis A and hepatitis B, vaccines can be vaccinated with the corresponding monovalent vaccines or combined vaccine." "" "" ""</seg>
<seg id="2741">The anti-Hepatitis B surface antigen (anti-HBsAg) and anti-hepatitis A virus (anti-HAV) anti-hepatitis A virus (anti-HAV) antibody values are in the same magnitude as after vaccination with the respective monovalent vaccines.</seg>
<seg id="2742">"" "" "" "it is not yet fully assured whether immune-competent persons who have responded to hepatitis AIDS vaccination, as they may be protected by immunological memory even in no longer detectable antibodies." "" "" ""</seg>
<seg id="2743">"" "" "" "3 As with all injection vaccines, appropriate possibilities of medical treatment and monitoring should always be available immediately after the injection of the vaccine." "" "" ""</seg>
<seg id="2744">"" "" "" "if a rapid protection against hepatitis B is required, the standardization scheme with the combination vaccine is recommended that contains 360 ELISA units of formalininactivated hepatitis A virus and 10 µg recombinant hepatitis B surface antigen." "" "" ""</seg>
<seg id="2745">"" "" "" "in case of hemodialysis patients and persons suffering from disorders of the immune system, there may be no adequate anti-HAV- and anti-HBs antibody value, so that in these cases the gift of other vaccine doses may be required." "" "" ""</seg>
<seg id="2746">"" "" "" "since intradermal injection or intramuscular administration in the gluteal muscle could lead to a suboptimal impact success, these injection routes should be avoided." "" "" ""</seg>
<seg id="2747">"" "" "" "however, in case of thrombocytopenia or anthrombosis, Ambirix may be subcutaneous subcutaneous, since it can occur in these cases after intramuscular administration of bleeding." "" "" ""</seg>
<seg id="2748">If ambirix was administered in the second year of life in the form of a separate intravenous injection with a combined diphtherie- and acellular polyomyelitis and haemophilus influenza vaccine (DTPA-IPV / HIB) or with a combined masern- mumps-rubella vaccine the immune response was sufficient to all antigens (see Section 5.1).</seg>
<seg id="2749">"" "" "" "in patients with immunosuppressive therapy or in patients with immune defects, it must be assumed that there is possibly no adequate immune response." "" "" ""</seg>
<seg id="2750">"" "" "" "in a clinical study conducted with 3 vaccines of this formulation in adults, the frequency of pain, redness, swelling, maturation, gastroenteritis, headache and fever was comparable to the frequency observed in previous thiomersal- and preservative-containing vaccine formulation." "" "" ""</seg>
<seg id="2751">"" "" "" "in clinical trials, 2029 vaccines were administered to a total of 1027 vaccines at the age of 1 to 15 years." "" "" ""</seg>
<seg id="2752">"" "" "" "in a study comprising 300 participants aged 12 to 15, the compatibility of ambirix was compared with the 3-dose combination vaccine." "" "" ""</seg>
<seg id="2753">"" "" "" "the only exceptions were the higher frequencies of pain and matiness on a calculation basis per vaccine ambirix, but not based on a calculation basis per person." "" "" ""</seg>
<seg id="2754">Pain was observed after the gift of Ambirix in 50.7% of the subjects compared to 39.1% in subjects following the gift of a dose of 3-doses combination vaccine.</seg>
<seg id="2755">"" "" "" "after the complete vaccination cycle, 66.4% of the subjects who had received Ambirix had pain, compared to 63.8% in subjects who had been vaccinated with the 3-dose combination vaccine." "" "" ""</seg>
<seg id="2756">"" "" "" "however, the frequency of matziness was comparable high per proband (i.e. over the entire vaccine cycle with 39.6% of the test persons who received the 3-dose combination vaccine)." "" "" ""</seg>
<seg id="2757">The frequency of severe pain and pain was low and comparable to the observed after administration of the combination vaccine with the 3-dose vaccine scheme.</seg>
<seg id="2758">In a comparative study of 1 to 11 years old vaccine the appearance of local reactions and general reactions in the AmbirixGroup was comparable to that observed when administered with the 3-dose combination vaccine with 360 ELISA units of formalininactivated hepatitis B virus and 10 µg recombinant hepatitis B surface antigen.</seg>
<seg id="2759">"" "" "" "however, a frequent occurrence of pain (at the injection point) per dose, not per proband, was reported for the 6- to 11-year-olds." "" "" ""</seg>
<seg id="2760">The share of vaccine that reported serious side effects during the 2-doses vaccine with Ambirix or during the 3-doses vaccine with the combination vaccine with 360 ELISA- units of formalininactivated hepatitis B and 10 µg recombinant hepatitis B- surface antigen was not statistically different.</seg>
<seg id="2761">"" "" "" "in clinical trials conducted at the age of 1 to 15 years, serum conversions for anti-HAV were 99.1% a month after the first dose and 100% a month after the second dose (i.e. in month 7)." "" "" ""</seg>
<seg id="2762">Serum conversion rates for anti-HBs were 74.2% a month after the first dose and 100% a month after the second dose and a month 6 administered dose (i.e. in month 7).</seg>
<seg id="2763">"" "" "" "7 In a comparative study conducted at 12- to including 15-year-olds, 142 Ambirix and 147 received the standard combination vaccine with three doses." "" "" ""</seg>
<seg id="2764">"" "" "" "in the 289 individuals whose immunogenicity was selectable, the Seroprotection rates (SP in the table below) were significantly higher compared to ambirix in the month 2 and 6 according to the 3-dose vaccine." "" "" ""</seg>
<seg id="2765">"" "" "" "the immune responses, which were achieved in a clinical trial study at 1 to 11-year-olds one month after completion of the full vaccine series (i.e., in month 7) are listed in the following table." "" "" ""</seg>
<seg id="2766">Both studies received either a 2-dose vaccine scheme with Ambirix or a 3-doses vaccine scheme with a combination vaccine with 360 ELISA units of formalininactivated hepatitis B virus and 10µg recombinant hepatitis B surface antigen.</seg>
<seg id="2767">The persistence of anti-HAVs and anti-HBs antibodies could be detected at least 24 months after immunisation with Ambirix in the 0-6-month vaccine.</seg>
<seg id="2768">The immune response observed in this study was comparable to that observed after inoculation of 3 doses with a combination vaccine consisting of 360 ELISA units of formalininactivated Hepatitis- A virus and 10 µg recombinant hepatitis B surface antigen in a dose volume of 0.5 ml.</seg>
<seg id="2769">"" "" "" "in a clinical study at 12- to including 15-year-olds, the persistence of anti-HAV- and anti-HBs antibodies is comparable to that in the 0-12 month vaccination scheme." "" "" ""</seg>
<seg id="2770">If the first dose of Ambirix in the second year of life is administered at the same time with the collection of a combined diphtherie- and acellular polyomyelitis and 8 Haemophilus influenza vaccine (DTPA-IPV / HIB) or with the first dose of a combined measles-mumps-rubella vaccine the immune response was sufficient to all antigens.</seg>
<seg id="2771">"" "" "" "a clinical study conducted with 3 doses of current formulation in adults showed similar serum and serum conversions, as for the earlier formulation." "" "" ""</seg>
<seg id="2772">"" "" "" "the vaccine is examined both before and after the examination by eye on any foreign particles, and / or physically visible changes." "" "" ""</seg>
<seg id="2773">"" "" "" "in accordance with Article 114 of the Directive 2001 / 83 / EC, state-owned batch sharing is carried out by a state laboratory or an authorised laboratory." "" "" ""</seg>
<seg id="2774">14 ANGABEN ROHNE NADEL 1 finished splash WITHOUT NADEL 10 finished syringes WITHOUT needles 10 finished syringes WITHOUT needles 50 finished syringes WITHOUT needles</seg>
<seg id="2775">"" "" "" "injector for injection 1 finished syringe, without needles, 10 pre-injections with needles 10 finished syringes with needles 50 pre-injections without needles 1 dose (1 ml)" "" "" ""</seg>
<seg id="2776">EU / 1 / 02 / 02 / 224 / 002 1 finished syringe with needle EU / 1 / 02 / 224 / 004 10 pre-splash with needles EU / 1 / 02 / 224 / 004 10 pre-splash with needles EU / 1 / 02 / 224 / 005 50 pre-injections with needles EU / 1 / 02 / 224 / 005 50 ready-to-use syringes without needles</seg>
<seg id="2777">"" "" "" "the hepatitis A virus is usually transmitted via viral foods and beverages, but can also be transmitted through other ways such as bathing in waters contaminated by effluent." "" "" ""</seg>
<seg id="2778">"" "" "" "you can feel very tired, have a dark urine, pale face, yellow skin and / or eyes (jaundice) and other symptoms that may require a steady treatment." "" "" ""</seg>
<seg id="2779">"" "" "" "as with all vaccines, Ambirix does not fully protect against infection with hepatitis B or hepatitis B virus even if the complete series of vaccines has been completed with 2 doses." "" "" ""</seg>
<seg id="2780">If you / your child are infected before the administration of both vaccination doses Ambirix is already infected with hepatitis B or hepatitis B virus (although you / your child does not feel uncomfortable or ill) a vaccination may not prevent a disease.</seg>
<seg id="2781">"" "" "" "protection against other infections affecting the liver or cause symptoms similar to those found after hepatitis B or hepatitis B infection, cannot be mediated." "" "" ""</seg>
<seg id="2782">"" "" "" "• If your child has an allergic reaction to ambirix or any component of this vaccine, including neomycin (an antibiotic) has been shown." "" "" ""</seg>
<seg id="2783">"" "" "" "an allergic reaction can be expressed by itching skin rash, shortness or swelling of the face or tongue. • If you have an allergic reaction to an earlier vaccine against hepatitis A or hepatitis B, an allergic reaction has occurred." "" "" ""</seg>
<seg id="2784">"" "" "" "• If you want to quickly protect against Hepatitis B (i.e., within 6 months and before the scheduled dose of the second vaccine)." "" "" ""</seg>
<seg id="2785">"" "" "" "with a possible risk of infection with hepatitis B between the first and second vaccination, the doctor will advise you / her child of an inoculation with ambirix." "" "" ""</seg>
<seg id="2786">Instead he will recommend 3 injections of a combined hepatitis B / hepatitis B vaccine with a reduced content of effective components per vaccine (360 ELISA units of a formalininactivated hepatitis B virus and 10 micrograms of a recombinant hepatitis B surface treatment).</seg>
<seg id="2787">"" "" "" "the second vaccination dose of this vaccine, with a reduced content of effective components, is usually given one month after the first dose and will give you / your child a vaccination protection before the end of the vaccine series." "" "" ""</seg>
<seg id="2788">"" "" "" "• If you / your child are weakened due to illness or treatment in your body's own defence, or if you / your child undergo a hemodialysis." "" "" ""</seg>
<seg id="2789">"" "" "" "Ambirix can be given in these cases, but the immune response of these individuals to vaccination may not be sufficient so that a blood test may be required to see how strongly the response is to vaccination." "" "" ""</seg>
<seg id="2790">"" "" "" "21 Tell your doctor if you / your child is taking other medicines (including those you can get without prescription), or if you / your child have been vaccinated / has been given or has been planned in the near future." "" "" ""</seg>
<seg id="2791">"" "" "" "however, it can be that in this case the immune response to the vaccine is not sufficient and the person is therefore not protected against one or both hepatitis A and B viruses." "" "" ""</seg>
<seg id="2792">"" "" "" "if another vaccine needs to be given at the same time with ambirix, it should be vaccinated in separate parts and as many as possible extremities." "" "" ""</seg>
<seg id="2793">"" "" "" "if ambirix is to be administered at the same time or shortly before or after an injection of immunoglobulins, it is likely that the reaction to the vaccine will still be adequate." "" "" ""</seg>
<seg id="2794">"" "" "" "usually ambirix pregnant or lactating women are not administered, unless it is urgently needed to vaccinate both hepatitis A and Hepatitis B." "" "" ""</seg>
<seg id="2795">"" "" "" "important information about certain other ingredients of Ambirix Please inform your doctor if you have already shown an allergic reaction to Neomycin (antibiotic), if you have an allergic reaction." "" "" ""</seg>
<seg id="2796">"" "" "" "if you miss the agreed date for the second vaccination, talk to your doctor and arrange a new date as soon as possible." "" "" ""</seg>
<seg id="2797">"" "" "" "often (more than 1 case per 10 verted doses): • pain or discomfort at the incision site or redness • matzability • headache • loss of appetite," "" "" ""</seg>
<seg id="2798">"" "" "" "(up to 1 case per 10 verted doses): • swelling at the injection site, fever (over 38 ° C) • Fadedness • gastrointestinal discomfort" "" "" ""</seg>
<seg id="2799">"" "" "" "other side effects, reported days or weeks following vaccination with comparable combination or single vaccines against hepatitis A and hepatitis B (less than 1 case per 10,000 blocked doses) are:" "" "" ""</seg>
<seg id="2800">"" "" "" "these include localised or extended rashes which can be itching or vesicle, swelling of the eyes and the face, difficult breathing or swallowing, sudden drop of blood pressure and unconsciousness." "" "" ""</seg>
<seg id="2801">"" "" "" "flu-like symptoms, including chills, muscle and joint pain varicose attacks, dizziness, abnormalities such as tingling and" ant walking ", multiple sclerosis, disorders of the optic nerve, severe headaches and stiffness of the neck, interruption of normal brain functions" "" "" ""</seg>
<seg id="2802">"" "" "" "fainting inflammation of some blood vessels may cause discomfort, loss of appetite, diarrhoea and stomach pain. abnormal bleeding or bruising (blue spots) caused by waste of the blood platelet." "" "" ""</seg>
<seg id="2803">23 Check your doctor or pharmacist if any of the listed side effects you / your child greatly affects or you notice side effects that are not stated in this packing supplement.</seg>
<seg id="2804">"" "" "" "ambirix is available in packs of 1 and 10 with or without needles, and in packs of 50 without needles." "" "" ""</seg>
<seg id="2805">"" "" "" "based on the data that has become known since the first approval for placing on the market, the CHMP assumed that the benefit-risk ratio for ambirix remains positive." "" "" ""</seg>
<seg id="2806">"" "" "" "however, because ambirix was only placed in a member state (in the Netherlands since May 2003), the available safety data for this drug is limited due to low patient exposure." "" "" ""</seg>
<seg id="2807">Ammonia can also be used in patients at the age of over a month with incomplete enzyme defect or with hyperammonia encephalopathy (brain damage as a result of high ammonia concentrations) in the prehistory.</seg>
<seg id="2808">Ammonze is divided into several single doses at meals - swallowed under the food or administered via a gastropostomy (through the abdominal wall into the stomach leading hose) or a nasal probe (through the nose into the stomach of leading hose).</seg>
<seg id="2809">"" "" "" "it was not a comparative study since Ammonze could not be compared with another treatment or with placebo (a pseudo-drug, i.e. without substance)." "" "" ""</seg>
<seg id="2810">"" "" "" "ammonia can also lead to loss of appetite, a abnormal acid content in the blood, depression, irritability, headache, impotence, malfunction or flavor, abdominal pain, vomiting, skin rash, unpleasant body odor, or weight gain." "" "" ""</seg>
<seg id="2811">"" "" "" "the Commission for Medicinal Products (CHMP) concluded that Ammonaps was effectively prevented in patients with disorders of the urinary cycle, too high ammonia levels." "" "" ""</seg>
<seg id="2812">"" "" "" "Ammonze was approved under" exceptional circumstances, "because due to the rarity of the disease at the time of approval only limited information on this drug was available." "" "" ""</seg>
<seg id="2813">"" "" "" "the use is indicated in all patients, where a complete enzyme shortage already manifests in newborns (within the first 28 days)." "" "" ""</seg>
<seg id="2814">"" "" "" "in patients with a late manifal form (incomplete enzyme defect, which manifests after the first life month), there is an indication of the use when a hyperammonium encephalopathy is in the anamnesis." "" "" ""</seg>
<seg id="2815">"" "" "" "for babies, for children who are unable to swallow tablets or for patients with swallowing disorders AMMONAPS is also available in granules." "" "" ""</seg>
<seg id="2816">"" "" "" "the daily dose is calculated individually, taking into account the protein tolerance and the daily protein intake required for the growth and development of the patient." "" "" ""</seg>
<seg id="2817">According to previous clinical experiences the normal daily dose is sodium phenylbutyrate: • 450 - 600 mg / kg / day with children weighing less than 20 kg • 9.9 - 13.0 g / m ² / day with children weighing over 20 kg as well as adolescents and adults.</seg>
<seg id="2818">In patients who suffer from an early manifest lack of carbamphosphate synthetase or ornithintrancarbamylase the substitution of citrulline or arginine is required in a dosing of 0.17 g / kg / day or 3.8 g / m ² / day.</seg>
<seg id="2819">Patients with arginine osuccinatsynthetase deficiency must receive arginine in a dose of 0.3 - 0.7 g / kg / day or 8.8 - 15.4 g / m ² / day.</seg>
<seg id="2820">"" "" "" "AMMONAPS tablets should not be administered to patients with swallowing disorders, as there is a risk of the development of esophagus ulcera if the tablets do not immediately get into the stomach." "" "" ""</seg>
<seg id="2821">Each tablet AMMONAPS contains 62 mg (2.7 mmol) sodium, corresponding to 2.5 g (108 mmol) sodium per 20 g sodium polyphenylbutyrate which corresponds to the maximum daily dose.</seg>
<seg id="2822">"" "" "" "AMMONAPS should therefore be used only with caution in patients with congestive heart failure or severe kidney failure, as well as with sodium retention and edema." "" "" ""</seg>
<seg id="2823">"" "" "" "since metabolism and excretion takes place via the liver and kidneys, AMMONAPS should only be used with extreme caution in patients with liver or kidney failure." "" "" ""</seg>
<seg id="2824">The importance of these results in relation to pregnant women is not known; the use of AMMONAPS during pregnancy is contraindicated (see 4.3).</seg>
<seg id="2825">"" "" "" "for subcutaneous administration of phenylacetate to young rats in high doses (190 - 474 mg / kg), there was a slowdown of neuronal multiplication and increased loss of neurons." "" "" ""</seg>
<seg id="2826">"" "" "" "there was also a delayed maturation of cerebral synapses and reduced number of functioning nerve damage in the brain, and thus a disability of brain growth." "" "" ""</seg>
<seg id="2827">"" "" "" "it could not be ascertained whether phenylacetate is excreted by humans into breast milk, and for this reason the use of AMMONAPS is contraindicated during breastfeeding (see 4.3)." "" "" ""</seg>
<seg id="2828">In clinical trials with AMMONAPS at least 56% of patients had at least an undesired event (AE) and 78% of these undesirable events were assumed that they were not related to AMMONAPS.</seg>
<seg id="2829">"" "" "" "the frequency is defined as follows: very common (≥ 1 / 10), often (≥ 1 / 100, &lt; 1 / 10) and occasionally (≥ 1 / 1000, &lt; 1 / 100)." "" "" ""</seg>
<seg id="2830">An improbable toxic reaction to AMMONAPS (450 mg / kg / day) was reported from an 18 year old abnormal patient who developed a metabolic encephalopathy associated with lactacidosis (severe hypocalemia) and peripheral neuropathy and pancreatitis.</seg>
<seg id="2831">"" "" "" "a case of overdose occurred during a 5 month old baby with an accidental single dose of 10 g (1370 mg / kg)." "" "" ""</seg>
<seg id="2832">"" "" "" "these symptoms go hand in hand with the accumulation of phenylacetate, which showed dose-limiting neurotoxicity when administered intravenous doses of up to 400 mg / kg per day." "" "" ""</seg>
<seg id="2833">Phenylacetate is a metabolic active compound that is conjugated with glutamine to phenylacetylglutamine that is excreted through the kidneys.</seg>
<seg id="2834">Phenylacetylglutamine is comparable to phenylacetylglutamine (both compounds contain 2 nitrogen atoms); therefore phenylacetylglutamine is suitable as an alternative carrier for the elimination of excess nitrogen.</seg>
<seg id="2835">"" "" "" "5 patients suffering from disorders of the urea cycle can be assumed, that sodium phenylbutyate can be produced between 0.12 and 0.15 g phenylacetylglutamine nitrogen for each gram." "" "" ""</seg>
<seg id="2836">"" "" "" "it is important that the diagnosis is made early and the treatment is started immediately, in order to improve survival chances and clinical results." "" "" ""</seg>
<seg id="2837">The prognosis of the early manifest form of the disease with the appearance of the first symptoms in newborns was almost always infectious and the disease even led to death in treatment with peritoneal dialysis and essential amino acids or with their nitrogen-free analogues in the first year of life.</seg>
<seg id="2838">"" "" "" "by haemodialysis, the exploitation of alternative ways of nitric oxide (sodium benzoate and sodium acetate), protein reduced food and possibly substitution of essential amino acids, it was possible to increase the survival rate of newborn at post-partal (but within the first months of life) to 80%." "" "" ""</seg>
<seg id="2839">"" "" "" "patients whose disease was diagnosed during pregnancy and which were treated before the first appearance of hyperammonia encephalopathy, the survival rate was 100%, but even in these patients it was time with many mental disabilities or other neurological deficiencies." "" "" ""</seg>
<seg id="2840">Patients with a late manifest form of the disease (including female patients with the heterozygous form of the ornithintrancarbamylase deficiency) recovered from hyperammonia encephalopathy and were subsequently treated with sodium phenylbutyate and a protein reduced diet were 98% survival.</seg>
<seg id="2841">"" "" "" "already existing neurological deficiencies are hardly reversible in treatment, and in some patients a further deterioration of the neurological condition can occur." "" "" ""</seg>
<seg id="2842">Phenylbutyrate is oxidized to phenylacetate which is conjugated in the liver and kidneys with glutamine using phenylacetylglutamine.</seg>
<seg id="2843">The concentrations of phenylbutyrat and its metabolites in plasma and urine were determined by taking a single dose of 5 g sodium phenylbutyate in sober healthy adults and in patients with disorders of the urinary cycle and hemoglobin metabolism and with repeated gifts of oral doses of up to 20 g / day (non-controlled studies).</seg>
<seg id="2844">The behavior of phenylbutyrat and its metabolites was also studied in cancer patients following IV administration of sodium polyphenylbutyrate (up to 2 g / m ²) or phenylacetate.</seg>
<seg id="2845">"" "" "" "after an oral single dose of 5 g sodium phenylbutyrat in tablet form, measured plasma concentrations of phenylbutyate were measured 15 minutes after ingesting." "" "" ""</seg>
<seg id="2846">In the majority of patients with urea-cycle disorders or hemoglobinopathies phenylbutyrat (300-650 mg / kg / day up to 20 g / day) the next morning no phenylacetate in the plasma was detected.</seg>
<seg id="2847">Three out of six patients with cirrhosis treated with sodium polyphenylbutyrate (20 g / day oral in three single doses) were five times higher than after the first gifts on the third day.</seg>
<seg id="2848">"" "" "" "excretion The medicine is excreted by the kidneys within 24 hours, approximately 80 - 100% in the form of the approved product phenylacetylglutamine." "" "" ""</seg>
<seg id="2849">"" "" "" "after the results of Micronucleus tests, sodium polyphenylbutyate had no complained effects (investigation 24 and 48 hours after oral administration of an individual dose of 878 to 2800 mg / kg)." "" "" ""</seg>
<seg id="2850">AMMONAPS Garulat is either taken orally (babies and children who have not yet swallowed tablets or patients with swallowing disorders) or via a gastropostomia or a nasal probe.</seg>
<seg id="2851">According to previous clinical experiences the normal daily dose of sodium phenylbutyrate is: • 450 - 600 mg / kg / day with newborns and infants with a body weight of less than 20 kg • 9.9 - 13.0 g / m ² / day with children weighing over 20 kg as well as adolescents and adults.</seg>
<seg id="2852">"" "" "" "the concentration of ammonia, arginine, essential amino acids (particularly branched-chain amino acids), carnitine and serum proteins in the plasma should be kept within the normal range." "" "" ""</seg>
<seg id="2853">In patients who suffer from an early manifest lack of carbamphosphate synthetase or ornithintrancarbamylase the substitution of citrulline or arginine is required in a dosing of 0.17 g / kg / day or 3.8 g / m ² / day.</seg>
<seg id="2854">AMMONAPS granulate contains 124 mg (5.4 mmol) sodium per gram sodium polyphenylbutyrate according to 2.5 g (108 mmol) sodium per 20 g sodium polyphenylbutyrate which corresponds to the maximum daily dose.</seg>
<seg id="2855">"" "" "" "when rats were exposed to phenylacetate (active metabolism of phenylbutyrat) before birth, it occurred to lesions in the pyramids of the brain-cortex." "" "" ""</seg>
<seg id="2856">An improbable toxic reaction to AMMONAPS (450 mg / kg / day) was reported from an 18 year old abnormal patient who developed a metabolic encephalopathy associated with lactacidosis (severe hypocalemia) and peripheral neuropathy and pancreatitis.</seg>
<seg id="2857">Phenylacetylglutamine with urea is comparable to phenylacetylglutamine (both compounds contain 2 nitrogen atoms); therefore phenylacetylglutamine is suitable as an alternative carrier for excretion of surplus</seg>
<seg id="2858">"" "" "" "based on studies on the excretion of phenylacetylglutamine in patients with disorders of the urea cycle, phenylacetylbutyrate can be produced between 0.12 and 0.15 g phenylacetylglutamine nitrogen." "" "" ""</seg>
<seg id="2859">"" "" "" "already existing neurological deficiencies are hardly reversible in the treatment, and in some patients a further deterioration of the neurological condition can occur." "" "" ""</seg>
<seg id="2860">"" "" "" "after an oral single dose of 5 g sodium phenylbutyrat in granules, measured plasma concentrations of phenylbutyrat were measured 15 minutes after ingesting." "" "" ""</seg>
<seg id="2861">"" "" "" "during durability, the patient can store the finished product for a period of 3 months at a temperature of not exceeding 25 ° C." "" "" ""</seg>
<seg id="2862">"" "" "" "this procedure contains the small measuring spoon 0,95 g, the average measuring spoon 2.9 g and the large measuring spoon 8.6 g sodium phenylbutyate." "" "" ""</seg>
<seg id="2863">"" "" "" "if a patient has to receive the medicine via a probe, AMMONAPS can also be dissolved in water before use (the solubility of sodium polyphenylbutyrate is up to 5 g in 10 ml of water)." "" "" ""</seg>
<seg id="2864">"" "" "" "in patients with these rare diseases, certain liver enzymes are missing, so that they cannot separate the sticky waste products that accumulate after consuming proteins in the body." "" "" ""</seg>
<seg id="2865">"" "" "" "if you are using laboratory tests, you must tell the doctor that you are taking AMMONAPS, since sodium phenylbutyrat may affect the results of certain laboratory tests." "" "" ""</seg>
<seg id="2866">"" "" "" "if you are taking AMMONAPS with other medicines, please inform your doctor or pharmacist if you have other medicines or recently taken, even if it is not prescription medicine." "" "" ""</seg>
<seg id="2867">"" "" "" "during breastfeeding, you may not take AMMONAPS, as the medicine may pass into breast milk and harm your baby." "" "" ""</seg>
<seg id="2868">"" "" "" "in rare cases abnormalities, headaches, taste disorders, impairment of hearing impaired, memory disorders, and worsening of existing neurological conditions were observed." "" "" ""</seg>
<seg id="2869">"" "" "" "if you notice any of these symptoms, contact your doctor or contact your hospital for an appropriate treatment." "" "" ""</seg>
<seg id="2870">"" "" "" "if you forgot to take AMMONAPS, take the appropriate dose as soon as possible with the next meal." "" "" ""</seg>
<seg id="2871">"" "" "" "changes in the blood flow (red blood cells, white blood cells, thrombocytes), decreased appetite, depression, irritability, headache, headache, nausea, malfunction, kidney function, weight gain and anomalous lab results." "" "" ""</seg>
<seg id="2872">Inform your doctor or pharmacist if any of the side effects listed you have considerably impaired or you notice side effects that are not stated in this use information.</seg>
<seg id="2873">"" "" "" "after the expiry date, AMMONAPS may no longer be used after the expiry date on the box and the container." "" "" ""</seg>
<seg id="2874">"" "" "" "as AMMONAPS looks and contents of the pack AMMONAPS tablets are of whitish color and oval shape, and they are provided with the embossing" UCY 500. "" "" "" ""</seg>
<seg id="2875">"" "" "" "30 If laboratory tests are carried out, you must tell the doctor that you are taking AMMONAPS, since sodium phenylbutyrat may affect the results of certain laboratory tests." "" "" ""</seg>
<seg id="2876">"" "" "" "if you are taking AMMONAPS with other medicines, please inform your doctor or pharmacist if you have other medicines or recently taken, even if it is not prescription medicine." "" "" ""</seg>
<seg id="2877">You should take AMMONAPS distributed on the same single doses orally or via a Magento (tube that runs through the abdominal wall directly into the stomach) or a nasal probe (tube that is guided through the nose into the stomach).</seg>
<seg id="2878">"" "" "" "• Take a straight edge, e.g. a knife back over the top edge of the measuring spoon, to remove excess granulate." "" "" ""</seg>
<seg id="2879">"" "" "" "angioplasty is used to treat adult patients with acute coronary syndrome (ACS, reduced blood supply to the heart), e.g. in instable angina (heart attack) or Myocardial infarction (abnormal measured value for electrocardiogram or ECG)." "" "" ""</seg>
<seg id="2880">"" "" "" "angiox is used to prevent blood clots in patients undergoing a higher dose, and the infusion can be continued up to four hours after the procedure." "" "" ""</seg>
<seg id="2881">"" "" "" "this can help in patients with angina or heart attack to maintain blood flow, and increase the effectiveness of a PCI." "" "" ""</seg>
<seg id="2882">Approximately 14 000 patients participated in the main study on the treatment of ACS in which the effect of angioplasty in combination with a glycoprotein IIb / IIIa inhibitor (GPI) was compared to conventional combination treatment with heparin (another anticoagulant) and a GPI.</seg>
<seg id="2883">"" "" "" "during PCI the patient was often used a stent (a short tube that remains in the artery to prevent a closure), and they additionally received other medicines to prevent blood clots like rituximab and aspirin." "" "" ""</seg>
<seg id="2884">"" "" "" "in the treatment of ACS, angioplasty was just as effective in preventing new events (death cases, heart attacks or revascularization) after 30 days or a year." "" "" ""</seg>
<seg id="2885">"" "" "" "in patients undergoing a PCI, angioplasty was as effective as heparin in relation to all indicators, except for severe bleeding where it was much more effective than heparin." "" "" ""</seg>
<seg id="2886">"" "" "" "angioplasty may not be used in patients who are possibly hypersensitive to Bivalirudin, other Hiridine or any of the other ingredients." "" "" ""</seg>
<seg id="2887">"" "" "" "it may also not be used in patients who recently had bleeding, as well as for people with strong high blood pressure or severe kidney problems or a heart infection." "" "" ""</seg>
<seg id="2888">The Commission for Medicinal Products (CHMP) concluded that angiox is an acceptable replacement for heparin during the treatment of ACS and a PCI.</seg>
<seg id="2889">"" "" "" "September 2004, the European Commission granted approval to the Medicines Company UK Ltd for the placing of angiox in the European Union." "" "" ""</seg>
<seg id="2890">"" "" "" "for the treatment of adult patients with acute coronary syndromes (unstable angina / non - ST) infarction (IA / NSTEMI)), an emergency intervention or an early intervention is provided." "" "" ""</seg>
<seg id="2891">The recommended initial dose of angiox in patients with ACS is an intravenous infusion of 0.1 mg / kg followed by an infusion of 0.25 mg / kg / h.</seg>
<seg id="2892">"" "" "" "if a PCI is carried out in another episode, an additional bolt of 0.5 mg / kg should be given and the infusion for the duration of the surgery is increased to 1.75 mg / kg / h." "" "" ""</seg>
<seg id="2893">"" "" "" "following clinical requirements, the reduced infusion dose of 0,25 mg / kg / h can be taken up for 4 to 12 hours after clinical requirements." "" "" ""</seg>
<seg id="2894">"" "" "" "immediately prior to the procedure, a studs of 0.5 mg / kg should be administered, followed by an infusion of 1.75 mg / kg / h for the duration of the operation." "" "" ""</seg>
<seg id="2895">The recommended dose of angiox in patients with a PCI consists of an initial intravenous release of 0.75 mg / kg body weight and an intravenous intravenous infusion with a dose of 1.75 mg / kg body weight / h at least for the duration of surgery.</seg>
<seg id="2896">"" "" "" "the safety and efficacy of a single Bolus gift of angioplasty has not been studied and is not recommended, even if a short PCI operation is planned." "" "" ""</seg>
<seg id="2897">"" "" "" "if this value (ACT after 5 minutes) is reduced to less than 225 seconds, a second bolt of 0.3 mg / kg / bodyweight should be achieved." "" "" ""</seg>
<seg id="2898">"" "" "" "in order to reduce the appearance of low ACT values, the reconstituted and diluted medicine should be carefully mixed before use and administered intravenously." "" "" ""</seg>
<seg id="2899">"" "" "" "as soon as the ACT value is more than 225 seconds, another monitoring is no longer required, provided that the 1.75 mg / kg infusion dose is administered correctly." "" "" ""</seg>
<seg id="2900">A lower infusion rate of 1.4 mg / kg / h should be used in patients with moderate kidney function restriction (GFR 30-59 ml / min).</seg>
<seg id="2901">"" "" "" "if the ACT value is less than 225 seconds, a second bolt dose of 0.3 mg / kg is to be administered and the ACT is reexamined 5 minutes after the second bolus dose." "" "" ""</seg>
<seg id="2902">"" "" "" "in patients with moderate kidney damage, which were included in the III- PCI study (REPLACE-2), the ACT value was 5 minutes after the gift of the Bivalirudin bolus without dose adjustment at an average of 366 ± 89 seconds." "" "" ""</seg>
<seg id="2903">"" "" "" "3 In patients with severe kidney damage (GFR &lt; 30 ml / min) and also in dialysis-based patients, angiox is contraindicated (see Section 4.3)." "" "" ""</seg>
<seg id="2904">Treatment with angiox can be initiated 30 minutes after termination of intravenous gift of fractional heparin or 8 hours after the subcutaneous administration of low-molecular heparin.</seg>
<seg id="2905">• Reliable hypersensitivity to the active ingredient or other ingredients or against Hirudine • Active hemorrhage and / or irreversible bacterial endocarditis. • severe uncontrolled hypertension and subacute bacterial endocarditis. • severe kidney damage (GFR &lt; 30 ml / min) and dialysis-based patients</seg>
<seg id="2906">"" "" "" "patients are carefully monitored during treatment with regard to symptoms and signs of bleeding, especially if Bivalirudin is administered in combination with another anticoagulant (see section 4.5)." "" "" ""</seg>
<seg id="2907">"" "" "" "even if in case of PCI patients under Bivalirudin, most of the hemorrhages can occur in patients who undergo a percutaneous coronary intervention (PCI) while in principle bleeding occurs everywhere." "" "" ""</seg>
<seg id="2908">In patients who are treated Warfarin and treated with Bivalirudin should consider a monitoring of the INR value (International Norised Ratio) to ensure that the value after setting the treatment with Bivalirudin once again reached the level existing prior to treatment.</seg>
<seg id="2909">"" "" "" "based on the knowledge of the efficacy mechanism of anticoagulants (heparin, warfarin, thrombocyte extraction inhibitor), it can be assumed that these active substances increase the risk of bleeding." "" "" ""</seg>
<seg id="2910">"" "" "" "in the combination of bivalirudin with platelets or anticoagulants, clinical and biological hemostasis parameters are regularly monitored." "" "" ""</seg>
<seg id="2911">"" "" "" "the animal experiments are insufficient in relation to pregnancy, embryonic and fetal development, fetching or postnatal development (see section 5.3)." "" "" ""</seg>
<seg id="2912">4612 were randomised to Bivalirudin alone; 4604 were randomized to Bivalirudin plus GPIIb / IIIa Inhibitor and 4603 were randomized to either unfractional or anox aparin plus GPIIb / IIIa inhibitor.</seg>
<seg id="2913">"" "" "" "both in the Bivalirudin group and in the comparative groups treated with heparin, women and patients over 65 years of age were more prone to adverse events than in male or younger patients." "" "" ""</seg>
<seg id="2914">Severe bleeding was defined according to the ACUITY and Timi scales for severe bleeding as in the footnotes of Table 2.</seg>
<seg id="2915">Both light and heavy bleeding performed significantly less frequently than in the groups with heparin plus GPIIb / IIIa inhibitor and Bivalidrun plus GPIIb / IIIa inhibitor (see table 2).</seg>
<seg id="2916">"" "" "" "an ACUITY bleeding was defined as one of the following events: intraarterial, retroperitoneal, intraocular hemoglobin levels of ≥ 3 g / dl with known blood supply, reoperation due to bleeding, application of blood products to transfusion." "" "" ""</seg>
<seg id="2917">"" "" "" "other, less frequently observed blood cell populations, which occurred in more than 0.1% (occasionally), were" other "puncturing points, retroperitoneal, gastrointestinal, ear, nose or throat." "" "" ""</seg>
<seg id="2918">"" "" "" "the following data about side effects are based on data from a clinical trial with bivalidate in 6,000 patients undergoing a PCI." "" "" ""</seg>
<seg id="2919">"" "" "" "both in the Bivalirudin group and in the comparative groups treated with heparin, women and patients over 65 years of age were more prone to adverse events than in male or younger patients." "" "" ""</seg>
<seg id="2920">Both light and heavy bleeding performed significantly less under Bivalirudin than in the comparative group of Heparin plus GPIIb / IIIa inhibitor.</seg>
<seg id="2921">"" "" "" "the following side effects, which are not listed above, were reported after extensive use in practice and are grouped according to system organclasses listed in table 6." "" "" ""</seg>
<seg id="2922">"" "" "" "in case of overdosing, the treatment with Bivalirudin is to be stopped immediately and the patient is closely monitored with regard to signs of bleeding." "" "" ""</seg>
<seg id="2923">"" "" "" "angiox contains Bivalirudin, a direct and specific thrombininhibitor, binds both at the catalytic centre and the anion binding region of Thrombine, regardless of whether thrommbin is trapped in the liquid phase or in tinns." "" "" ""</seg>
<seg id="2924">"" "" "" "the binding of Bivalirudin to Thrombin, and hence its effect, is reversible because Thrombin is slowly splitting the binding of Bivalirudin-ARG3-Pro4, which regenerates the function of the active center of thrombin." "" "" ""</seg>
<seg id="2925">"" "" "" "in addition, serum-induced Thrombocytopenia / heparinindusty thrombocytopenia / heparinindusty thrombocytopenia / heparinindusty thrombocytopenia / heparinindusty thrombocytopenia was not induced." "" "" ""</seg>
<seg id="2926">"" "" "" "in healthy subjects and in patients, Bivalirudin shows a dose-dependent anti-coagulatory effect which is documented by the extension of ACT, aPTT, PT, INR and TT." "" "" ""</seg>
<seg id="2927">"" "" "" "if a PCI was carried out in the patients, an additional bolt of 0.5mg / kg of bivalidate should be given and the infusion for the duration of the surgery should be increased to 1.75mg / kg / h." "" "" ""</seg>
<seg id="2928">In the arm A of ACUITY study unfractionated heparin or enoxaparin was administered in accordance with the relevant guidelines for treatment of acute coronary syndrome (ACS) in patients with unstable angina / non-ST lift infarction (IA / NSTEMI).</seg>
<seg id="2929">Patients in arm A and B were also randomized to obtain a GPIIb / IIIa inhibitor either before angiography (at the time of randomisation) or PCI.</seg>
<seg id="2930">"" "" "" "in the ACUITY study, the characteristics of high-risk patients, which required angiography within 72 hours, were evenly distributed across the 3 treatment arms." "" "" ""</seg>
<seg id="2931">"" "" "" "about 77% of patients had recurring ischemia, 70% had dynamic EKG changes or increased cardiac biomarkers, 28% had diabetes and about 99% of all patients underwent angiography within 72 hours." "" "" ""</seg>
<seg id="2932">The primary analysis and results from the ACUITY study for the 30-key and 1 year endpoint for the total population (ITT) and for patients who received aspirin and Clopidogrel according to protocol (before angiography or before PCI) are presented in tables 7 and 8.</seg>
<seg id="2933">ACUITY study; 30-day and 1-year risk difference for the combined ischemic endpoint and its components for patients who received aspirin and Clopidogrel according to protocol *</seg>
<seg id="2934">Patients receiving aspirin and Clopidogrel according to the protocol arm A arm B arm B arm C UFH / Enox Bival + GPIIb / IIIa + GPIIb / IIIa Risk Diff.</seg>
<seg id="2935">The frequency of bleeding both in the ACUITY- and Timi-degree to day 30 for the total population (ITT) and for patients who received Aspirin and Clopidogrel according to protocol is shown in table 9.</seg>
<seg id="2936">Patients Aspirin and Clopidogrel total population (ITT) according to the protocol were given to the class UFH / Enox Bival Bival Bival + + alone + + GPIIb / IIIa (N = 4612) GPIIb / IIIa Inhibitor (N = 4604) (N = 4604)</seg>
<seg id="2937">"" "" "" "* Clopidogrel before angiography or before PCI 1 A ACUITY bleeding was defined as one of the following events: intraocular, retroperito-neural, intraocular hemoglobin levels of ≥ 3 g / dl with known blood supply, reoperation due to bleeding, application of blood products to transfusion." "" "" ""</seg>
<seg id="2938">"" "" "" "the 30-day results, based on four and triple endpoints of a randomised double blind study with over 6,000 patients undergoing a PCI (REPLACE-2), are shown in table 10." "" "" ""</seg>
<seg id="2939">Clinical studies with a small number of patients provided limited information on the use of angiox in patients with HIT / HITTS.</seg>
<seg id="2940">The pharmacokinetic properties of Bivalirudin were evaluated in patients with a percutaneous coronary intervention (PCI) as well as in patients with ACS.</seg>
<seg id="2941">"" "" "" "as a peptide, Bivalirudin is expected to go through a catabolism in its amino acid components with subsequent revaluation of amino acids in the body pool." "" "" ""</seg>
<seg id="2942">The primary metabolite resulting from the split of the ARG3-Pro4 bond of the N-terminale sequence by thrombine is not effective because of the loss of its affinity to the catalytic center of thrombin.</seg>
<seg id="2943">"" "" "" "the elimination occurs in patients with normal renal function after a process of first order, with a terminal half-life of 25 ± 12 minutes." "" "" ""</seg>
<seg id="2944">"" "" "" "based on the conventional research on safety spatology, toxicity in repeated application, genotoxicity or reproductive toxicity, pre-clinical data do not reveal any particular danger to humans." "" "" ""</seg>
<seg id="2945">The toxicity of animals in repeated or continuous exposure (1 day to 4 weeks during exposure to 10-times of the clinical Steady-state plasma concentration) was limited to overshooting pharmacological effects.</seg>
<seg id="2946">"" "" "" "side effects as a result of long-term physiological stress in response to non-homeopathic coagulation were observed after short-term exposure, even with a much higher dosage, not observed." "" "" ""</seg>
<seg id="2947">"" "" "" "if the ready-to-use solution is not carried out under controlled and validated aseptic conditions, it is no longer than 24 hours to be stored at 2 ° C to 8 ° C." "" "" ""</seg>
<seg id="2948">"" "" "" "angioplasty is a freeze-dried powder in single dose 1-1 glass, sealed with butyl rubber stoppers and sealed with pressed aluminum cap." "" "" ""</seg>
<seg id="2949">"" "" "" "5 ml of sterile water for injection purposes are given in a penetration bottle of angiox, and slightly waved until everything has dissolved and the solution is clear." "" "" ""</seg>
<seg id="2950">5 ml are taken from the glass bottle and diluted with 5% glucose solution for injection or with 9 mg / ml (0.9%) sodium chloride solution for injection in a total volume of 50 ml in order to obtain a final concentration of 5mg / ml bivalirudin.</seg>
<seg id="2951">"" "" "" "the owner of the license agreement agrees to carry out the trials and pharmacovigilance activities listed in the Pharmacovigilance Plan, as stated in Version 4 of the Risk Management Plan (RMP) and any follow-up changes of the MP approved by CHMP." "" "" ""</seg>
<seg id="2952">"" "" "" "according to the CHMP Guideline, the revised RMP should be submitted at the same time with the next Periodic Safety Update Report (PSUR)." "" "" ""</seg>
<seg id="2953">• Patients with chest pain caused by heart disease (acute coronary syndromes - ACS) • patients that are operated in the blood vessels (angioplasty and / or percutaneous coronary angioplasty - PCI).</seg>
<seg id="2954">"" "" "" "• You are pregnant or suspect that you might be pregnant, you intend to become pregnant at present." "" "" ""</seg>
<seg id="2955">"" "" "" "no examinations of the effects on the transport and the ability to serve machines were carried out, but we know that the effects of this drug are only short-term." "" "" ""</seg>
<seg id="2956">"" "" "" "should bleeding occur, treatment with angiox is stopped. • Before starting the injection or infusion, you will inform your doctor about the possible signs of an allergic reaction." "" "" ""</seg>
<seg id="2957">Such reactions are rare (they occur in less than 1 out of 1000 patients). • A particularly careful observation is carried out if you have radiotherapy for the vessels that supply the heart with blood (this treatment is referred to as beta or gamma-brachytherapy).</seg>
<seg id="2958">• 0.1 mg / kg bodyweight as an injection followed by an infusion (Tropical solution) with 0.25 mg / kg bodyweight per hour (0.1 mg / kg bodyweight per hour means a quarter of a millimeter of the medicine for every kilogram of body weight per hour).</seg>
<seg id="2959">More likely if angiox is administered in combination with other coagulant or antithrombotic medications (see Section 2 "For the use of angiox with other drugs").</seg>
<seg id="2960">"" "" "" "these are occasional side effects (in less than 1 out of 100 patients). • thrombosis (blood clots), which could lead to serious complications such as heart attack." "" "" ""</seg>
<seg id="2961">"" "" "" "this is an occasional side effect (in less than 1 out of 100 patients). • Pain, bleeding and bleeding at the point of insertion (after PCI treatment)." "" "" ""</seg>
<seg id="2962">"" "" "" "inform your doctor, if any of the side effects listed you have considerably impaired or you notice side effects that are not stated in this information." "" "" ""</seg>
<seg id="2963">"" "" "" "angioplasty may no longer be applied after the expiry date, on the label and the box after" "" "" ""</seg>
<seg id="2964">Polska The Medicines Company UK Ltd.: + 800 843 633 26 lub + 41 61 564 1320. ης: + 30 210 5281700 E-mail:</seg>
<seg id="2965">"" "" "" "Apidra is used for treatment of adults, adolescents and children aged six and over with diabetes requiring treatment with insulin." "" "" ""</seg>
<seg id="2966">"" "" "" "Apidra is subcutaneous (under the skin) into the abdominal wall, the thighs or upper arm injected or administered as a permanent infusion with an insulin pump." "" "" ""</seg>
<seg id="2967">"" "" "" "diabetes is a disease in which the body does not produce enough insulin to regulate glucose levels (sugars) in the blood, or cannot process insulin effectively." "" "" ""</seg>
<seg id="2968">"" "" "" "insulin lulisin differs very slightly from human insulin, and the change means that it works faster and has a shorter time of operation than a short-acting human insulin." "" "" ""</seg>
<seg id="2969">"" "" "" "Apidra was studied in combination with a long-acting insulin in patients with type 1 diabetes in which the body cannot produce insulin, in two studies involving a total of 1 549 adults and in a study with 572 children aged between four and 17 years." "" "" ""</seg>
<seg id="2970">"" "" "" "in type 2 diabetes, in which the body is unable to work insulin effectively, Apidra was examined in a study of 878 adults." "" "" ""</seg>
<seg id="2971">The main indicator of efficacy was the change in the concentration of the substance glycosylated hemoglobin (HbA1c) in the blood that indicates how well the blood sugar is set.</seg>
<seg id="2972">"" "" "" "in the first study of adults with type 1 diabetes, a decrease of 0.14% (from 7.60% to 7.46%) compared to a decrease of 0.14% was observed in insulin." "" "" ""</seg>
<seg id="2973">In adults with type 2 diabetes the decrease of HbA1c concentration was 0.46% after six months with Apidra compared to 0.30% in human normal insulin.</seg>
<seg id="2974">"" "" "" "Apidra may not be used in patients who are possibly hypersensitive to insulin lulisin or any of the other ingredients, or in patients who are already suffering from hypoglycemia." "" "" ""</seg>
<seg id="2975">"" "" "" "the doses of Apidra must be adjusted, if it is administered together with a number of other medicines that can affect blood glucose levels." "" "" ""</seg>
<seg id="2976">"" "" "" "in September 2004, the European Commission granted Sanofi-Aventis Germany GmbH a permit for the placing of Apidra in the European Union." "" "" ""</seg>
<seg id="2977">"" "" "" "as a subcutaneous injection, Apidra can be applied either in the area of abdominal wall, thigh or deltoid or subcutted by continuous infusion into the abdominal wall." "" "" ""</seg>
<seg id="2978">"" "" "" "due to reduced gluconogenesis capacity and reduced insulin metabolism, insulin demand in patients with reduced liver function can be reduced." "" "" ""</seg>
<seg id="2979">"" "" "" "any change of the effect of the insulin, the type of insulin (normal, NPH, zinc delayed, etc.), the type of insulin (animal insulin) and / or the manufacturing method can change the insulin requirement." "" "" ""</seg>
<seg id="2980">"" "" "" "3. insufficient dosage or breakdown of treatment, especially in patients with insulin-based diabetes, can lead to hyperglycemia and diabetic ketoacidosis; these conditions are potentially life-threatening." "" "" ""</seg>
<seg id="2981">Switching a patient to another type of insulin or insulin from another manufacturer should take place under strict medical supervision and may require a change of dosage.</seg>
<seg id="2982">"" "" "" "the point of occurrence of hypoglycaemia depends on the actual profile of the insulin used, and can therefore change when the treatment plan is converted." "" "" ""</seg>
<seg id="2983">"" "" "" "oral antidiabetic, angiotensin-converting enzyme (ACE) inhibitors, disopyramide, monoamin-oxidase (MAO) inhibitors, propoxyphene, Salizylates and sulfonamide antibiotics belong to the substances that increase blood sugar-lowering activity." "" "" ""</seg>
<seg id="2984">"" "" "" "in addition, the symptoms of adrenergic counterregulation can be weakened or missing under the effect of Sympatholytics like beta-blockers, Clonidin, Guanethidin and Reserpine." "" "" ""</seg>
<seg id="2985">"" "" "" "animal experimental studies on reproductive toxicity showed no differences between insu- linglulisin and human insulin regarding pregnancy, embryonic and fetal development, birth or postnatal development (see Section 5.3)." "" "" ""</seg>
<seg id="2986">"" "" "" "it is not known whether insulin lulisin surpasses the human breast milk, but in general insulin does not enter the mother's milk nor is it resorbed after oral use." "" "" ""</seg>
<seg id="2987">"" "" "" "≥ 1 / 100, &lt; 1 / 100; rare: ≥ 1 / 100, &lt; 1 / 100; very rare: ≥ 1 / 1000, &lt; 1 / 10; very rare: ≥ 1 / 10; not known (frequency based on available data)." "" "" ""</seg>
<seg id="2988">"" "" "" "cold - sweat, cool and pale skin, fatigue, nervousness or tremor, anxiety, unusual creation or weakness, confusion, concentration problems, drowsiness, headache, nausea and palpitations." "" "" ""</seg>
<seg id="2989">"" "" "" "Lipodystrophy is neglected to continuously change the injection site within the injection area, and can subsequently occur a lipodystrophy at the injection site." "" "" ""</seg>
<seg id="2990">Severe hypoglycemia associated with loss of consciousness can be given by means of an intramuscular or subcutaneous injection of glucosagon (0.5 to 1 mg) administered by a correspondingly-trained person or by an intravenous gift of glucose by a doctor.</seg>
<seg id="2991">"" "" "" "after glucoagulation, the patient should be monitored in a hospital to determine the cause of the severe hypoglycaemia and to avoid similar episodes." "" "" ""</seg>
<seg id="2992">"" "" "" "insulin reduces blood sugar levels by stimulating the peripheral glucose absorption (especially skeletal muscles and fat), as well as the inhibition of glucose production in the liver." "" "" ""</seg>
<seg id="2993">Studies with healthy volunteers and patients with diabetes have shown that in subcutaneous GA- be of insulin lulisin the effect occurs faster and the time of operation is shorter than with cou- manem normal insulin.</seg>
<seg id="2994">In a study with 18 male persons aged 21 to 50 years with type 1 diabetes melli- tus insulin lulisin showed a disproportionate glucosome effect in the therapeutically relevant dosage range and at 0.3 E / kg or more an underproportional increase in the glucosa-healing effect as human insulin.</seg>
<seg id="2995">"" "" "" "insulin lulisin has a twice as fast response as normal human insulin, and achieves the complete glucosa-healing effect approximately 2 hours earlier than human insulin." "" "" ""</seg>
<seg id="2996">From the data it was evident that at an application of insulin lulisin 2 minutes before the meal a comparable post-pranic glycaemic control is achieved as with human normal insulin that is given 30 minutes before the meal.</seg>
<seg id="2997">"" "" "" "was insulin lulisin 2 minutes before the meal, a better post-pranic control was achieved than with human normal insulin, which was given 2 minutes before the meal." "" "" ""</seg>
<seg id="2998">"" "" "" "if insulin lulisin is turned 15 minutes after the beginning of the meal, a similar glycaemic control, like in human normal insulin, is given before the meal (see Figure 1)." "" "" ""</seg>
<seg id="2999">Insulin lulisin in gift 2 minutes (GLULISIN - previously) given before the beginning of the meal compared to human normal insulin that was given 30 minutes (Figure 1A) and compared to human normal insulin that was given 2 minutes (NORMAL - before) before a meal (Figure 1B).</seg>
<seg id="3000">Insulin lulisin in gift 15 minutes (GLULISIN - afterwards) after the beginning of the meal compared to human Nor- maline that was given 2 minutes (NORMAL before) before the beginning of the meal (Figure 1C).</seg>
</doc>
</tstset>
